{"31788d53ca943f792c6e2971629015508a472104": [["Pathogenesis of severe acute respiratory syndromeYu Lung Lau 1 and JS Malik Peiris 2 Severe acute respiratory syndrome (SARS) is a zoonotic infectious disease caused by a novel coronavirus (CoV).", [["acute respiratory syndrome", "DISEASE", 92, 118], ["SARS", "DISEASE", 120, 124], ["zoonotic infectious disease", "DISEASE", 131, 158], ["coronavirus", "ORGANISM", 177, 188], ["CoV", "ORGANISM", 190, 193], ["coronavirus", "SPECIES", 177, 188], ["Malik Peiris 2 Severe acute respiratory syndrome (SARS)", "SPECIES", 70, 125], ["CoV", "SPECIES", 190, 193], ["severe acute respiratory syndromeYu Lung Lau", "PROBLEM", 16, 60], ["Severe acute respiratory syndrome", "PROBLEM", 85, 118], ["SARS", "PROBLEM", 120, 124], ["a zoonotic infectious disease", "PROBLEM", 129, 158], ["a novel coronavirus", "PROBLEM", 169, 188], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory syndromeYu", "OBSERVATION", 29, 51], ["Lung", "ANATOMY", 52, 56], ["Lau", "ANATOMY_MODIFIER", 57, 60], ["Severe", "OBSERVATION_MODIFIER", 85, 91], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["respiratory syndrome", "OBSERVATION", 98, 118], ["zoonotic", "OBSERVATION_MODIFIER", 131, 139], ["infectious", "OBSERVATION", 140, 150]]], ["The tissue tropism of SARS-CoV includes not only the lung, but also the gastrointestinal tract, kidney and liver.", [["tissue", "ANATOMY", 4, 10], ["lung", "ANATOMY", 53, 57], ["gastrointestinal tract", "ANATOMY", 72, 94], ["kidney", "ANATOMY", 96, 102], ["liver", "ANATOMY", 107, 112], ["SARS", "DISEASE", 22, 26], ["tissue", "TISSUE", 4, 10], ["SARS-CoV", "ORGANISM", 22, 30], ["lung", "ORGAN", 53, 57], ["gastrointestinal tract", "ORGAN", 72, 94], ["kidney", "ORGAN", 96, 102], ["liver", "ORGAN", 107, 112], ["SARS-CoV", "SPECIES", 22, 30], ["The tissue tropism", "TEST", 0, 18], ["SARS-CoV", "TEST", 22, 30], ["tropism", "OBSERVATION_MODIFIER", 11, 18], ["lung", "ANATOMY", 53, 57], ["gastrointestinal tract", "ANATOMY", 72, 94], ["kidney", "ANATOMY", 96, 102], ["liver", "ANATOMY", 107, 112]]], ["Angiotensinconverting enzyme 2 (ACE2), the C-type lectin CD209L (also known L-SIGN), and DC-SIGN bind SARS-CoV, but ACE2 appears to be the key functional receptor for the virus.", [["Angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 0, 30], ["ACE2", "GENE_OR_GENE_PRODUCT", 32, 36], ["C-type lectin CD209L", "GENE_OR_GENE_PRODUCT", 43, 63], ["L-SIGN", "GENE_OR_GENE_PRODUCT", 76, 82], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 89, 96], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 102, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 116, 120], ["Angiotensinconverting enzyme 2", "PROTEIN", 0, 30], ["ACE2", "PROTEIN", 32, 36], ["C-type lectin", "PROTEIN", 43, 56], ["CD209L", "PROTEIN", 57, 63], ["L", "PROTEIN", 76, 77], ["SIGN", "PROTEIN", 78, 82], ["DC", "PROTEIN", 89, 91], ["SIGN", "PROTEIN", 92, 96], ["ACE2", "PROTEIN", 116, 120], ["SARS-CoV", "SPECIES", 102, 110], ["Angiotensinconverting enzyme", "TEST", 0, 28], ["ACE2", "TEST", 32, 36], ["the C-type lectin CD209L", "TEST", 39, 63], ["DC", "TEST", 89, 91], ["bind SARS", "PROBLEM", 97, 106], ["CoV", "PROBLEM", 107, 110], ["ACE2", "PROBLEM", 116, 120], ["the virus", "PROBLEM", 167, 176]]], ["There is a prominent innate immune response to SARS-CoV infection, including acute-phase proteins, chemokines, inflammatory cytokines and C-type lectins such as mannose-binding lectin, which plays a protective role against SARS.", [["SARS-CoV infection", "DISEASE", 47, 65], ["SARS", "DISEASE", 223, 227], ["mannose", "CHEMICAL", 161, 168], ["SARS-CoV", "ORGANISM", 47, 55], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 138, 152], ["mannose-binding lectin", "GENE_OR_GENE_PRODUCT", 161, 183], ["acute-phase proteins", "PROTEIN", 77, 97], ["chemokines", "PROTEIN", 99, 109], ["inflammatory cytokines", "PROTEIN", 111, 133], ["C-type lectins", "PROTEIN", 138, 152], ["mannose-binding lectin", "PROTEIN", 161, 183], ["SARS-CoV", "SPECIES", 47, 55], ["SARS", "PROBLEM", 47, 51], ["CoV infection", "PROBLEM", 52, 65], ["acute-phase proteins", "PROBLEM", 77, 97], ["chemokines", "PROBLEM", 99, 109], ["inflammatory cytokines", "PROBLEM", 111, 133], ["C-type lectins", "PROBLEM", 138, 152], ["mannose-binding lectin", "PROBLEM", 161, 183], ["SARS", "PROBLEM", 223, 227], ["prominent", "OBSERVATION_MODIFIER", 11, 20], ["innate immune response", "OBSERVATION", 21, 43], ["CoV", "OBSERVATION_MODIFIER", 52, 55], ["infection", "OBSERVATION", 56, 65], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["-phase", "OBSERVATION_MODIFIER", 82, 88], ["inflammatory", "OBSERVATION_MODIFIER", 111, 123], ["C-type lectins", "OBSERVATION_MODIFIER", 138, 152]]], ["By contrast there may be a lack of type 1 interferon response.", [["type 1 interferon", "GENE_OR_GENE_PRODUCT", 35, 52], ["interferon", "PROTEIN", 42, 52], ["type 1 interferon response", "PROBLEM", 35, 61]]], ["Moreover, lymphopenia with decreased numbers of CD4 + and CD8 + T cells is common during the acute phase.", [["CD4 + and CD8 + T cells", "ANATOMY", 48, 71], ["lymphopenia", "DISEASE", 10, 21], ["CD4", "GENE_OR_GENE_PRODUCT", 48, 51], ["CD8", "GENE_OR_GENE_PRODUCT", 58, 61], ["CD4 + and CD8 + T cells", "CELL_TYPE", 48, 71], ["lymphopenia", "PROBLEM", 10, 21], ["CD4", "TEST", 48, 51], ["CD8 + T cells", "PROBLEM", 58, 71], ["lymphopenia", "OBSERVATION", 10, 21], ["decreased", "OBSERVATION_MODIFIER", 27, 36], ["numbers", "OBSERVATION_MODIFIER", 37, 44], ["T cells", "OBSERVATION", 64, 71]]], ["Convalescent patients have IgG-class neutralizing antibodies that recognize amino acids 441-700 of the spike protein (S protein) as the major epitope.IntroductionSevere acute respiratory syndrome (SARS), a newly emerged infectious disease, appeared in Guangdong Province, People's Republic of China, in November 2002 and spread globally to infect more than 8,000 people with over 770 deaths in a few months [1] .", [["amino acids", "CHEMICAL", 76, 87], ["acute respiratory syndrome", "DISEASE", 169, 195], ["SARS", "DISEASE", 197, 201], ["infectious disease", "DISEASE", 220, 238], ["deaths", "DISEASE", 384, 390], ["amino acids", "CHEMICAL", 76, 87], ["patients", "ORGANISM", 13, 21], ["amino acids", "AMINO_ACID", 76, 87], ["S protein", "GENE_OR_GENE_PRODUCT", 118, 127], ["people", "ORGANISM", 363, 369], ["IgG-class neutralizing antibodies", "PROTEIN", 27, 60], ["amino acids 441-700", "PROTEIN", 76, 95], ["spike protein", "PROTEIN", 103, 116], ["S protein", "PROTEIN", 118, 127], ["patients", "SPECIES", 13, 21], ["people", "SPECIES", 363, 369], ["IgG", "TEST", 27, 30], ["neutralizing antibodies", "TEST", 37, 60], ["amino acids", "TEST", 76, 87], ["the spike protein", "TEST", 99, 116], ["the major epitope", "PROBLEM", 132, 149], ["acute respiratory syndrome", "PROBLEM", 169, 195], ["SARS", "PROBLEM", 197, 201], ["a newly emerged infectious disease", "PROBLEM", 204, 238], ["acute", "OBSERVATION_MODIFIER", 169, 174], ["respiratory syndrome", "OBSERVATION", 175, 195], ["infectious", "OBSERVATION", 220, 230]]], ["The etiological agent was identified as a coronavirus (CoV) [2 ,3,4] and the genome sequence established it as a novel member of the family [5, 6] .", [["CoV", "ORGANISM", 55, 58], ["a coronavirus (CoV)", "PROBLEM", 40, 59]]], ["This novel CoV has satisfied Koch's postulates for causation, including the consistent detection of the virus and an antibody response to the virus in patients with SARS [2 ] and the reproduction of the disease in non-human primates after experimental inoculation [7, 8] .IntroductionPrevious reviews have addressed issues on the clinical presentation [9] , aetiology and laboratory diagnosis [10], epidemiology and viral genetics [11] , vaccines and therapeutics [1, 12] , and public health [13] .", [["SARS", "DISEASE", 165, 169], ["CoV", "ORGANISM", 11, 14], ["patients", "ORGANISM", 151, 159], ["non-human", "ORGANISM", 214, 223], ["primates", "ORGANISM", 224, 232], ["patients", "SPECIES", 151, 159], ["the virus", "PROBLEM", 100, 109], ["an antibody response", "PROBLEM", 114, 134], ["the virus", "PROBLEM", 138, 147], ["SARS", "PROBLEM", 165, 169], ["the disease", "PROBLEM", 199, 210], ["vaccines", "TREATMENT", 438, 446], ["disease", "OBSERVATION", 203, 210]]], ["Here we will focus on the host-pathogen interaction, including tropism of SARS-CoV, viral entry into host cells, innate and adaptive immune responses, and host genetic susceptibility to SARS.Tropism of SARS-CoVTropism from animals to humans Markets selling live poultry and fish for human consumption ('wet markets') are common place across South-East Asia, and they service the cultural demand for freshly killed meat and poultry products.", [["cells", "ANATOMY", 106, 111], ["meat", "ANATOMY", 414, 418], ["SARS", "DISEASE", 74, 78], ["SARS", "DISEASE", 186, 190], ["SARS", "DISEASE", 202, 206], ["SARS-CoV", "ORGANISM", 74, 82], ["host cells", "CELL", 101, 111], ["humans", "ORGANISM", 234, 240], ["fish", "ORGANISM_SUBDIVISION", 274, 278], ["human", "ORGANISM", 283, 288], ["meat", "ORGANISM_SUBDIVISION", 414, 418], ["host cells", "CELL_TYPE", 101, 111], ["humans", "SPECIES", 234, 240], ["human", "SPECIES", 283, 288], ["SARS-CoV", "SPECIES", 74, 82], ["humans", "SPECIES", 234, 240], ["human", "SPECIES", 283, 288], ["SARS", "PROBLEM", 74, 78], ["CoV", "PROBLEM", 79, 82], ["SARS", "PROBLEM", 202, 206], ["CoVTropism", "TREATMENT", 207, 217], ["poultry products", "TREATMENT", 423, 439], ["SARS", "OBSERVATION", 202, 206]]], ["In parts of southern China, Guangdong province in particular, increasing affluence has resulted in large markets, which house a diversity of animals, including reptile and mammalian species, to serve the restaurant trade for exotic foods.Tropism of SARS-CoVSARS-CoV-like viruses were isolated from Himalayan palm civets found in a wildlife wet market in Guangdong (Figure 1a; [14 ] ).", [["SARS-CoVSARS-CoV-like viruses", "ORGANISM", 249, 278], ["SARS-CoVSARS-CoV", "SPECIES", 249, 265], ["Himalayan palm civets", "SPECIES", 298, 319], ["SARS-CoVSARS", "TEST", 249, 261], ["CoV", "PROBLEM", 262, 265], ["like viruses", "PROBLEM", 266, 278], ["large", "OBSERVATION_MODIFIER", 99, 104], ["markets", "OBSERVATION", 105, 112], ["viruses", "OBSERVATION", 271, 278]]], ["Serological evidence of infection in raccoon dogs and humans in the same market was also found, supporting a zoonotic origin of SARS.", [["infection", "DISEASE", 24, 33], ["SARS", "DISEASE", 128, 132], ["raccoon dogs", "ORGANISM", 37, 49], ["humans", "ORGANISM", 54, 60], ["dogs", "SPECIES", 45, 49], ["humans", "SPECIES", 54, 60], ["humans", "SPECIES", 54, 60], ["infection in raccoon dogs", "PROBLEM", 24, 49], ["evidence of", "UNCERTAINTY", 12, 23], ["infection", "OBSERVATION", 24, 33], ["raccoon dogs", "OBSERVATION", 37, 49]]], ["The animal CoV isolates were different from the human SARS-CoV in that they had an additional 29-nucleotide sequence not found in most human isolates.", [["SARS", "DISEASE", 54, 58], ["CoV", "ORGANISM", 11, 14], ["human", "ORGANISM", 48, 53], ["SARS-CoV", "ORGANISM", 54, 62], ["human", "ORGANISM", 135, 140], ["29-nucleotide sequence", "DNA", 94, 116], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 135, 140], ["human SARS-CoV", "SPECIES", 48, 62], ["human", "SPECIES", 135, 140], ["The animal CoV isolates", "TEST", 0, 23], ["the human SARS", "TEST", 44, 58], ["nucleotide sequence", "TEST", 97, 116]]], ["This additional 29-nucleotide sequence in the animal CoV results in merging opening reading frames (ORF) 10 and 11 into a new ORF encoding a putative protein of 122 amino acids of unknown biological significance.", [["amino acids", "CHEMICAL", 165, 176], ["amino acids", "CHEMICAL", 165, 176], ["animal CoV", "ORGANISM", 46, 56], ["amino acids", "AMINO_ACID", 165, 176], ["29-nucleotide sequence", "DNA", 16, 38], ["opening reading frames", "DNA", 76, 98], ["ORF", "DNA", 100, 103], ["ORF", "DNA", 126, 129], ["nucleotide sequence", "TEST", 19, 38], ["a new ORF", "PROBLEM", 120, 129], ["a putative protein", "TEST", 139, 157], ["amino acids", "TEST", 165, 176]]], ["How the precursor animal CoV adapted itself in humans to achieve efficient man-to-man transmission remains unknown, but molecular epidemiological study of SARS-CoV has suggested that several introductions of the animal CoV into humans had occurred, with only the one with the 29-nucleotide deletion associated with the subsequent outbreak in Hong Kong spreading globally [15] .", [["SARS", "DISEASE", 155, 159], ["animal CoV", "ORGANISM", 18, 28], ["humans", "ORGANISM", 47, 53], ["SARS-CoV", "ORGANISM", 155, 163], ["animal CoV", "ORGANISM", 212, 222], ["humans", "ORGANISM", 228, 234], ["29-nucleotide deletion", "DNA", 276, 298], ["humans", "SPECIES", 47, 53], ["man", "SPECIES", 75, 78], ["man", "SPECIES", 82, 85], ["humans", "SPECIES", 228, 234], ["humans", "SPECIES", 47, 53], ["SARS-CoV", "SPECIES", 155, 163], ["humans", "SPECIES", 228, 234], ["molecular epidemiological study", "TEST", 120, 151], ["SARS", "PROBLEM", 155, 159], ["nucleotide deletion", "PROBLEM", 279, 298]]], ["Phylogenetic analysis of the few human cases in Guangdong in December 2003 revealed that this SARS-CoV is much closer to the palm civet CoV than to any human SARS-CoV detected in the epidemic in early 2003 [16] .", [["SARS", "DISEASE", 94, 98], ["SARS-CoV", "DISEASE", 158, 166], ["human", "ORGANISM", 33, 38], ["SARS-CoV", "ORGANISM", 94, 102], ["palm civet CoV", "ORGANISM", 125, 139], ["human", "ORGANISM", 152, 157], ["SARS-CoV", "ORGANISM", 158, 166], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 33, 38], ["SARS-CoV", "SPECIES", 94, 102], ["palm civet CoV", "SPECIES", 125, 139], ["human SARS-CoV", "SPECIES", 152, 166], ["Phylogenetic analysis", "TEST", 0, 21], ["this SARS", "PROBLEM", 89, 98], ["any human SARS", "PROBLEM", 148, 162], ["CoV", "PROBLEM", 163, 166], ["few", "OBSERVATION_MODIFIER", 29, 32]]], ["This again strengthens the contention that SARS is of zoonotic origin, and that the wet markets serve as a continuing source of SARS-CoV crossing species -from animals to humans [17] .Tropism of SARS-CoVTropism from lung to multiple organs SARS is largely a viral pneumonia and the lung pathology shows diffuse alveolar damage with multinucleate giantcells and a prominent increase of macrophages in the alveoli and lung interstitium [18] .", [["lung", "ANATOMY", 216, 220], ["organs", "ANATOMY", 233, 239], ["lung", "ANATOMY", 282, 286], ["alveolar", "ANATOMY", 311, 319], ["multinucleate giantcells", "ANATOMY", 332, 356], ["macrophages", "ANATOMY", 385, 396], ["alveoli", "ANATOMY", 404, 411], ["lung interstitium", "ANATOMY", 416, 433], ["SARS", "DISEASE", 43, 47], ["SARS", "DISEASE", 195, 199], ["SARS", "DISEASE", 240, 244], ["pneumonia", "DISEASE", 264, 273], ["alveolar damage", "DISEASE", 311, 326], ["SARS-CoV", "ORGANISM", 128, 136], ["humans", "ORGANISM", 171, 177], ["lung", "ORGAN", 216, 220], ["organs", "ORGAN", 233, 239], ["lung", "ORGAN", 282, 286], ["alveolar", "TISSUE", 311, 319], ["macrophages", "CELL", 385, 396], ["alveoli", "MULTI-TISSUE_STRUCTURE", 404, 411], ["lung interstitium", "MULTI-TISSUE_STRUCTURE", 416, 433], ["macrophages", "CELL_TYPE", 385, 396], ["humans", "SPECIES", 171, 177], ["SARS-CoV", "SPECIES", 128, 136], ["humans", "SPECIES", 171, 177], ["SARS", "PROBLEM", 43, 47], ["the wet markets", "PROBLEM", 80, 95], ["SARS", "PROBLEM", 128, 132], ["CoV crossing species", "PROBLEM", 133, 153], ["SARS", "PROBLEM", 195, 199], ["CoVTropism", "PROBLEM", 200, 210], ["multiple organs SARS", "PROBLEM", 224, 244], ["a viral pneumonia", "PROBLEM", 256, 273], ["the lung pathology", "TEST", 278, 296], ["diffuse alveolar damage", "PROBLEM", 303, 326], ["multinucleate giantcells", "PROBLEM", 332, 356], ["a prominent increase of macrophages in the alveoli and lung interstitium", "PROBLEM", 361, 433], ["SARS", "OBSERVATION", 195, 199], ["lung", "ANATOMY", 216, 220], ["viral", "OBSERVATION_MODIFIER", 258, 263], ["pneumonia", "OBSERVATION", 264, 273], ["lung", "ANATOMY", 282, 286], ["diffuse", "OBSERVATION_MODIFIER", 303, 310], ["alveolar damage", "OBSERVATION", 311, 326], ["multinucleate giantcells", "OBSERVATION", 332, 356], ["prominent", "OBSERVATION_MODIFIER", 363, 372], ["increase", "OBSERVATION_MODIFIER", 373, 381], ["macrophages", "OBSERVATION", 385, 396], ["alveoli", "ANATOMY_MODIFIER", 404, 411], ["lung", "ANATOMY", 416, 420], ["interstitium", "ANATOMY_MODIFIER", 421, 433]]], ["Apart from the pneumonia, 38% and 73% of patients, respectively, had diarrhoea in two separate cohorts of patients [19, 20] .", [["pneumonia", "DISEASE", 15, 24], ["diarrhoea", "DISEASE", 69, 78], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 106, 114], ["the pneumonia", "PROBLEM", 11, 24], ["diarrhoea", "PROBLEM", 69, 78], ["pneumonia", "OBSERVATION", 15, 24]]], ["Despite the active viral replication in the enterocytes, there is minimal disruption of the intestinal architecture or cellular infiltrate, and the mechanism of pathogenesis of the diarrhoea remains unclear.", [["enterocytes", "ANATOMY", 44, 55], ["intestinal", "ANATOMY", 92, 102], ["cellular", "ANATOMY", 119, 127], ["diarrhoea", "DISEASE", 181, 190], ["enterocytes", "MULTI-TISSUE_STRUCTURE", 44, 55], ["intestinal architecture", "MULTI-TISSUE_STRUCTURE", 92, 115], ["cellular", "CELL", 119, 127], ["the active viral replication in the enterocytes", "PROBLEM", 8, 55], ["minimal disruption of the intestinal architecture", "PROBLEM", 66, 115], ["cellular infiltrate", "PROBLEM", 119, 138], ["the diarrhoea", "PROBLEM", 177, 190], ["active", "OBSERVATION_MODIFIER", 12, 18], ["viral replication", "OBSERVATION", 19, 36], ["enterocytes", "ANATOMY", 44, 55], ["minimal", "OBSERVATION_MODIFIER", 66, 73], ["disruption", "OBSERVATION", 74, 84], ["intestinal architecture", "ANATOMY", 92, 115], ["cellular", "OBSERVATION_MODIFIER", 119, 127], ["infiltrate", "OBSERVATION", 128, 138], ["diarrhoea", "OBSERVATION", 181, 190]]], ["The absence of intestinal inflammation and destruction has been speculated to be a result of upregulation of potent immunosuppressive cytokine TGF-b [21] and an antiapoptotic host cellular response in the intestinal epithelial cells respectively [1].Tropism of SARS-CoVUsing immunohistochemistry and in situ hybridization to examine organs from four SARS patients who died, SARS-CoV was found not only in the lung and intestine, but also in liver, distal convoluted renal tubules, sweat glands, parathyroid, pituitary, pancreas, adrenal gland and cerebrum [22] .", [["intestinal", "ANATOMY", 15, 25], ["cellular", "ANATOMY", 180, 188], ["intestinal epithelial cells", "ANATOMY", 205, 232], ["organs", "ANATOMY", 333, 339], ["lung", "ANATOMY", 409, 413], ["intestine", "ANATOMY", 418, 427], ["liver", "ANATOMY", 441, 446], ["distal convoluted renal tubules", "ANATOMY", 448, 479], ["sweat glands", "ANATOMY", 481, 493], ["parathyroid", "ANATOMY", 495, 506], ["pituitary", "ANATOMY", 508, 517], ["pancreas", "ANATOMY", 519, 527], ["adrenal gland", "ANATOMY", 529, 542], ["cerebrum", "ANATOMY", 547, 555], ["intestinal inflammation", "DISEASE", 15, 38], ["SARS", "DISEASE", 261, 265], ["SARS", "DISEASE", 350, 354], ["SARS", "DISEASE", 374, 378], ["intestinal", "ORGAN", 15, 25], ["TGF-b [21]", "GENE_OR_GENE_PRODUCT", 143, 153], ["cellular", "CELL", 180, 188], ["intestinal epithelial cells", "CELL", 205, 232], ["organs", "ORGAN", 333, 339], ["patients", "ORGANISM", 355, 363], ["SARS-CoV", "ORGANISM", 374, 382], ["lung", "ORGAN", 409, 413], ["intestine", "ORGAN", 418, 427], ["liver", "ORGAN", 441, 446], ["convoluted renal tubules", "TISSUE", 455, 479], ["sweat glands", "ORGAN", 481, 493], ["parathyroid", "ORGAN", 495, 506], ["pituitary", "ORGAN", 508, 517], ["pancreas", "ORGAN", 519, 527], ["adrenal gland", "MULTI-TISSUE_STRUCTURE", 529, 542], ["cerebrum", "ORGAN", 547, 555], ["TGF", "PROTEIN", 143, 146], ["intestinal epithelial cells", "CELL_TYPE", 205, 232], ["patients", "SPECIES", 355, 363], ["SARS-CoV", "SPECIES", 374, 382], ["intestinal inflammation", "PROBLEM", 15, 38], ["destruction", "PROBLEM", 43, 54], ["potent immunosuppressive cytokine TGF", "TREATMENT", 109, 146], ["SARS", "PROBLEM", 261, 265], ["CoVUsing immunohistochemistry", "TEST", 266, 295], ["SARS", "PROBLEM", 374, 378], ["CoV", "PROBLEM", 379, 382], ["distal convoluted renal tubules, sweat glands, parathyroid, pituitary, pancreas, adrenal gland and cerebrum", "PROBLEM", 448, 555], ["intestinal", "ANATOMY", 15, 25], ["inflammation", "OBSERVATION", 26, 38], ["destruction", "OBSERVATION", 43, 54], ["antiapoptotic host", "OBSERVATION", 161, 179], ["cellular response", "OBSERVATION", 180, 197], ["intestinal epithelial cells", "OBSERVATION", 205, 232], ["lung", "ANATOMY", 409, 413], ["intestine", "ANATOMY", 418, 427], ["liver", "ANATOMY", 441, 446], ["distal", "ANATOMY_MODIFIER", 448, 454], ["convoluted", "ANATOMY_MODIFIER", 455, 465], ["renal", "ANATOMY", 466, 471], ["tubules", "ANATOMY_MODIFIER", 472, 479], ["sweat glands", "ANATOMY", 481, 493], ["parathyroid", "ANATOMY", 495, 506], ["pituitary", "ANATOMY", 508, 517], ["pancreas", "ANATOMY", 519, 527], ["adrenal gland", "ANATOMY", 529, 542], ["cerebrum", "ANATOMY", 547, 555]]], ["Using reverse-transcriptase polymerase chain reaction to examine 19 fatal SARS cases, SARS-CoV RNA was detected in lung, small and large bowels, lymph nodes, spleen, liver, heart, kidney and skeletal muscle, in descending order of viral load per gram of tissue [23] .", [["lung", "ANATOMY", 115, 119], ["small", "ANATOMY", 121, 126], ["bowels", "ANATOMY", 137, 143], ["lymph nodes", "ANATOMY", 145, 156], ["spleen", "ANATOMY", 158, 164], ["liver", "ANATOMY", 166, 171], ["heart", "ANATOMY", 173, 178], ["kidney", "ANATOMY", 180, 186], ["skeletal muscle", "ANATOMY", 191, 206], ["tissue", "ANATOMY", 254, 260], ["SARS", "DISEASE", 74, 78], ["SARS", "DISEASE", 86, 90], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 86, 94], ["lung", "ORGAN", 115, 119], ["bowels", "ORGAN", 137, 143], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 145, 156], ["spleen", "ORGAN", 158, 164], ["liver", "ORGAN", 166, 171], ["heart", "ORGAN", 173, 178], ["kidney", "ORGAN", 180, 186], ["skeletal muscle", "TISSUE", 191, 206], ["tissue", "TISSUE", 254, 260], ["reverse-transcriptase", "PROTEIN", 6, 27], ["SARS-CoV RNA", "RNA", 86, 98], ["SARS-CoV", "SPECIES", 86, 94], ["reverse-transcriptase polymerase chain reaction", "TREATMENT", 6, 53], ["19 fatal SARS cases", "PROBLEM", 65, 84], ["SARS", "PROBLEM", 86, 90], ["CoV RNA", "TEST", 91, 98], ["small and large bowels, lymph nodes, spleen, liver, heart, kidney and skeletal muscle", "PROBLEM", 121, 206], ["lung", "ANATOMY", 115, 119], ["small", "OBSERVATION_MODIFIER", 121, 126], ["large", "ANATOMY_MODIFIER", 131, 136], ["bowels", "ANATOMY", 137, 143], ["lymph nodes", "OBSERVATION", 145, 156], ["spleen", "ANATOMY", 158, 164], ["liver", "ANATOMY", 166, 171], ["heart", "ANATOMY", 173, 178], ["kidney", "ANATOMY", 180, 186], ["skeletal muscle", "ANATOMY", 191, 206], ["descending", "ANATOMY_MODIFIER", 211, 221], ["viral load", "OBSERVATION", 231, 241]]], ["These findings suggest that SARS is a systemic disease with widespread extrapulmonary dissemination, resulting in viral shedding in respiratory secretions, stools, urine and possibly even in sweat [22, 23] .", [["extrapulmonary", "ANATOMY", 71, 85], ["respiratory secretions", "ANATOMY", 132, 154], ["stools", "ANATOMY", 156, 162], ["urine", "ANATOMY", 164, 169], ["sweat", "ANATOMY", 191, 196], ["SARS", "DISEASE", 28, 32], ["stools", "ORGANISM_SUBSTANCE", 156, 162], ["urine", "ORGANISM_SUBSTANCE", 164, 169], ["sweat", "ORGANISM_SUBDIVISION", 191, 196], ["SARS", "PROBLEM", 28, 32], ["a systemic disease", "PROBLEM", 36, 54], ["widespread extrapulmonary dissemination", "PROBLEM", 60, 99], ["viral shedding in respiratory secretions", "PROBLEM", 114, 154], ["systemic", "OBSERVATION_MODIFIER", 38, 46], ["disease", "OBSERVATION", 47, 54], ["widespread", "OBSERVATION_MODIFIER", 60, 70], ["extrapulmonary", "ANATOMY", 71, 85], ["dissemination", "OBSERVATION", 86, 99], ["viral", "OBSERVATION_MODIFIER", 114, 119], ["respiratory secretions", "OBSERVATION", 132, 154]]], ["The organ damage in patients with SARS could be due to both local viral replication and the immunopathologic consequences of the host response, hence it is important to delineate what human cells the SARS-CoV can infect and replicate in as well as the subsequent host immune response.Cellular receptors for SARS-CoV to gain entry into target cellsCoronaviruses, including SARS-CoV, associate with cellular receptors to mediate infection of their target cells via the surface spike protein (S protein; Figure 1 ; [24] ).", [["organ", "ANATOMY", 4, 9], ["cells", "ANATOMY", 190, 195], ["Cellular", "ANATOMY", 284, 292], ["cells", "ANATOMY", 342, 347], ["cellular", "ANATOMY", 397, 405], ["cells", "ANATOMY", 453, 458], ["surface", "ANATOMY", 467, 474], ["organ damage", "DISEASE", 4, 16], ["SARS", "DISEASE", 34, 38], ["infection", "DISEASE", 427, 436], ["organ", "ORGAN", 4, 9], ["patients", "ORGANISM", 20, 28], ["human", "ORGANISM", 184, 189], ["cells", "CELL", 190, 195], ["SARS-CoV", "ORGANISM", 200, 208], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 307, 315], ["cells", "CELL", 342, 347], ["SARS-CoV", "ORGANISM", 372, 380], ["cellular", "CELL", 397, 405], ["cells", "CELL", 453, 458], ["surface spike protein", "GENE_OR_GENE_PRODUCT", 467, 488], ["human cells", "CELL_TYPE", 184, 195], ["Cellular receptors", "PROTEIN", 284, 302], ["target cells", "CELL_TYPE", 335, 347], ["cellular receptors", "PROTEIN", 397, 415], ["target cells", "CELL_TYPE", 446, 458], ["surface spike protein", "PROTEIN", 467, 488], ["S protein", "PROTEIN", 490, 499], ["patients", "SPECIES", 20, 28], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 184, 189], ["SARS-CoV", "SPECIES", 200, 208], ["SARS-CoV", "SPECIES", 307, 315], ["SARS-CoV", "SPECIES", 372, 380], ["The organ damage", "PROBLEM", 0, 16], ["SARS", "PROBLEM", 34, 38], ["both local viral replication", "PROBLEM", 55, 83], ["Cellular receptors", "TEST", 284, 302], ["SARS", "PROBLEM", 307, 311], ["Coronaviruses", "PROBLEM", 347, 360], ["SARS", "PROBLEM", 372, 376], ["CoV", "PROBLEM", 377, 380], ["cellular receptors", "PROBLEM", 397, 415], ["mediate infection", "PROBLEM", 419, 436], ["the surface spike protein", "TEST", 463, 488], ["S protein", "TEST", 490, 499], ["Figure", "TEST", 501, 507], ["organ", "ANATOMY", 4, 9], ["damage", "OBSERVATION", 10, 16], ["cells", "OBSERVATION", 342, 347], ["infection", "OBSERVATION", 427, 436]]], ["A metallopeptidase, angiotensin-converting enzyme 2 (ACE2), has been shown to be a functional receptor for SARS-CoV [25 ,26] , with amino acids 270-510 of the SARS-CoV S protein critical for interaction with ACE2 [27] .Cellular receptors for SARS-CoV to gain entry into target cellsThe SARS-CoV S protein has striking similarities with class I fusion proteins, which include the influenza virus haemagglutinin and paramyxovirus F protein.", [["Cellular", "ANATOMY", 219, 227], ["cells", "ANATOMY", 277, 282], ["angiotensin", "CHEMICAL", 20, 31], ["SARS", "DISEASE", 107, 111], ["amino acids 270-510", "CHEMICAL", 132, 151], ["amino acids", "CHEMICAL", 132, 143], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 20, 51], ["ACE2", "GENE_OR_GENE_PRODUCT", 53, 57], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 107, 115], ["amino acids", "AMINO_ACID", 132, 143], ["ACE2", "GENE_OR_GENE_PRODUCT", 208, 212], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 242, 250], ["cells", "CELL", 277, 282], ["class I fusion proteins", "GENE_OR_GENE_PRODUCT", 336, 359], ["influenza virus haemagglutinin", "ORGANISM", 379, 409], ["paramyxovirus F protein", "GENE_OR_GENE_PRODUCT", 414, 437], ["metallopeptidase", "PROTEIN", 2, 18], ["angiotensin-converting enzyme 2", "PROTEIN", 20, 51], ["ACE2", "PROTEIN", 53, 57], ["SARS-CoV S protein", "PROTEIN", 159, 177], ["ACE2", "PROTEIN", 208, 212], ["Cellular receptors", "PROTEIN", 219, 237], ["target cells", "CELL_TYPE", 270, 282], ["SARS-CoV S protein", "PROTEIN", 286, 304], ["class I fusion proteins", "PROTEIN", 336, 359], ["influenza virus haemagglutinin", "PROTEIN", 379, 409], ["paramyxovirus F protein", "PROTEIN", 414, 437], ["influenza virus haemagglutinin", "SPECIES", 379, 409], ["SARS-CoV", "SPECIES", 107, 115], ["SARS-CoV", "SPECIES", 242, 250], ["A metallopeptidase", "TREATMENT", 0, 18], ["angiotensin", "TEST", 20, 31], ["converting enzyme", "TEST", 32, 49], ["SARS", "PROBLEM", 107, 111], ["CoV", "TEST", 112, 115], ["amino acids", "TEST", 132, 143], ["the SARS", "TEST", 155, 163], ["CoV S protein", "TEST", 164, 177], ["ACE2", "TEST", 208, 212], ["Cellular receptors", "TEST", 219, 237], ["SARS", "PROBLEM", 242, 246], ["The SARS-CoV S protein", "TEST", 282, 304], ["class I fusion proteins", "PROBLEM", 336, 359], ["the influenza virus haemagglutinin", "TREATMENT", 375, 409], ["paramyxovirus F protein", "TREATMENT", 414, 437], ["cells", "OBSERVATION", 277, 282]]], ["The Nterminal half of the S protein (S1) contains the receptorbinding domain whereas the C-terminal half (S2) is the membrane-anchored membrane-fusion subunit, which contains two heptad repeat regions (HR1 and HR2) [28, 29] .", [["membrane", "ANATOMY", 117, 125], ["membrane", "ANATOMY", 135, 143], ["C", "CHEMICAL", 89, 90], ["S protein", "GENE_OR_GENE_PRODUCT", 26, 35], ["S1", "GENE_OR_GENE_PRODUCT", 37, 39], ["S2", "GENE_OR_GENE_PRODUCT", 106, 108], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["membrane", "CELLULAR_COMPONENT", 135, 143], ["Nterminal half", "PROTEIN", 4, 18], ["S protein", "PROTEIN", 26, 35], ["S1", "PROTEIN", 37, 39], ["receptorbinding domain", "PROTEIN", 54, 76], ["C-terminal half", "PROTEIN", 89, 104], ["S2", "PROTEIN", 106, 108], ["membrane-anchored membrane-fusion subunit", "PROTEIN", 117, 158], ["heptad repeat regions", "PROTEIN", 179, 200], ["HR1", "PROTEIN", 202, 205], ["HR2", "PROTEIN", 210, 213], ["the receptorbinding domain", "PROBLEM", 50, 76], ["the membrane-anchored membrane-fusion subunit", "TREATMENT", 113, 158], ["Nterminal", "OBSERVATION_MODIFIER", 4, 13], ["half", "OBSERVATION_MODIFIER", 14, 18], ["terminal", "ANATOMY_MODIFIER", 91, 99], ["half", "ANATOMY_MODIFIER", 100, 104], ["S2", "ANATOMY_MODIFIER", 106, 108], ["fusion subunit", "OBSERVATION", 144, 158]]], ["After binding to ACE2 on the target cells, the transmembrane S protein changes conformation by association between the HR1 and HR2 regions to form a sixhelix oligomeric complex, leading to fusion between the viral and target-cell membranes.", [["cells", "ANATOMY", 36, 41], ["transmembrane", "ANATOMY", 47, 60], ["cell membranes", "ANATOMY", 225, 239], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["cells", "CELL", 36, 41], ["transmembrane", "CELLULAR_COMPONENT", 47, 60], ["HR1", "GENE_OR_GENE_PRODUCT", 119, 122], ["HR2", "GENE_OR_GENE_PRODUCT", 127, 130], ["cell membranes", "CELLULAR_COMPONENT", 225, 239], ["ACE2", "PROTEIN", 17, 21], ["target cells", "CELL_TYPE", 29, 41], ["transmembrane S protein", "PROTEIN", 47, 70], ["HR1", "PROTEIN", 119, 122], ["HR2 regions", "PROTEIN", 127, 138], ["sixhelix oligomeric complex", "PROTEIN", 149, 176], ["the transmembrane S protein changes conformation", "PROBLEM", 43, 91], ["the HR1 and HR2 regions", "PROBLEM", 115, 138], ["a sixhelix oligomeric complex", "PROBLEM", 147, 176], ["fusion", "TREATMENT", 189, 195], ["viral", "OBSERVATION", 208, 213], ["cell membranes", "OBSERVATION", 225, 239]]], ["The X-ray crystallographic structure of the SARS-CoV S2 fusion-protein core provides a framework for the design of entry inhibitors [30] .Cellular receptors for SARS-CoV to gain entry into target cellsApart from direct membrane fusion at the target cell surface, SARS-CoV might gain cell entry via pH-dependent endocytosis, which is also mediated by the S protein [31] .", [["Cellular", "ANATOMY", 138, 146], ["cells", "ANATOMY", 196, 201], ["membrane", "ANATOMY", 219, 227], ["cell surface", "ANATOMY", 249, 261], ["cell", "ANATOMY", 283, 287], ["SARS-CoV S2", "GENE_OR_GENE_PRODUCT", 44, 55], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 161, 169], ["cells", "CELL", 196, 201], ["membrane", "CELLULAR_COMPONENT", 219, 227], ["cell surface", "CELLULAR_COMPONENT", 249, 261], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 263, 271], ["cell", "CELL", 283, 287], ["SARS-CoV S2 fusion-protein core", "PROTEIN", 44, 75], ["Cellular receptors", "PROTEIN", 138, 156], ["target cells", "CELL_TYPE", 189, 201], ["S protein", "PROTEIN", 354, 363], ["SARS-CoV", "SPECIES", 44, 52], ["SARS-CoV", "SPECIES", 161, 169], ["SARS-CoV", "SPECIES", 263, 271], ["The X-ray", "TEST", 0, 9], ["the SARS", "TEST", 40, 48], ["CoV S2 fusion", "TREATMENT", 49, 62], ["entry inhibitors", "TREATMENT", 115, 131], ["Cellular receptors", "TEST", 138, 156], ["SARS", "PROBLEM", 161, 165], ["direct membrane fusion", "TREATMENT", 212, 234], ["SARS", "PROBLEM", 263, 267], ["pH-dependent endocytosis", "PROBLEM", 298, 322], ["the S protein", "TEST", 350, 363], ["cells", "OBSERVATION", 196, 201], ["membrane fusion", "OBSERVATION", 219, 234], ["target cell", "OBSERVATION", 242, 253], ["surface", "OBSERVATION_MODIFIER", 254, 261], ["dependent", "OBSERVATION_MODIFIER", 301, 310], ["endocytosis", "OBSERVATION", 311, 322]]], ["Furthermore the glycosylated S protein has been shown to bind to the C-type lectin DC-SIGN (DC-specific ICAM-3-grabbing non-integrin) expressed on the DCs; these cells then mediate SARS-CoV infection in trans of cells that express human ACE2, but the DC-SIGN does not initiate SARS-CoV entry into the DCs.", [["DC", "ANATOMY", 92, 94], ["DCs", "ANATOMY", 151, 154], ["cells", "ANATOMY", 162, 167], ["cells", "ANATOMY", 212, 217], ["DC", "ANATOMY", 251, 253], ["DCs", "ANATOMY", 301, 304], ["infection", "DISEASE", 190, 199], ["glycosylated S protein", "GENE_OR_GENE_PRODUCT", 16, 38], ["C-type lectin DC-SIGN", "GENE_OR_GENE_PRODUCT", 69, 90], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 104, 110], ["non-integrin", "GENE_OR_GENE_PRODUCT", 120, 132], ["DCs", "CELL", 151, 154], ["cells", "CELL", 162, 167], ["SARS-CoV", "ORGANISM", 181, 189], ["cells", "CELL", 212, 217], ["human", "ORGANISM", 231, 236], ["ACE2", "GENE_OR_GENE_PRODUCT", 237, 241], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 277, 285], ["DCs", "CELL", 301, 304], ["glycosylated S protein", "PROTEIN", 16, 38], ["C-type lectin DC-SIGN (DC-specific ICAM-3", "PROTEIN", 69, 110], ["grabbing non-integrin", "PROTEIN", 111, 132], ["DCs", "CELL_TYPE", 151, 154], ["human ACE2", "PROTEIN", 231, 241], ["DC", "CELL_TYPE", 251, 253], ["SIGN", "PROTEIN", 254, 258], ["DCs", "CELL_TYPE", 301, 304], ["human", "SPECIES", 231, 236], ["SARS-CoV", "SPECIES", 181, 189], ["human", "SPECIES", 231, 236], ["the glycosylated S protein", "TREATMENT", 12, 38], ["ICAM", "TEST", 104, 108], ["these cells", "PROBLEM", 156, 167], ["SARS", "PROBLEM", 181, 185], ["CoV infection", "PROBLEM", 186, 199], ["CoV", "OBSERVATION_MODIFIER", 186, 189], ["infection", "OBSERVATION", 190, 199]]], ["Human CD209L (also known as liver/lymph-nodespecific [L]-SIGN), which is 77% identical to human DC-SIGN, can also bind to S protein and mediate virus entry [32 ] but its role in initiating productive virus replication remains unclear.Cellular receptors for SARS-CoV to gain entry into target cellsACE2 protein is reportedly present in type 1 and type 2 pneumocytes, enterocytes of all parts of the small intestine, the brush border of the proximal tubular cells of the kidney, as well as the endothelial cells of small and large arteries and veins of all tissues studied and arterial smooth muscle cells [33] .", [["liver", "ANATOMY", 28, 33], ["DC", "ANATOMY", 96, 98], ["Cellular", "ANATOMY", 234, 242], ["type 1", "ANATOMY", 335, 341], ["type 2 pneumocytes", "ANATOMY", 346, 364], ["enterocytes", "ANATOMY", 366, 377], ["small intestine", "ANATOMY", 398, 413], ["brush border", "ANATOMY", 419, 431], ["proximal tubular cells", "ANATOMY", 439, 461], ["kidney", "ANATOMY", 469, 475], ["endothelial cells", "ANATOMY", 492, 509], ["arteries", "ANATOMY", 529, 537], ["veins", "ANATOMY", 542, 547], ["tissues", "ANATOMY", 555, 562], ["arterial smooth muscle cells", "ANATOMY", 575, 603], ["Human", "ORGANISM", 0, 5], ["CD209L", "GENE_OR_GENE_PRODUCT", 6, 12], ["liver", "ORGAN", 28, 33], ["-SIGN", "GENE_OR_GENE_PRODUCT", 56, 61], ["human", "ORGANISM", 90, 95], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 96, 103], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 257, 265], ["cellsACE2", "GENE_OR_GENE_PRODUCT", 292, 301], ["type 2 pneumocytes", "CELL", 346, 364], ["enterocytes", "MULTI-TISSUE_STRUCTURE", 366, 377], ["small intestine", "ORGAN", 398, 413], ["brush border", "MULTI-TISSUE_STRUCTURE", 419, 431], ["tubular cells", "CELL", 448, 461], ["kidney", "ORGAN", 469, 475], ["endothelial cells", "CELL", 492, 509], ["large arteries", "MULTI-TISSUE_STRUCTURE", 523, 537], ["veins", "MULTI-TISSUE_STRUCTURE", 542, 547], ["tissues", "TISSUE", 555, 562], ["arterial smooth muscle cells", "CELL", 575, 603], ["Human CD209L", "PROTEIN", 0, 12], ["SIGN", "PROTEIN", 57, 61], ["human DC", "CELL_TYPE", 90, 98], ["SIGN", "PROTEIN", 99, 103], ["S protein", "PROTEIN", 122, 131], ["Cellular receptors", "PROTEIN", 234, 252], ["SARS-CoV", "PROTEIN", 257, 265], ["cellsACE2 protein", "PROTEIN", 292, 309], ["type 1 and type 2 pneumocytes", "CELL_TYPE", 335, 364], ["proximal tubular cells", "CELL_TYPE", 439, 461], ["endothelial cells", "CELL_TYPE", 492, 509], ["arterial smooth muscle cells", "CELL_TYPE", 575, 603], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 90, 95], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 90, 95], ["SARS-CoV", "SPECIES", 257, 265], ["Human CD209L", "TEST", 0, 12], ["liver/lymph", "TEST", 28, 39], ["S protein", "TEST", 122, 131], ["mediate virus entry", "PROBLEM", 136, 155], ["productive virus replication", "TREATMENT", 189, 217], ["Cellular receptors", "TEST", 234, 252], ["SARS", "PROBLEM", 257, 261], ["target cellsACE2 protein", "TEST", 285, 309], ["type 2 pneumocytes", "PROBLEM", 346, 364], ["the endothelial cells", "TEST", 488, 509], ["arterial smooth muscle cells", "TEST", 575, 603], ["liver", "ANATOMY", 28, 33], ["lymph", "ANATOMY", 34, 39], ["productive virus", "OBSERVATION", 189, 205], ["pneumocytes", "OBSERVATION", 353, 364], ["enterocytes", "ANATOMY_MODIFIER", 366, 377], ["all parts", "ANATOMY_MODIFIER", 381, 390], ["small intestine", "ANATOMY", 398, 413], ["brush", "ANATOMY_MODIFIER", 419, 424], ["border", "ANATOMY_MODIFIER", 425, 431], ["proximal", "ANATOMY_MODIFIER", 439, 447], ["tubular cells", "OBSERVATION", 448, 461], ["kidney", "ANATOMY", 469, 475], ["endothelial cells", "OBSERVATION", 492, 509], ["small", "OBSERVATION_MODIFIER", 513, 518], ["large arteries", "ANATOMY", 523, 537], ["veins", "ANATOMY", 542, 547], ["all tissues", "ANATOMY", 551, 562], ["arterial", "ANATOMY_MODIFIER", 575, 583], ["smooth muscle cells", "OBSERVATION", 584, 603]]], ["This localization of ACE2 explains the tissue tropism of SARS-CoV for the lung, small intestine and kidney; however, notable discrepancies include virus replication in colonic epithelium, which has no ACE2, and no virus infection in endothelial cells, which have ACE2.", [["tissue", "ANATOMY", 39, 45], ["lung", "ANATOMY", 74, 78], ["small intestine", "ANATOMY", 80, 95], ["kidney", "ANATOMY", 100, 106], ["colonic epithelium", "ANATOMY", 168, 186], ["endothelial cells", "ANATOMY", 233, 250], ["SARS", "DISEASE", 57, 61], ["infection", "DISEASE", 220, 229], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["tissue", "TISSUE", 39, 45], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 57, 65], ["lung", "ORGAN", 74, 78], ["small intestine", "ORGAN", 80, 95], ["kidney", "ORGAN", 100, 106], ["colonic epithelium", "TISSUE", 168, 186], ["ACE2", "GENE_OR_GENE_PRODUCT", 201, 205], ["endothelial cells", "CELL", 233, 250], ["ACE2", "GENE_OR_GENE_PRODUCT", 263, 267], ["ACE2", "PROTEIN", 21, 25], ["ACE2", "PROTEIN", 201, 205], ["endothelial cells", "CELL_TYPE", 233, 250], ["ACE2", "PROTEIN", 263, 267], ["SARS-CoV", "SPECIES", 57, 65], ["the tissue tropism", "TEST", 35, 53], ["SARS", "PROBLEM", 57, 61], ["the lung, small intestine and kidney", "PROBLEM", 70, 106], ["notable discrepancies", "PROBLEM", 117, 138], ["virus replication in colonic epithelium", "PROBLEM", 147, 186], ["ACE2", "PROBLEM", 201, 205], ["virus infection in endothelial cells", "PROBLEM", 214, 250], ["ACE2", "TEST", 263, 267], ["lung", "ANATOMY", 74, 78], ["small intestine", "ANATOMY", 80, 95], ["kidney", "ANATOMY", 100, 106], ["virus replication", "OBSERVATION", 147, 164], ["colonic epithelium", "ANATOMY", 168, 186], ["no", "UNCERTAINTY", 198, 200], ["no", "UNCERTAINTY", 211, 213], ["virus", "OBSERVATION_MODIFIER", 214, 219], ["infection", "OBSERVATION", 220, 229], ["endothelial cells", "OBSERVATION", 233, 250]]], ["Other receptors or co-receptors such as L-SIGN may explain such discrepancies.", [["L-SIGN", "GENE_OR_GENE_PRODUCT", 40, 46], ["L-SIGN", "PROTEIN", 40, 46], ["such discrepancies", "PROBLEM", 59, 77]]], ["Since only the basal layer of the non-keratinized squamous epithelium of the upper respiratory tract expresses ACE2, undamaged epithelium of the nasopharynx is not likely to support SARS-CoV replication.", [["basal layer", "ANATOMY", 15, 26], ["squamous epithelium", "ANATOMY", 50, 69], ["upper respiratory tract", "ANATOMY", 77, 100], ["epithelium", "ANATOMY", 127, 137], ["nasopharynx", "ANATOMY", 145, 156], ["SARS", "DISEASE", 182, 186], ["basal layer", "CELLULAR_COMPONENT", 15, 26], ["squamous epithelium", "TISSUE", 50, 69], ["upper respiratory", "ORGANISM_SUBDIVISION", 77, 94], ["tract", "ORGAN", 95, 100], ["ACE2", "GENE_OR_GENE_PRODUCT", 111, 115], ["undamaged epithelium", "TISSUE", 117, 137], ["nasopharynx", "ORGAN", 145, 156], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 182, 190], ["ACE2", "PROTEIN", 111, 115], ["SARS-CoV", "SPECIES", 182, 190], ["SARS", "PROBLEM", 182, 186], ["CoV replication", "TREATMENT", 187, 202], ["basal", "ANATOMY_MODIFIER", 15, 20], ["layer", "ANATOMY_MODIFIER", 21, 26], ["non-keratinized", "OBSERVATION_MODIFIER", 34, 49], ["squamous epithelium", "OBSERVATION", 50, 69], ["upper", "ANATOMY_MODIFIER", 77, 82], ["respiratory tract", "ANATOMY", 83, 100], ["epithelium", "ANATOMY_MODIFIER", 127, 137], ["nasopharynx", "ANATOMY", 145, 156], ["not likely to", "UNCERTAINTY", 160, 173]]], ["This raises the interesting possibility that a preceding infection by another pathogen may expose the basal layer and facilitate SARS-CoV infecting the damaged upper respiratory tract before spreading to involve the lung.Cellular receptors for SARS-CoV to gain entry into target cellsFurthermore, this may partly explain the longer incubation period (mean 4.6 days, variance 15.9 days) of SARS [34] and the gradual increase of viral load in nasopharyngeal aspirates of SARS patients in the first 10 days of illness [19] , as compared with influenza, since SARS-CoV may take a longer time than influenza virus does to establish infection in the respiratory tract.The innate immune response to SARS-CoVThe gradual increase in viral load in the first 10 days of SARS also suggests that the virus may be evading some of the innate immune defences of the host.", [["basal layer", "ANATOMY", 102, 113], ["upper respiratory tract", "ANATOMY", 160, 183], ["lung", "ANATOMY", 216, 220], ["Cellular", "ANATOMY", 221, 229], ["nasopharyngeal aspirates", "ANATOMY", 441, 465], ["respiratory tract", "ANATOMY", 644, 661], ["infection", "DISEASE", 57, 66], ["SARS", "DISEASE", 389, 393], ["SARS", "DISEASE", 469, 473], ["illness", "DISEASE", 507, 514], ["influenza", "DISEASE", 539, 548], ["SARS", "DISEASE", 556, 560], ["infection", "DISEASE", 627, 636], ["SARS", "DISEASE", 692, 696], ["SARS", "DISEASE", 759, 763], ["SARS-CoV", "ORGANISM", 129, 137], ["upper respiratory", "ORGANISM_SUBDIVISION", 160, 177], ["tract", "ORGANISM_SUBDIVISION", 178, 183], ["lung", "ORGAN", 216, 220], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 244, 252], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 441, 465], ["patients", "ORGANISM", 474, 482], ["SARS-CoV", "ORGANISM", 556, 564], ["influenza virus", "ORGANISM", 593, 608], ["respiratory tract", "ORGANISM_SUBDIVISION", 644, 661], ["Cellular receptors", "PROTEIN", 221, 239], ["patients", "SPECIES", 474, 482], ["SARS-CoV", "SPECIES", 129, 137], ["SARS-CoV", "SPECIES", 244, 252], ["SARS-CoV", "SPECIES", 556, 564], ["influenza virus", "SPECIES", 593, 608], ["a preceding infection", "PROBLEM", 45, 66], ["another pathogen", "PROBLEM", 70, 86], ["SARS", "PROBLEM", 129, 133], ["the damaged upper respiratory tract", "PROBLEM", 148, 183], ["Cellular receptors", "TEST", 221, 239], ["SARS", "PROBLEM", 244, 248], ["SARS", "PROBLEM", 389, 393], ["viral load", "PROBLEM", 427, 437], ["nasopharyngeal aspirates", "PROBLEM", 441, 465], ["SARS", "PROBLEM", 469, 473], ["illness", "PROBLEM", 507, 514], ["influenza", "PROBLEM", 539, 548], ["SARS", "PROBLEM", 556, 560], ["CoV", "PROBLEM", 561, 564], ["influenza virus", "PROBLEM", 593, 608], ["infection in the respiratory tract", "PROBLEM", 627, 661], ["SARS", "PROBLEM", 692, 696], ["CoVThe gradual increase", "PROBLEM", 697, 720], ["viral load", "PROBLEM", 724, 734], ["SARS", "PROBLEM", 759, 763], ["the virus", "PROBLEM", 783, 792], ["raises the interesting possibility", "UNCERTAINTY", 5, 39], ["infection", "OBSERVATION", 57, 66], ["basal", "ANATOMY_MODIFIER", 102, 107], ["layer", "OBSERVATION_MODIFIER", 108, 113], ["SARS", "OBSERVATION", 129, 133], ["upper", "ANATOMY_MODIFIER", 160, 165], ["respiratory tract", "ANATOMY", 166, 183], ["lung", "ANATOMY", 216, 220], ["gradual", "OBSERVATION_MODIFIER", 407, 414], ["increase", "OBSERVATION_MODIFIER", 415, 423], ["viral load", "OBSERVATION", 427, 437], ["nasopharyngeal", "ANATOMY", 441, 455], ["aspirates", "OBSERVATION", 456, 465], ["infection", "OBSERVATION", 627, 636], ["respiratory tract", "ANATOMY", 644, 661], ["gradual", "OBSERVATION_MODIFIER", 704, 711], ["increase", "OBSERVATION_MODIFIER", 712, 720], ["viral load", "OBSERVATION", 724, 734], ["virus", "OBSERVATION", 787, 792]]], ["It may be relevant that SARS-CoV infection of human macrophages in vitro leads to initiation of viral replication and viral protein synthesis without a detectable type-1 interferon response [35] .", [["macrophages", "ANATOMY", 52, 63], ["SARS", "DISEASE", 24, 28], ["infection", "DISEASE", 33, 42], ["SARS-CoV", "ORGANISM", 24, 32], ["human", "ORGANISM", 46, 51], ["macrophages", "CELL", 52, 63], ["type-1 interferon", "GENE_OR_GENE_PRODUCT", 163, 180], ["human macrophages", "CELL_TYPE", 46, 63], ["viral protein", "PROTEIN", 118, 131], ["interferon", "PROTEIN", 170, 180], ["human", "SPECIES", 46, 51], ["SARS-CoV", "SPECIES", 24, 32], ["human", "SPECIES", 46, 51], ["SARS", "PROBLEM", 24, 28], ["CoV infection of human macrophages", "PROBLEM", 29, 63], ["viral replication", "TREATMENT", 96, 113], ["viral protein synthesis", "PROBLEM", 118, 141], ["may be", "UNCERTAINTY", 3, 9], ["viral replication", "OBSERVATION", 96, 113]]], ["Furthermore, in marked contrast to patients with influenza, there was a lack of expression of mRNA for the type-1 interferons, interferon a and b in peripheral blood mononuclear cells of patients with SARS [36] .", [["peripheral blood mononuclear cells", "ANATOMY", 149, 183], ["influenza", "DISEASE", 49, 58], ["SARS", "DISEASE", 201, 205], ["patients", "ORGANISM", 35, 43], ["type-1 interferons", "GENE_OR_GENE_PRODUCT", 107, 125], ["interferon a", "GENE_OR_GENE_PRODUCT", 127, 139], ["b", "GENE_OR_GENE_PRODUCT", 144, 145], ["peripheral blood mononuclear cells", "CELL", 149, 183], ["patients", "ORGANISM", 187, 195], ["mRNA", "RNA", 94, 98], ["type-1 interferons", "PROTEIN", 107, 125], ["interferon a and b", "PROTEIN", 127, 145], ["peripheral blood mononuclear cells", "CELL_TYPE", 149, 183], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 187, 195], ["influenza", "PROBLEM", 49, 58], ["the type-1 interferons", "TREATMENT", 103, 125], ["interferon a and b in peripheral blood mononuclear cells", "TREATMENT", 127, 183], ["SARS", "PROBLEM", 201, 205], ["peripheral", "ANATOMY_MODIFIER", 149, 159], ["blood", "ANATOMY", 160, 165], ["mononuclear cells", "OBSERVATION", 166, 183]]], ["On the other hand, other innate immune defences such as the collectins that can bind the glycosylated SARS-CoV S protein may play an important role in host defence.", [["collectins", "GENE_OR_GENE_PRODUCT", 60, 70], ["-CoV S protein", "GENE_OR_GENE_PRODUCT", 106, 120], ["collectins", "PROTEIN", 60, 70], ["glycosylated SARS-CoV S protein", "PROTEIN", 89, 120], ["the glycosylated SARS-CoV S protein", "TREATMENT", 85, 120]]], ["Such collectins include the lung surfactant proteins A and D as well as the mannose-binding lectin (MBL), which is present in serum.", [["lung", "ANATOMY", 28, 32], ["serum", "ANATOMY", 126, 131], ["mannose", "CHEMICAL", 76, 83], ["lung", "ORGAN", 28, 32], ["A", "GENE_OR_GENE_PRODUCT", 53, 54], ["D", "GENE_OR_GENE_PRODUCT", 59, 60], ["mannose-binding lectin", "GENE_OR_GENE_PRODUCT", 76, 98], ["MBL", "GENE_OR_GENE_PRODUCT", 100, 103], ["serum", "ORGANISM_SUBSTANCE", 126, 131], ["lung surfactant proteins", "PROTEIN", 28, 52], ["A", "PROTEIN", 53, 54], ["D", "PROTEIN", 59, 60], ["mannose-binding lectin", "PROTEIN", 76, 98], ["MBL", "PROTEIN", 100, 103], ["the mannose", "TEST", 72, 83], ["lung", "ANATOMY", 28, 32], ["surfactant", "OBSERVATION", 33, 43]]], ["In a case-control gene-association study of 569 Hong Kong Chinese SARS patients and 1188 healthy controls, low-MBL-producing genotypes have been shown to be associated with increased risk of SARS [37 ] .", [["SARS", "DISEASE", 66, 70], ["SARS", "DISEASE", 191, 195], ["patients", "ORGANISM", 71, 79], ["MBL", "GENE_OR_GENE_PRODUCT", 111, 114], ["MBL", "PROTEIN", 111, 114], ["patients", "SPECIES", 71, 79], ["low-MBL-producing genotypes", "PROBLEM", 107, 134], ["SARS", "PROBLEM", 191, 195]]], ["Moreover MBL can bind SARS-CoV, resulting in protective biological effects in a calcium-dependent and mannan-inhibitable fashion, suggesting the binding is through the carbohydrate-recognition domains of MBL with the S protein.", [["calcium", "CHEMICAL", 80, 87], ["calcium", "CHEMICAL", 80, 87], ["carbohydrate", "CHEMICAL", 168, 180], ["MBL", "GENE_OR_GENE_PRODUCT", 9, 12], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 22, 30], ["calcium", "SIMPLE_CHEMICAL", 80, 87], ["mannan", "SIMPLE_CHEMICAL", 102, 108], ["MBL", "GENE_OR_GENE_PRODUCT", 204, 207], ["MBL", "PROTEIN", 9, 12], ["carbohydrate-recognition domains", "PROTEIN", 168, 200], ["MBL", "PROTEIN", 204, 207], ["S protein", "PROTEIN", 217, 226], ["SARS-CoV", "SPECIES", 22, 30], ["CoV", "PROBLEM", 27, 30], ["a calcium", "TEST", 78, 87], ["the binding", "PROBLEM", 141, 152], ["MBL", "PROBLEM", 204, 207]]], ["Plasma proteomic analysis of four patients revealed active innate immune responses to SARS-CoV, including increased acute-phase proteins such as serum amyloid A, and C-type lectins such as MBL and tetranectin [38 ] .", [["serum", "ANATOMY", 145, 150], ["SARS", "DISEASE", 86, 90], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["patients", "ORGANISM", 34, 42], ["SARS-CoV", "ORGANISM", 86, 94], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["amyloid A", "SIMPLE_CHEMICAL", 151, 160], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 166, 180], ["MBL", "GENE_OR_GENE_PRODUCT", 189, 192], ["tetranectin [38 ]", "SIMPLE_CHEMICAL", 197, 214], ["acute-phase proteins", "PROTEIN", 116, 136], ["serum amyloid A", "PROTEIN", 145, 160], ["C-type lectins", "PROTEIN", 166, 180], ["MBL", "PROTEIN", 189, 192], ["patients", "SPECIES", 34, 42], ["SARS-CoV", "SPECIES", 86, 94], ["Plasma proteomic analysis", "TEST", 0, 25], ["active innate immune responses", "PROBLEM", 52, 82], ["SARS", "PROBLEM", 86, 90], ["CoV", "PROBLEM", 91, 94], ["increased acute-phase proteins", "PROBLEM", 106, 136], ["serum amyloid A", "TEST", 145, 160], ["C-type lectins", "PROBLEM", 166, 180], ["MBL", "TEST", 189, 192], ["tetranectin", "TREATMENT", 197, 208], ["active", "OBSERVATION_MODIFIER", 52, 58], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["acute", "OBSERVATION_MODIFIER", 116, 121]]], ["These observations suggest that MBL plays a protective role against development of SARS.The innate immune response to SARS-CoVHigh-density oligonucleotide array analysis of geneexpression changes in peripheral blood mononuclear cells from normal healthy donors inoculated in vitro with SARS-CoV showed an early activation of the innate immunity pathway in the first 12 h, including enhanced expression of CD14, Toll-like receptor 9 (TLR9), CC chemokines (CCL4, CCL20, CCL22, CCL25, CCL27) and their receptors (CCR4, CCR7), IL-8 and IL-17 [39] .", [["peripheral blood mononuclear cells", "ANATOMY", 199, 233], ["SARS", "DISEASE", 83, 87], ["MBL", "GENE_OR_GENE_PRODUCT", 32, 35], ["peripheral blood mononuclear cells", "CELL", 199, 233], ["donors", "ORGANISM", 254, 260], ["SARS-CoV", "ORGANISM", 286, 294], ["CD14", "GENE_OR_GENE_PRODUCT", 405, 409], ["Toll-like receptor 9", "GENE_OR_GENE_PRODUCT", 411, 431], ["TLR9", "GENE_OR_GENE_PRODUCT", 433, 437], ["CC chemokines", "GENE_OR_GENE_PRODUCT", 440, 453], ["CCL4", "GENE_OR_GENE_PRODUCT", 455, 459], ["CCL20", "GENE_OR_GENE_PRODUCT", 461, 466], ["CCL22", "GENE_OR_GENE_PRODUCT", 468, 473], ["CCL25", "GENE_OR_GENE_PRODUCT", 475, 480], ["CCL27", "GENE_OR_GENE_PRODUCT", 482, 487], ["CCR4", "GENE_OR_GENE_PRODUCT", 510, 514], ["CCR7", "GENE_OR_GENE_PRODUCT", 516, 520], ["IL-8", "GENE_OR_GENE_PRODUCT", 523, 527], ["IL-17", "GENE_OR_GENE_PRODUCT", 532, 537], ["MBL", "PROTEIN", 32, 35], ["peripheral blood mononuclear cells", "CELL_TYPE", 199, 233], ["CD14", "PROTEIN", 405, 409], ["Toll-like receptor 9", "PROTEIN", 411, 431], ["TLR9", "PROTEIN", 433, 437], ["CC chemokines", "PROTEIN", 440, 453], ["CCL4", "PROTEIN", 455, 459], ["CCL20", "PROTEIN", 461, 466], ["CCL22", "PROTEIN", 468, 473], ["CCL25", "PROTEIN", 475, 480], ["CCL27", "PROTEIN", 482, 487], ["CCR4", "PROTEIN", 510, 514], ["CCR7", "PROTEIN", 516, 520], ["IL", "PROTEIN", 532, 534], ["SARS-CoV", "SPECIES", 286, 294], ["SARS", "PROBLEM", 83, 87], ["SARS", "TEST", 118, 122], ["geneexpression changes", "PROBLEM", 173, 195], ["peripheral blood mononuclear cells", "PROBLEM", 199, 233], ["SARS-CoV", "TEST", 286, 294], ["CD14", "TEST", 405, 409], ["CC chemokines", "TEST", 440, 453], ["CCL20", "TEST", 461, 466], ["CCL22", "TEST", 468, 473], ["CCL25", "TEST", 475, 480], ["CCR7", "TEST", 516, 520], ["IL", "TEST", 523, 525], ["IL", "TEST", 532, 534], ["SARS", "OBSERVATION", 83, 87], ["peripheral", "ANATOMY_MODIFIER", 199, 209], ["blood", "ANATOMY", 210, 215], ["mononuclear cells", "OBSERVATION", 216, 233]]], ["This pattern indicates a rapid mobilization and increased trafficking of the monocyte-macrophage lineage into the lung very early on in the infection.", [["monocyte", "ANATOMY", 77, 85], ["macrophage lineage", "ANATOMY", 86, 104], ["lung", "ANATOMY", 114, 118], ["infection", "DISEASE", 140, 149], ["monocyte", "CELL", 77, 85], ["macrophage lineage", "CELL", 86, 104], ["lung", "ORGAN", 114, 118], ["monocyte-macrophage lineage", "CELL_TYPE", 77, 104], ["a rapid mobilization", "TREATMENT", 23, 43], ["the infection", "PROBLEM", 136, 149], ["rapid", "OBSERVATION_MODIFIER", 25, 30], ["mobilization", "OBSERVATION", 31, 43], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["trafficking", "OBSERVATION_MODIFIER", 58, 69], ["monocyte", "ANATOMY", 77, 85], ["macrophage lineage", "OBSERVATION", 86, 104], ["lung", "ANATOMY", 114, 118], ["very", "OBSERVATION_MODIFIER", 119, 123], ["early", "OBSERVATION_MODIFIER", 124, 129], ["infection", "OBSERVATION", 140, 149]]], ["In another study, the SARS-CoV was shown to induce chemokine release in lung epithelial cells and fibroblasts via amino acids 324-688 of the S protein [40] .", [["lung epithelial cells", "ANATOMY", 72, 93], ["fibroblasts", "ANATOMY", 98, 109], ["SARS", "DISEASE", 22, 26], ["amino acids 324-688", "CHEMICAL", 114, 133], ["amino acids", "CHEMICAL", 114, 125], ["SARS-CoV", "ORGANISM", 22, 30], ["lung epithelial cells", "CELL", 72, 93], ["fibroblasts", "CELL", 98, 109], ["amino acids", "AMINO_ACID", 114, 125], ["324-688", "AMINO_ACID", 126, 133], ["chemokine", "PROTEIN", 51, 60], ["lung epithelial cells", "CELL_TYPE", 72, 93], ["fibroblasts", "CELL_TYPE", 98, 109], ["S protein", "PROTEIN", 141, 150], ["SARS-CoV", "SPECIES", 22, 30], ["another study", "TEST", 3, 16], ["chemokine release in lung epithelial cells", "PROBLEM", 51, 93], ["amino acids", "TEST", 114, 125], ["the S protein", "TEST", 137, 150], ["lung", "ANATOMY", 72, 76], ["epithelial cells", "OBSERVATION", 77, 93]]], ["In addition to S protein, the structural N protein was found to activate the IL-8 promoter in lung cells as well.The innate immune response to SARS-CoVA model of SARS-CoV infection in C57BL/6 mice showed increased production of proinflammatory chemokines and their receptors in the lung but, surprisingly, Th1 cytokines (IL12 p70 and interferon-g) were not detectable and there was little pulmonary infiltration [41] .", [["lung cells", "ANATOMY", 94, 104], ["lung", "ANATOMY", 282, 286], ["pulmonary", "ANATOMY", 389, 398], ["SARS-CoV infection", "DISEASE", 162, 180], ["S protein", "GENE_OR_GENE_PRODUCT", 15, 24], ["IL-8", "GENE_OR_GENE_PRODUCT", 77, 81], ["lung cells", "CELL", 94, 104], ["SARS-CoV", "ORGANISM", 162, 170], ["C57BL/6 mice", "ORGANISM", 184, 196], ["lung", "ORGAN", 282, 286], ["IL12 p70", "GENE_OR_GENE_PRODUCT", 321, 329], ["interferon-g", "GENE_OR_GENE_PRODUCT", 334, 346], ["pulmonary", "ORGAN", 389, 398], ["S protein", "PROTEIN", 15, 24], ["structural N protein", "PROTEIN", 30, 50], ["IL-8 promoter", "DNA", 77, 90], ["lung cells", "CELL_TYPE", 94, 104], ["proinflammatory chemokines", "PROTEIN", 228, 254], ["Th1 cytokines", "PROTEIN", 306, 319], ["IL12", "PROTEIN", 321, 325], ["p70", "PROTEIN", 326, 329], ["interferon", "PROTEIN", 334, 344], ["mice", "SPECIES", 192, 196], ["SARS-CoV", "SPECIES", 162, 170], ["mice", "SPECIES", 192, 196], ["S protein", "TEST", 15, 24], ["the structural N protein", "TEST", 26, 50], ["the IL", "TEST", 73, 79], ["SARS", "TEST", 143, 147], ["SARS", "PROBLEM", 162, 166], ["CoV infection", "PROBLEM", 167, 180], ["increased production of proinflammatory chemokines", "PROBLEM", 204, 254], ["Th1 cytokines", "TEST", 306, 319], ["interferon", "TREATMENT", 334, 344], ["little pulmonary infiltration", "PROBLEM", 382, 411], ["lung", "ANATOMY", 94, 98], ["increased", "OBSERVATION_MODIFIER", 204, 213], ["production", "OBSERVATION_MODIFIER", 214, 224], ["proinflammatory chemokines", "OBSERVATION", 228, 254], ["lung", "ANATOMY", 282, 286], ["little", "OBSERVATION_MODIFIER", 382, 388], ["pulmonary", "ANATOMY", 389, 398], ["infiltration", "OBSERVATION", 399, 411]]], ["Moreover beige, CD1 \u00c0/\u00c0 , or RAG1 \u00c0/\u00c0 mice cleared SARS-CoV normally.", [["CD1 \u00c0/\u00c0", "ANATOMY", 16, 23], ["SARS", "DISEASE", 51, 55], ["CD1", "GENE_OR_GENE_PRODUCT", 16, 19], ["\u00c0", "GENE_OR_GENE_PRODUCT", 22, 23], ["RAG1", "GENE_OR_GENE_PRODUCT", 29, 33], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 51, 59], ["CD1", "PROTEIN", 16, 19], ["RAG1", "PROTEIN", 29, 33], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["SARS-CoV", "SPECIES", 51, 59], ["\u00c0", "TEST", 22, 23], ["RAG1", "TEST", 29, 33], ["SARS", "TEST", 51, 55], ["CoV", "OBSERVATION", 56, 59]]], ["These observations suggest proinflammatory chemokines may co-ordinate a highly effective innate antiviral response in the lung, and NK cells and adaptive cellular immunity are not required for viral clearance in this species [41] .", [["lung", "ANATOMY", 122, 126], ["NK cells", "ANATOMY", 132, 140], ["cellular", "ANATOMY", 154, 162], ["lung", "ORGAN", 122, 126], ["NK cells", "CELL", 132, 140], ["cellular", "CELL", 154, 162], ["proinflammatory chemokines", "PROTEIN", 27, 53], ["NK cells", "CELL_TYPE", 132, 140], ["proinflammatory chemokines", "PROBLEM", 27, 53], ["a highly effective innate antiviral response in the lung", "PROBLEM", 70, 126], ["NK cells", "PROBLEM", 132, 140], ["adaptive cellular immunity", "TREATMENT", 145, 171], ["viral clearance", "PROBLEM", 193, 208], ["proinflammatory chemokines", "OBSERVATION", 27, 53], ["antiviral response", "OBSERVATION", 96, 114], ["lung", "ANATOMY", 122, 126], ["NK cells", "OBSERVATION", 132, 140]]], ["On the other hand, Stat-1 appears to contribute to host defence in SARS-infected mice [42] .", [["SARS-infected", "DISEASE", 67, 80], ["Stat-1", "GENE_OR_GENE_PRODUCT", 19, 25], ["SARS", "ORGANISM", 67, 71], ["mice", "ORGANISM", 81, 85], ["Stat-1", "PROTEIN", 19, 25], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85], ["SARS", "PROBLEM", 67, 71]]], ["Deficiency of Stat-1 leads to resistance to the antiviral effects of interferons and this may be relevant to the above observation.The innate immune response to SARS-CoVCytokines and chemokines measurements in the plasma from SARS patients are difficult to interpret partly because of the many confounding factors during the disease course [43] .", [["plasma", "ANATOMY", 214, 220], ["SARS", "DISEASE", 226, 230], ["Stat-1", "GENE_OR_GENE_PRODUCT", 14, 20], ["interferons", "GENE_OR_GENE_PRODUCT", 69, 80], ["SARS-CoVCytokines", "GENE_OR_GENE_PRODUCT", 161, 178], ["plasma", "ORGANISM_SUBSTANCE", 214, 220], ["patients", "ORGANISM", 231, 239], ["Stat-1", "PROTEIN", 14, 20], ["interferons", "PROTEIN", 69, 80], ["chemokines", "PROTEIN", 183, 193], ["patients", "SPECIES", 231, 239], ["Deficiency of Stat", "PROBLEM", 0, 18], ["the antiviral effects of interferons", "TREATMENT", 44, 80], ["the above observation", "TEST", 109, 130], ["SARS", "TEST", 161, 165], ["CoVCytokines", "TEST", 166, 178], ["chemokines measurements", "TEST", 183, 206], ["antiviral", "OBSERVATION", 48, 57]]], ["Nevertheless both chemokines (IL-8, MCP-1 and IP-10) and inflammatory cytokines (IL-1, IL-6 and IL-12) were found to be elevated in patients.", [["IL-8", "GENE_OR_GENE_PRODUCT", 30, 34], ["MCP-1", "GENE_OR_GENE_PRODUCT", 36, 41], ["IP-10", "GENE_OR_GENE_PRODUCT", 46, 51], ["IL-1", "GENE_OR_GENE_PRODUCT", 81, 85], ["IL-6", "GENE_OR_GENE_PRODUCT", 87, 91], ["IL-12", "GENE_OR_GENE_PRODUCT", 96, 101], ["patients", "ORGANISM", 132, 140], ["chemokines", "PROTEIN", 18, 28], ["IL-8", "PROTEIN", 30, 34], ["MCP", "PROTEIN", 36, 39], ["IP-10", "PROTEIN", 46, 51], ["inflammatory cytokines", "PROTEIN", 57, 79], ["IL", "PROTEIN", 96, 98], ["patients", "SPECIES", 132, 140], ["both chemokines", "TEST", 13, 28], ["IL", "TEST", 30, 32], ["MCP", "TEST", 36, 39], ["IP", "TEST", 46, 48], ["inflammatory cytokines", "TEST", 57, 79], ["IL", "TEST", 81, 83], ["IL", "TEST", 87, 89], ["IL", "TEST", 96, 98], ["elevated", "OBSERVATION", 120, 128]]], ["Interestingly, prolonged disturbances of in vitro cytokine production in SARS patients have also been demonstrated [44] .The adaptive immune response to SARS-CoVLymphopenia with a rapid decrease in both CD4 and CD8 T cells is common during the acute phase of SARS and may be associated with an adverse outcome [45, 46] .", [["CD4", "ANATOMY", 203, 206], ["CD8 T cells", "ANATOMY", 211, 222], ["SARS", "DISEASE", 73, 77], ["SARS", "DISEASE", 153, 157], ["SARS", "DISEASE", 259, 263], ["patients", "ORGANISM", 78, 86], ["SARS-CoVLymphopenia", "ORGANISM", 153, 172], ["CD4", "GENE_OR_GENE_PRODUCT", 203, 206], ["CD8", "GENE_OR_GENE_PRODUCT", 211, 214], ["cytokine", "PROTEIN", 50, 58], ["CD4 and CD8 T cells", "CELL_TYPE", 203, 222], ["patients", "SPECIES", 78, 86], ["prolonged disturbances of in vitro cytokine production", "PROBLEM", 15, 69], ["SARS", "PROBLEM", 73, 77], ["SARS", "PROBLEM", 153, 157], ["CoVLymphopenia", "PROBLEM", 158, 172], ["a rapid decrease", "PROBLEM", 178, 194], ["CD8 T cells", "PROBLEM", 211, 222], ["SARS", "PROBLEM", 259, 263], ["an adverse outcome", "PROBLEM", 291, 309], ["prolonged", "OBSERVATION_MODIFIER", 15, 24], ["disturbances", "OBSERVATION", 25, 37], ["rapid", "OBSERVATION_MODIFIER", 180, 185], ["decrease", "OBSERVATION_MODIFIER", 186, 194], ["both CD4", "OBSERVATION", 198, 206]]], ["In recovering patients, rapid restoration of T cell subsets was seen [46] .", [["T cell", "ANATOMY", 45, 51], ["patients", "ORGANISM", 14, 22], ["T cell", "CELL", 45, 51], ["T cell subsets", "CELL_TYPE", 45, 59], ["patients", "SPECIES", 14, 22], ["T cell subsets", "PROBLEM", 45, 59], ["cell subsets", "OBSERVATION", 47, 59]]], ["The mechanism underlying the acute lymphopenia remains unclear, and may be related to induced apoptosis of uninfected lymphocytes as in measles, since the consistent absence of ACE2 in T and B lymphocytes and macrophages in all haematolymphoid organs suggests that direct viral infection may not be the cause [33] .", [["lymphocytes", "ANATOMY", 118, 129], ["T", "ANATOMY", 185, 186], ["B lymphocytes", "ANATOMY", 191, 204], ["macrophages", "ANATOMY", 209, 220], ["haematolymphoid organs", "ANATOMY", 228, 250], ["lymphopenia", "DISEASE", 35, 46], ["measles", "DISEASE", 136, 143], ["viral infection", "DISEASE", 272, 287], ["lymphocytes", "CELL", 118, 129], ["ACE2", "GENE_OR_GENE_PRODUCT", 177, 181], ["T", "CELL", 185, 186], ["B lymphocytes", "CELL", 191, 204], ["macrophages", "CELL", 209, 220], ["organs", "ORGAN", 244, 250], ["uninfected lymphocytes", "CELL_TYPE", 107, 129], ["ACE2", "PROTEIN", 177, 181], ["T and B lymphocytes", "CELL_TYPE", 185, 204], ["macrophages", "CELL_TYPE", 209, 220], ["the acute lymphopenia", "PROBLEM", 25, 46], ["uninfected lymphocytes", "PROBLEM", 107, 129], ["ACE2 in T and B lymphocytes", "TEST", 177, 204], ["macrophages in all haematolymphoid organs", "PROBLEM", 209, 250], ["direct viral infection", "PROBLEM", 265, 287], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["lymphopenia", "OBSERVATION", 35, 46], ["may be related to", "UNCERTAINTY", 68, 85], ["uninfected lymphocytes", "OBSERVATION", 107, 129], ["lymphocytes", "ANATOMY", 193, 204], ["macrophages", "OBSERVATION", 209, 220]]], ["Overexpression of 7a, a protein specifically encoded by SARS-CoV, can induce apoptosis via a caspase-dependent pathway and in cell lines derived from different organs, including lung, liver and kidney.", [["cell lines", "ANATOMY", 126, 136], ["organs", "ANATOMY", 160, 166], ["lung", "ANATOMY", 178, 182], ["liver", "ANATOMY", 184, 189], ["kidney", "ANATOMY", 194, 200], ["7a", "GENE_OR_GENE_PRODUCT", 18, 20], ["SARS-CoV", "ORGANISM", 56, 64], ["caspase", "GENE_OR_GENE_PRODUCT", 93, 100], ["cell lines", "CELL", 126, 136], ["organs", "ORGAN", 160, 166], ["lung", "ORGAN", 178, 182], ["liver", "ORGAN", 184, 189], ["kidney", "ORGAN", 194, 200], ["7a", "PROTEIN", 18, 20], ["caspase", "PROTEIN", 93, 100], ["cell lines", "CELL_LINE", 126, 136], ["SARS-CoV", "SPECIES", 56, 64], ["a protein", "TEST", 22, 31], ["apoptosis", "PROBLEM", 77, 86], ["a caspase-dependent pathway", "TREATMENT", 91, 118], ["lung, liver and kidney", "PROBLEM", 178, 200], ["cell lines", "OBSERVATION", 126, 136], ["lung", "ANATOMY", 178, 182], ["liver", "ANATOMY", 184, 189], ["kidney", "ANATOMY", 194, 200]]], ["Expression of 7a may be one of the underlying mechanisms for the pathogenesis of SARS-CoV infection [47] .The adaptive immune response to SARS-CoVDetection of serum IgG, IgM and IgA against SARS-CoV using immunofluorescent assays and by ELISA against nucleocapsid antigen occurs around the same time with most patients seroconverted by day 14 after onset of illness [48] .", [["serum", "ANATOMY", 159, 164], ["SARS-CoV infection", "DISEASE", 81, 99], ["SARS", "DISEASE", 138, 142], ["illness", "DISEASE", 358, 365], ["7a", "GENE_OR_GENE_PRODUCT", 14, 16], ["SARS-CoV", "ORGANISM", 81, 89], ["serum", "ORGANISM_SUBSTANCE", 159, 164], ["IgG", "GENE_OR_GENE_PRODUCT", 165, 168], ["IgM", "GENE_OR_GENE_PRODUCT", 170, 173], ["IgA", "GENE_OR_GENE_PRODUCT", 178, 181], ["SARS-CoV", "ORGANISM", 190, 198], ["nucleocapsid antigen", "GENE_OR_GENE_PRODUCT", 251, 271], ["patients", "ORGANISM", 310, 318], ["serum IgG", "PROTEIN", 159, 168], ["IgM", "PROTEIN", 170, 173], ["IgA", "PROTEIN", 178, 181], ["nucleocapsid antigen", "PROTEIN", 251, 271], ["patients", "SPECIES", 310, 318], ["SARS-CoV", "SPECIES", 81, 89], ["SARS-CoV", "SPECIES", 190, 198], ["SARS", "PROBLEM", 81, 85], ["CoV infection", "PROBLEM", 86, 99], ["SARS", "TEST", 138, 142], ["CoVDetection", "TEST", 143, 155], ["serum IgG", "TEST", 159, 168], ["IgM", "TEST", 170, 173], ["IgA", "TEST", 178, 181], ["SARS", "PROBLEM", 190, 194], ["immunofluorescent assays", "TEST", 205, 229], ["ELISA", "TEST", 237, 242], ["nucleocapsid antigen", "PROBLEM", 251, 271], ["illness", "PROBLEM", 358, 365]]], ["IgG can be detected as early as 4 days after the onset of illness.", [["illness", "DISEASE", 58, 65], ["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgG", "PROTEIN", 0, 3], ["IgG", "TEST", 0, 3], ["illness", "PROBLEM", 58, 65]]], ["The kinetics of neutralization antibodies nearly parallel those for IgG [48] and most of the neutralizing-antibody activity is attributed to IgG [49] .", [["neutralization antibodies", "PROTEIN", 16, 41], ["IgG", "PROTEIN", 68, 71], ["IgG", "PROTEIN", 141, 144], ["neutralization antibodies", "TREATMENT", 16, 41], ["IgG", "TEST", 68, 71], ["the neutralizing-antibody activity", "PROBLEM", 89, 123], ["IgG", "TEST", 141, 144]]], ["In a study of 623 SARS patients, the neutralizing-antibody levels peaked at 20-30 days and were sustained for over 150 days.", [["SARS", "DISEASE", 18, 22], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["a study", "TEST", 3, 10], ["the neutralizing-antibody levels", "TEST", 33, 65]]], ["These antibodies can neutralize the pseudotype particles bearing the S protein from different SARS-CoV strains, suggesting that these antibodies are broadly active and that the S protein is highly immunogenic [49] .", [["SARS-CoV strains", "ORGANISM", 94, 110], ["antibodies", "PROTEIN", 6, 16], ["S protein", "PROTEIN", 69, 78], ["antibodies", "PROTEIN", 134, 144], ["S protein", "PROTEIN", 177, 186], ["SARS-CoV", "SPECIES", 94, 102], ["These antibodies", "TREATMENT", 0, 16], ["the pseudotype particles", "PROBLEM", 32, 56], ["the S protein", "TEST", 65, 78], ["different SARS-CoV strains", "PROBLEM", 84, 110], ["these antibodies", "TEST", 128, 144], ["the S protein", "TEST", 173, 186]]], ["Indeed the S protein, among the other structural proteins, such as M, E or N, is the only significant SARS-CoV neutralization antigen and protective antigen [50] , with amino acids 441-700 as the major immunodominant epitope [51] .The adaptive immune response to SARS-CoVAn anti-S1 human monoclonal antibody 80R has been shown to have nanomolar affinity, to potently neutralize SARS-CoV infection and to inhibit syncytia formation through blocking of receptor binding [52] .", [["syncytia", "ANATOMY", 412, 420], ["amino acids 441-700", "CHEMICAL", 169, 188], ["80R", "CHEMICAL", 308, 311], ["SARS-CoV infection", "DISEASE", 378, 396], ["amino acids", "CHEMICAL", 169, 180], ["M, E", "GENE_OR_GENE_PRODUCT", 67, 71], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 102, 110], ["amino acids", "AMINO_ACID", 169, 180], ["441-700", "AMINO_ACID", 181, 188], ["human", "ORGANISM", 282, 287], ["SARS-CoV", "ORGANISM", 378, 386], ["syncytia", "CELL", 412, 420], ["S protein", "PROTEIN", 11, 20], ["structural proteins", "PROTEIN", 38, 57], ["M, E or N", "PROTEIN", 67, 76], ["SARS-CoV neutralization antigen", "PROTEIN", 102, 133], ["amino acids 441-700", "PROTEIN", 169, 188], ["SARS-CoVAn anti-S1 human monoclonal antibody 80R", "PROTEIN", 263, 311], ["human", "SPECIES", 282, 287], ["human", "SPECIES", 282, 287], ["SARS-CoV", "SPECIES", 378, 386], ["the S protein", "TEST", 7, 20], ["significant SARS", "PROBLEM", 90, 106], ["CoV neutralization antigen", "TEST", 107, 133], ["protective antigen", "TEST", 138, 156], ["amino acids", "TEST", 169, 180], ["SARS", "TEST", 263, 267], ["CoVAn", "TREATMENT", 268, 273], ["S1 human monoclonal antibody", "TEST", 279, 307], ["nanomolar affinity", "PROBLEM", 335, 353], ["SARS", "PROBLEM", 378, 382], ["CoV infection", "PROBLEM", 383, 396], ["syncytia formation", "PROBLEM", 412, 430], ["infection", "OBSERVATION", 387, 396]]], ["The 80R epitope is located within the N-terminal 261-672 amino acids of S protein and is not glycosylation-dependent.", [["amino acids", "CHEMICAL", 57, 68], ["amino acids", "CHEMICAL", 57, 68], ["80R", "GENE_OR_GENE_PRODUCT", 4, 7], ["amino acids", "AMINO_ACID", 57, 68], ["80R epitope", "PROTEIN", 4, 15], ["N-terminal 261-672 amino acids", "PROTEIN", 38, 68], ["S protein", "PROTEIN", 72, 81], ["amino acids", "TEST", 57, 68], ["S protein", "TEST", 72, 81], ["not", "UNCERTAINTY", 89, 92], ["glycosylation", "OBSERVATION", 93, 106], ["dependent", "OBSERVATION_MODIFIER", 107, 116]]], ["Immortalization of memory B cells from a SARS patient who recovered also enabled the isolation of human monoclonal antibodies with potent neutralization of SARS-CoV [53] .", [["memory B cells", "ANATOMY", 19, 33], ["SARS", "DISEASE", 41, 45], ["SARS", "DISEASE", 156, 160], ["memory B cells", "CELL", 19, 33], ["patient", "ORGANISM", 46, 53], ["human", "ORGANISM", 98, 103], ["SARS-CoV", "ORGANISM", 156, 164], ["memory B cells", "CELL_TYPE", 19, 33], ["human monoclonal antibodies", "PROTEIN", 98, 125], ["patient", "SPECIES", 46, 53], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["SARS-CoV", "SPECIES", 156, 164], ["memory B cells", "PROBLEM", 19, 33], ["human monoclonal antibodies", "TREATMENT", 98, 125], ["memory B cells", "OBSERVATION", 19, 33]]], ["These antibodies have two patterns of staining the S protein and neutralizing activity: some antibodies have high-avidity binding to spike transfectants and a neutralizing titer proportional to the degree of binding, whereas others have low-avidity binding in spite of efficient viral neutralization.", [["transfectants", "ANATOMY", 139, 152], ["transfectants", "CELL", 139, 152], ["antibodies", "PROTEIN", 6, 16], ["S protein", "PROTEIN", 51, 60], ["antibodies", "PROTEIN", 93, 103], ["These antibodies", "TEST", 0, 16], ["the S protein", "TEST", 47, 60], ["neutralizing activity", "PROBLEM", 65, 86], ["some antibodies", "PROBLEM", 88, 103], ["high-avidity binding", "PROBLEM", 109, 129], ["spike transfectants", "PROBLEM", 133, 152], ["a neutralizing titer", "PROBLEM", 157, 177], ["low-avidity binding", "PROBLEM", 237, 256], ["efficient viral neutralization", "PROBLEM", 269, 299], ["neutralizing activity", "OBSERVATION", 65, 86], ["viral neutralization", "OBSERVATION", 279, 299]]], ["The B cell memory repertoire of patients can be analyzed by this approach.The adaptive immune response to SARS-CoVIn a study of the functional effects of S-protein mutations in terms of their affinity for cellular receptor ACE2 and their sensitivity to antibody neutralization with viral pseudotypes, substantial functional changes were found in S-proteins derived from a case in late 2003 from Guangdong [S(GD03T0013)] [54] .", [["B cell", "ANATOMY", 4, 10], ["cellular", "ANATOMY", 205, 213], ["B cell", "CELL", 4, 10], ["patients", "ORGANISM", 32, 40], ["S-protein", "GENE_OR_GENE_PRODUCT", 154, 163], ["cellular", "CELL", 205, 213], ["ACE2", "GENE_OR_GENE_PRODUCT", 223, 227], ["cellular receptor", "PROTEIN", 205, 222], ["ACE2", "PROTEIN", 223, 227], ["S-proteins", "PROTEIN", 346, 356], ["patients", "SPECIES", 32, 40], ["SARS", "TEST", 106, 110], ["a study", "TEST", 117, 124], ["S-protein mutations", "PROBLEM", 154, 173], ["cellular receptor ACE2", "TREATMENT", 205, 227], ["antibody neutralization", "PROBLEM", 253, 276], ["viral pseudotypes", "PROBLEM", 282, 299], ["substantial functional changes", "PROBLEM", 301, 331], ["cell memory", "OBSERVATION", 6, 17]]], ["S(GD03T0013) depends much less on ACE2 as receptor for cell entry and is markedly resistant to antibody neutralization in comparison to eight strains transmitted during human outbreaks in early 2003.", [["cell", "ANATOMY", 55, 59], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["cell", "CELL", 55, 59], ["human", "ORGANISM", 169, 174], ["ACE2", "PROTEIN", 34, 38], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 169, 174], ["cell entry", "TEST", 55, 65], ["markedly resistant to antibody neutralization", "PROBLEM", 73, 118], ["markedly", "OBSERVATION_MODIFIER", 73, 81], ["resistant", "OBSERVATION_MODIFIER", 82, 91]]], ["Moreover, antibodies that neutralize most human S proteins can enhance entry mediated by the palm civet virus S proteins [54] .", [["human", "ORGANISM", 42, 47], ["antibodies", "PROTEIN", 10, 20], ["human S proteins", "PROTEIN", 42, 58], ["palm civet virus S proteins", "PROTEIN", 93, 120], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["palm civet virus", "SPECIES", 93, 109], ["antibodies", "TREATMENT", 10, 20]]], ["This underscores the need to address the evolving diversity of SARS-CoV for vaccine development; progress in experimental vaccine candidates for SARS has been previously reviewed [1] .", [["SARS", "DISEASE", 63, 67], ["SARS", "DISEASE", 145, 149], ["SARS-CoV", "ORGANISM", 63, 71], ["SARS-CoV", "SPECIES", 63, 71], ["SARS", "PROBLEM", 63, 67], ["vaccine development", "TREATMENT", 76, 95], ["experimental vaccine candidates", "TREATMENT", 109, 140], ["SARS", "PROBLEM", 145, 149]]], ["Insight into the mechanisms of antibodydependent enhancement will help to avoid complications during vaccine development.", [["antibodydependent enhancement", "PROBLEM", 31, 60], ["complications during vaccine development", "PROBLEM", 80, 120]]], ["The inability to maintain, using in vitro culture, the animal SARS-CoV precursor virus from palm civets makes it difficult to confirm whether these findings with pseudotyped virus are relevant to infectious SARS-CoV-like virus isolates.", [["SARS", "DISEASE", 62, 66], ["SARS-CoV-like virus", "DISEASE", 207, 226], ["animal", "ORGANISM", 55, 61], ["SARS-CoV precursor virus", "ORGANISM", 62, 86], ["palm", "ORGANISM_SUBDIVISION", 92, 96], ["pseudotyped virus", "ORGANISM", 162, 179], ["infectious", "ORGANISM", 196, 206], ["SARS-CoV-like virus", "ORGANISM", 207, 226], ["SARS-CoV", "SPECIES", 62, 70], ["pseudotyped virus", "SPECIES", 162, 179], ["SARS-CoV-like virus", "SPECIES", 207, 226], ["vitro culture", "TEST", 36, 49], ["the animal SARS", "TEST", 51, 66], ["CoV precursor virus", "PROBLEM", 67, 86], ["pseudotyped virus", "PROBLEM", 162, 179], ["infectious SARS", "PROBLEM", 196, 211], ["CoV", "TEST", 212, 215], ["like virus isolates", "PROBLEM", 216, 235]]], ["An alternative approach will be to address this question using techniques of SARS-CoV reverse genetics, which are now becoming available.The adaptive immune response to SARS-CoVThe cytotoxic T-cell response is the other major specific defence against viral infection.", [["T-cell", "ANATOMY", 191, 197], ["SARS", "DISEASE", 169, 173], ["viral infection", "DISEASE", 251, 266], ["T-cell", "CELL", 191, 197], ["SARS-CoV", "SPECIES", 77, 85], ["SARS", "TEST", 169, 173], ["viral infection", "PROBLEM", 251, 266], ["viral", "OBSERVATION_MODIFIER", 251, 256], ["infection", "OBSERVATION", 257, 266]]], ["Two HLA-A2-restricted T-cell epitopes capable of eliciting a CD8 T-cell response in patients who had recovered from SARS-CoV infection have been identified [55] .Host genetic susceptibility to SARSSince SARS is an entirely new disease, it offers a unique opportunity to study the genetics of innate immunity in SARS at population level.", [["T-cell", "ANATOMY", 22, 28], ["CD8 T-cell", "ANATOMY", 61, 71], ["SARS-CoV infection", "DISEASE", 116, 134], ["SARS", "DISEASE", 203, 207], ["SARS", "DISEASE", 311, 315], ["HLA-A2", "GENE_OR_GENE_PRODUCT", 4, 10], ["CD8", "GENE_OR_GENE_PRODUCT", 61, 64], ["patients", "ORGANISM", 84, 92], ["SARS-CoV", "ORGANISM", 116, 124], ["HLA-A2-restricted T-cell epitopes", "PROTEIN", 4, 37], ["patients", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 116, 124], ["Two HLA", "TEST", 0, 7], ["SARS", "PROBLEM", 116, 120], ["CoV infection", "PROBLEM", 121, 134], ["an entirely new disease", "PROBLEM", 211, 234], ["infection", "OBSERVATION", 125, 134], ["new", "OBSERVATION_MODIFIER", 223, 226], ["disease", "OBSERVATION", 227, 234]]], ["As mentioned above, individuals carrying the low-MBL-producing haplotype YB have an odds ratio (OR) of 1.5 in developing SARS [37 ] .", [["SARS", "DISEASE", 121, 125], ["MBL", "GENE_OR_GENE_PRODUCT", 49, 52], ["MBL", "PROTEIN", 49, 52], ["an odds ratio", "TEST", 81, 94]]], ["Association of HLA-B0703 (OR 4.08) and HLA-DR B1*0301 (OR 0.06) with the development of SARS.", [["SARS", "DISEASE", 88, 92], ["HLA-B0703", "GENE_OR_GENE_PRODUCT", 15, 24], ["HLA-DR B1", "GENE_OR_GENE_PRODUCT", 39, 48], ["HLA", "TEST", 15, 18], ["HLA", "TEST", 39, 42], ["SARS", "PROBLEM", 88, 92], ["SARS", "OBSERVATION", 88, 92]]], ["ACE2 gene polymorphisms were not associated with SARS susceptibility or outcome in a study of 168 patients and 328 healthy controls [58] .ConclusionsAlthough much has been learnt of the SARS in the two years since its discovery, aspects of the pathogenesis of the disease are still not fully understood.", [["SARS", "DISEASE", 49, 53], ["SARS", "DISEASE", 186, 190], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 98, 106], ["ACE2", "PROTEIN", 0, 4], ["patients", "SPECIES", 98, 106], ["ACE2 gene polymorphisms", "PROBLEM", 0, 23], ["SARS susceptibility", "PROBLEM", 49, 68], ["a study", "TEST", 83, 90], ["the SARS", "PROBLEM", 182, 190], ["the disease", "PROBLEM", 260, 271], ["disease", "OBSERVATION", 264, 271]]], ["This is because there are no further human cases of SARS and because there is no animal model that accurately reflects the human disease (reviewed in [1]).", [["SARS", "DISEASE", 52, 56], ["human", "ORGANISM", 37, 42], ["human", "ORGANISM", 123, 128], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 123, 128], ["SARS", "PROBLEM", 52, 56], ["the human disease", "PROBLEM", 119, 136], ["no", "UNCERTAINTY", 78, 80]]], ["Although the kinetics and protective role of the host antibody responses are better defined, the roles of the adaptive cell-mediated and the innate immune responses to SARS are still being unravelled.", [["cell", "ANATOMY", 119, 123], ["SARS", "DISEASE", 168, 172], ["cell", "CELL", 119, 123], ["the host antibody responses", "TEST", 45, 72], ["the innate immune responses", "TREATMENT", 137, 164], ["SARS", "PROBLEM", 168, 172]]], ["Empirical approaches to vaccine development are progressing rapidly but it remains important to better elucidate the mechanisms of disease pathogenesis so as to minimize the risk of being unpleasantly surprised by unintended consequences of vaccination.UpdateThe lack of a b-interferon response in cells infected with SARS CoV has now been documented in two other cell culture models in vitro; human primary myeloid-derived DCs [59 ] and the epithelial cell line 293 [60 ] .", [["cells", "ANATOMY", 298, 303], ["cell culture", "ANATOMY", 364, 376], ["primary myeloid-derived DCs", "ANATOMY", 400, 427], ["epithelial cell line 293", "ANATOMY", 442, 466], ["SARS", "DISEASE", 318, 322], ["b-interferon", "GENE_OR_GENE_PRODUCT", 273, 285], ["cells", "CELL", 298, 303], ["SARS CoV", "ORGANISM", 318, 326], ["cell culture", "CELL", 364, 376], ["human", "ORGANISM", 394, 399], ["myeloid-derived DCs", "CELL", 408, 427], ["epithelial cell line 293 [60", "CELL", 442, 470], ["b-interferon", "PROTEIN", 273, 285], ["human primary myeloid-derived DCs", "CELL_TYPE", 394, 427], ["epithelial cell line 293", "CELL_LINE", 442, 466], ["human", "SPECIES", 394, 399], ["SARS CoV", "SPECIES", 318, 326], ["human", "SPECIES", 394, 399], ["Empirical approaches", "TREATMENT", 0, 20], ["disease pathogenesis", "PROBLEM", 131, 151], ["vaccination", "TREATMENT", 241, 252], ["a b-interferon response in cells", "TREATMENT", 271, 303], ["SARS CoV", "PROBLEM", 318, 326], ["the epithelial cell line", "TEST", 438, 462], ["disease", "OBSERVATION", 131, 138], ["epithelial cell line", "OBSERVATION", 442, 462]]], ["SARS CoV induced the nuclear translocation of interferon regulatory factor (IRF)-3 in 293 cells but it was proposed that the lack of an interferon response is due to a block in subsequent dimerization and hyper-phosphorylation of IRF-3.", [["nuclear", "ANATOMY", 21, 28], ["293 cells", "ANATOMY", 86, 95], ["SARS", "DISEASE", 0, 4], ["SARS CoV", "ORGANISM", 0, 8], ["interferon regulatory factor (IRF)-3", "GENE_OR_GENE_PRODUCT", 46, 82], ["293 cells", "CELL", 86, 95], ["interferon", "GENE_OR_GENE_PRODUCT", 136, 146], ["IRF-3", "GENE_OR_GENE_PRODUCT", 230, 235], ["interferon regulatory factor (IRF)-3", "PROTEIN", 46, 82], ["293 cells", "CELL_LINE", 86, 95], ["interferon", "PROTEIN", 136, 146], ["IRF-3", "PROTEIN", 230, 235], ["SARS CoV", "SPECIES", 0, 8], ["SARS CoV", "PROBLEM", 0, 8], ["interferon regulatory factor", "PROBLEM", 46, 74], ["an interferon response", "PROBLEM", 133, 155], ["a block in subsequent dimerization", "PROBLEM", 166, 200], ["hyper-phosphorylation of IRF", "PROBLEM", 205, 233]]]], "75c1ea866cd9ae9a6d68f19de2815d86a05ad9bb": [["Schemes used in practice today (RSA [30] , DSA [14] , ECDSA [20] , and EdDSA [4] ) are based on assumptions regarding the computational difficulty of solving certain mathematical problems.", [["DSA", "TEST", 43, 46], ["ECDSA", "TEST", 54, 59]]], ["Due to Shor's algorithm [32] and its variants, some of these problems, such as integer factorisation and discrete logarithms, can be efficiently solved on a quantum computer.", [["Shor's algorithm", "TEST", 7, 23], ["these problems", "PROBLEM", 55, 69], ["integer factorisation and discrete logarithms", "PROBLEM", 79, 124]]], ["Since the National Institute of Standards and Technology (NIST) started a project (NIST-PQC 1 ) to evaluate and standardise postquantum cryptographic algorithms, many solutions have been proposed.", [["a project (NIST-PQC", "TREATMENT", 72, 91], ["standardise postquantum cryptographic algorithms", "TREATMENT", 112, 160], ["many solutions", "TREATMENT", 162, 176]]], ["Hash-based signature schemes (HBS) are among the most attractive candidates for quantum-safe Cortex-M4.", [["Cortex-M4", "CELL", 93, 102], ["signature schemes", "OBSERVATION", 11, 28]]], ["For this, we provide an adapted implementation of LMS for the Cortex-M4, which represents the first implementation to date to the best of the authors' knowledge.", [["Cortex-M4", "CELL", 62, 71]]], ["We evaluated suitable parameter sets for constrained devices from the NIST recommendation for stateful hash-based signature schemes [11] .", [["constrained devices", "TREATMENT", 41, 60]]], ["Furthermore, deviating from the RFC 8391 [18] , we slightly modified the reference implementation of XMSS, leading to noticeable speedups.", [["the RFC", "TEST", 28, 35], ["noticeable speedups", "PROBLEM", 118, 137]]], ["We provide a comparative performance and stack consumption analysis for several parameter sets of the instantiated versions of LMS and XMSS.", [["stack consumption analysis", "TEST", 41, 67], ["LMS", "ANATOMY", 127, 130]]], ["Further, we refer to the respective projects included in our implementation for licensing information.IntroductionOrganisation.", [["IntroductionOrganisation", "TREATMENT", 102, 126]]], ["3, we reflect the main structural differences between LMS and XMSS.", [["LMS", "CANCER", 54, 57], ["main", "OBSERVATION_MODIFIER", 18, 22]]], ["Finally, Appendix A contains further evaluated results.Hash-Based Signature SchemesWhile the security of other post-quantum cryptographic approaches like isogeny-based cryptography is still object to further research, hash-based schemes come with wellunderstood security assumptions.Hash-Based Signature SchemesBoth discussed stateful schemes in this work use a tree construction along with a variant of a one-time signature schemes (OTS).", [["quantum cryptographic approaches", "TREATMENT", 116, 148], ["a tree construction", "TREATMENT", 360, 379], ["Appendix", "ANATOMY", 9, 17], ["Signature SchemesWhile", "OBSERVATION", 66, 88], ["Signature SchemesBoth", "OBSERVATION", 294, 315]]], ["Unlike in stateless schemes, in LMS and XMSS the signer needs to keep track of which key pairs have already been used.", [["LMS", "CANCER", 32, 35], ["LMS", "CELL_LINE", 32, 35]]], ["One of the most prominent OTS is the Winternitz OTS (WOTS) scheme [27] , which is relatively efficient, has been used in practice and allows space/time trade-offs.", [["OTS", "CANCER", 26, 29], ["most prominent", "OBSERVATION_MODIFIER", 11, 25], ["OTS", "OBSERVATION_MODIFIER", 26, 29]]], ["LMS and XMSS use variants of WOTS.One-Time Signature SchemesWinternitz One-Time Signature Scheme.", [["LMS", "TEST", 0, 3], ["variants of WOTS", "PROBLEM", 17, 33]]], ["The main idea of all WOTS variants is to use a function chain to sign multiple bits starting from random inputs.", [["WOTS variants", "CELL_LINE", 21, 34], ["a function chain", "TREATMENT", 45, 61], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Increasing the value of the Winternitz parameter w will linearly shrink the size of a signature and increase exponentially the effort to perform key generation, signing and verification.", [["size", "OBSERVATION_MODIFIER", 76, 80], ["increase", "OBSERVATION_MODIFIER", 100, 108]]], ["Thus, the Winternitz parameter w enables space/time trade-offs.Algorithm 1: Key generation.Input : security parameter n, Winternitz paramater w.", [["the Winternitz parameter", "TREATMENT", 6, 30]]], ["Output: one-time key pair: (secret key X, public key Y ).Algorithm 1: Key generation.In order to protect against trivial attacks, a checksum C is computed and signed along with the message, as shown in Algorithm 2 in line 5-7.", [["Output", "TEST", 0, 6], ["trivial attacks", "PROBLEM", 113, 128], ["a checksum C", "TEST", 130, 142]]], ["A signature is computed by mapping the i-th chunk of M to one intermediary value of the respective function chain, by iterating the one-way function M i times.", [["chain", "OBSERVATION_MODIFIER", 108, 113]]], ["Output: signature \u03c3 .Algorithm 2: Signing.According to [13] , assuming f is a collision-resistant one-way function, this scheme is existentially unforgeable under chosen-message attacks.", [["signature \u03c3", "OBSERVATION", 8, 19]]], ["XMSS makes use of the variant WOTS + .", [["WOTS", "PROTEIN", 30, 34]]], ["WOTS + , proposed by H\u00fclsing [16] , introduced a slight modification of the chaining function by adding a random bitmask r i for each iteration, such that f 0 (x) = x, and f i (x) = f ( f i\u22121 (x) \u2295 r i ) for i > 0.", [["WOTS", "SIMPLE_CHEMICAL", 0, 4]]], ["Output: valid or invalid.Many-Time Signature SchemesMerkle trees enable the use of a single long-term public key created from a large set of OTS public keys.", [["Output", "TEST", 0, 6], ["a single long-term public", "TREATMENT", 83, 108], ["invalid", "OBSERVATION", 17, 24]]], ["In the following we will only briefly describe the methods for the construction of many-time schemes and refer to [26] and [18] for further details on the respective approach.Many-Time Signature SchemesMerkle Trees.", [["SchemesMerkle Trees", "OBSERVATION", 195, 214]]], ["The leaves of the tree are represented by the public keys X j of the OTS which are derived from the secret keys Y j for 0 \u2264 j < 2 h .", [["leaves", "ANATOMY", 4, 10], ["leaves", "OBSERVATION_MODIFIER", 4, 10], ["tree", "ANATOMY_MODIFIER", 18, 22]]], ["Parameter h defines the height of the resulting binary tree whose inner nodes are represented by the value computed as n = f (n l || n r ), where n l and n r are the values of the left and right children of n.", [["inner nodes", "ANATOMY", 66, 77], ["left", "ANATOMY", 180, 184], ["inner nodes", "MULTI-TISSUE_STRUCTURE", 66, 77], ["children", "SPECIES", 195, 203], ["the values", "TEST", 162, 172], ["height", "OBSERVATION_MODIFIER", 24, 30], ["binary", "OBSERVATION_MODIFIER", 48, 54], ["tree", "OBSERVATION_MODIFIER", 55, 59], ["inner nodes", "OBSERVATION", 66, 77], ["left", "ANATOMY_MODIFIER", 180, 184], ["right", "ANATOMY_MODIFIER", 189, 194]]], ["To verify a signature at leaf with index i, one additionally needs the authentication path of i which is a sequence of h nodes.", [["leaf", "ANATOMY", 25, 29], ["leaf", "ORGAN", 25, 29], ["nodes", "OBSERVATION", 121, 126]]], ["This authentication path contains the siblings of all the nodes on the path between leaf i and the root.", [["nodes", "ANATOMY", 58, 63], ["leaf i", "ANATOMY", 84, 90], ["root", "ANATOMY", 99, 103], ["leaf i", "MULTI-TISSUE_STRUCTURE", 84, 90], ["root", "TISSUE", 99, 103], ["nodes", "OBSERVATION", 58, 63], ["leaf", "ANATOMY_MODIFIER", 84, 88], ["root", "ANATOMY_MODIFIER", 99, 103]]], ["Thus summarizing, a signature on a message m contains the one-time signature on m produced using X j , the authentication path, and the index j to indicate which key pair of the OTS was used.Multi-trees.Rather than scaling up a single tree, LMS and XMSS define single and multi-tree (hypertree) variants of their signature schemes.", [["XMSS", "TEST", 249, 253], ["LMS", "ANATOMY", 241, 244]]], ["In the multi-tree variant, the trees on the lowest layer are used to sign messages and the trees on higher layers are used to sign the roots of the trees on the layer below.", [["roots", "ANATOMY", 135, 140], ["tree variant", "OBSERVATION", 13, 25], ["higher layers", "OBSERVATION_MODIFIER", 100, 113]]], ["Considering a hypertree of total height h that has d layers of trees of height h/d, the top layer d \u2212 1 contains one tree, layer d \u2212 2 contains 2 (h/d) trees, and so on.", [["layers", "OBSERVATION_MODIFIER", 53, 59], ["tree", "ANATOMY_MODIFIER", 117, 121]]], ["Finally, the lowest layer contains 2 (h\u2212(h/d)) trees.", [["lowest", "OBSERVATION_MODIFIER", 13, 19], ["layer", "OBSERVATION_MODIFIER", 20, 25]]], ["This requires generating the OTS keys along the bottom of this tree.", [["OTS keys", "DNA", 29, 37], ["tree", "ANATOMY_MODIFIER", 63, 67]]], ["The lower trees are generated deterministically as required.", [["lower", "ANATOMY_MODIFIER", 4, 9], ["trees", "ANATOMY_MODIFIER", 10, 15]]], ["A signature consists of all the signatures on the way to the highest tree.", [["highest", "ANATOMY_MODIFIER", 61, 68], ["tree", "ANATOMY_MODIFIER", 69, 73]]], ["Hence, the signature size increases and signing and verifying takes slightly longer.", [["size", "OBSERVATION_MODIFIER", 21, 25], ["increases", "OBSERVATION_MODIFIER", 26, 35], ["slightly", "OBSERVATION_MODIFIER", 68, 76]]], ["The root of the top-level tree is the public key.", [["root", "ANATOMY", 4, 8], ["root", "ORGAN", 4, 8], ["root", "ANATOMY_MODIFIER", 4, 8], ["top", "OBSERVATION_MODIFIER", 16, 19], ["tree", "ANATOMY_MODIFIER", 26, 30]]], ["For further details on the multi-tree variants of LMS and XMSS, we refer to [26] and [18] , respectively.ComparisonRoughly speaking, LMS and XMSS have a very similar construction.", [["LMS", "ANATOMY", 50, 53]]], ["Both schemes use Merkle trees [27] along with a variant of WOTS.", [["WOTS", "PROTEIN", 59, 63]]], ["For further details on the definition of the parameters, we refer to [26] and [18] .Prefixes and BitmasksIn order to move away from collision resistance and towards collision resilience, within LMS and XMSS whenever an input is hashed, a specific prefix is added to the input.", [["LMS", "CELL_LINE", 194, 197], ["Prefixes", "TREATMENT", 84, 92]]], ["2.1, WOTS + [16] requires a random bitmask for each chaining iteration as additional input.", [["a random bitmask", "TREATMENT", 26, 42]]], ["Although LMS and XMSS apply different mechanisms to strengthen the security, the underlying constructions are very similar.", [["LMS", "PROBLEM", 9, 12], ["XMSS", "TEST", 17, 21], ["very", "OBSERVATION_MODIFIER", 110, 114], ["similar", "OBSERVATION", 115, 122]]], ["To describe this principle theoretically, Bernstein, H\u00fclsing, K\u00f6lbl, Niederhagen, Rijneveld, Schwabe [5] introduced an abstraction called tweakable hash functions (Th) as follows.Prefixes and BitmasksDefinition 1 (Tweakable hash function): Let n, \u03b1 \u2208 N, P be the public parameters space, and T be the tweak space.", [["P", "DNA", 254, 255]]], ["A tweakable hash function is an efficient functionPrefixes and Bitmasksmapping an \u03b1-bit message M to an n-bit hash value MD using a public parameter P \u2208 P, also called function key, and a tweak T \u2208 T .Prefixes and BitmasksThus, a tweakable hash function adds specific context information (tweak) and public parameters (function key) to the input.", [["P", "DNA", 153, 154], ["public parameters", "TEST", 300, 317]]], ["According to this definition, the constructions within LMS and XMSS can roughly be described as follows.Construction 2 (Prefix and bitmask construction/XMSS): Given two hash functionsAs defined in Construction 2, while XMSS additionally generates distinct random inputs for each invocation of the hash function, LMS provides inputs with predictable changes to the hash function.", [["LMS", "CANCER", 55, 58], ["XMSS", "PROTEIN", 219, 223], ["LMS", "CELL_LINE", 312, 315]]], ["For further details on the security model of LMS and XMSS, we refer to [21] and for further security notions for the defined constructions, we refer to [5] .WOTS Public Key CompressionBoth schemes combine the public keys (final values) of a WOTS chain into an n-bit value.", [["WOTS chain", "PROTEIN", 241, 251]]], ["While LMS hashes them together as a single message (see Fig. 2 ), XMSS uses a tree (called L-tree) to compress these values (see Fig. 1 ).", [["LMS", "CANCER", 6, 9], ["XMSS", "PROTEIN", 66, 70]]], ["The construction in XMSS obviously leads to a higher number of hash operations.LMS and XMSS on the Cortex-M4In the case of XMSS 3 , we removed all file-based procedures and implemented an interface to the pqm4 framework.", [["The construction in XMSS", "TREATMENT", 0, 24], ["hash operations", "TREATMENT", 63, 78], ["LMS", "TEST", 79, 82], ["XMSS", "TEST", 87, 91], ["Cortex", "ANATOMY_MODIFIER", 99, 105]]], ["For this, we used a slightly modified version of the pqm4 framework.", [["a slightly modified version of the pqm4 framework", "TREATMENT", 18, 67]]], ["To port the reference implementation of LMS 4 to Cortex-M4, apart from smaller modifications, we integrated the single-thread version, and turned floating-point operations off.Implemented Hash FunctionsPrimarily for the purpose of speedup and to achieve a broader comparison range, we integrated two more lightweight hash functions in addition to those recommended by NIST [11] (SHA-256 and SHAKE256) and already available in pqm4.", [["Cortex-M4", "CELL", 49, 58], ["pqm4", "GENE_OR_GENE_PRODUCT", 426, 430], ["pqm4", "PROTEIN", 426, 430], ["the single-thread version", "TREATMENT", 108, 133], ["floating-point operations", "TREATMENT", 146, 171], ["M4", "ANATOMY", 56, 58], ["smaller", "OBSERVATION_MODIFIER", 71, 78]]], ["In particular, we additionally evaluated LMS and XMSS using different variants of KECCAK and Gimli-Hash.KECCAK-f [800].", [["LMS", "TEST", 41, 44], ["XMSS", "TEST", 49, 53], ["KECCAK", "TEST", 82, 88]]], ["KECCAK-f describes a family of permutations originally specified in [1].", [["KECCAK", "PROTEIN", 0, 6]]], ["The KECCAK-p permutations within KECCAK-f are specified by a fixed width of the permutation (b) and the respective number of rounds (n r ) required.", [["KECCAK-p permutations", "DNA", 4, 25], ["KECCAK", "DNA", 33, 39], ["The KECCAK", "TEST", 0, 10]]], ["Furthermore, the permutation is denoted by In the case of KECCAK-f [800], we additionally considered a KECCAK permutation with only 12 rounds (KECCAK-p[800, 12] similar to River Keyak 5 ) to reduce the computational workload per hash invocation.", [["a KECCAK permutation", "TREATMENT", 101, 121]]], ["Evidently, a reduced number of rounds provides a smaller safety margin than the full 22 rounds recommended for KECCAKf [800] [28] .", [["a smaller safety margin", "TREATMENT", 47, 70], ["reduced", "OBSERVATION_MODIFIER", 13, 20], ["number", "OBSERVATION_MODIFIER", 21, 27]]], ["Nevertheless, since the best known practical collision attack against SHA-3 exists only up to 5 rounds [15] , the margin provided by 12 rounds is still comfortable.", [["SHA-3", "CHEMICAL", 70, 75], ["collision", "OBSERVATION", 45, 54]]], ["In a similar manner, Aumasson [2] proposed a general revision of the number of rounds of widely used symmetric primitives to speed up the standards without increasing the security risk.", [["a general revision", "TREATMENT", 43, 61], ["revision", "OBSERVATION", 53, 61]]], ["The family of hash functions Gimli-Hash is built on top of a 384-bit permutation called Gimli.", [["Hash", "DNA", 35, 39], ["Gimli", "DNA", 88, 93]]], ["The Gimli permutation [6] was designed to achieve high security with high performance.", [["The Gimli permutation", "TREATMENT", 0, 21]]], ["Grey nodes are the private keys and the black nodes the public keys of the WOTS chains.", [["Grey nodes", "ANATOMY", 0, 10], ["Grey nodes", "MULTI-TISSUE_STRUCTURE", 0, 10], ["WOTS chains", "PROTEIN", 75, 86], ["Grey nodes", "PROBLEM", 0, 10], ["nodes", "OBSERVATION", 5, 10], ["black", "OBSERVATION_MODIFIER", 40, 45], ["nodes", "OBSERVATION", 46, 51]]], ["The black node at the top is the public key.KECCAK-f [800]achieves high performance in lightweight as well as in non-lightweight environments.", [["black node", "ANATOMY", 4, 14], ["black node", "MULTI-TISSUE_STRUCTURE", 4, 14], ["The black node", "PROBLEM", 0, 14], ["black", "OBSERVATION_MODIFIER", 4, 9], ["node", "OBSERVATION", 10, 14], ["top", "OBSERVATION_MODIFIER", 22, 25]]], ["Due to the selected design, Gimli fits into 14 easily usable integer registers on 32-bit ARM microcontrollers.", [["bit ARM microcontrollers", "TREATMENT", 85, 109]]], ["Gimli-Hash works on a 48-byte state with a rate of 16-byte.KECCAK-f [800]We chose Gimli-Hash as an exemplary approach for the current round-2 candidates in NIST's Lightweight Cryptography Standardisation 6 process.", [["a rate", "TEST", 41, 47]]], ["It is of practical importance to investigate the performance of the remaining candidates.Speeding up XMSSIn this section, we discuss three methods for speeding up XMSS deviating from RFC 8391 [18] .", [["this section", "TREATMENT", 108, 120]]], ["The first described technique replaces the tree-based WOTS public-key compression with a single hash call.", [["tree", "OBSERVATION_MODIFIER", 43, 47], ["compression", "OBSERVATION", 70, 81]]], ["This approach was first proposed in SPHINCS+ [3] .", [["This approach", "TREATMENT", 0, 13]]], ["The second one, a structure omitting the use of bitmasks (the so-called \"simple\" version) was proposed in the round-2 submission of SPHINCS+ [3] at NIST-PQC.", [["bitmasks", "TREATMENT", 48, 56], ["SPHINCS", "TEST", 132, 139]]], ["However, during the signature verification, the hash pre-computation method only leads to small speedups in certain parameter sets.", [["the signature verification", "TEST", 16, 42], ["small", "OBSERVATION_MODIFIER", 90, 95]]], ["Other approaches, which lead to possible speedups in both LMS and XMSS, were intentionally not considered in this work.Speeding up XMSSOther acceleration methods, such as storing some top nodes in the secret key [12] , applying a more efficient tree traversal scheme [33] (already part of the XMSS reference implementation 7 and our implementation), or instantiating the schemes with shorter hash functions, were intentionally not considered in this work.", [["speedups", "PROBLEM", 41, 49], ["both LMS", "ANATOMY", 53, 61], ["nodes", "OBSERVATION", 188, 193]]], ["Although these methods lead to significant speedups, they can be applied in LMS and XMSS and therefore have no fundamental impact in our comparison.Speeding up XMSSThe instantiation of the different parameter sets is managed by conditional compilation.", [["significant speedups", "PROBLEM", 31, 51], ["the different parameter sets", "TREATMENT", 185, 213]]], ["In the case of XMSS, the modifications presented in this section are also controlled by preprocessing allowing to compile different versions of XMSS.", [["this section", "TREATMENT", 52, 64]]], ["A tree-based compression (see Ltrees in Fig. 1) is slower than using a single call to a tweakable hash function with the concatenated digest of all end nodes of the WOTS chains (see black nodes in Fig. 2 ) as input.Tree-Less WOTS+ Public Key Compression.", [["black nodes", "MULTI-TISSUE_STRUCTURE", 182, 193], ["WOTS chains", "PROTEIN", 165, 176], ["A tree-based compression", "PROBLEM", 0, 24], ["the WOTS chains", "PROBLEM", 161, 176], ["tree", "OBSERVATION_MODIFIER", 2, 6], ["compression", "OBSERVATION", 13, 24], ["slower", "OBSERVATION_MODIFIER", 51, 57], ["end", "OBSERVATION_MODIFIER", 148, 151], ["nodes", "OBSERVATION", 152, 157], ["black nodes", "OBSERVATION", 182, 193], ["Less", "OBSERVATION_MODIFIER", 220, 224], ["Key Compression", "OBSERVATION", 238, 253]]], ["As described in SPHINCS+ [3], we compress the end nodes of the WOTS chains (black nodes inBitmask-Less Hashing.", [["WOTS chains", "PROTEIN", 63, 74], ["black nodes inBitmask", "TREATMENT", 76, 97], ["end", "OBSERVATION_MODIFIER", 46, 49], ["nodes", "OBSERVATION", 50, 55], ["black nodes", "OBSERVATION", 76, 87], ["Less", "OBSERVATION_MODIFIER", 98, 102]]], ["For the resulting implications for security by applying Construction 1 in XMSS, we strongly refer to [5] .Tree-Less WOTS+ Public Key Compression.", [["Less", "OBSERVATION_MODIFIER", 111, 115], ["Key Compression", "OBSERVATION", 129, 144]]], ["As described in SPHINCS+ [3], we compress the end nodes of the WOTS chains (black nodes inHash Pre-computation.", [["WOTS chains", "PROTEIN", 63, 74], ["end", "OBSERVATION_MODIFIER", 46, 49], ["nodes", "OBSERVATION", 50, 55], ["black nodes", "OBSERVATION", 76, 87]]], ["Within XMSS, for a given key pair and a security parameter n, the first 2n-bit block (n-bit domain separator and n-bit hash-function key) of the input to the pseudo-random function (of type F : {0, 1} 3n \u2192 {0, 1} n ) is the same for all calls.", [["XMSS", "PROTEIN", 7, 11], ["first 2n-bit block", "PROTEIN", 66, 84], ["n-bit domain separator", "PROTEIN", 86, 108], ["the first 2n-bit block (n-bit domain separator", "TREATMENT", 62, 108]]], ["Considering this fact, we store the digest of the first 2n-bit block at the first call to the pseudorandom function (PRF) and skip this effort by reusing this result in all further calls.", [["the first 2n-bit block", "TREATMENT", 46, 68]]], ["This approach can easily be applied whenever the internal block size/rate of the used hash function is less than or equal to 2n bits.", [["This approach", "TREATMENT", 0, 13], ["the internal block size/rate", "TREATMENT", 45, 73], ["size", "OBSERVATION_MODIFIER", 64, 68]]], ["Depending on the internal block size of the used hash function, the number of saved calls to the internal compression respectively permutation function (Speedup PRF ) can be calculated as follows.", [["size", "OBSERVATION_MODIFIER", 32, 36]]], ["Let B bits \u2265 2n bits be the internal block size/rate in bits and #call PRF be the number of calls to the PRF, then Speedup PRF (B bits , #call PRF ) = 2n bits/B bits * #call PRF .", [["Let B", "GENE_OR_GENE_PRODUCT", 0, 5], ["Let B bits", "DNA", 0, 10], ["PRF", "DNA", 105, 108], ["Speedup PRF", "DNA", 115, 126], ["PRF", "DNA", 174, 177], ["the internal block size", "TREATMENT", 24, 47]]], ["Fig. 3 exemplified for the case of KECCAK-f [800] and n = 256, this method can basically be applied in every sponge construction, by reducing the rate to 2n bits whenever the rate is longer than 2n bits.", [["KECCAK", "TEST", 35, 41], ["this method", "TREATMENT", 63, 74], ["the rate", "TEST", 171, 179]]], ["Hence, even in the case n = 256, it can be implemented in SHAKE256 (KECCAK-f [1600]) by reducing the width of the rate from 1088 bits to 2n bits.", [["the rate", "TEST", 110, 118]]], ["However, in hash calls apart from the PRF invocations this would increase the number of permutations required for inputs longer than 2n bits.", [["the PRF invocations", "TREATMENT", 34, 53]]], ["A \"hybrid approach\" (not considered in this paper) with variable rate width (512 bits for PRF calls and 1088 for other hashing cases) could lead to a possible acceleration.As inIn the case of SHA-256 and n = 256, where the 512-bit block fits into a 512 bit SHA-256 internal block, this approach reduces the number of calls to the compression function by half.", [["fits", "DISEASE", 237, 241], ["A \"hybrid approach", "TREATMENT", 0, 18], ["variable rate width", "PROBLEM", 56, 75], ["SHA", "TEST", 192, 195], ["bit block fits", "PROBLEM", 227, 241], ["SHA", "TEST", 257, 260], ["internal block", "PROBLEM", 265, 279], ["the compression function", "TEST", 326, 350], ["compression", "OBSERVATION", 330, 341]]], ["According to the standard definition [28] in KECCAK-f [800] with a capacity of 256-bit length, the length of the rate should be 544 bits.", [["a capacity", "TEST", 65, 75], ["the rate", "TEST", 109, 117]]], ["In other words, the rate within an instantiation of XMSS using KECCAK-f [800] applying hash precomputation is 512 bits long, while a version without hash pre-computation makes use of the whole 544 bits.", [["the rate", "TEST", 16, 24]]], ["This modified design with a longer capacity obviously has no negative influence on the security of the hash function.", [["a longer capacity", "PROBLEM", 26, 43]]], ["In the case of KECCAK-f [800], this approach reduces the number of required permutations by half.", [["this approach", "TREATMENT", 31, 44]]], ["Since the rate in the sponge construction within Gimli-Hash is 128 bits long, it results in saving 4 permutation runs per PRF invocation.As inFrom now on as shown in Table 2 , we call an implementation of XMSS with L-trees using Construction 2 (see Sect.", [["Gimli", "DNA", 49, 54], ["Hash", "DNA", 55, 59], ["the rate", "TEST", 6, 14], ["the sponge construction", "TREATMENT", 18, 41], ["PRF invocation", "TREATMENT", 122, 136]]], ["3.1) without hash pre-computation XMSS_ROBUST, the variant without L-trees using Construction 1 XMSS_SIMPLE, and the one without L-trees applying Construction 1 and hash pre-computation XMSS_SIMPLE+PRE.", [["Construction 1 XMSS_SIMPLE", "DNA", 81, 107], ["Construction 1 and hash pre-computation XMSS_SIMPLE+PRE", "DNA", 146, 201], ["without", "UNCERTAINTY", 5, 12]]], ["The multi-tree variants are called XMSS MT ROBUST, XMSS MT SIMPLE, and XMSS MT SIMPLE+PRE, respectively.", [["PRE", "DNA", 86, 89], ["MT ROBUST", "TEST", 40, 49], ["MT SIMPLE", "TEST", 56, 65], ["XMSS MT SIMPLE", "TEST", 71, 85], ["multi-", "OBSERVATION_MODIFIER", 4, 10], ["tree variants", "OBSERVATION", 10, 23]]], ["XMSS_ROBUST and XMSS MT ROBUST represent the current version of XMSS from RFC 8391 8 .", [["RFC 8391", "CHEMICAL", 74, 82]]], ["Implemented variants of XMSS.DesignMulti-tree Tree-less WOTS+ Bitmask-less hashing Pre-computationEvaluationWe measured the performance of our implementations on a commercially available microcontroller.", [["XMSS", "DNA", 24, 28]]], ["We use the widely available board STM32F4DISCOVERY featuring a 32-bit ARM Cortex-M4 with FPU core, 1-Mbyte Flash ROM, and 192-Kbyte RAM.", [["a 32-bit ARM Cortex", "TREATMENT", 61, 80], ["FPU core", "TEST", 89, 97]]], ["The reference implementation of LMS 9 and XMSS 10 provided the basis for our implementation.", [["LMS", "TEST", 32, 35], ["XMSS", "TEST", 42, 46]]], ["The methods used for cycle counter reading, device communication at runtime, and hardware-based random byte generation were provided by the pqm4 11 framework.", [["The methods", "TREATMENT", 0, 11], ["cycle counter", "TREATMENT", 21, 34], ["device communication at runtime", "TREATMENT", 44, 75], ["hardware-based random byte generation", "TREATMENT", 81, 118]]], ["This framework in turn includes the libopencm3 12 library for providing these methods.", [["libopencm3 12 library", "DNA", 36, 57], ["these methods", "TREATMENT", 72, 85]]], ["All test instances were compiled with GNU Tools for ARM Embedded Processors 9-2019-q4-major 13 In this work, LMS and XMSS share the same implementations to perform the hash computations, clock-cycle measurement, and stack analysis, hence yielding an unbiased comparison.", [["q4", "DNA", 83, 85], ["XMSS", "DNA", 117, 121], ["All test instances", "TEST", 0, 18], ["ARM Embedded Processors", "TREATMENT", 52, 75], ["the hash computations", "TEST", 164, 185], ["clock-cycle measurement", "TEST", 187, 210], ["stack analysis", "TEST", 216, 230]]], ["The parameter sets from Table 3 were implemented in combination with Gimli-Hash, KECCAK (KECCAK-p[800, 22] and KECCAK-p[800, 12]), SHAKE256, and SHA-256.", [["SHA-256", "CHEMICAL", 145, 152], ["SHAKE256", "SIMPLE_CHEMICAL", 131, 139], ["Gimli", "TEST", 69, 74], ["KECCAK", "TEST", 89, 95], ["KECCAK", "TEST", 111, 117], ["SHAKE256", "TEST", 131, 139], ["SHA", "TEST", 145, 148]]], ["The resulting signature size for each parameter set is also shown in Table 3 .EvaluationAs shown in Table 4 , the implemented modifications in XMSS and XMSS MT lead to significant speedups.", [["modifications in XMSS", "TREATMENT", 126, 147], ["significant speedups", "PROBLEM", 168, 188], ["size", "OBSERVATION_MODIFIER", 24, 28], ["significant", "OBSERVATION_MODIFIER", 168, 179], ["speedups", "OBSERVATION", 180, 188]]], ["In combination with the hash precomputation approach, key generation and signing achieve accelerations up to 3.11 times.", [["the hash precomputation approach", "TREATMENT", 20, 52]]], ["However, when applying the hash pre-computation method, a speedup only occurs in certain parameter sets, mostly when the number of rounds of the hash function and the number of calls to the PRF are large enough to compensate for the additional effort.", [["PRF", "DNA", 190, 193]]], ["Reducing the number of rounds in KECCAK-f [800] to 12 instead of 22 yields a speedup of up to roughly 1.66\u00d7 for key generation and signing, and 1.72\u00d7 for verifying in all implemented variants of XMSS, and up to roughly 1.70\u00d7 for key generation and signing, and 1.76\u00d7 for verifying in all implemented variants of LMS (see Table 9 , Table 10, and Table 11 ).", [["LMS", "ANATOMY", 312, 315]]], ["Structurally, XMSS_SIMPLE, the variant without L-trees using Construction 1, differs only marginally from LMS.", [["LMS", "CANCER", 106, 109], ["XMSS_SIMPLE", "DNA", 14, 25], ["LMS", "ANATOMY", 106, 109]]], ["To confirm this analysis, we measured the number of hash operations required in LMS and XMSS_SIMPLE.", [["LMS", "CELL_LINE", 80, 83], ["this analysis", "TEST", 11, 24], ["hash operations", "TREATMENT", 52, 67]]], ["As Table 5 shows, XMSS_SIMPLE and XMSS MT SIMPLE hash operations are almost equivalent to LMS and HSS, respectively.", [["XMSS_SIMPLE", "TEST", 18, 29], ["HSS", "TEST", 98, 101], ["hash operations", "OBSERVATION", 49, 64]]], ["As shown in Table 6 , although the changes in XMSS result in a slightly smaller number of hash calls than in LMS, LMS unexpectedly requires fewer clock cycles for all tested cases.", [["fewer clock cycles", "TREATMENT", 140, 158], ["all tested cases", "TEST", 163, 179], ["slightly", "OBSERVATION_MODIFIER", 63, 71], ["smaller", "OBSERVATION_MODIFIER", 72, 79]]], ["We further measured the time spent performing hash operations for each scheme.", [["hash operations", "TREATMENT", 46, 61]]], ["The results of this measurement are given in Table 7 .", [["this measurement", "TEST", 15, 31]]], ["During key generation, the stack consumption of XMSS is on average slightly higher than for LMS.", [["XMSS", "CHEMICAL", 48, 52]]], ["However, as shown in Table 8 , the difference during signing and verification is 1.6\u00d7 and almost 4\u00d7 as high, respectively.", [["verification", "TEST", 65, 77]]], ["The round-reduced version of KECCAK (KECCAK-p[800, 12]) achieved the best performance (see Table 9 , Table 10, and Table 11 ) while Gimli-Hash the lowest stack consumption (see Table 12 ).EvaluationA complete overview of our results can be found in Appendix A.ConclusionWe showed that the current reference implementation of LMS with some required modifications achieves good performance results on a Cortex-M4.", [["LMS", "CANCER", 325, 328], ["Cortex-M4", "CELL", 401, 410], ["KECCAK", "TEST", 29, 35], ["Gimli", "TEST", 132, 137], ["round", "OBSERVATION_MODIFIER", 4, 9], ["reduced", "OBSERVATION_MODIFIER", 10, 17], ["Appendix", "ANATOMY", 249, 257]]], ["Although the XMSS_SIMPLE version of XMSS is structurally very similar to LMS, LMS still achieves significantly better performance.", [["LMS", "CANCER", 78, 81], ["LMS", "CELL_LINE", 73, 76], ["LMS", "CELL_LINE", 78, 81], ["the XMSS_SIMPLE version", "TEST", 9, 32], ["structurally", "OBSERVATION_MODIFIER", 44, 56], ["very", "OBSERVATION_MODIFIER", 57, 61]]], ["In addition, the currently discussed correct selection of safety margins for round-based symmetric cryptographic primitives is also considered in this work.", [["round-based symmetric cryptographic primitives", "PROBLEM", 77, 123], ["symmetric", "OBSERVATION_MODIFIER", 89, 98], ["cryptographic primitives", "OBSERVATION", 99, 123]]], ["In considering the fact that post-quantum approaches are more resource intensive than those currently in use, it is worth considering round-reduced and lightweight designs and concepts of hash functions in an embedded environment.ConclusionOur results based on reference implementations should merely give an idea on how practical the evaluated stateful schemes could be in an embedded environment.A.1 Speed and Stack MemorySpeed is measured in CPU clock cycles.", [["post-quantum approaches", "TREATMENT", 29, 52]]]], "607c06eeb368f3af035e0acced0733ffe0a198d4": [["R\u00fcckschl\u00fcsse auf die Nierenfunktion sollen sich zuk\u00fcnftig aus einem intelligenten Pflaster ziehen lassen 6 .", [["sich", "PROBLEM", 43, 47], ["Pflaster ziehen lassen", "TREATMENT", 82, 104]]], ["Mit ihrem Gr\u00fcnbuch hat die Kommission einen Diskurs der Interessentr\u00e4ger angesto\u00dfen.II. Rechtliche RahmenbedingungenDie rechtlichen Rahmenbedingungen f\u00fcr mHealth-L\u00f6sungen finden sich insbesondere im Medizinprodukte-, Datenschutz-, Haftungs-und Erstattungsrecht.MedizinprodukterechtOb mHealth-Anwendungen der medizinprodukterechtlichen Regulierung unterliegen, richtet sich nach dem Medizinproduktegesetz 8 .", [["Rechtliche", "TREATMENT", 88, 98], ["Datenschutz", "TREATMENT", 217, 228], ["Haftungs", "TREATMENT", 231, 239], ["MedizinprodukterechtOb mHealth", "TREATMENT", 261, 291], ["Anwendungen der medizinprodukterechtlichen Regulierung unterliegen", "TREATMENT", 292, 358], ["richtet sich nach dem Medizinproduktegesetz", "TREATMENT", 360, 403]]], ["Auslegungshilfen enthalten die rechtlich unverbindlichen Leitlinien der Europ\u00e4ischen Kommission zur Stand-Alone-Software (nachfolgend EU Guidelines) 9KostenerstattungDie vielf\u00e4ltigen Einsatzm\u00f6glichkeiten von mHealth-L\u00f6sungen k\u00f6nnen zu Kostensenkungen im Gesundheitswesen beitragen.", [["Auslegungshilfen enthalten die rechtlich unverbindlichen Leitlinien der Europ\u00e4ischen Kommission zur Stand-Alone-Software (nachfolgend EU Guidelines) 9KostenerstattungDie vielf\u00e4ltigen Einsatzm\u00f6glichkeiten von mHealth-L\u00f6sungen k\u00f6nnen zu Kostensenkungen im Gesundheitswesen beitragen", "SPECIES", 0, 280], ["Auslegungshilfen enthalten die", "TREATMENT", 0, 30], ["Software (nachfolgend EU Guidelines", "TREATMENT", 112, 147], ["L\u00f6sungen k\u00f6nnen", "TREATMENT", 216, 231]]], ["W\u00e4hrend ihre Aufnahme in die Regelversorgung der gesetzlichen Krankenversicherung noch aussteht, stellen Krankenkassen ihren Versicherten bereits Apps zur Gesundheitsf\u00f6rderung, Auf kl\u00e4rung, Beratung und Pr\u00e4vention zur Verf\u00fcgung. a) Gesundheitsf\u00f6rderung, Aufkl\u00e4rung, Beratung, Pr\u00e4vention Mit einer App, die trainingsbegleitend physiologische Messwerte und \"Lifestyle\"-Daten zur Ermittlung eines \"Health Scores\" kombiniert, will die AOK Nordost die Selbstverantwortung der Versicherten f\u00f6rdern und zur gesundheitsbewussten Lebensf\u00fchrung anregen 66 .", [["Pr\u00e4vention Mit einer App, die trainingsbegleitend physiologische Messwerte und \"Lifestyle\"-Daten zur Ermittlung eines \"Health Scores\" kombiniert, will die AOK Nordost die Selbstverantwortung der Versicherten f\u00f6rdern und zur gesundheitsbewussten Lebensf\u00fchrung anregen 66", "SPECIES", 276, 545]]]], "PMC7315906": [["In Freiburg waren es zum Vergleich 200 (Intensivstation: 70, verstorben: 50); 82.246 verstorbene Menschen bedeuten laut dem Statistischen Bundesamt eine Erh\u00f6hung um 8 % (+5942 F\u00e4lle) gegen\u00fcber dem Durchschnitt der 4 Vorjahre.", [["verstorbene", "TREATMENT", 85, 96]]], ["Obwohl diese sog.", [["diese sog", "OBSERVATION", 7, 16]]], ["\u00dcbersterblichkeit in Deutschland also geringer war als in den europ\u00e4ischen Nachbarl\u00e4ndern (Frankreich: +27 % 01.03.\u201320.04.2020; Italien: +49 % 03.2020), trugen ma\u00dfgeblich 3 Bundesl\u00e4nder zu erh\u00f6hten Sterbefallzahlen bei (Bayern: +18 %, Baden-W\u00fcrttemberg: 16 %, Nordrhein-Westfalen: +5 %).", [["Italien", "TEST", 128, 135], ["ma\u00dfgeblich", "TEST", 160, 170], ["Baden", "TEST", 235, 240]]], ["Das eindr\u00fcckliche Beispiel verdeutlicht gut, dass die Ausbreitung \u00fcber Pflegepersonal und \u00c4rzte eine relevante Gefahr darstellt.Immunantwort und unterschiedliche TestverfahrenRelativ zeitgleich, 10 bis 14 Tage nach Beginn der Infektion, wurde die Bildung von IgM- und IgG-Antik\u00f6rpern beschrieben [17\u201319].", [["IgM", "PROTEIN", 259, 262], ["IgG", "PROTEIN", 268, 271], ["Immunantwort und unterschiedliche TestverfahrenRelativ zeitgleich, 10 bis 14 Tage nach Beginn der Infektion, wurde die Bildung von IgM- und IgG-Antik\u00f6rpern beschrieben", "SPECIES", 128, 295], ["Immunantwort", "TEST", 128, 140], ["TestverfahrenRelativ zeitgleich", "TREATMENT", 162, 193], ["von IgM", "TEST", 255, 262], ["Antik\u00f6rpern beschrieben", "TREATMENT", 272, 295], ["gut", "ANATOMY", 40, 43]]], ["Dar\u00fcber hinaus wurde beschrieben, dass Alter und Geschlecht Einfluss auf Zeitpunkt und St\u00e4rke der Antik\u00f6rperformation haben k\u00f6nnen [20].", [["Dar\u00fcber hinaus wurde beschrieben, dass Alter und Geschlecht Einfluss auf Zeitpunkt und St\u00e4rke der Antik\u00f6rperformation haben k\u00f6nnen", "SPECIES", 0, 130]]], ["Erste Berichte von keinen (6 %) oder geringen Antik\u00f6rperspiegeln (30 %) best\u00e4tigten sich nicht [22].", [["Erste Berichte von keinen", "TREATMENT", 0, 25], ["Antik\u00f6rperspiegeln", "TREATMENT", 46, 64]]], ["Trotz enormer und andauernder Bem\u00fchungen, Immunreaktionen auf SARS-CoV\u20112 in verschiedenen klinischen Umgebungen zu untersuchen, gibt es bisher unzureichende Daten und ein schlechtes Verst\u00e4ndnis des Ausma\u00dfes und der Dauer von Antik\u00f6rperreaktionen (IgM, IgG und IgA) nach asymptomatischen, leichten und schweren Infektionen.", [["SARS-CoV\u20112", "DISEASE", 62, 72], ["IgM", "PROTEIN", 247, 250], ["Trotz enormer und andauernder Bem\u00fchungen, Immunreaktionen auf SARS-CoV\u20112 in verschiedenen klinischen Umgebungen zu untersuchen, gibt es bisher unzureichende Daten und ein schlechtes Verst\u00e4ndnis des Ausma\u00dfes und der Dauer von Antik\u00f6rperreaktionen", "SPECIES", 0, 245], ["Antik\u00f6rperreaktionen", "TEST", 225, 245], ["IgM", "TEST", 247, 250], ["IgG", "TEST", 252, 255]]], ["Die M\u00f6glichkeit einer T\u2011Zell-vermittelten Immunit\u00e4t bedeutet, dass doch einige der Infizierten \u00fcberhaupt keine Antik\u00f6rper ausbilden [18].Immunantwort und unterschiedliche TestverfahrenAussagekraft und Informationsgehalt der Testverfahren k\u00f6nnen sich erheblich unterscheiden [23, 24].", [["Immunantwort", "TEST", 137, 149]]], ["Obwohl die Pr\u00e4analytik, also die Gewinnung einer Serum- oder Plasmaprobe relativ unempfindlich gegen\u00fcber m\u00f6glichen Fehlern ist, hat ein fehlendes schnelles oder erleichtertes Zulassungsverfahren der Beh\u00f6rden anfangs dazu gef\u00fchrt, dass Tests mit einer Genauigkeit unter 30 % verwendet wurden [25].Immunantwort und unterschiedliche TestverfahrenSchnelltests (POC: \u201epoint of care\u201c) auf Antik\u00f6rper boten anfangs eine einfache Anwendung mit wenig logistischem Aufwand (Abb.", [["Serum", "TEST", 49, 54], ["Plasmaprobe", "TREATMENT", 61, 72], ["hat ein fehlendes schnelles", "TREATMENT", 128, 155]]], ["Quantitative ELISA-Assays liefern dagegen einen Titer; sie erfordern eine sorgf\u00e4ltige Kalibrierung (Abb.", [["Quantitative ELISA", "TEST", 0, 18], ["Assays", "TEST", 19, 25]]], ["Nachdem gerade anfangs zahlreiche unseri\u00f6se und unzuverl\u00e4ssige Schnelltests angeboten wurden, hat die Bedeutung der POC-Tests abgenommen.", [["Nachdem gerade anfangs", "TREATMENT", 0, 22]]], ["Angesichts ausgezeichneter Plattformen und schnell verf\u00fcgbarer Tests mit stark verbesserter Spezifit\u00e4t (ATELICA\u00ae [Siemens Healthcare GmbH, Erlangen, Deutschland], ELECYS\u00ae [Roche Diagnostics Deutschland GmbH, Mannheim, Deutschland], ARCHITECT\u00ae [Abbott GmbH, Wiesbaden, Deutschland], VITROS\u00ae [Ortho, Ortho-Clinical Diagnostics GmbH, Neckargm\u00fcnd, Deutschland]; LIAISON\u00ae [Diasorrin, Saluggia Italien]) ist eine fl\u00e4chendeckende und schnelle Testung mit hohem Durchsatz m\u00f6glich.Immunantwort und unterschiedliche TestverfahrenNeutralisationstests, bei denen Antik\u00f6rper einer Serumprobe verhindern sollen, dass anf\u00e4llige Zellen infiziert werden, stellen als Goldstandard die Referenzmethode dar.", [["Angesichts ausgezeichneter Plattformen und schnell verf\u00fcgbarer Tests mit stark verbesserter Spezifit\u00e4t", "SPECIES", 0, 102], ["Angesichts", "TEST", 0, 10], ["Plattformen", "TEST", 27, 38], ["Diasorrin", "TREATMENT", 368, 377], ["Saluggia Italien]", "TREATMENT", 379, 396], ["ist eine fl\u00e4chendeckende", "TREATMENT", 398, 422], ["Immunantwort", "TREATMENT", 472, 484]]], ["Eine Alternative ist das Ausweichen auf pseudotypisierte Viren (PV).Information schafft Sicherheit: Seropr\u00e4valenz in GesundheitsberufenAugen\u00e4rzte und Mitarbeiter entsprechender Einrichtungen sind aufgrund der k\u00f6rperlichen N\u00e4he einem erh\u00f6hten Risiko ausgesetzt [28].", [["Eine Alternative ist das Ausweichen auf pseudotypisierte Viren (PV)", "SPECIES", 0, 67], ["Seropr\u00e4valenz in GesundheitsberufenAugen\u00e4rzte und Mitarbeiter entsprechender", "TREATMENT", 100, 176]]], ["Seroepidemiologie kann das Verst\u00e4ndnis der \u00dcbertragungsintensit\u00e4t und der Anf\u00e4lligkeit in der Bev\u00f6lkerung verbessern.", [["kann das Verst\u00e4ndnis der \u00dcbertragungsintensit\u00e4t und der Anf\u00e4lligkeit in der Bev\u00f6lkerung verbessern", "SPECIES", 18, 116]]], ["Trotz Restunsicherheiten auf individueller Ebene sind serologische Tests in definierten Stichproben (Sero-Surveillance) sinnvoll.", [["Trotz", "TEST", 0, 5], ["serologische", "TEST", 54, 66], ["Tests", "TEST", 67, 72], ["Stichproben", "TEST", 88, 99]]], ["Nach den amerikanischen Centers for Disease Control and Prevention (CDC) sind 3 Strategien empfohlen [29]:Die initiale Verwendung eines Tests mit einer hohen Spezifit\u00e4t erm\u00f6glicht eine hohe Zuverl\u00e4ssigkeit ab einer Pr\u00e4valenz von \u22655 %.Eine sequenzielle Testung erh\u00f6ht die Zuverl\u00e4ssigkeit, falls der zweite Test ein anderes Design (z.", [["Disease Control", "TREATMENT", 36, 51], ["Die", "PROBLEM", 106, 109], ["ab einer Pr\u00e4valenz von \u2265", "TREATMENT", 206, 230]]], ["B. Antigenepitop oder Format) aufweisen.Eine Konzentration der Testung auf Personen mit hoher Erkrankungswahrscheinlichkeit (Symptomatik und zeitlicher Bezug von infizierten Kontaktpersonen) ist eine m\u00f6gliche Strategie.Information schafft Sicherheit: Seropr\u00e4valenz in GesundheitsberufenIm Hinblick auf die letzten beiden Punkte wurde allen Mitarbeitern der T\u00fcbinger Augenklinik und des Forschungsinstituts die Testung mittels validierter Assays (hohe Schwellenwerte und geringe Kreuzreaktivit\u00e4t der Coronaviren Untergruppe B) angeboten (Abb.", [["Eine Konzentration der Testung auf Personen mit hoher Erkrankungswahrscheinlichkeit (Symptomatik und zeitlicher Bezug von infizierten Kontaktpersonen) ist eine m\u00f6gliche", "SPECIES", 40, 208], ["GesundheitsberufenIm Hinblick auf die letzten beiden Punkte wurde allen Mitarbeitern der T\u00fcbinger Augenklinik und des Forschungsinstituts die Testung mittels validierter Assays (hohe Schwellenwerte und geringe Kreuzreaktivit\u00e4t der Coronaviren Untergruppe B) angeboten", "SPECIES", 268, 535], ["Symptomatik und zeitlicher Bezug von infizierten Kontaktpersonen", "TREATMENT", 125, 189], ["Seropr\u00e4valenz", "TREATMENT", 251, 264], ["Assays", "TEST", 438, 444]]], ["Antik\u00f6rper gegen die S1-Dom\u00e4ne des Spike-Proteins von SARS-CoV\u20112 (ELISA, Euroimmun AG, L\u00fcbeck, Deutschland [EI 2606\u20139601 G], Sensitivit\u00e4t >10 Tage: 75 %, \u226521 Tage: 93,8 %; Spezifit\u00e4t: 99,0 %) werden bestimmt.", [["Antik\u00f6rper gegen die S1-Dom\u00e4ne des Spike-Proteins von SARS-CoV\u20112", "SPECIES", 0, 64], ["Antik\u00f6rper", "TEST", 0, 10], ["von SARS", "TEST", 50, 58], ["CoV\u20112", "TEST", 59, 64], ["ELISA", "TEST", 66, 71], ["Euroimmun", "TEST", 73, 82], ["AG", "TEST", 83, 85], ["L\u00fcbeck", "TEST", 87, 93], ["Deutschland", "TEST", 95, 106], ["Sensitivit\u00e4t", "TEST", 125, 137], ["Tage", "TEST", 158, 162], ["Spezifit\u00e4t", "TEST", 172, 182]]], ["In weiteren Tests wird ein rekombinantes Antigen des Nukleocapsid(N-)Proteins zur Bestimmung der SARS-CoV-2-Antik\u00f6rper mittels Elektrochemilumineszenz-Immunoassay (ECLIA, Roche Deutschland GmbH, Grenzach-Wyhlen, Deutschland [Elecys\u00ae], Sensitivit\u00e4t >14 Tage: 100 %, Spezifit\u00e4t: 99,8 %) verwendet.", [["Nukleocapsid", "TEST", 53, 65], ["der SARS", "TEST", 93, 101], ["CoV", "TEST", 102, 105], ["Antik\u00f6rper", "TEST", 108, 118], ["Elektrochemilumineszenz", "TEST", 127, 150], ["ECLIA", "TEST", 164, 169], ["Grenzach", "TEST", 195, 203], ["Sensitivit\u00e4t", "TEST", 235, 247]]], ["Chemilumineszenz-markiertes rekombinantes SARS-CoV-2 Antigen (S1 RBD-Antigen-Sandwich-Immuntest, Siemens Healthcare Diagnostics GmbH, Erlangen, Deutschland [ADVIA Centaur\u00ae] dient zur Bestimmung der Gesamtantik\u00f6rper (IgM und IgG).Kritische Diskussion der Aussagekraft und Validit\u00e4tEs darf nicht vergessen werden, dass die Pr\u00e4valenz einer Erkrankung entscheidenden Einfluss auf die Eignung eines diagnostischen Tests hat (Tab.", [["Chemilumineszenz", "SIMPLE_CHEMICAL", 0, 16], ["IgM und IgG", "GENE_OR_GENE_PRODUCT", 216, 227], ["RBD", "PROTEIN", 65, 68], ["IgM", "PROTEIN", 216, 219], ["IgG", "PROTEIN", 224, 227], ["Chemilumineszenz", "TEST", 0, 16], ["markiertes", "TEST", 17, 27], ["SARS", "TEST", 42, 46], ["CoV", "TEST", 47, 50], ["Antigen", "TEST", 53, 60], ["S1 RBD", "TEST", 62, 68], ["Antigen", "TEST", 69, 76], ["Sandwich", "TEST", 77, 85], ["Deutschland", "TEST", 144, 155], ["Centaur\u00ae", "TEST", 163, 171]]], ["Augen\u00e4rzten sind die Probleme vom Thema Fr\u00fcherkennung vor dem Hintergrund einer niedrigen Glaukompr\u00e4valenz gut bekannt [30].", [["Augen\u00e4rzten sind die", "PROBLEM", 0, 20], ["Probleme", "PROBLEM", 21, 29]]], ["M\u00f6gliche Limitationen und die Relevanz falsch positiver Befunde sind erst recht dann von Bedeutung, wenn die Hoffnungen auf eine unklare Immunit\u00e4t oder die R\u00fcckkehr an den Arbeitsplatz damit verbunden werden.", [["M\u00f6gliche Limitationen und die Relevanz falsch positiver Befunde sind erst recht dann von Bedeutung, wenn die Hoffnungen auf eine unklare Immunit\u00e4t oder die R\u00fcckkehr an den Arbeitsplatz damit verbunden werden", "SPECIES", 0, 207], ["M\u00f6gliche", "TREATMENT", 0, 8]]], ["Ob das Vorhandensein von Antik\u00f6rpern eine ausreichende Immunit\u00e4t gegen weitere Infektionen und ggf. \u00fcber welchen Zeitraum bietet, ist dar\u00fcber hinaus eine Pr\u00e4misse, die erst noch durch Studien belegt werden muss.Kritische Diskussion der Aussagekraft und Validit\u00e4tDie Zuverl\u00e4ssigkeit eines positiven Testergebnisses wird durch den \u201epr\u00e4diktiven Wert\u201c angegeben, dessen Bedeutung f\u00fcr die SARS-CoV-2-Infektion au\u00dferhalb von Hotspots bereits hervorgehoben wurde [31]: Angesichts einer mittleren Sensitivit\u00e4t bzw.", [["Kritische Diskussion der Aussagekraft und Validit\u00e4tDie Zuverl\u00e4ssigkeit eines positiven Testergebnisses wird durch den \u201epr\u00e4diktiven Wert\u201c angegeben, dessen Bedeutung f\u00fcr die SARS-CoV-2-Infektion au\u00dferhalb von Hotspots bereits hervorgehoben wurde", "SPECIES", 211, 455], ["Vorhandensein von Antik\u00f6rpern eine ausreichende", "TREATMENT", 7, 54], ["Kritische Diskussion der Aussagekraft und Validit\u00e4tDie Zuverl\u00e4ssigkeit eines", "TREATMENT", 211, 287], ["CoV", "TEST", 389, 392], ["Angesichts", "TREATMENT", 462, 472]]], ["Spezifit\u00e4t zugelassener Antik\u00f6rpertests zwischen 84,90 % bzw.", [["Spezifit\u00e4t zugelassener Antik\u00f6rpertests zwischen", "TREATMENT", 0, 48]]], ["98,63 % kann der positive Vorhersagewert (a / (a + b) mit a: Anzahl der richtig positiv getesteten Personen und a + b: Anzahl aller positiv getesteten Personen) in Gebieten mit geringer Pr\u00e4valenz nur 30\u201350 % betragen.", [["Anzahl der richtig positiv getesteten Personen und a + b: Anzahl aller positiv getesteten Personen", "SPECIES", 61, 159], ["Anzahl", "TREATMENT", 119, 125], ["Gebieten mit geringer Pr\u00e4valenz nur", "TREATMENT", 164, 199]]]], "PMC7191626": [["INTRODUCTIONThe renin-angiotensin system (RAS) is one of the most potent cardiovascular regulators and an important target for therapeutic drugs.", [["cardiovascular", "ANATOMY", 73, 87], ["renin-angiotensin system", "GENE_OR_GENE_PRODUCT", 16, 40], ["RAS", "GENE_OR_GENE_PRODUCT", 42, 45], ["INTRODUCTIONThe renin-angiotensin system", "TREATMENT", 0, 40], ["therapeutic drugs", "TREATMENT", 127, 144]]], ["From 120 yr ago, when renin was discovered (148), until 30 yr ago, only one peptide was thought to be active in this system: angiotensin II (ANG II).", [["angiotensin II", "CHEMICAL", 125, 139], ["ANG II", "CHEMICAL", 141, 147], ["renin", "GENE_OR_GENE_PRODUCT", 22, 27], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 125, 139], ["ANG II", "GENE_OR_GENE_PRODUCT", 141, 147], ["renin", "PROTEIN", 22, 27], ["angiotensin II", "PROTEIN", 125, 139], ["ANG II", "PROTEIN", 141, 147], ["angiotensin II (ANG II)", "TREATMENT", 125, 148], ["active", "OBSERVATION", 102, 108]]], ["It was shown to be produced by successive digestion of angiotensinogen by the enzymes renin and angiotensin-converting enzyme (ACE), with ANG I as an intermediate, and to interact with a receptor, now called the ANG II type 1 receptor (AT1R).", [["angiotensin", "CHEMICAL", 96, 107], ["angiotensinogen", "GENE_OR_GENE_PRODUCT", 55, 70], ["renin", "GENE_OR_GENE_PRODUCT", 86, 91], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 96, 125], ["ACE", "GENE_OR_GENE_PRODUCT", 127, 130], ["ANG I", "GENE_OR_GENE_PRODUCT", 138, 143], ["ANG II type 1 receptor", "GENE_OR_GENE_PRODUCT", 212, 234], ["AT1R", "GENE_OR_GENE_PRODUCT", 236, 240], ["angiotensinogen", "PROTEIN", 55, 70], ["renin", "PROTEIN", 86, 91], ["angiotensin-converting enzyme", "PROTEIN", 96, 125], ["ACE", "PROTEIN", 127, 130], ["ANG I", "PROTEIN", 138, 143], ["ANG II type 1 receptor", "PROTEIN", 212, 234], ["AT1R", "PROTEIN", 236, 240], ["successive digestion of angiotensinogen", "PROBLEM", 31, 70], ["the enzymes renin", "TEST", 74, 91], ["angiotensin", "TEST", 96, 107]]], ["Physiologically, AT1R activation by ANG II elicits vasoconstriction, water intake, and Na+ retention.", [["ANG II", "CHEMICAL", 36, 42], ["Na", "CHEMICAL", 87, 89], ["Na+", "CHEMICAL", 87, 90], ["AT1R", "GENE_OR_GENE_PRODUCT", 17, 21], ["ANG II", "GENE_OR_GENE_PRODUCT", 36, 42], ["water", "SIMPLE_CHEMICAL", 69, 74], ["Na+", "SIMPLE_CHEMICAL", 87, 90], ["AT1R", "PROTEIN", 17, 21], ["ANG II", "PROTEIN", 36, 42], ["vasoconstriction", "PROBLEM", 51, 67], ["Na+ retention", "PROBLEM", 87, 100]]], ["Pathophysiologically, activation of ACE/ANG II/AT1R signaling is associated with oxidative stress, hypertrophy, fibrosis, and inflammation.", [["hypertrophy", "DISEASE", 99, 110], ["fibrosis", "DISEASE", 112, 120], ["inflammation", "DISEASE", 126, 138], ["ACE", "GENE_OR_GENE_PRODUCT", 36, 39], ["ANG II", "GENE_OR_GENE_PRODUCT", 40, 46], ["AT1R", "GENE_OR_GENE_PRODUCT", 47, 51], ["ACE", "PROTEIN", 36, 39], ["ANG II", "PROTEIN", 40, 46], ["AT1R", "PROTEIN", 47, 51], ["ACE/ANG II/AT1R signaling", "PROBLEM", 36, 61], ["oxidative stress", "PROBLEM", 81, 97], ["hypertrophy", "PROBLEM", 99, 110], ["fibrosis", "PROBLEM", 112, 120], ["inflammation", "PROBLEM", 126, 138], ["associated with", "UNCERTAINTY", 65, 80], ["oxidative stress", "OBSERVATION", 81, 97], ["hypertrophy", "OBSERVATION", 99, 110], ["fibrosis", "OBSERVATION", 112, 120], ["inflammation", "OBSERVATION", 126, 138]]], ["This view of the RAS began to change when, in 1988, Santos et al. (125) discovered the formation of ANG-(1\u22127) from ANG I by an ACE-independent pathway, and Schiavone et al. (131) showed the vasopressin-releasing activity of this heptapeptide in neural tissue explants.", [["neural tissue explants", "ANATOMY", 245, 267], ["ANG", "CHEMICAL", 100, 103], ["vasopressin", "CHEMICAL", 190, 201], ["RAS", "GENE_OR_GENE_PRODUCT", 17, 20], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 100, 109], ["ANG I", "GENE_OR_GENE_PRODUCT", 115, 120], ["ACE", "GENE_OR_GENE_PRODUCT", 127, 130], ["vasopressin", "SIMPLE_CHEMICAL", 190, 201], ["neural tissue explants", "TISSUE", 245, 267], ["RAS", "PROTEIN", 17, 20], ["ANG", "PROTEIN", 100, 103], ["ANG I", "PROTEIN", 115, 120], ["ACE", "PROTEIN", 127, 130], ["ANG", "TEST", 100, 103], ["an ACE-independent pathway", "TREATMENT", 124, 150], ["the vasopressin", "TREATMENT", 186, 201], ["this heptapeptide in neural tissue explants", "TREATMENT", 224, 267], ["neural tissue", "ANATOMY", 245, 258]]], ["One year later, the first in vivo actions of ANG-(1\u22127) were described (16).", [["ANG", "CHEMICAL", 45, 48], ["ANG", "GENE_OR_GENE_PRODUCT", 45, 48], ["1\u22127", "SIMPLE_CHEMICAL", 50, 53], ["ANG", "PROTEIN", 45, 48], ["ANG", "TEST", 45, 48]]], ["At about the same time, a second receptor for ANG II [the ANG II type 2 receptor (AT2R)] was found (21, 159).", [["ANG II", "CHEMICAL", 46, 52], ["ANG II", "GENE_OR_GENE_PRODUCT", 46, 52], ["ANG II type 2 receptor", "GENE_OR_GENE_PRODUCT", 58, 80], ["AT2R", "GENE_OR_GENE_PRODUCT", 82, 86], ["ANG II", "PROTEIN", 46, 52], ["ANG II type 2 receptor", "PROTEIN", 58, 80], ["AT2R", "PROTEIN", 82, 86], ["a second receptor", "TREATMENT", 24, 41], ["ANG II [the ANG II type 2 receptor (AT2R", "TREATMENT", 46, 86]]], ["In the following 30 yr until now, the physiological functions of these two alternative pathways of the RAS have been extensively studied, and it was shown that ANG-(1\u22127) via its receptor, Mas (127), as well as ANG II via AT2R counteract the classical RAS resulting in vasodilation, anti-inflammation, antifibrosis, and antiapoptosis, conferring beneficial effects in the settings of cardiovascular diseases (19, 128, 144).", [["cardiovascular", "ANATOMY", 383, 397], ["cardiovascular diseases", "DISEASE", 383, 406], ["RAS", "GENE_OR_GENE_PRODUCT", 103, 106], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 160, 169], ["Mas (127)", "GENE_OR_GENE_PRODUCT", 188, 197], ["ANG II", "GENE_OR_GENE_PRODUCT", 210, 216], ["AT2R", "GENE_OR_GENE_PRODUCT", 221, 225], ["RAS", "GENE_OR_GENE_PRODUCT", 251, 254], ["cardiovascular", "ANATOMICAL_SYSTEM", 383, 397], ["RAS", "PROTEIN", 103, 106], ["ANG II", "PROTEIN", 210, 216], ["AT2R", "PROTEIN", 221, 225], ["classical RAS", "PROTEIN", 241, 254], ["ANG", "TEST", 160, 163], ["Mas", "TEST", 188, 191], ["ANG II via AT2R", "TREATMENT", 210, 225], ["the classical RAS", "PROBLEM", 237, 254], ["vasodilation", "PROBLEM", 268, 280], ["anti-inflammation", "TREATMENT", 282, 299], ["antifibrosis", "PROBLEM", 301, 313], ["antiapoptosis", "PROBLEM", 319, 332], ["cardiovascular diseases", "PROBLEM", 383, 406], ["vasodilation", "OBSERVATION", 268, 280], ["anti-inflammation", "OBSERVATION_MODIFIER", 282, 299], ["cardiovascular", "ANATOMY", 383, 397], ["diseases", "OBSERVATION", 398, 406]]], ["A central role in regulating the relative activities of the RAS arms in a tissue is played by the local levels of the enzyme ACE2, which transforms ANG II into ANG-(1\u22127) (31, 149).", [["tissue", "ANATOMY", 74, 80], ["ANG II", "CHEMICAL", 148, 154], ["RAS", "GENE_OR_GENE_PRODUCT", 60, 63], ["tissue", "TISSUE", 74, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 125, 129], ["ANG II", "GENE_OR_GENE_PRODUCT", 148, 154], ["ANG", "GENE_OR_GENE_PRODUCT", 160, 163], ["ACE2", "PROTEIN", 125, 129], ["ANG II", "PROTEIN", 148, 154], ["the enzyme ACE2", "TEST", 114, 129], ["ANG", "TEST", 160, 163], ["central", "OBSERVATION_MODIFIER", 2, 9], ["relative", "OBSERVATION_MODIFIER", 33, 41], ["activities", "OBSERVATION_MODIFIER", 42, 52], ["tissue", "OBSERVATION", 74, 80]]], ["It was only a logical consequence of these findings that compounds were developed to activate the two protective arms of the RAS, which are undergoing clinical evaluation at the moment (5).", [["RAS", "GENE_OR_GENE_PRODUCT", 125, 128], ["clinical evaluation", "TEST", 151, 170], ["RAS", "OBSERVATION", 125, 128]]], ["However, the full complement of angiotensin peptides is still not completed, because Lautner et al. (74) and Jankowsky et al. (60) recently discovered a novel class, which we suggest to call \u201calatensins,\u201d with an alanine at the amino-terminal position instead of the aspartate in the classical angiotensin peptides.", [["angiotensin", "CHEMICAL", 32, 43], ["alanine", "CHEMICAL", 213, 220], ["aspartate", "CHEMICAL", 267, 276], ["angiotensin", "CHEMICAL", 294, 305], ["alatensins", "CHEMICAL", 192, 202], ["alanine", "CHEMICAL", 213, 220], ["amino", "CHEMICAL", 228, 233], ["aspartate", "CHEMICAL", 267, 276], ["angiotensin peptides", "GENE_OR_GENE_PRODUCT", 32, 52], ["alatensins", "SIMPLE_CHEMICAL", 192, 202], ["alanine", "AMINO_ACID", 213, 220], ["amino-terminal", "AMINO_ACID", 228, 242], ["aspartate", "SIMPLE_CHEMICAL", 267, 276], ["angiotensin peptides", "GENE_OR_GENE_PRODUCT", 294, 314], ["amino-terminal position", "PROTEIN", 228, 251], ["angiotensin peptides", "TREATMENT", 32, 52], ["an alanine at the amino-terminal position", "TREATMENT", 210, 251], ["the classical angiotensin peptides", "TREATMENT", 280, 314]]], ["Although Ala1-ANG II interacts with the same receptors as ANG II, AT1R, and AT2R, Ala1-ANG-(1\u22127) (alamandine) has its own receptor, Mas-related G protein-coupled receptor D (MrgD) (74).INTRODUCTIONThis review will summarize novel findings on the physiological and pathophysiological actions of the new beneficial RAS components, which were presented at the symposium on \u201cThe Renin-Angiotensin System: Going Beyond the Classical Paradigms\u201d at the International Union of Physiological Sciences 2017 Rhythms of Life Congress in Rio de Janeiro, Brazil.Biochemistry and Regulation of ACE2 ::: ANG-(1\u22127) AS A CRITICAL MEDIATOR OF THE ACE2-RELATED PROTECTIVE AXIS OF THE RASACE2 is a type I transmembrane protein consisting of an extracellular amino-terminal domain containing the catalytic site and an intracellular carboxy-terminal tail (31, 149).", [["extracellular", "ANATOMY", 723, 736], ["intracellular", "ANATOMY", 796, 809], ["Ala1-ANG-(1\u22127)", "CHEMICAL", 82, 96], ["alamandine", "CHEMICAL", 98, 108], ["Angiotensin", "CHEMICAL", 381, 392], ["amino-terminal", "CHEMICAL", 737, 751], ["alamandine", "CHEMICAL", 98, 108], ["amino", "CHEMICAL", 737, 742], ["carboxy", "CHEMICAL", 810, 817], ["Ala1-ANG II", "GENE_OR_GENE_PRODUCT", 9, 20], ["ANG II", "GENE_OR_GENE_PRODUCT", 58, 64], ["AT1R", "GENE_OR_GENE_PRODUCT", 66, 70], ["AT2R", "GENE_OR_GENE_PRODUCT", 76, 80], ["Ala1-ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 82, 96], ["alamandine", "SIMPLE_CHEMICAL", 98, 108], ["Mas-related G protein-coupled receptor D", "GENE_OR_GENE_PRODUCT", 132, 172], ["MrgD", "GENE_OR_GENE_PRODUCT", 174, 178], ["ACE2", "GENE_OR_GENE_PRODUCT", 579, 583], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 796, 809], ["Ala1", "PROTEIN", 9, 13], ["ANG II", "PROTEIN", 14, 20], ["ANG II", "PROTEIN", 58, 64], ["AT1R", "PROTEIN", 66, 70], ["AT2R", "PROTEIN", 76, 80], ["Mas-related G protein-coupled receptor D", "PROTEIN", 132, 172], ["MrgD", "PROTEIN", 174, 178], ["ACE2", "PROTEIN", 579, 583], ["ACE2", "PROTEIN", 628, 632], ["RASACE2", "PROTEIN", 664, 671], ["type I transmembrane protein", "PROTEIN", 677, 705], ["extracellular amino-terminal domain", "PROTEIN", 723, 758], ["catalytic site", "PROTEIN", 774, 788], ["intracellular carboxy-terminal tail", "PROTEIN", 796, 831], ["Ala1", "TEST", 9, 13], ["AT1R", "TEST", 66, 70], ["AT2R", "TEST", 76, 80], ["Ala1", "TEST", 82, 86], ["ANG", "TEST", 87, 90], ["the new beneficial RAS components", "PROBLEM", 294, 327], ["Biochemistry", "TEST", 548, 560], ["ACE2", "TEST", 579, 583], ["ANG", "TEST", 588, 591], ["THE ACE2", "TEST", 624, 632], ["a type I transmembrane protein", "PROBLEM", 675, 705], ["an extracellular amino-terminal domain containing the catalytic site", "PROBLEM", 720, 788], ["ANG II", "OBSERVATION_MODIFIER", 14, 20], ["AT2R", "ANATOMY", 76, 80], ["PROTECTIVE AXIS", "OBSERVATION", 641, 656], ["extracellular amino", "OBSERVATION", 723, 742], ["terminal", "ANATOMY_MODIFIER", 743, 751], ["catalytic site", "OBSERVATION", 774, 788], ["intracellular", "OBSERVATION_MODIFIER", 796, 809], ["carboxy", "OBSERVATION_MODIFIER", 810, 817], ["terminal", "ANATOMY_MODIFIER", 818, 826], ["tail", "ANATOMY_MODIFIER", 827, 831]]], ["ACE2 functions as a carboxymonopeptidase with the Arg273 residue being critical for substrate binding and enzymatic activity (49).", [["Arg273", "CHEMICAL", 50, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["carboxymonopeptidase", "GENE_OR_GENE_PRODUCT", 20, 40], ["Arg273", "GENE_OR_GENE_PRODUCT", 50, 56], ["ACE2", "PROTEIN", 0, 4], ["a carboxymonopeptidase", "TREATMENT", 18, 40], ["the Arg273 residue", "TREATMENT", 46, 64]]], ["As a carboxymonopeptidase, ACE2 degrades ANG II to generate the heptapeptide ANG-(1\u22127) and ANG I to generate the nonapeptide ANG-(1\u22129) by hydrolyzing the carboxy-terminal amino acid (31, 121, 149).", [["ANG II", "CHEMICAL", 41, 47], ["ANG", "CHEMICAL", 77, 80], ["ANG", "CHEMICAL", 125, 128], ["carboxy-terminal amino acid", "CHEMICAL", 154, 181], ["carboxy", "CHEMICAL", 154, 161], ["amino acid", "CHEMICAL", 171, 181], ["carboxymonopeptidase", "GENE_OR_GENE_PRODUCT", 5, 25], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["ANG II", "GENE_OR_GENE_PRODUCT", 41, 47], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 77, 86], ["ANG I", "GENE_OR_GENE_PRODUCT", 91, 96], ["ANG", "GENE_OR_GENE_PRODUCT", 125, 128], ["1\u22129", "SIMPLE_CHEMICAL", 130, 133], ["amino acid", "AMINO_ACID", 171, 181], ["carboxymonopeptidase", "PROTEIN", 5, 25], ["ACE2", "PROTEIN", 27, 31], ["ANG II", "PROTEIN", 41, 47], ["ANG I", "PROTEIN", 91, 96], ["a carboxymonopeptidase, ACE2 degrades ANG II", "TREATMENT", 3, 47], ["the heptapeptide ANG", "TREATMENT", 60, 80], ["ANG I", "TREATMENT", 91, 96], ["the nonapeptide ANG", "TREATMENT", 109, 128], ["terminal amino acid", "TEST", 162, 181]]], ["ANG-(1\u22129) can be further converted to ANG-(1\u22127) by ACE.", [["ANG", "CHEMICAL", 0, 3], ["ANG", "GENE_OR_GENE_PRODUCT", 0, 3], ["1\u22129", "SIMPLE_CHEMICAL", 5, 8], ["ANG", "SIMPLE_CHEMICAL", 38, 41], ["1\u22127", "SIMPLE_CHEMICAL", 43, 46], ["ACE", "GENE_OR_GENE_PRODUCT", 51, 54], ["ACE", "PROTEIN", 51, 54], ["ANG", "TEST", 0, 3], ["ANG", "TEST", 38, 41]]], ["In the same manner, ACE2 can also cleave and partially inactivate pyr-apelin-13 and apelin-17 peptides (155).", [["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["pyr-apelin-13", "GENE_OR_GENE_PRODUCT", 66, 79], ["apelin-17", "GENE_OR_GENE_PRODUCT", 84, 93], ["ACE2", "PROTEIN", 20, 24], ["pyr-apelin", "PROTEIN", 66, 76], ["pyr-apelin", "TEST", 66, 76], ["apelin", "TEST", 84, 90]]], ["In addition to being an enzyme, ACE2 is a transmembrane protein that also acts as an amino acid transporter and is targeted by severe acute respiratory syndrome coronavirus (109).", [["amino acid", "CHEMICAL", 85, 95], ["acute respiratory syndrome coronavirus", "DISEASE", 134, 172], ["amino acid", "CHEMICAL", 85, 95], ["ACE2", "GENE_OR_GENE_PRODUCT", 32, 36], ["transmembrane", "CELLULAR_COMPONENT", 42, 55], ["amino acid", "AMINO_ACID", 85, 95], ["ACE2", "PROTEIN", 32, 36], ["transmembrane protein", "PROTEIN", 42, 63], ["amino acid transporter", "PROTEIN", 85, 107], ["severe acute respiratory syndrome coronavirus", "SPECIES", 127, 172], ["an enzyme", "TEST", 21, 30], ["ACE2", "TEST", 32, 36], ["a transmembrane protein", "TEST", 40, 63], ["an amino acid transporter", "TEST", 82, 107], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 127, 172], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["respiratory syndrome coronavirus", "OBSERVATION", 140, 172]]], ["ACE2 is widely expressed in the cardiovascular system, kidneys, lungs, and brain to protect these organs from excessive ANG II signaling (32, 42, 54, 71, 99, 161).", [["cardiovascular system", "ANATOMY", 32, 53], ["kidneys", "ANATOMY", 55, 62], ["lungs", "ANATOMY", 64, 69], ["brain", "ANATOMY", 75, 80], ["organs", "ANATOMY", 98, 104], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cardiovascular system", "ANATOMICAL_SYSTEM", 32, 53], ["kidneys", "ORGAN", 55, 62], ["lungs", "ORGAN", 64, 69], ["brain", "ORGAN", 75, 80], ["organs", "ORGAN", 98, 104], ["ANG II", "GENE_OR_GENE_PRODUCT", 120, 126], ["ACE2", "PROTEIN", 0, 4], ["ANG II", "PROTEIN", 120, 126], ["ACE2", "TREATMENT", 0, 4], ["excessive ANG II signaling", "TEST", 110, 136], ["cardiovascular system", "ANATOMY", 32, 53], ["kidneys", "ANATOMY", 55, 62], ["lungs", "ANATOMY", 64, 69], ["brain", "ANATOMY", 75, 80], ["excessive", "OBSERVATION_MODIFIER", 110, 119]]], ["In the heart, both ACE2 and Mas are expressed in cardiomyocytes, cardiofibroblasts, and the coronary vasculature (58, 103, 108, 123, 124, 126).", [["heart", "ANATOMY", 7, 12], ["cardiomyocytes", "ANATOMY", 49, 63], ["cardiofibroblasts", "ANATOMY", 65, 82], ["coronary vasculature", "ANATOMY", 92, 112], ["heart", "ORGAN", 7, 12], ["ACE2", "GENE_OR_GENE_PRODUCT", 19, 23], ["Mas", "GENE_OR_GENE_PRODUCT", 28, 31], ["cardiomyocytes", "CELL", 49, 63], ["cardiofibroblasts", "CELL", 65, 82], ["coronary vasculature", "MULTI-TISSUE_STRUCTURE", 92, 112], ["ACE2", "PROTEIN", 19, 23], ["Mas", "PROTEIN", 28, 31], ["cardiomyocytes", "CELL_TYPE", 49, 63], ["cardiofibroblasts", "CELL_TYPE", 65, 82], ["cardiofibroblasts", "TEST", 65, 82], ["heart", "ANATOMY", 7, 12], ["both", "ANATOMY_MODIFIER", 14, 18], ["ACE2", "ANATOMY_MODIFIER", 19, 23], ["cardiomyocytes", "ANATOMY", 49, 63], ["coronary vasculature", "ANATOMY", 92, 112]]], ["ACE2 activity is regulated by a disintegrin and metalloproteinase domain-containing protein 17 (ADAM-17; also known as TNF-\u03b1-converting enzyme) and apelin.", [["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["disintegrin and metalloproteinase domain-containing protein 17", "GENE_OR_GENE_PRODUCT", 32, 94], ["ADAM-17", "GENE_OR_GENE_PRODUCT", 96, 103], ["TNF-\u03b1-converting enzyme", "GENE_OR_GENE_PRODUCT", 119, 142], ["apelin", "GENE_OR_GENE_PRODUCT", 148, 154], ["ACE2", "PROTEIN", 0, 4], ["disintegrin and metalloproteinase domain-containing protein 17", "PROTEIN", 32, 94], ["ADAM-17", "PROTEIN", 96, 103], ["TNF", "PROTEIN", 119, 122], ["\u03b1-converting enzyme", "PROTEIN", 123, 142], ["apelin", "PROTEIN", 148, 154], ["a disintegrin and metalloproteinase domain", "TREATMENT", 30, 72], ["protein", "TEST", 84, 91], ["TNF", "TEST", 119, 122], ["apelin", "PROBLEM", 148, 154]]], ["ADAM-17 acts as a negative regulator of ACE2 tissue activity by proteolytically cleaving ACE2, resulting in the shedding of ACE2 into the interstitium, leading to decreased ACE2 activity in the tissue and elevated circulating ACE2 activity (103, 109).", [["tissue", "ANATOMY", 45, 51], ["interstitium", "ANATOMY", 138, 150], ["tissue", "ANATOMY", 194, 200], ["ADAM-17", "GENE_OR_GENE_PRODUCT", 0, 7], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["tissue", "TISSUE", 45, 51], ["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["ACE2", "GENE_OR_GENE_PRODUCT", 124, 128], ["interstitium", "TISSUE", 138, 150], ["ACE2", "GENE_OR_GENE_PRODUCT", 173, 177], ["tissue", "TISSUE", 194, 200], ["ACE2", "GENE_OR_GENE_PRODUCT", 226, 230], ["ADAM-17", "PROTEIN", 0, 7], ["ACE2", "PROTEIN", 40, 44], ["ACE2", "PROTEIN", 89, 93], ["ACE2", "PROTEIN", 124, 128], ["ACE2", "PROTEIN", 173, 177], ["ACE2", "PROTEIN", 226, 230], ["ACE2 tissue activity", "TREATMENT", 40, 60], ["decreased ACE2 activity in the tissue", "PROBLEM", 163, 200], ["elevated circulating ACE2 activity", "PROBLEM", 205, 239], ["interstitium", "ANATOMY", 138, 150], ["decreased", "OBSERVATION_MODIFIER", 163, 172], ["ACE2 activity", "OBSERVATION", 173, 186], ["tissue", "ANATOMY", 194, 200], ["elevated", "OBSERVATION_MODIFIER", 205, 213], ["circulating", "OBSERVATION_MODIFIER", 214, 225], ["ACE2 activity", "OBSERVATION", 226, 239]]], ["Deletion of this negative regulator (ADAM-17 or TNF-\u03b1-converting enzyme) protects the heart and vasculature in conditions of myocardial infarction, hypertension, pressure overload, and aortic aneurysm (34, 35, 43, 135, 136).", [["heart", "ANATOMY", 86, 91], ["vasculature", "ANATOMY", 96, 107], ["myocardial", "ANATOMY", 125, 135], ["aortic aneurysm", "ANATOMY", 185, 200], ["myocardial infarction", "DISEASE", 125, 146], ["hypertension", "DISEASE", 148, 160], ["pressure overload", "DISEASE", 162, 179], ["aortic aneurysm", "DISEASE", 185, 200], ["ADAM-17", "GENE_OR_GENE_PRODUCT", 37, 44], ["TNF-\u03b1-converting enzyme", "GENE_OR_GENE_PRODUCT", 48, 71], ["heart", "ORGAN", 86, 91], ["vasculature", "MULTI-TISSUE_STRUCTURE", 96, 107], ["myocardial", "MULTI-TISSUE_STRUCTURE", 125, 135], ["aortic aneurysm", "MULTI-TISSUE_STRUCTURE", 185, 200], ["ADAM-17", "PROTEIN", 37, 44], ["TNF", "PROTEIN", 48, 51], ["\u03b1-converting enzyme", "PROTEIN", 52, 71], ["ADAM", "TEST", 37, 41], ["TNF", "TEST", 48, 51], ["myocardial infarction", "PROBLEM", 125, 146], ["hypertension", "PROBLEM", 148, 160], ["pressure overload", "PROBLEM", 162, 179], ["aortic aneurysm", "PROBLEM", 185, 200], ["heart", "ANATOMY", 86, 91], ["vasculature", "ANATOMY", 96, 107], ["myocardial", "ANATOMY", 125, 135], ["infarction", "OBSERVATION", 136, 146], ["hypertension", "OBSERVATION", 148, 160], ["pressure overload", "OBSERVATION", 162, 179], ["aortic", "ANATOMY", 185, 191], ["aneurysm", "OBSERVATION", 192, 200]]], ["Unlike ADAM-17, apelin regulates ACE2 expression.", [["ADAM-17", "GENE_OR_GENE_PRODUCT", 7, 14], ["apelin", "GENE_OR_GENE_PRODUCT", 16, 22], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["ADAM-17", "PROTEIN", 7, 14], ["apelin", "PROTEIN", 16, 22], ["ACE2", "PROTEIN", 33, 37]]], ["In mice, knockout of apelin is associated with lower ACE2 expression levels and exacerbated ANG II-induced cardiac hypertrophy and dysfunction (172).", [["cardiac", "ANATOMY", 107, 114], ["ANG II", "CHEMICAL", 92, 98], ["cardiac hypertrophy", "DISEASE", 107, 126], ["mice", "ORGANISM", 3, 7], ["apelin", "GENE_OR_GENE_PRODUCT", 21, 27], ["ACE2", "GENE_OR_GENE_PRODUCT", 53, 57], ["ANG II", "GENE_OR_GENE_PRODUCT", 92, 98], ["cardiac", "ORGAN", 107, 114], ["ACE2", "PROTEIN", 53, 57], ["ANG II", "PROTEIN", 92, 98], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["lower ACE2 expression levels", "PROBLEM", 47, 75], ["exacerbated ANG II-induced cardiac hypertrophy", "PROBLEM", 80, 126], ["dysfunction", "PROBLEM", 131, 142], ["cardiac", "ANATOMY", 107, 114], ["hypertrophy", "OBSERVATION", 115, 126]]], ["Treatment of apelin knockouts with pyr1-apelin-13 normalized ACE2 expression and counteracted ANG II-induced cardiac hypertrophy and dysfunction (172).", [["cardiac", "ANATOMY", 109, 116], ["pyr1-apelin-13", "CHEMICAL", 35, 49], ["ANG II", "CHEMICAL", 94, 100], ["cardiac hypertrophy", "DISEASE", 109, 128], ["apelin", "GENE_OR_GENE_PRODUCT", 13, 19], ["pyr1-apelin-13", "GENE_OR_GENE_PRODUCT", 35, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["ANG II", "GENE_OR_GENE_PRODUCT", 94, 100], ["cardiac", "ORGAN", 109, 116], ["pyr1", "PROTEIN", 35, 39], ["ACE2", "PROTEIN", 61, 65], ["ANG II", "PROTEIN", 94, 100], ["apelin knockouts", "PROBLEM", 13, 29], ["pyr1", "TEST", 35, 39], ["apelin", "TEST", 40, 46], ["ACE2 expression", "TREATMENT", 61, 76], ["counteracted ANG II-induced cardiac hypertrophy", "PROBLEM", 81, 128], ["dysfunction", "PROBLEM", 133, 144], ["cardiac", "ANATOMY", 109, 116], ["hypertrophy", "OBSERVATION", 117, 128]]], ["Interestingly, ACE2 can also degrade and inactivate apelin peptides, creating a self-regulating negative feedback loop (155).Generation and Metabolism of ANG-(1\u22127) ::: ANG-(1\u22127) AS A CRITICAL MEDIATOR OF THE ACE2-RELATED PROTECTIVE AXIS OF THE RASRecombinant human ACE2 (rhACE) produces both ANG-(1\u22127) and ANG-(1\u22129) (from ANG II and ANG I, respectively), whereas recombinant murine ACE2 generates predominantly ANG-(1\u22127) from ANG II (6, 169).", [["ANG", "CHEMICAL", 154, 157], ["ANG II", "CHEMICAL", 426, 432], ["ANG-(1\u22127)", "CHEMICAL", 154, 163], ["ANG-(1\u22127)", "CHEMICAL", 168, 177], ["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["apelin", "GENE_OR_GENE_PRODUCT", 52, 58], ["ANG-(1\u22127)", "SIMPLE_CHEMICAL", 154, 163], ["ANG-(1\u22127", "SIMPLE_CHEMICAL", 168, 176], ["human", "ORGANISM", 259, 264], ["ACE2", "GENE_OR_GENE_PRODUCT", 265, 269], ["rhACE", "GENE_OR_GENE_PRODUCT", 271, 276], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 292, 301], ["ANG-(1\u22129)", "GENE_OR_GENE_PRODUCT", 306, 315], ["ANG II", "GENE_OR_GENE_PRODUCT", 322, 328], ["ANG I", "GENE_OR_GENE_PRODUCT", 333, 338], ["murine", "ORGANISM", 375, 381], ["ACE2", "GENE_OR_GENE_PRODUCT", 382, 386], ["ANG", "GENE_OR_GENE_PRODUCT", 411, 414], ["ANG II", "GENE_OR_GENE_PRODUCT", 426, 432], ["ACE2", "PROTEIN", 15, 19], ["RASRecombinant human ACE2", "PROTEIN", 244, 269], ["rhACE", "PROTEIN", 271, 276], ["ANG", "PROTEIN", 292, 295], ["ANG II", "PROTEIN", 322, 328], ["ANG I", "PROTEIN", 333, 338], ["recombinant murine ACE2", "PROTEIN", 363, 386], ["ANG", "PROTEIN", 411, 414], ["ANG II", "PROTEIN", 426, 432], ["human", "SPECIES", 259, 264], ["murine", "SPECIES", 375, 381], ["human", "SPECIES", 259, 264], ["apelin peptides", "PROBLEM", 52, 67], ["ANG", "TEST", 154, 157], ["ANG", "TEST", 168, 171], ["THE ACE2", "TEST", 204, 212], ["ANG", "TEST", 292, 295], ["ANG", "TEST", 306, 309], ["recombinant murine ACE2", "TEST", 363, 386], ["ANG", "TEST", 411, 414], ["PROTECTIVE AXIS", "OBSERVATION", 221, 236]]], ["Studies using rhACE2 and ACE2 purified from sheep tissues showed that ANG II is the preferred substrate for ACE2 (48, 107, 134, 149, 153, 162, 173).", [["tissues", "ANATOMY", 50, 57], ["ANG II", "CHEMICAL", 70, 76], ["rhACE2", "GENE_OR_GENE_PRODUCT", 14, 20], ["ACE2", "GENE_OR_GENE_PRODUCT", 25, 29], ["sheep", "ORGANISM", 44, 49], ["tissues", "TISSUE", 50, 57], ["ANG II", "GENE_OR_GENE_PRODUCT", 70, 76], ["ACE2", "GENE_OR_GENE_PRODUCT", 108, 112], ["rhACE2", "PROTEIN", 14, 20], ["ACE2", "PROTEIN", 25, 29], ["ANG II", "PROTEIN", 70, 76], ["ACE2", "PROTEIN", 108, 112], ["sheep", "SPECIES", 44, 49], ["sheep", "SPECIES", 44, 49], ["Studies", "TEST", 0, 7], ["rhACE2", "TEST", 14, 20], ["ACE2", "TEST", 25, 29], ["ACE2", "TEST", 108, 112]]], ["In rats, changes in ACE2 correlated with plasma ANG-(1\u22129) levels (93), whereas rhACE2 efficiently converted infused ANG II into ANG-(1\u22127) (80).", [["plasma", "ANATOMY", 41, 47], ["ANG II", "CHEMICAL", 116, 122], ["ANG", "CHEMICAL", 128, 131], ["rats", "ORGANISM", 3, 7], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["plasma", "ORGANISM_SUBSTANCE", 41, 47], ["ANG-(1\u22129)", "GENE_OR_GENE_PRODUCT", 48, 57], ["rhACE2", "SIMPLE_CHEMICAL", 79, 85], ["ANG II", "GENE_OR_GENE_PRODUCT", 116, 122], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 128, 137], ["ACE2", "PROTEIN", 20, 24], ["rhACE2", "PROTEIN", 79, 85], ["ANG II", "PROTEIN", 116, 122], ["rats", "SPECIES", 3, 7], ["ACE2", "TEST", 20, 24], ["plasma ANG", "TEST", 41, 51], ["levels", "TEST", 58, 64], ["ANG", "TEST", 128, 131]]], ["In mice, rhACE2 counteracts detrimental ANG II signaling, and these therapeutic effects are mediated via ANG-(1\u22127) (102, 107, 173).", [["rhACE2", "CHEMICAL", 9, 15], ["mice", "ORGANISM", 3, 7], ["rhACE2", "SIMPLE_CHEMICAL", 9, 15], ["ANG II", "GENE_OR_GENE_PRODUCT", 40, 46], ["ANG", "GENE_OR_GENE_PRODUCT", 105, 108], ["ANG II", "PROTEIN", 40, 46], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["ANG II signaling", "PROBLEM", 40, 56]]], ["Also, in human studies, rhACE2 clearly lowered plasma ANG II levels and increased plasma ANG-(1\u22127) levels (6, 109).", [["plasma", "ANATOMY", 47, 53], ["plasma", "ANATOMY", 82, 88], ["ANG II", "CHEMICAL", 54, 60], ["human", "ORGANISM", 9, 14], ["rhACE2", "SIMPLE_CHEMICAL", 24, 30], ["plasma", "ORGANISM_SUBSTANCE", 47, 53], ["ANG II", "GENE_OR_GENE_PRODUCT", 54, 60], ["plasma", "ORGANISM_SUBSTANCE", 82, 88], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 89, 98], ["rhACE2", "PROTEIN", 24, 30], ["ANG II", "PROTEIN", 54, 60], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["human studies", "TEST", 9, 22], ["rhACE2", "TEST", 24, 30], ["plasma ANG II levels", "TEST", 47, 67], ["increased plasma ANG", "TEST", 72, 92], ["increased", "OBSERVATION_MODIFIER", 72, 81]]], ["In the heart, ANG-(1\u22127) is primarily generated by ACE2 (41, 173), whereas plasma ANG-(1\u22127) is primarily produced by neprilysin from ANG I because inhibition of neprilysin reduced ANG-(1\u22127) levels and increased ANG II levels (111).", [["heart", "ANATOMY", 7, 12], ["plasma", "ANATOMY", 74, 80], ["ANG", "CHEMICAL", 14, 17], ["ANG II", "CHEMICAL", 210, 216], ["heart", "ORGAN", 7, 12], ["ANG-(1\u22127", "GENE_OR_GENE_PRODUCT", 14, 22], ["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["plasma", "ORGANISM_SUBSTANCE", 74, 80], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 81, 90], ["neprilysin", "GENE_OR_GENE_PRODUCT", 116, 126], ["ANG I", "GENE_OR_GENE_PRODUCT", 132, 137], ["neprilysin", "GENE_OR_GENE_PRODUCT", 160, 170], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 179, 188], ["ANG II", "GENE_OR_GENE_PRODUCT", 210, 216], ["ACE2", "PROTEIN", 50, 54], ["neprilysin", "PROTEIN", 116, 126], ["ANG I", "PROTEIN", 132, 137], ["neprilysin", "PROTEIN", 160, 170], ["ANG II", "PROTEIN", 210, 216], ["ANG", "TEST", 14, 17], ["ACE2", "TEST", 50, 54], ["plasma ANG", "TEST", 74, 84], ["neprilysin", "TEST", 160, 170], ["ANG", "TEST", 179, 182], ["levels", "TEST", 189, 195], ["increased ANG II levels", "TEST", 200, 223], ["heart", "ANATOMY", 7, 12], ["ANG", "ANATOMY", 14, 17], ["increased", "OBSERVATION_MODIFIER", 200, 209]]], ["The degradation of ANG-(1\u22127) is governed predominantly by the amino-terminal catalytic domain of ACE, which degrades ANG-(1\u22127) to ANG-(1\u22125) (28).", [["ANG", "CHEMICAL", 19, 22], ["ANG-(1\u22125)", "CHEMICAL", 130, 139], ["ANG", "GENE_OR_GENE_PRODUCT", 19, 22], ["ACE", "GENE_OR_GENE_PRODUCT", 97, 100], ["ANG", "GENE_OR_GENE_PRODUCT", 117, 120], ["ANG-(1\u22125)", "SIMPLE_CHEMICAL", 130, 139], ["ANG", "PROTEIN", 19, 22], ["amino-terminal catalytic domain", "PROTEIN", 62, 93], ["ACE", "PROTEIN", 97, 100], ["ANG", "PROTEIN", 117, 120], ["ANG", "TEST", 19, 22], ["ANG", "TEST", 117, 120], ["ANG", "TEST", 130, 133], ["ANG", "OBSERVATION_MODIFIER", 19, 22], ["amino-terminal catalytic", "OBSERVATION", 62, 86]]], ["Inhibition of ACE increases plasma levels of ANG-(1\u22127) in both rodents and humans (3, 6, 20).Role of ACE2 and ANG-(1\u22127) in Heart Failure ::: ANG-(1\u22127) AS A CRITICAL MEDIATOR OF THE ACE2-RELATED PROTECTIVE AXIS OF THE RASHeart failure (HF) is driven by activation of multiple neurohumoral and signaling pathways resulting in pathological hypertrophy and maladaptive ventricular remodeling.", [["plasma", "ANATOMY", 28, 34], ["Heart", "ANATOMY", 123, 128], ["ventricular", "ANATOMY", 365, 376], ["ANG", "CHEMICAL", 45, 48], ["RASHeart failure", "DISEASE", 217, 233], ["HF", "DISEASE", 235, 237], ["hypertrophy", "DISEASE", 337, 348], ["ACE", "GENE_OR_GENE_PRODUCT", 14, 17], ["plasma", "ORGANISM_SUBSTANCE", 28, 34], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 45, 54], ["humans", "ORGANISM", 75, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 101, 105], ["ANG", "GENE_OR_GENE_PRODUCT", 110, 113], ["Heart", "ORGAN", 123, 128], ["ANG-(1\u22127", "SIMPLE_CHEMICAL", 141, 149], ["ventricular", "MULTI-TISSUE_STRUCTURE", 365, 376], ["ACE", "PROTEIN", 14, 17], ["ACE2", "PROTEIN", 101, 105], ["humans", "SPECIES", 75, 81], ["humans", "SPECIES", 75, 81], ["ACE", "TEST", 14, 17], ["plasma levels", "TEST", 28, 41], ["ANG", "TEST", 45, 48], ["ACE2", "TEST", 101, 105], ["ANG", "TEST", 110, 113], ["Heart Failure", "PROBLEM", 123, 136], ["THE RASHeart failure", "PROBLEM", 213, 233], ["HF", "PROBLEM", 235, 237], ["multiple neurohumoral and signaling pathways", "PROBLEM", 266, 310], ["pathological hypertrophy", "PROBLEM", 324, 348], ["maladaptive ventricular remodeling", "PROBLEM", 353, 387], ["ACE", "OBSERVATION", 14, 17], ["ANG", "OBSERVATION_MODIFIER", 45, 48], ["both", "ANATOMY_MODIFIER", 58, 62], ["rodents", "ANATOMY_MODIFIER", 63, 70], ["Heart", "ANATOMY", 123, 128], ["Failure", "OBSERVATION", 129, 136], ["PROTECTIVE AXIS", "OBSERVATION_MODIFIER", 194, 209], ["RASHeart failure", "OBSERVATION", 217, 233], ["pathological", "OBSERVATION_MODIFIER", 324, 336], ["hypertrophy", "OBSERVATION", 337, 348], ["maladaptive ventricular remodeling", "OBSERVATION", 353, 387]]], ["Activation of the RAS and increased ANG II levels play a pivotal role in adverse myocardial remodeling and disease progression (6, 85, 87) contributing to systolic and diastolic dysfunction in patients with HF (13, 57).", [["myocardial", "ANATOMY", 81, 91], ["systolic and diastolic dysfunction", "DISEASE", 155, 189], ["HF", "DISEASE", 207, 209], ["RAS", "GENE_OR_GENE_PRODUCT", 18, 21], ["ANG II", "GENE_OR_GENE_PRODUCT", 36, 42], ["myocardial", "MULTI-TISSUE_STRUCTURE", 81, 91], ["patients", "ORGANISM", 193, 201], ["RAS", "PROTEIN", 18, 21], ["ANG II", "PROTEIN", 36, 42], ["patients", "SPECIES", 193, 201], ["the RAS", "PROBLEM", 14, 21], ["increased ANG II levels", "PROBLEM", 26, 49], ["adverse myocardial remodeling", "PROBLEM", 73, 102], ["disease progression", "PROBLEM", 107, 126], ["systolic and diastolic dysfunction", "PROBLEM", 155, 189], ["HF", "PROBLEM", 207, 209], ["myocardial", "ANATOMY", 81, 91], ["remodeling", "OBSERVATION", 92, 102], ["disease", "OBSERVATION", 107, 114], ["diastolic dysfunction", "OBSERVATION", 168, 189]]], ["Use of ACE inhibitors does not necessarily result in lower ANG II formation because ANG II levels can remain elevated in optimally treated patients with HF.", [["ACE inhibitors", "CHEMICAL", 7, 21], ["ANG II", "CHEMICAL", 84, 90], ["HF", "DISEASE", 153, 155], ["ACE", "GENE_OR_GENE_PRODUCT", 7, 10], ["ANG II", "GENE_OR_GENE_PRODUCT", 59, 65], ["ANG II", "GENE_OR_GENE_PRODUCT", 84, 90], ["patients", "ORGANISM", 139, 147], ["ANG II", "PROTEIN", 59, 65], ["ANG II", "PROTEIN", 84, 90], ["patients", "SPECIES", 139, 147], ["ACE inhibitors", "TREATMENT", 7, 21], ["lower ANG II formation", "PROBLEM", 53, 75], ["ANG II levels", "TEST", 84, 97], ["elevated", "PROBLEM", 109, 117], ["HF", "PROBLEM", 153, 155]]], ["In fact, ~50% of patients using current ACE inhibition therapies exhibit elevated levels of ANG II, which is probably the result of increased ANG I levels and activity of mast cell chymase (6, 62, 78, 113, 158).", [["mast cell", "ANATOMY", 171, 180], ["patients", "ORGANISM", 17, 25], ["ACE", "GENE_OR_GENE_PRODUCT", 40, 43], ["ANG II", "GENE_OR_GENE_PRODUCT", 92, 98], ["ANG I", "GENE_OR_GENE_PRODUCT", 142, 147], ["mast cell chymase", "GENE_OR_GENE_PRODUCT", 171, 188], ["ANG II", "PROTEIN", 92, 98], ["ANG I", "PROTEIN", 142, 147], ["mast cell chymase", "PROTEIN", 171, 188], ["patients", "SPECIES", 17, 25], ["current ACE inhibition therapies", "TREATMENT", 32, 64], ["elevated levels of ANG II", "PROBLEM", 73, 98], ["increased ANG I levels", "PROBLEM", 132, 154], ["mast cell chymase", "TEST", 171, 188], ["elevated", "OBSERVATION", 73, 81], ["ANG II", "OBSERVATION_MODIFIER", 92, 98], ["increased", "OBSERVATION_MODIFIER", 132, 141], ["ANG", "OBSERVATION", 142, 145], ["activity", "OBSERVATION_MODIFIER", 159, 167], ["mast cell chymase", "OBSERVATION", 171, 188]]], ["This ACE-independent ANG II production highlights a need for a better understanding of the contribution of various parts of the RAS to HF progression.Role of ACE2 and ANG-(1\u22127) in Heart Failure ::: ANG-(1\u22127) AS A CRITICAL MEDIATOR OF THE ACE2-RELATED PROTECTIVE AXIS OF THE RASOur current understanding of the role of various parts of the RAS in the development of HF is shown in Fig. 1B.", [["Heart", "ANATOMY", 180, 185], ["ANG II", "CHEMICAL", 21, 27], ["HF", "DISEASE", 135, 137], ["HF", "DISEASE", 365, 367], ["1B.", "CHEMICAL", 385, 388], ["ACE", "GENE_OR_GENE_PRODUCT", 5, 8], ["ANG II", "GENE_OR_GENE_PRODUCT", 21, 27], ["RAS", "GENE_OR_GENE_PRODUCT", 128, 131], ["ACE2", "GENE_OR_GENE_PRODUCT", 158, 162], ["ANG", "GENE_OR_GENE_PRODUCT", 167, 170], ["Heart", "ORGAN", 180, 185], ["ANG-(1\u22127", "SIMPLE_CHEMICAL", 198, 206], ["RAS", "GENE_OR_GENE_PRODUCT", 339, 342], ["ACE", "PROTEIN", 5, 8], ["ANG II", "PROTEIN", 21, 27], ["ACE2", "PROTEIN", 158, 162], ["RAS", "PROTEIN", 339, 342], ["1B.", "SPECIES", 385, 388], ["HF progression", "PROBLEM", 135, 149], ["ACE2", "TEST", 158, 162], ["ANG", "TEST", 167, 170], ["Heart Failure", "PROBLEM", 180, 193], ["HF", "PROBLEM", 365, 367], ["Heart", "ANATOMY", 180, 185], ["Failure", "OBSERVATION", 186, 193], ["HF", "OBSERVATION", 365, 367]]], ["In models of HF with reduced ejection fraction, loss of ACE2 worsened the HF phenotype (67, 102).", [["HF", "DISEASE", 13, 15], ["HF", "DISEASE", 74, 76], ["ACE2", "GENE_OR_GENE_PRODUCT", 56, 60], ["ACE2", "PROTEIN", 56, 60], ["HF", "PROBLEM", 13, 15], ["reduced ejection fraction", "PROBLEM", 21, 46], ["loss of ACE2", "PROBLEM", 48, 60], ["the HF phenotype", "PROBLEM", 70, 86], ["HF", "OBSERVATION", 13, 15], ["reduced", "OBSERVATION_MODIFIER", 21, 28], ["ejection fraction", "OBSERVATION", 29, 46]]], ["Under the conditions of elevated ANG II levels, loss of protective ACE2 activity worsens cardiac dysfunction, hypertrophy, and fibrosis, leading to greater diastolic dysfunction (2, 173).", [["cardiac", "ANATOMY", 89, 96], ["ANG II", "CHEMICAL", 33, 39], ["cardiac dysfunction", "DISEASE", 89, 108], ["hypertrophy", "DISEASE", 110, 121], ["fibrosis", "DISEASE", 127, 135], ["diastolic dysfunction", "DISEASE", 156, 177], ["ANG II", "GENE_OR_GENE_PRODUCT", 33, 39], ["ACE2", "GENE_OR_GENE_PRODUCT", 67, 71], ["cardiac", "ORGAN", 89, 96], ["ANG II", "PROTEIN", 33, 39], ["ACE2", "PROTEIN", 67, 71], ["elevated ANG II levels", "PROBLEM", 24, 46], ["loss of protective ACE2 activity", "PROBLEM", 48, 80], ["cardiac dysfunction", "PROBLEM", 89, 108], ["hypertrophy", "PROBLEM", 110, 121], ["fibrosis", "PROBLEM", 127, 135], ["greater diastolic dysfunction", "PROBLEM", 148, 177], ["elevated", "OBSERVATION", 24, 32], ["protective ACE2", "OBSERVATION_MODIFIER", 56, 71], ["activity", "OBSERVATION_MODIFIER", 72, 80], ["cardiac", "ANATOMY", 89, 96], ["dysfunction", "OBSERVATION", 97, 108], ["hypertrophy", "OBSERVATION", 110, 121], ["fibrosis", "OBSERVATION", 127, 135], ["greater", "OBSERVATION_MODIFIER", 148, 155], ["diastolic dysfunction", "OBSERVATION", 156, 177]]], ["Supplying rhACE2 decreased plasma and myocardial ANG II levels and increased plasma ANG-(1\u22127) levels, resulting in attenuated pathological remodeling and corrected diastolic dysfunction (173).", [["plasma", "ANATOMY", 27, 33], ["myocardial", "ANATOMY", 38, 48], ["plasma", "ANATOMY", 77, 83], ["diastolic dysfunction", "DISEASE", 164, 185], ["rhACE2", "GENE_OR_GENE_PRODUCT", 10, 16], ["plasma", "ORGANISM_SUBSTANCE", 27, 33], ["myocardial", "MULTI-TISSUE_STRUCTURE", 38, 48], ["ANG II", "GENE_OR_GENE_PRODUCT", 49, 55], ["plasma", "ORGANISM_SUBSTANCE", 77, 83], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 84, 93], ["rhACE2", "PROTEIN", 10, 16], ["ANG II", "PROTEIN", 49, 55], ["plasma", "TEST", 27, 33], ["myocardial ANG II levels", "TEST", 38, 62], ["increased plasma ANG", "TEST", 67, 87], ["attenuated pathological remodeling", "PROBLEM", 115, 149], ["corrected diastolic dysfunction", "PROBLEM", 154, 185], ["myocardial", "ANATOMY", 38, 48], ["ANG", "OBSERVATION", 49, 52], ["attenuated", "OBSERVATION_MODIFIER", 115, 125], ["pathological remodeling", "OBSERVATION", 126, 149], ["diastolic dysfunction", "OBSERVATION", 164, 185]]], ["Even partial loss of ACE2 (in heterozygous female mice) is sufficient to enhance the susceptibility to heart disease, which is a clinically relevant observation because ACE2 is downregulated in human hearts with dilated cardiomyopathy (156).", [["heart", "ANATOMY", 103, 108], ["hearts", "ANATOMY", 200, 206], ["heart disease", "DISEASE", 103, 116], ["dilated cardiomyopathy", "DISEASE", 212, 234], ["ACE2", "GENE_OR_GENE_PRODUCT", 21, 25], ["female mice", "ORGANISM", 43, 54], ["heart", "ORGAN", 103, 108], ["ACE2", "GENE_OR_GENE_PRODUCT", 169, 173], ["human", "ORGANISM", 194, 199], ["hearts", "ORGAN", 200, 206], ["ACE2", "PROTEIN", 21, 25], ["ACE2", "PROTEIN", 169, 173], ["mice", "SPECIES", 50, 54], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 194, 199], ["partial loss of ACE2", "PROBLEM", 5, 25], ["the susceptibility to heart disease", "PROBLEM", 81, 116], ["ACE2", "TEST", 169, 173], ["dilated cardiomyopathy", "PROBLEM", 212, 234], ["partial", "OBSERVATION_MODIFIER", 5, 12], ["loss", "OBSERVATION_MODIFIER", 13, 17], ["ACE2", "OBSERVATION_MODIFIER", 21, 25], ["heart", "ANATOMY", 103, 108], ["disease", "OBSERVATION", 109, 116], ["human hearts", "ANATOMY", 194, 206], ["dilated", "OBSERVATION_MODIFIER", 212, 219], ["cardiomyopathy", "OBSERVATION", 220, 234]]], ["Increase in soluble ACE2, which reflects loss of tissue-bound ACE2, is associated with severity of HF and serves as an independent predictor of major adverse cardiac events (6, 33, 119).", [["tissue", "ANATOMY", 49, 55], ["cardiac", "ANATOMY", 158, 165], ["HF", "DISEASE", 99, 101], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["tissue", "TISSUE", 49, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["cardiac", "ORGAN", 158, 165], ["ACE2", "PROTEIN", 20, 24], ["ACE2", "PROTEIN", 62, 66], ["Increase in soluble ACE2", "PROBLEM", 0, 24], ["loss of tissue-bound ACE2", "PROBLEM", 41, 66], ["HF", "PROBLEM", 99, 101], ["major adverse cardiac events", "PROBLEM", 144, 172], ["soluble ACE2", "OBSERVATION", 12, 24], ["loss", "OBSERVATION_MODIFIER", 41, 45], ["of tissue", "OBSERVATION_MODIFIER", 46, 55], ["bound ACE2", "OBSERVATION_MODIFIER", 56, 66], ["HF", "OBSERVATION", 99, 101]]], ["Because shedding of ACE2 is mediated via ADAM-17 (59, 103, 163), it suggests a possible involvement of ADAM-17 in the development of HF.", [["HF", "DISEASE", 133, 135], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["ADAM-17", "GENE_OR_GENE_PRODUCT", 41, 48], ["ADAM-17", "GENE_OR_GENE_PRODUCT", 103, 110], ["ACE2", "PROTEIN", 20, 24], ["ADAM", "PROTEIN", 41, 45], ["ADAM-17", "PROTEIN", 103, 110], ["ACE2", "TEST", 20, 24], ["involvement of ADAM", "PROBLEM", 88, 107], ["HF", "PROBLEM", 133, 135], ["HF", "OBSERVATION", 133, 135]]], ["Involvement of ADAM-17 in HF development has been shown primarily in relation to the TNF-\u03b1 signaling pathway in humans (129, 130) and in mouse models of heart disease (34, 66).", [["heart", "ANATOMY", 153, 158], ["HF", "DISEASE", 26, 28], ["heart disease", "DISEASE", 153, 166], ["ADAM-17", "GENE_OR_GENE_PRODUCT", 15, 22], ["HF", "CANCER", 26, 28], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 85, 90], ["humans", "ORGANISM", 112, 118], ["mouse", "ORGANISM", 137, 142], ["heart", "ORGAN", 153, 158], ["ADAM-17", "PROTEIN", 15, 22], ["TNF", "PROTEIN", 85, 88], ["humans", "SPECIES", 112, 118], ["mouse", "SPECIES", 137, 142], ["humans", "SPECIES", 112, 118], ["mouse", "SPECIES", 137, 142], ["HF", "PROBLEM", 26, 28], ["the TNF", "TEST", 81, 88], ["heart disease", "PROBLEM", 153, 166], ["heart", "ANATOMY", 153, 158], ["disease", "OBSERVATION", 159, 166]]], ["However, in light of the findings that ANG II induces ADAM-17-dependent cleavage of ACE2, it becomes clear that ANG II, ADAM-17, and ACE2 create a potentially dangerous positive feedback loop conducive to the development of HF (103).", [["ANG II", "CHEMICAL", 39, 45], ["HF", "DISEASE", 224, 226], ["ANG II", "GENE_OR_GENE_PRODUCT", 39, 45], ["ADAM-17", "GENE_OR_GENE_PRODUCT", 54, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["ANG II", "GENE_OR_GENE_PRODUCT", 112, 118], ["ADAM-17", "GENE_OR_GENE_PRODUCT", 120, 127], ["ACE2", "GENE_OR_GENE_PRODUCT", 133, 137], ["ANG II", "PROTEIN", 39, 45], ["ADAM-17", "PROTEIN", 54, 61], ["ACE2", "PROTEIN", 84, 88], ["ANG II", "PROTEIN", 112, 118], ["ADAM-17", "PROTEIN", 120, 127], ["ACE2", "PROTEIN", 133, 137], ["ADAM", "TEST", 54, 58], ["dependent cleavage of ACE2", "PROBLEM", 62, 88], ["ADAM", "TEST", 120, 124], ["ACE2", "TREATMENT", 133, 137], ["HF", "PROBLEM", 224, 226]]], ["Conversely, loss of ANG-(1\u22127) actions exacerbated heart disease in an ACE2-deficient state (102), whereas inhibition of ANG-(1\u22127)/Mas signaling prevented rhACE2-mediated cardioprotection (107), confirming the importance of ANG-(1\u22127) contribution to the cardioprotective effects of ACE2.", [["heart", "ANATOMY", 50, 55], ["heart disease", "DISEASE", 50, 63], ["rhACE2", "CHEMICAL", 154, 160], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 20, 29], ["heart", "ORGAN", 50, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 120, 129], ["Mas", "GENE_OR_GENE_PRODUCT", 130, 133], ["rhACE2", "SIMPLE_CHEMICAL", 154, 160], ["ANG", "GENE_OR_GENE_PRODUCT", 223, 226], ["1\u22127", "SIMPLE_CHEMICAL", 228, 231], ["ACE2", "GENE_OR_GENE_PRODUCT", 281, 285], ["ACE2", "PROTEIN", 70, 74], ["rhACE2", "PROTEIN", 154, 160], ["ACE2", "PROTEIN", 281, 285], ["ANG", "TEST", 20, 23], ["exacerbated heart disease", "PROBLEM", 38, 63], ["an ACE2-deficient state", "PROBLEM", 67, 90], ["ANG", "TEST", 120, 123], ["ACE2", "PROBLEM", 281, 285], ["heart", "ANATOMY", 50, 55], ["disease", "OBSERVATION", 56, 63]]], ["Supplying ANG-(1\u22127) directly was also cardioprotective in preclinical models of heart disease (81, 88, 118, 145).", [["heart", "ANATOMY", 80, 85], ["ANG", "CHEMICAL", 10, 13], ["heart disease", "DISEASE", 80, 93], ["ANG-(1\u22127)", "CHEMICAL", 10, 19], ["ANG", "SIMPLE_CHEMICAL", 10, 13], ["1\u22127", "SIMPLE_CHEMICAL", 15, 18], ["heart", "ORGAN", 80, 85], ["heart disease", "PROBLEM", 80, 93], ["heart", "ANATOMY", 80, 85], ["disease", "OBSERVATION", 86, 93]]], ["ANG-(1\u22127) suppressed cardiomyocyte growth and myocardial infarction-induced ventricular hypertrophy and decreased myocardial levels of proinflammatory cytokines, leading to a reduction in myocardial inflammation (118, 145).", [["cardiomyocyte", "ANATOMY", 21, 34], ["myocardial", "ANATOMY", 46, 56], ["ventricular", "ANATOMY", 76, 87], ["myocardial", "ANATOMY", 114, 124], ["myocardial", "ANATOMY", 188, 198], ["ANG", "CHEMICAL", 0, 3], ["myocardial infarction", "DISEASE", 46, 67], ["ventricular hypertrophy", "DISEASE", 76, 99], ["myocardial inflammation", "DISEASE", 188, 211], ["ANG", "SIMPLE_CHEMICAL", 0, 3], ["1\u22127", "SIMPLE_CHEMICAL", 5, 8], ["cardiomyocyte", "CELL", 21, 34], ["myocardial", "MULTI-TISSUE_STRUCTURE", 46, 56], ["ventricular", "MULTI-TISSUE_STRUCTURE", 76, 87], ["myocardial", "MULTI-TISSUE_STRUCTURE", 114, 124], ["myocardial", "MULTI-TISSUE_STRUCTURE", 188, 198], ["proinflammatory cytokines", "PROTEIN", 135, 160], ["ANG", "TEST", 0, 3], ["suppressed cardiomyocyte growth", "PROBLEM", 10, 41], ["myocardial infarction", "PROBLEM", 46, 67], ["ventricular hypertrophy", "PROBLEM", 76, 99], ["decreased myocardial levels of proinflammatory cytokines", "PROBLEM", 104, 160], ["a reduction in myocardial inflammation", "PROBLEM", 173, 211], ["cardiomyocyte", "ANATOMY", 21, 34], ["myocardial", "ANATOMY", 46, 56], ["infarction", "OBSERVATION", 57, 67], ["ventricular", "ANATOMY", 76, 87], ["hypertrophy", "OBSERVATION", 88, 99], ["decreased", "OBSERVATION_MODIFIER", 104, 113], ["myocardial levels", "OBSERVATION", 114, 131], ["proinflammatory cytokines", "OBSERVATION", 135, 160], ["reduction", "OBSERVATION_MODIFIER", 175, 184], ["myocardial", "ANATOMY", 188, 198], ["inflammation", "OBSERVATION", 199, 211]]], ["ANG-(1\u22127) activation of Mas results in the activation of phosphatidylinositol 3-kinase (PI3K)-Akt-endothelial nitric oxide (NO) synthase (eNOS), upregulation of MAPK phosphatase (84), inhibition of PKC-p38 MAPK and reactive oxygen species production (50, 102, 173), and suppression of collagen expression (reducing myocardial fibrosis) (29, 44, 124), thereby antagonizing pathological effects of ANG II (88, 109, 127).", [["myocardial", "ANATOMY", 315, 325], ["nitric oxide", "CHEMICAL", 110, 122], ["NO", "CHEMICAL", 124, 126], ["oxygen", "CHEMICAL", 224, 230], ["myocardial fibrosis", "DISEASE", 315, 334], ["ANG II", "CHEMICAL", 396, 402], ["phosphatidylinositol", "CHEMICAL", 57, 77], ["nitric oxide", "CHEMICAL", 110, 122], ["NO", "CHEMICAL", 124, 126], ["oxygen", "CHEMICAL", 224, 230], ["ANG-(1\u22127", "GENE_OR_GENE_PRODUCT", 0, 8], ["Mas", "GENE_OR_GENE_PRODUCT", 24, 27], ["phosphatidylinositol 3-kinase", "GENE_OR_GENE_PRODUCT", 57, 86], ["PI3K)-Akt-endothelial nitric oxide (NO) synthase", "GENE_OR_GENE_PRODUCT", 88, 136], ["eNOS", "GENE_OR_GENE_PRODUCT", 138, 142], ["MAPK phosphatase (84)", "GENE_OR_GENE_PRODUCT", 161, 182], ["PKC-p38 MAPK", "GENE_OR_GENE_PRODUCT", 198, 210], ["reactive oxygen species", "SIMPLE_CHEMICAL", 215, 238], ["collagen", "GENE_OR_GENE_PRODUCT", 285, 293], ["myocardial", "MULTI-TISSUE_STRUCTURE", 315, 325], ["ANG II", "GENE_OR_GENE_PRODUCT", 396, 402], ["Mas", "PROTEIN", 24, 27], ["phosphatidylinositol 3-kinase", "PROTEIN", 57, 86], ["PI3K", "PROTEIN", 88, 92], ["Akt", "PROTEIN", 94, 97], ["endothelial nitric oxide (NO) synthase", "PROTEIN", 98, 136], ["eNOS", "PROTEIN", 138, 142], ["MAPK phosphatase", "PROTEIN", 161, 177], ["PKC", "PROTEIN", 198, 201], ["p38 MAPK", "PROTEIN", 202, 210], ["collagen", "PROTEIN", 285, 293], ["ANG II", "PROTEIN", 396, 402], ["ANG", "TEST", 0, 3], ["phosphatidylinositol", "TEST", 57, 77], ["PI3K", "TEST", 88, 92], ["Akt-endothelial nitric oxide", "TREATMENT", 94, 122], ["upregulation of MAPK phosphatase", "TEST", 145, 177], ["PKC", "TEST", 198, 201], ["p38 MAPK", "TEST", 202, 210], ["reactive oxygen species production", "PROBLEM", 215, 249], ["collagen expression (reducing myocardial fibrosis", "PROBLEM", 285, 334], ["ANG II", "TEST", 396, 402], ["reactive", "OBSERVATION_MODIFIER", 215, 223], ["oxygen species", "OBSERVATION", 224, 238], ["collagen expression", "OBSERVATION", 285, 304], ["myocardial", "ANATOMY", 315, 325], ["fibrosis", "OBSERVATION", 326, 334]]], ["In addition to ANG-(1\u22127), ANG-(1\u22129), the product of ACE2 degradation of ANG I, is antihypertrophic, antifibrotic, and antihypertensive in models of hypertension and myocardial infarction (36, 37, 94, 95).Role of ACE2 and ANG-(1\u22127) in Heart Failure ::: ANG-(1\u22127) AS A CRITICAL MEDIATOR OF THE ACE2-RELATED PROTECTIVE AXIS OF THE RASACE2 and ANG-(1\u22127) also play important roles in vascular disease and hypertension (109).", [["myocardial", "ANATOMY", 165, 175], ["Heart", "ANATOMY", 234, 239], ["vascular", "ANATOMY", 379, 387], ["ANG", "CHEMICAL", 15, 18], ["hypertension", "DISEASE", 148, 160], ["myocardial infarction", "DISEASE", 165, 186], ["vascular disease", "DISEASE", 379, 395], ["hypertension", "DISEASE", 400, 412], ["ANG", "SIMPLE_CHEMICAL", 15, 18], ["1\u22127", "SIMPLE_CHEMICAL", 20, 23], ["ANG-(1\u22129", "SIMPLE_CHEMICAL", 26, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["ANG I", "GENE_OR_GENE_PRODUCT", 72, 77], ["myocardial", "MULTI-TISSUE_STRUCTURE", 165, 175], ["ACE2", "GENE_OR_GENE_PRODUCT", 212, 216], ["ANG", "GENE_OR_GENE_PRODUCT", 221, 224], ["Heart", "ORGAN", 234, 239], ["ANG-(1\u22127", "SIMPLE_CHEMICAL", 252, 260], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 340, 349], ["vascular", "MULTI-TISSUE_STRUCTURE", 379, 387], ["ACE2", "PROTEIN", 52, 56], ["ANG I", "PROTEIN", 72, 77], ["ACE2", "PROTEIN", 212, 216], ["ANG", "TEST", 15, 18], ["ANG", "TEST", 26, 29], ["ACE2 degradation", "PROBLEM", 52, 68], ["ANG I", "PROBLEM", 72, 77], ["antihypertrophic", "PROBLEM", 82, 98], ["antifibrotic", "TREATMENT", 100, 112], ["antihypertensive", "TREATMENT", 118, 134], ["hypertension", "PROBLEM", 148, 160], ["myocardial infarction", "PROBLEM", 165, 186], ["ACE2", "TEST", 212, 216], ["ANG", "TEST", 221, 224], ["Heart Failure", "PROBLEM", 234, 247], ["vascular disease", "PROBLEM", 379, 395], ["hypertension", "PROBLEM", 400, 412], ["antifibrotic", "OBSERVATION", 100, 112], ["hypertension", "OBSERVATION", 148, 160], ["myocardial", "ANATOMY", 165, 175], ["infarction", "OBSERVATION", 176, 186], ["Heart", "ANATOMY", 234, 239], ["Failure", "OBSERVATION", 240, 247], ["PROTECTIVE AXIS", "OBSERVATION_MODIFIER", 305, 320], ["vascular", "ANATOMY", 379, 387], ["disease", "OBSERVATION", 388, 395], ["hypertension", "OBSERVATION", 400, 412]]], ["For example, rhACE2 pretreatment partially reversed ANG II-mediated hypertension because of decreased plasma ANG II and increased plasma ANG-(1\u22127) levels (80, 162), whereas loss of ACE2 exacerbates ANG II-mediated hypertension (108).", [["plasma", "ANATOMY", 102, 108], ["plasma", "ANATOMY", 130, 136], ["rhACE2", "CHEMICAL", 13, 19], ["ANG II", "CHEMICAL", 52, 58], ["hypertension", "DISEASE", 68, 80], ["ANG II", "CHEMICAL", 198, 204], ["hypertension", "DISEASE", 214, 226], ["rhACE2", "CHEMICAL", 13, 19], ["rhACE2", "SIMPLE_CHEMICAL", 13, 19], ["ANG II", "GENE_OR_GENE_PRODUCT", 52, 58], ["plasma", "ORGANISM_SUBSTANCE", 102, 108], ["ANG II", "GENE_OR_GENE_PRODUCT", 109, 115], ["plasma", "ORGANISM_SUBSTANCE", 130, 136], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 137, 146], ["ACE2", "GENE_OR_GENE_PRODUCT", 181, 185], ["ANG II", "GENE_OR_GENE_PRODUCT", 198, 204], ["ANG II", "PROTEIN", 52, 58], ["ANG II", "PROTEIN", 109, 115], ["ACE2", "PROTEIN", 181, 185], ["ANG II", "PROTEIN", 198, 204], ["ANG II-mediated hypertension", "PROBLEM", 52, 80], ["decreased plasma ANG II", "PROBLEM", 92, 115], ["increased plasma ANG", "TEST", 120, 140], ["levels", "TEST", 147, 153], ["ACE2 exacerbates ANG II-mediated hypertension", "PROBLEM", 181, 226], ["hypertension", "OBSERVATION", 68, 80], ["hypertension", "OBSERVATION", 214, 226]]], ["Cyclodextrin-encapsulated ANG-(1\u22127) and Mas agonists (AVE0091 and CGEN856S) have demonstrated antihypertensive effects in preclinical models (146).", [["Cyclodextrin", "CHEMICAL", 0, 12], ["ANG", "CHEMICAL", 26, 29], ["AVE0091", "CHEMICAL", 54, 61], ["CGEN856S", "CHEMICAL", 66, 74], ["Cyclodextrin", "CHEMICAL", 0, 12], ["AVE0091", "CHEMICAL", 54, 61], ["CGEN856S", "CHEMICAL", 66, 74], ["Cyclodextrin", "SIMPLE_CHEMICAL", 0, 12], ["ANG-(1\u22127)", "SIMPLE_CHEMICAL", 26, 35], ["Mas agonists", "SIMPLE_CHEMICAL", 40, 52], ["AVE0091", "SIMPLE_CHEMICAL", 54, 61], ["CGEN856S", "SIMPLE_CHEMICAL", 66, 74], ["Cyclodextrin", "TREATMENT", 0, 12], ["Mas agonists", "TREATMENT", 40, 52], ["antihypertensive effects", "TREATMENT", 94, 118]]], ["These antihypertensive effects of ACE2/ANG-(1\u22127) suggest new possible therapeutic options against hypertensive heart disease.Role of ACE2/ANG-(1\u22127) in Obesity-Associated Cardiomyopathy ::: ANG-(1\u22127) AS A CRITICAL MEDIATOR OF THE ACE2-RELATED PROTECTIVE AXIS OF THE RASDiabetes and obesity are major causes of cardiovascular morbidity and mortality worldwide and result in microvascular and macrovascular complications, including hypertension (174).", [["heart", "ANATOMY", 111, 116], ["cardiovascular", "ANATOMY", 309, 323], ["microvascular", "ANATOMY", 372, 385], ["macrovascular", "ANATOMY", 390, 403], ["hypertensive heart disease", "DISEASE", 98, 124], ["Obesity", "DISEASE", 151, 158], ["Cardiomyopathy", "DISEASE", 170, 184], ["obesity", "DISEASE", 281, 288], ["cardiovascular morbidity", "DISEASE", 309, 333], ["microvascular and macrovascular complications", "DISEASE", 372, 417], ["hypertension", "DISEASE", 429, 441], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["ANG", "GENE_OR_GENE_PRODUCT", 39, 42], ["heart", "ORGAN", 111, 116], ["ACE2", "GENE_OR_GENE_PRODUCT", 133, 137], ["ANG", "GENE_OR_GENE_PRODUCT", 138, 141], ["ANG-(1\u22127", "SIMPLE_CHEMICAL", 189, 197], ["cardiovascular", "ANATOMICAL_SYSTEM", 309, 323], ["microvascular", "TISSUE", 372, 385], ["ACE2", "PROTEIN", 34, 38], ["ACE2", "PROTEIN", 133, 137], ["ACE2/ANG", "TREATMENT", 34, 42], ["hypertensive heart disease", "PROBLEM", 98, 124], ["ACE2/ANG", "TREATMENT", 133, 141], ["Obesity", "PROBLEM", 151, 158], ["Cardiomyopathy", "PROBLEM", 170, 184], ["THE RASDiabetes", "PROBLEM", 261, 276], ["obesity", "PROBLEM", 281, 288], ["cardiovascular morbidity", "PROBLEM", 309, 333], ["microvascular and macrovascular complications", "PROBLEM", 372, 417], ["hypertension", "PROBLEM", 429, 441], ["heart", "ANATOMY", 111, 116], ["disease", "OBSERVATION", 117, 124], ["Cardiomyopathy", "OBSERVATION", 170, 184], ["PROTECTIVE AXIS", "OBSERVATION", 242, 257], ["obesity", "OBSERVATION", 281, 288], ["cardiovascular", "ANATOMY", 309, 323], ["morbidity", "OBSERVATION", 324, 333], ["microvascular", "ANATOMY", 372, 385], ["macrovascular", "OBSERVATION_MODIFIER", 390, 403], ["complications", "OBSERVATION", 404, 417], ["hypertension", "OBSERVATION", 429, 441]]], ["Diabetic heart disease, linked to systolic and diastolic dysfunctions, and HF (39, 47, 70, 174) are associated with activation of the RAS (11, 12, 56, 90).", [["heart", "ANATOMY", 9, 14], ["Diabetic heart disease", "DISEASE", 0, 22], ["systolic and diastolic dysfunctions", "DISEASE", 34, 69], ["HF", "DISEASE", 75, 77], ["heart", "ORGAN", 9, 14], ["RAS", "GENE_OR_GENE_PRODUCT", 134, 137], ["RAS", "PROTEIN", 134, 137], ["Diabetic heart disease", "PROBLEM", 0, 22], ["systolic and diastolic dysfunctions", "PROBLEM", 34, 69], ["HF", "PROBLEM", 75, 77], ["heart", "ANATOMY", 9, 14], ["disease", "OBSERVATION", 15, 22], ["systolic", "OBSERVATION_MODIFIER", 34, 42], ["diastolic dysfunctions", "OBSERVATION", 47, 69]]], ["Obesity, the major metabolic precursor to type 2 diabetes, is an independent risk factor for the development of HF with preserved ejection fraction (HFpEF) (68, 69, 98, 166).", [["Obesity", "DISEASE", 0, 7], ["type 2 diabetes", "DISEASE", 42, 57], ["HF", "DISEASE", 112, 114], ["Obesity", "PROBLEM", 0, 7], ["type 2 diabetes", "PROBLEM", 42, 57], ["an independent risk factor", "PROBLEM", 62, 88], ["HF", "PROBLEM", 112, 114], ["HFpEF", "TEST", 149, 154], ["metabolic precursor", "OBSERVATION", 19, 38], ["diabetes", "OBSERVATION", 49, 57], ["HF", "OBSERVATION", 112, 114], ["ejection fraction", "OBSERVATION", 130, 147]]], ["Emerging preclinical and clinical data strongly support a key pathogenic role for ACE2 and ANG-(1\u22127) in the progression of cardiovascular diseases (109, 132, 142).", [["cardiovascular", "ANATOMY", 123, 137], ["cardiovascular diseases", "DISEASE", 123, 146], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 91, 100], ["cardiovascular", "ANATOMICAL_SYSTEM", 123, 137], ["ACE2", "PROTEIN", 82, 86], ["ANG", "PROTEIN", 91, 94], ["ACE2", "TEST", 82, 86], ["ANG", "TEST", 91, 94], ["cardiovascular diseases", "PROBLEM", 123, 146], ["cardiovascular", "ANATOMY", 123, 137], ["diseases", "OBSERVATION", 138, 146]]], ["In a model of type 2 diabetes (db/db), ANG-(1\u22127) rescued diastolic dysfunction and reduced cardiac hypertrophy, fibrosis, lipotoxicity, and adipose inflammation (89, 100).", [["cardiac", "ANATOMY", 91, 98], ["adipose", "ANATOMY", 140, 147], ["type 2 diabetes", "DISEASE", 14, 29], ["ANG-(1\u22127)", "CHEMICAL", 39, 48], ["diastolic dysfunction", "DISEASE", 57, 78], ["cardiac hypertrophy", "DISEASE", 91, 110], ["fibrosis", "DISEASE", 112, 120], ["lipotoxicity", "DISEASE", 122, 134], ["adipose inflammation", "DISEASE", 140, 160], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 39, 48], ["cardiac", "ORGAN", 91, 98], ["adipose", "TISSUE", 140, 147], ["type 2 diabetes", "PROBLEM", 14, 29], ["ANG", "TEST", 39, 42], ["rescued diastolic dysfunction", "PROBLEM", 49, 78], ["reduced cardiac hypertrophy", "PROBLEM", 83, 110], ["fibrosis", "PROBLEM", 112, 120], ["lipotoxicity", "PROBLEM", 122, 134], ["adipose inflammation", "PROBLEM", 140, 160], ["diabetes", "OBSERVATION", 21, 29], ["diastolic dysfunction", "OBSERVATION", 57, 78], ["reduced", "OBSERVATION_MODIFIER", 83, 90], ["cardiac", "ANATOMY", 91, 98], ["hypertrophy", "OBSERVATION", 99, 110], ["fibrosis", "OBSERVATION", 112, 120], ["lipotoxicity", "OBSERVATION", 122, 134], ["adipose", "ANATOMY", 140, 147], ["inflammation", "OBSERVATION", 148, 160]]], ["Conversely, in the settings of high-fat diet-induced obesity, loss of ACE2 worsened heart disease because of increased epicardial adipose tissue inflammation, myocardial lipotoxicity, and worsened cardiac insulin resistance (105).", [["heart", "ANATOMY", 84, 89], ["epicardial adipose tissue", "ANATOMY", 119, 144], ["myocardial", "ANATOMY", 159, 169], ["cardiac", "ANATOMY", 197, 204], ["obesity", "DISEASE", 53, 60], ["heart disease", "DISEASE", 84, 97], ["inflammation", "DISEASE", 145, 157], ["myocardial lipotoxicity", "DISEASE", 159, 182], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["heart", "ORGAN", 84, 89], ["epicardial adipose tissue", "TISSUE", 119, 144], ["myocardial", "MULTI-TISSUE_STRUCTURE", 159, 169], ["cardiac", "ORGAN", 197, 204], ["insulin", "GENE_OR_GENE_PRODUCT", 205, 212], ["ACE2", "PROTEIN", 70, 74], ["high-fat diet", "TREATMENT", 31, 44], ["induced obesity", "PROBLEM", 45, 60], ["ACE2 worsened heart disease", "PROBLEM", 70, 97], ["increased epicardial adipose tissue inflammation", "PROBLEM", 109, 157], ["myocardial lipotoxicity", "PROBLEM", 159, 182], ["worsened cardiac insulin resistance", "PROBLEM", 188, 223], ["fat diet", "OBSERVATION", 36, 44], ["obesity", "OBSERVATION", 53, 60], ["heart", "ANATOMY", 84, 89], ["disease", "OBSERVATION", 90, 97], ["increased", "OBSERVATION_MODIFIER", 109, 118], ["epicardial", "ANATOMY_MODIFIER", 119, 129], ["adipose tissue", "ANATOMY", 130, 144], ["inflammation", "OBSERVATION", 145, 157], ["myocardial", "ANATOMY", 159, 169], ["lipotoxicity", "OBSERVATION", 170, 182], ["worsened", "OBSERVATION_MODIFIER", 188, 196], ["cardiac", "ANATOMY", 197, 204], ["insulin resistance", "OBSERVATION", 205, 223]]], ["ANG-(1\u22127) prevented these changes and rescued HFpEF in ACE2 knockout mice (105).", [["ANG", "CHEMICAL", 0, 3], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 0, 9], ["HFpEF", "GENE_OR_GENE_PRODUCT", 46, 51], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["mice", "ORGANISM", 69, 73], ["HFpEF", "PROTEIN", 46, 51], ["ACE2", "PROTEIN", 55, 59], ["mice", "SPECIES", 69, 73], ["ANG", "TEST", 0, 3], ["rescued HFpEF", "TREATMENT", 38, 51], ["HFpEF", "OBSERVATION", 46, 51]]], ["These findings, coupled with the protective effects of ACE2 and ANG-(1\u22127) in the vasculature and adipose tissue, support inflammation and microvascular dysfunction as key mediators of HFpEF (110, 116).", [["vasculature", "ANATOMY", 81, 92], ["adipose tissue", "ANATOMY", 97, 111], ["microvascular", "ANATOMY", 138, 151], ["inflammation", "DISEASE", 121, 133], ["microvascular dysfunction", "DISEASE", 138, 163], ["HFpEF", "CHEMICAL", 184, 189], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 64, 73], ["vasculature", "MULTI-TISSUE_STRUCTURE", 81, 92], ["adipose tissue", "TISSUE", 97, 111], ["microvascular", "TISSUE", 138, 151], ["ACE2", "PROTEIN", 55, 59], ["ACE2", "TEST", 55, 59], ["ANG", "TEST", 64, 67], ["adipose tissue", "PROBLEM", 97, 111], ["inflammation", "PROBLEM", 121, 133], ["microvascular dysfunction", "PROBLEM", 138, 163], ["HFpEF", "TEST", 184, 189], ["vasculature", "ANATOMY", 81, 92], ["adipose tissue", "OBSERVATION", 97, 111], ["inflammation", "OBSERVATION", 121, 133], ["microvascular dysfunction", "OBSERVATION", 138, 163], ["HFpEF", "OBSERVATION", 184, 189]]], ["These results suggest that in patients with HFpEF, epicardial adipose tissue inflammation may be related to cardiac dysfunction and adverse remodeling (105, 106).", [["epicardial adipose tissue", "ANATOMY", 51, 76], ["cardiac", "ANATOMY", 108, 115], ["HFpEF", "DISEASE", 44, 49], ["inflammation", "DISEASE", 77, 89], ["cardiac dysfunction", "DISEASE", 108, 127], ["patients", "ORGANISM", 30, 38], ["epicardial adipose tissue", "TISSUE", 51, 76], ["cardiac", "ORGAN", 108, 115], ["patients", "SPECIES", 30, 38], ["HFpEF", "PROBLEM", 44, 49], ["epicardial adipose tissue inflammation", "PROBLEM", 51, 89], ["cardiac dysfunction", "PROBLEM", 108, 127], ["adverse remodeling", "PROBLEM", 132, 150], ["HFpEF", "OBSERVATION", 44, 49], ["epicardial", "ANATOMY", 51, 61], ["adipose tissue", "OBSERVATION", 62, 76], ["inflammation", "OBSERVATION", 77, 89], ["may be related to", "UNCERTAINTY", 90, 107], ["cardiac", "ANATOMY", 108, 115], ["dysfunction", "OBSERVATION", 116, 127], ["adverse", "OBSERVATION_MODIFIER", 132, 139], ["remodeling", "OBSERVATION_MODIFIER", 140, 150]]], ["In patients with obesity, administration of ANG-(1\u22127) improved insulin-stimulated endothelium-dependent vasodilation and blunted endothelin-1-dependent vasoconstrictor tone (132).", [["endothelium", "ANATOMY", 82, 93], ["obesity", "DISEASE", 17, 24], ["ANG-(1\u22127)", "CHEMICAL", 44, 53], ["patients", "ORGANISM", 3, 11], ["ANG-(1\u22127)", "SIMPLE_CHEMICAL", 44, 53], ["insulin", "GENE_OR_GENE_PRODUCT", 63, 70], ["endothelium", "TISSUE", 82, 93], ["endothelin-1", "GENE_OR_GENE_PRODUCT", 129, 141], ["patients", "SPECIES", 3, 11], ["obesity", "PROBLEM", 17, 24], ["ANG", "TEST", 44, 47], ["insulin", "TREATMENT", 63, 70], ["dependent vasodilation", "PROBLEM", 94, 116], ["blunted endothelin", "PROBLEM", 121, 139], ["dependent vasoconstrictor tone", "PROBLEM", 142, 172], ["obesity", "OBSERVATION", 17, 24], ["blunted endothelin", "OBSERVATION", 121, 139]]], ["Therefore, enhancing the ACE2 and ANG-(1\u22127) pathways represents a potential therapy for HFpEF, a condition with an adverse prognosis that lacks effective therapy.Physiological Effects of Alamandine ::: ALATENSINSAlamandine has been reported to reverse hyperhomocysteinemia-induced vascular dysfunction.", [["HFpEF", "ANATOMY", 88, 93], ["vascular", "ANATOMY", 281, 289], ["HFpEF", "DISEASE", 88, 93], ["Alamandine", "CHEMICAL", 187, 197], ["ALATENSINSAlamandine", "CHEMICAL", 202, 222], ["hyperhomocysteinemia", "DISEASE", 252, 272], ["vascular dysfunction", "DISEASE", 281, 301], ["Alamandine", "CHEMICAL", 187, 197], ["ALATENSINSAlamandine", "CHEMICAL", 202, 222], ["ACE2", "GENE_OR_GENE_PRODUCT", 25, 29], ["ANG-(1\u22127", "GENE_OR_GENE_PRODUCT", 34, 42], ["HFpEF", "CANCER", 88, 93], ["Alamandine", "SIMPLE_CHEMICAL", 187, 197], ["ALATENSINSAlamandine", "SIMPLE_CHEMICAL", 202, 222], ["vascular", "MULTI-TISSUE_STRUCTURE", 281, 289], ["ACE2", "PROTEIN", 25, 29], ["ANG", "TEST", 34, 37], ["a potential therapy", "TREATMENT", 64, 83], ["HFpEF", "PROBLEM", 88, 93], ["an adverse prognosis", "PROBLEM", 112, 132], ["effective therapy", "TREATMENT", 144, 161], ["Alamandine", "TREATMENT", 187, 197], ["ALATENSINSAlamandine", "TREATMENT", 202, 222], ["reverse hyperhomocysteinemia", "PROBLEM", 244, 272], ["vascular dysfunction", "PROBLEM", 281, 301], ["hyperhomocysteinemia", "OBSERVATION", 252, 272], ["vascular", "ANATOMY", 281, 289], ["dysfunction", "OBSERVATION", 290, 301]]], ["Activation of PKA appears to be involved in this effect (117).", [["PKA", "GENE_OR_GENE_PRODUCT", 14, 17], ["PKA", "PROTEIN", 14, 17], ["Activation of PKA", "PROBLEM", 0, 17]]], ["In adipose tissue, an alamandine-induced reduction of leptin has been described through a mechanism involving Src/p38 MAPK (150).", [["adipose tissue", "ANATOMY", 3, 17], ["alamandine", "CHEMICAL", 22, 32], ["alamandine", "CHEMICAL", 22, 32], ["adipose tissue", "TISSUE", 3, 17], ["alamandine", "SIMPLE_CHEMICAL", 22, 32], ["leptin", "GENE_OR_GENE_PRODUCT", 54, 60], ["Src", "GENE_OR_GENE_PRODUCT", 110, 113], ["p38 MAPK (150)", "GENE_OR_GENE_PRODUCT", 114, 128], ["leptin", "PROTEIN", 54, 60], ["Src", "PROTEIN", 110, 113], ["p38 MAPK", "PROTEIN", 114, 122], ["an alamandine-induced reduction of leptin", "TREATMENT", 19, 60], ["Src/p38 MAPK", "TEST", 110, 122], ["adipose tissue", "ANATOMY", 3, 17]]], ["As previously described for ANG-(1\u22127), an inclusion compound of alamandine/2-hydroxypropyl (HP)-\u03b2-cyclodextrin reduced blood pressure in nonanesthetized spontaneously hypertensive rats.", [["blood", "ANATOMY", 119, 124], ["ANG", "CHEMICAL", 28, 31], ["alamandine", "CHEMICAL", 64, 74], ["2-hydroxypropyl (HP)-\u03b2-cyclodextrin", "CHEMICAL", 75, 110], ["hypertensive", "DISEASE", 167, 179], ["ANG-(1\u22127)", "CHEMICAL", 28, 37], ["alamandine", "CHEMICAL", 64, 74], ["2-hydroxypropyl", "CHEMICAL", 75, 90], ["HP)-\u03b2-cyclodextrin", "CHEMICAL", 92, 110], ["ANG-(1\u22127)", "SIMPLE_CHEMICAL", 28, 37], ["alamandine", "SIMPLE_CHEMICAL", 64, 74], ["2-hydroxypropyl (HP)-\u03b2-cyclodextrin", "SIMPLE_CHEMICAL", 75, 110], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["rats", "ORGANISM", 180, 184], ["rats", "SPECIES", 180, 184], ["ANG", "TEST", 28, 31], ["alamandine", "TREATMENT", 64, 74], ["hydroxypropyl (HP)", "TREATMENT", 77, 95], ["cyclodextrin", "TREATMENT", 98, 110], ["blood pressure", "TEST", 119, 133], ["nonanesthetized spontaneously hypertensive rats", "PROBLEM", 137, 184]]], ["Likewise, as previously observed for ANG-(1\u22127) (83), oral administration of alamandine/HP-\u03b2-cyclodextrin attenuated the cardiac profibrotic effect of isoproterenol in Sprague-Dawley rats (50).", [["oral", "ANATOMY", 53, 57], ["cardiac", "ANATOMY", 120, 127], ["ANG", "CHEMICAL", 37, 40], ["alamandine", "CHEMICAL", 76, 86], ["HP-\u03b2-cyclodextrin", "CHEMICAL", 87, 104], ["isoproterenol", "CHEMICAL", 150, 163], ["alamandine", "CHEMICAL", 76, 86], ["HP-\u03b2-cyclodextrin", "CHEMICAL", 87, 104], ["isoproterenol", "CHEMICAL", 150, 163], ["ANG-(1\u22127)", "SIMPLE_CHEMICAL", 37, 46], ["oral", "ORGANISM_SUBDIVISION", 53, 57], ["alamandine", "SIMPLE_CHEMICAL", 76, 86], ["HP-\u03b2-cyclodextrin", "SIMPLE_CHEMICAL", 87, 104], ["cardiac", "ORGAN", 120, 127], ["isoproterenol", "SIMPLE_CHEMICAL", 150, 163], ["Sprague-Dawley rats", "ORGANISM", 167, 186], ["Sprague-Dawley rats", "SPECIES", 167, 186], ["Sprague-Dawley rats", "SPECIES", 167, 186], ["ANG", "TEST", 37, 40], ["alamandine/HP", "TREATMENT", 76, 89], ["\u03b2-cyclodextrin", "TREATMENT", 90, 104], ["the cardiac profibrotic effect", "TREATMENT", 116, 146], ["isoproterenol in Sprague", "TREATMENT", 150, 174], ["cardiac", "ANATOMY", 120, 127], ["profibrotic", "OBSERVATION", 128, 139]]], ["More recently, a cardioprotective effect of alamandine has been described in an experimental model of sepsis (79).", [["alamandine", "CHEMICAL", 44, 54], ["sepsis", "DISEASE", 102, 108], ["alamandine", "CHEMICAL", 44, 54], ["alamandine", "SIMPLE_CHEMICAL", 44, 54], ["alamandine", "TREATMENT", 44, 54], ["sepsis", "PROBLEM", 102, 108], ["sepsis", "OBSERVATION", 102, 108]]], ["In keeping with these effects, it has been reported that knockdown of MrgD in mice leads to marked dilated cardiomyopathy (96).", [["dilated cardiomyopathy", "DISEASE", 99, 121], ["MrgD", "GENE_OR_GENE_PRODUCT", 70, 74], ["mice", "ORGANISM", 78, 82], ["MrgD", "PROTEIN", 70, 74], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 78, 82], ["marked dilated cardiomyopathy", "PROBLEM", 92, 121], ["marked", "OBSERVATION_MODIFIER", 92, 98], ["dilated", "OBSERVATION_MODIFIER", 99, 106], ["cardiomyopathy", "OBSERVATION", 107, 121]]], ["Centrally, the action of alamandine resembles those described for ANG\u2010(1\u22127) in the rostral ventrolateral medulla, caudal ventrolateral medulla, and hypothalamus (38, 74, 137, 140).", [["rostral ventrolateral medulla", "ANATOMY", 83, 112], ["caudal ventrolateral medulla", "ANATOMY", 114, 142], ["hypothalamus", "ANATOMY", 148, 160], ["alamandine", "CHEMICAL", 25, 35], ["alamandine", "CHEMICAL", 25, 35], ["alamandine", "SIMPLE_CHEMICAL", 25, 35], ["ANG\u2010(1\u22127", "GENE_OR_GENE_PRODUCT", 66, 74], ["rostral ventrolateral medulla", "MULTI-TISSUE_STRUCTURE", 83, 112], ["caudal ventrolateral medulla", "MULTI-TISSUE_STRUCTURE", 114, 142], ["hypothalamus", "ORGAN", 148, 160], ["alamandine", "TREATMENT", 25, 35], ["ANG\u2010", "TEST", 66, 70], ["rostral", "ANATOMY_MODIFIER", 83, 90], ["ventrolateral", "ANATOMY_MODIFIER", 91, 104], ["medulla", "ANATOMY", 105, 112], ["caudal", "ANATOMY_MODIFIER", 114, 120], ["ventrolateral", "ANATOMY_MODIFIER", 121, 134], ["medulla", "ANATOMY", 135, 142], ["hypothalamus", "ANATOMY", 148, 160]]], ["These observations suggest that, as described for ANG II and ANG\u2010(1\u22127), alamandine may act as a neuronal excitatory molecule in the brain.", [["neuronal", "ANATOMY", 96, 104], ["brain", "ANATOMY", 132, 137], ["alamandine", "CHEMICAL", 72, 82], ["alamandine", "CHEMICAL", 72, 82], ["ANG II", "GENE_OR_GENE_PRODUCT", 50, 56], ["ANG\u2010(1\u22127", "GENE_OR_GENE_PRODUCT", 61, 69], ["alamandine", "SIMPLE_CHEMICAL", 72, 82], ["neuronal", "CELL", 96, 104], ["brain", "ORGAN", 132, 137], ["ANG II", "PROTEIN", 50, 56], ["neuronal excitatory molecule", "PROTEIN", 96, 124], ["ANG II and ANG\u2010", "TEST", 50, 65], ["alamandine", "TREATMENT", 72, 82], ["a neuronal excitatory molecule in the brain", "PROBLEM", 94, 137], ["brain", "ANATOMY", 132, 137]]], ["However, striking differences between these two peptides are becoming progressively evident (61, 82).", [["progressively", "OBSERVATION_MODIFIER", 70, 83]]], ["For instance, in the insular cortex, alamandine but not ANG\u2010(1\u22127) promotes excitatory cardiovascular effects, including increases in blood pressure and heart rate associated with increased renal sympathetic activity (82).", [["insular cortex", "ANATOMY", 21, 35], ["cardiovascular", "ANATOMY", 86, 100], ["blood", "ANATOMY", 133, 138], ["heart", "ANATOMY", 152, 157], ["renal", "ANATOMY", 189, 194], ["alamandine", "CHEMICAL", 37, 47], ["ANG\u2010(1\u22127)", "CHEMICAL", 56, 65], ["increases in blood pressure", "DISEASE", 120, 147], ["alamandine", "CHEMICAL", 37, 47], ["insular cortex", "CANCER", 21, 35], ["alamandine", "SIMPLE_CHEMICAL", 37, 47], ["ANG\u2010(1\u22127", "GENE_OR_GENE_PRODUCT", 56, 64], ["cardiovascular", "ANATOMICAL_SYSTEM", 86, 100], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["heart", "ORGAN", 152, 157], ["renal", "ORGAN", 189, 194], ["alamandine", "TREATMENT", 37, 47], ["blood pressure", "TEST", 133, 147], ["heart rate", "TEST", 152, 162], ["increased renal sympathetic activity", "PROBLEM", 179, 215], ["insular cortex", "ANATOMY", 21, 35], ["heart", "ANATOMY", 152, 157], ["renal", "ANATOMY", 189, 194], ["sympathetic activity", "OBSERVATION", 195, 215]]], ["Moreover, ANG-(1\u22127) [and ANG II/AT2Rs (112, 168)] promotes NO release mainly by activating the PI3K/Akt/eNOS pathway (124), whereas alamandine leads to NO release by a mechanism not involving this pathway (Fig. 2).", [["ANG", "CHEMICAL", 10, 13], ["NO", "CHEMICAL", 59, 61], ["alamandine", "CHEMICAL", 132, 142], ["NO", "CHEMICAL", 152, 154], ["NO", "CHEMICAL", 59, 61], ["alamandine", "CHEMICAL", 132, 142], ["NO", "CHEMICAL", 152, 154], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 10, 19], ["ANG II", "GENE_OR_GENE_PRODUCT", 25, 31], ["AT2Rs (112, 168)", "GENE_OR_GENE_PRODUCT", 32, 48], ["NO", "SIMPLE_CHEMICAL", 59, 61], ["PI3K", "GENE_OR_GENE_PRODUCT", 95, 99], ["Akt", "GENE_OR_GENE_PRODUCT", 100, 103], ["NOS", "GENE_OR_GENE_PRODUCT", 105, 108], ["alamandine", "SIMPLE_CHEMICAL", 132, 142], ["NO", "SIMPLE_CHEMICAL", 152, 154], ["PI3K", "PROTEIN", 95, 99], ["Akt", "PROTEIN", 100, 103], ["NOS", "PROTEIN", 105, 108], ["ANG", "TEST", 10, 13], ["ANG II/AT2Rs", "TEST", 25, 37], ["the PI3K", "TEST", 91, 99], ["Akt/eNOS pathway", "TEST", 100, 116]]], ["AMP-activated protein kinase (AMPK) appears to be the main target for alamandine-induced NO formation (61).Physiological Effects of Alamandine ::: ALATENSINSIt was well demonstrated by Jankowski and colleagues that ANG A binds and produces biological effects through interactions with AT1Rs (60).", [["AMP", "CHEMICAL", 0, 3], ["alamandine", "CHEMICAL", 70, 80], ["NO", "CHEMICAL", 89, 91], ["Alamandine", "CHEMICAL", 132, 142], ["ANG", "CHEMICAL", 215, 218], ["AMP", "CHEMICAL", 0, 3], ["alamandine", "CHEMICAL", 70, 80], ["NO", "CHEMICAL", 89, 91], ["Alamandine", "CHEMICAL", 132, 142], ["AMP-activated protein kinase", "GENE_OR_GENE_PRODUCT", 0, 28], ["AMPK", "GENE_OR_GENE_PRODUCT", 30, 34], ["alamandine", "SIMPLE_CHEMICAL", 70, 80], ["NO", "SIMPLE_CHEMICAL", 89, 91], ["Alamandine", "SIMPLE_CHEMICAL", 132, 142], ["ANG A", "GENE_OR_GENE_PRODUCT", 215, 220], ["AT1Rs", "GENE_OR_GENE_PRODUCT", 285, 290], ["AMP-activated protein kinase", "PROTEIN", 0, 28], ["AMPK", "PROTEIN", 30, 34], ["AT1Rs", "PROTEIN", 285, 290], ["AMP", "TEST", 0, 3], ["activated protein kinase", "TEST", 4, 28], ["AMPK", "TEST", 30, 34], ["alamandine", "TEST", 70, 80]]], ["However, the relationship of ANG A and AT1Rs apparently is not as straightforward as it appears.", [["ANG A", "GENE_OR_GENE_PRODUCT", 29, 34], ["AT1Rs", "GENE_OR_GENE_PRODUCT", 39, 44], ["ANG A", "PROTEIN", 29, 34]]], ["The vasoconstrictor effect of ANG A is smaller than that of ANG II, despite the fact that the affinity of both peptides for AT1Rs is remarkably similar (60).", [["ANG", "CHEMICAL", 30, 33], ["ANG II", "CHEMICAL", 60, 66], ["ANG A", "CHEMICAL", 30, 35], ["ANG A", "GENE_OR_GENE_PRODUCT", 30, 35], ["ANG II", "GENE_OR_GENE_PRODUCT", 60, 66], ["AT1Rs", "GENE_OR_GENE_PRODUCT", 124, 129], ["ANG II", "PROTEIN", 60, 66], ["ANG A", "PROBLEM", 30, 35], ["AT1Rs", "TEST", 124, 129], ["vasoconstrictor effect", "OBSERVATION", 4, 26], ["ANG", "OBSERVATION", 30, 33], ["smaller", "OBSERVATION_MODIFIER", 39, 46]]], ["This could be because of the formation of alamandine, as we have previously hypothesized (74).", [["alamandine", "CHEMICAL", 42, 52], ["alamandine", "CHEMICAL", 42, 52], ["alamandine", "SIMPLE_CHEMICAL", 42, 52], ["alamandine", "TREATMENT", 42, 52]]], ["However, in isolated cardiomyocytes, ANG A was essentially ineffective in promoting electrically stimulated Ca2+ influx (23).", [["cardiomyocytes", "ANATOMY", 21, 35], ["ANG A", "CHEMICAL", 37, 42], ["Ca2", "CHEMICAL", 108, 111], ["ANG A", "CHEMICAL", 37, 42], ["Ca2+", "CHEMICAL", 108, 112], ["cardiomyocytes", "CELL", 21, 35], ["ANG A", "GENE_OR_GENE_PRODUCT", 37, 42], ["Ca2+", "SIMPLE_CHEMICAL", 108, 112], ["isolated cardiomyocytes", "CELL_TYPE", 12, 35], ["Ca2", "PROTEIN", 108, 111], ["isolated cardiomyocytes", "PROBLEM", 12, 35], ["cardiomyocytes", "ANATOMY", 21, 35], ["ineffective", "OBSERVATION_MODIFIER", 59, 70]]], ["In the same preparation, ANG II was active.", [["ANG II", "CHEMICAL", 25, 31], ["ANG II", "GENE_OR_GENE_PRODUCT", 25, 31], ["ANG II", "PROTEIN", 25, 31], ["active", "OBSERVATION_MODIFIER", 36, 42]]], ["Accordingly, a 10-fold difference between ANG II and ANG A for intracellular Ca2+ release in vascular smooth muscle cells was observed by Jankowski et al. (60).", [["intracellular", "ANATOMY", 63, 76], ["vascular smooth muscle cells", "ANATOMY", 93, 121], ["Ca2", "CHEMICAL", 77, 80], ["Ca2+", "CHEMICAL", 77, 81], ["ANG II", "GENE_OR_GENE_PRODUCT", 42, 48], ["ANG A", "GENE_OR_GENE_PRODUCT", 53, 58], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 76], ["Ca2+", "SIMPLE_CHEMICAL", 77, 81], ["vascular smooth muscle cells", "CELL", 93, 121], ["ANG II", "PROTEIN", 42, 48], ["ANG A", "PROTEIN", 53, 58], ["Ca2", "PROTEIN", 77, 80], ["vascular smooth muscle cells", "CELL_TYPE", 93, 121], ["a 10-fold difference", "PROBLEM", 13, 33], ["ANG II", "TREATMENT", 42, 48], ["intracellular Ca2", "TREATMENT", 63, 80], ["vascular", "ANATOMY", 93, 101], ["smooth muscle", "ANATOMY", 102, 115]]], ["These observations suggest that ANG A could be a biased agonist of AT1Rs.", [["ANG A", "CHEMICAL", 32, 37], ["ANG A", "CHEMICAL", 32, 37], ["ANG A", "GENE_OR_GENE_PRODUCT", 32, 37], ["AT1Rs", "GENE_OR_GENE_PRODUCT", 67, 72], ["AT1Rs", "PROTEIN", 67, 72], ["ANG A", "PROBLEM", 32, 37], ["a biased agonist of AT1Rs", "PROBLEM", 47, 72]]], ["This possibility has not been explored yet.Novel Findings on Alamandine and AT1R Interactions ::: ALATENSINSCanta et al. (17) compared the effects of alamandine and ANG-(1\u22127) in nonanesthetized normotensive Sprague-Dawley rats.", [["Alamandine", "CHEMICAL", 61, 71], ["alamandine", "CHEMICAL", 150, 160], ["ANG", "CHEMICAL", 165, 168], ["Alamandine", "CHEMICAL", 61, 71], ["alamandine", "CHEMICAL", 150, 160], ["ANG-(1\u22127)", "CHEMICAL", 165, 174], ["Alamandine", "SIMPLE_CHEMICAL", 61, 71], ["AT1R", "GENE_OR_GENE_PRODUCT", 76, 80], ["alamandine", "SIMPLE_CHEMICAL", 150, 160], ["ANG-(1\u22127", "SIMPLE_CHEMICAL", 165, 173], ["Sprague-Dawley rats", "ORGANISM", 207, 226], ["Sprague-Dawley rats", "SPECIES", 207, 226], ["alamandine", "TREATMENT", 150, 160], ["ANG", "TREATMENT", 165, 168]]], ["In contrast to ANG-(1\u22127), which has no effect on blood pressure, alamandine produced a dose-response U-shaped decrease in blood pressure.", [["blood", "ANATOMY", 49, 54], ["blood", "ANATOMY", 122, 127], ["ANG", "CHEMICAL", 15, 18], ["alamandine", "CHEMICAL", 65, 75], ["alamandine", "CHEMICAL", 65, 75], ["ANG", "SIMPLE_CHEMICAL", 15, 18], ["1\u22127", "SIMPLE_CHEMICAL", 20, 23], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["alamandine", "SIMPLE_CHEMICAL", 65, 75], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["ANG", "TEST", 15, 18], ["blood pressure", "TEST", 49, 63], ["alamandine", "TREATMENT", 65, 75], ["blood pressure", "TEST", 122, 136], ["no", "UNCERTAINTY", 36, 38], ["effect", "OBSERVATION_MODIFIER", 39, 45], ["shaped", "OBSERVATION_MODIFIER", 103, 109], ["decrease", "OBSERVATION_MODIFIER", 110, 118], ["blood pressure", "OBSERVATION", 122, 136]]], ["The maximal decrease in blood pressure was achieved by intravenous administration of 20 pg/animal.", [["blood", "ANATOMY", 24, 29], ["intravenous", "ANATOMY", 55, 66], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 55, 66], ["The maximal decrease in blood pressure", "TREATMENT", 0, 38], ["maximal", "OBSERVATION_MODIFIER", 4, 11], ["decrease", "OBSERVATION_MODIFIER", 12, 20], ["blood pressure", "OBSERVATION", 24, 38]]], ["To test whether the U-shaped dose-response was because of stimulation of AT1Rs, the experiments were repeated in losartan-treated rats.", [["losartan", "CHEMICAL", 113, 121], ["losartan", "CHEMICAL", 113, 121], ["AT1Rs", "GENE_OR_GENE_PRODUCT", 73, 78], ["losartan", "SIMPLE_CHEMICAL", 113, 121], ["rats", "ORGANISM", 130, 134], ["AT1Rs", "PROTEIN", 73, 78], ["rats", "SPECIES", 130, 134], ["the U-shaped dose", "TREATMENT", 16, 33], ["stimulation of AT1Rs", "PROBLEM", 58, 78], ["losartan", "TREATMENT", 113, 121]]], ["In this condition, a magnification of the hypotensive response was observed (Fig. 3).", [["hypotensive", "DISEASE", 42, 53], ["the hypotensive response", "TEST", 38, 62]]], ["However, the U-shaped form was still evident.", [["U-shaped", "OBSERVATION_MODIFIER", 13, 21]]], ["These results suggest that alamandine is more potent than ANG-(1\u22127) as a vasodilator and that AT1Rs are involved in alamandine effects.", [["alamandine", "CHEMICAL", 27, 37], ["ANG", "CHEMICAL", 58, 61], ["alamandine", "CHEMICAL", 116, 126], ["alamandine", "CHEMICAL", 27, 37], ["ANG-(1\u22127)", "CHEMICAL", 58, 67], ["alamandine", "CHEMICAL", 116, 126], ["alamandine", "SIMPLE_CHEMICAL", 27, 37], ["ANG-(1\u22127)", "SIMPLE_CHEMICAL", 58, 67], ["AT1Rs", "GENE_OR_GENE_PRODUCT", 94, 99], ["alamandine", "SIMPLE_CHEMICAL", 116, 126], ["AT1Rs", "PROTEIN", 94, 99], ["alamandine", "TREATMENT", 27, 37], ["a vasodilator", "TREATMENT", 71, 84]]], ["A similar conclusion was drawn by Soltani Hekmat et al. (141) in pentobarbital-anesthetized rats.", [["pentobarbital", "CHEMICAL", 65, 78], ["pentobarbital", "CHEMICAL", 65, 78], ["pentobarbital", "SIMPLE_CHEMICAL", 65, 78], ["rats", "ORGANISM", 92, 96], ["rats", "SPECIES", 92, 96], ["pentobarbital-anesthetized rats", "TREATMENT", 65, 96]]], ["However, a more general conclusion about the modulatory role of AT1Rs on the cardiovascular effects of alamandine cannot be drawn in other rat strains (Wistar and spontaneously hypertensive stroke-prone rats), because losartan abolished rather than increased alamandine vasorelaxant action (75).", [["cardiovascular", "ANATOMY", 77, 91], ["alamandine", "CHEMICAL", 103, 113], ["hypertensive stroke", "DISEASE", 177, 196], ["losartan", "CHEMICAL", 218, 226], ["alamandine", "CHEMICAL", 259, 269], ["alamandine", "CHEMICAL", 103, 113], ["losartan", "CHEMICAL", 218, 226], ["alamandine", "CHEMICAL", 259, 269], ["AT1Rs", "GENE_OR_GENE_PRODUCT", 64, 69], ["cardiovascular", "ANATOMICAL_SYSTEM", 77, 91], ["alamandine", "SIMPLE_CHEMICAL", 103, 113], ["rat", "ORGANISM", 139, 142], ["Wistar", "ORGANISM", 152, 158], ["rats", "ORGANISM", 203, 207], ["losartan", "SIMPLE_CHEMICAL", 218, 226], ["alamandine", "SIMPLE_CHEMICAL", 259, 269], ["AT1Rs", "PROTEIN", 64, 69], ["rat", "SPECIES", 139, 142], ["rats", "SPECIES", 203, 207], ["alamandine", "TREATMENT", 103, 113], ["spontaneously hypertensive stroke", "PROBLEM", 163, 196], ["losartan", "TREATMENT", 218, 226], ["increased alamandine vasorelaxant action", "TREATMENT", 249, 289]]], ["In addition, in the caudal ventrolateral medulla, blockade of AT1Rs did not alter the hypotensive effect of alamandine (140).ANG-(1\u22127)/Mas Signaling ::: NOVEL DOWNSTREAM PLAYERS OF ANG-(1\u22127)/MAS AND ALAMANDINE/MRGD SIGNALING NETWORKS IDENTIFIED BY PHOSPHOPROTEOMICSBecause ANG-(1\u22127) was identified as the endogenous ligand of Mas in 2003 (127), Western blot-based studies have contributed to build a solid knowledge of ANG-(1\u22127)/Mas signaling.", [["caudal ventrolateral medulla", "ANATOMY", 20, 48], ["hypotensive", "DISEASE", 86, 97], ["alamandine", "CHEMICAL", 108, 118], ["ANG", "CHEMICAL", 273, 276], ["alamandine", "CHEMICAL", 108, 118], ["caudal ventrolateral medulla", "MULTI-TISSUE_STRUCTURE", 20, 48], ["AT1Rs", "GENE_OR_GENE_PRODUCT", 62, 67], ["alamandine", "SIMPLE_CHEMICAL", 108, 118], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 125, 134], ["Mas", "GENE_OR_GENE_PRODUCT", 135, 138], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 273, 282], ["Mas", "GENE_OR_GENE_PRODUCT", 326, 329], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 419, 428], ["Mas", "GENE_OR_GENE_PRODUCT", 429, 432], ["Mas", "PROTEIN", 429, 432], ["alamandine", "TREATMENT", 108, 118], ["ANG", "TEST", 125, 128], ["ANG", "TEST", 181, 184], ["ANG", "TEST", 273, 276], ["Western blot", "TEST", 345, 357], ["ANG", "TEST", 419, 422], ["Mas signaling", "PROBLEM", 429, 442], ["caudal", "ANATOMY_MODIFIER", 20, 26], ["ventrolateral", "ANATOMY_MODIFIER", 27, 40], ["medulla", "ANATOMY", 41, 48]]], ["For example, using this method, it was reported that ANG-(1\u22127)-induced NO production is dependent on the activation of the PI3K/Akt/eNOS pathway (124) and that ANG-(1\u22127) activates Src homology region 2 domain-containing phosphatase (SHP)-2 to counterregulate ANG II/AT1R signaling (123).ANG-(1\u22127)/Mas Signaling ::: NOVEL DOWNSTREAM PLAYERS OF ANG-(1\u22127)/MAS AND ALAMANDINE/MRGD SIGNALING NETWORKS IDENTIFIED BY PHOSPHOPROTEOMICSPhosphoproteomics has been used to build a comprehensive time-resolved signaling network of ANG-(1\u22127) in human endothelial cells (152).", [["endothelial cells", "ANATOMY", 538, 555], ["ANG-(1\u22127)", "CHEMICAL", 53, 62], ["NO", "CHEMICAL", 71, 73], ["ANG", "CHEMICAL", 519, 522], ["NO", "CHEMICAL", 71, 73], ["ANG-(1\u22127)", "SIMPLE_CHEMICAL", 53, 62], ["NO", "SIMPLE_CHEMICAL", 71, 73], ["PI3K", "GENE_OR_GENE_PRODUCT", 123, 127], ["Akt", "GENE_OR_GENE_PRODUCT", 128, 131], ["NOS", "GENE_OR_GENE_PRODUCT", 133, 136], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 160, 169], ["Src homology region 2 domain-containing phosphatase (SHP)-2", "GENE_OR_GENE_PRODUCT", 180, 239], ["ANG II", "GENE_OR_GENE_PRODUCT", 259, 265], ["AT1R", "GENE_OR_GENE_PRODUCT", 266, 270], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 287, 296], ["Mas", "GENE_OR_GENE_PRODUCT", 297, 300], ["ANG", "GENE_OR_GENE_PRODUCT", 519, 522], ["1\u22127", "SIMPLE_CHEMICAL", 524, 527], ["human", "ORGANISM", 532, 537], ["endothelial cells", "CELL", 538, 555], ["PI3K", "PROTEIN", 123, 127], ["Akt", "PROTEIN", 128, 131], ["NOS", "PROTEIN", 133, 136], ["Src homology region 2 domain-containing phosphatase (SHP)-2", "PROTEIN", 180, 239], ["ANG II", "PROTEIN", 259, 265], ["AT1R", "PROTEIN", 266, 270], ["ANG", "PROTEIN", 519, 522], ["human endothelial cells", "CELL_TYPE", 532, 555], ["human", "SPECIES", 532, 537], ["human", "SPECIES", 532, 537], ["this method", "TEST", 19, 30], ["ANG", "TEST", 53, 56], ["the PI3K", "TEST", 119, 127], ["Akt/eNOS pathway", "TEST", 128, 144], ["ANG", "TEST", 160, 163], ["Src homology region", "TEST", 180, 199], ["phosphatase (SHP)", "TEST", 220, 237], ["ANG II/AT1R signaling", "TEST", 259, 280], ["ANG", "TEST", 287, 290], ["ANG", "TEST", 343, 346], ["ANG", "TEST", 519, 522], ["endothelial cells", "ANATOMY", 538, 555]]], ["ANG-(1\u22127) stimulation led to differential regulation of 121 phosphosites from 79 proteins, including dephosphorylation of Ser256 on the transcription factor FOXO1, leading to its activation.", [["ANG", "CHEMICAL", 0, 3], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 0, 9], ["Ser256", "GENE_OR_GENE_PRODUCT", 122, 128], ["FOXO1", "GENE_OR_GENE_PRODUCT", 157, 162], ["121 phosphosites", "PROTEIN", 56, 72], ["79 proteins", "PROTEIN", 78, 89], ["Ser256", "PROTEIN", 122, 128], ["transcription factor", "PROTEIN", 136, 156], ["FOXO1", "PROTEIN", 157, 162], ["ANG", "TEST", 0, 3], ["stimulation", "TREATMENT", 10, 21], ["differential regulation", "TEST", 29, 52], ["phosphosites", "TEST", 60, 72], ["dephosphorylation of Ser256", "PROBLEM", 101, 128]]], ["FOXO1 is an important regulator of tumor suppression and cell metabolism (46, 72).", [["tumor", "ANATOMY", 35, 40], ["cell", "ANATOMY", 57, 61], ["tumor", "DISEASE", 35, 40], ["FOXO1", "GENE_OR_GENE_PRODUCT", 0, 5], ["tumor", "CANCER", 35, 40], ["cell", "CELL", 57, 61], ["FOXO1", "PROTEIN", 0, 5], ["tumor suppression", "PROBLEM", 35, 52], ["cell metabolism", "TEST", 57, 72], ["tumor suppression", "OBSERVATION", 35, 52]]], ["FOXO1 activation by ANG-(1\u22127) seems to be an important molecular event on the antitumoral effect attributed to this heptapeptide.", [["ANG", "CHEMICAL", 20, 23], ["FOXO1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 20, 29], ["antitumoral", "CANCER", 78, 89], ["FOXO1", "PROTEIN", 0, 5], ["ANG", "TEST", 20, 23], ["the antitumoral effect", "TREATMENT", 74, 96], ["this heptapeptide", "TREATMENT", 111, 128]]], ["One could not anticipate that ANG-(1\u22127) would induce FOXO1 activation before this phosphoproteomic study because Akt1, a crucial player of ANG-(1\u22127) signaling (124), induces FOXO1 phosphorylation and inhibition (15).", [["ANG", "CHEMICAL", 30, 33], ["ANG", "SIMPLE_CHEMICAL", 30, 33], ["1\u22127", "SIMPLE_CHEMICAL", 35, 38], ["FOXO1", "GENE_OR_GENE_PRODUCT", 53, 58], ["Akt1", "GENE_OR_GENE_PRODUCT", 113, 117], ["ANG-(1\u22127) signaling (124)", "GENE_OR_GENE_PRODUCT", 139, 164], ["FOXO1", "GENE_OR_GENE_PRODUCT", 174, 179], ["FOXO1", "PROTEIN", 53, 58], ["Akt1", "PROTEIN", 113, 117], ["FOXO1", "PROTEIN", 174, 179], ["ANG", "TEST", 30, 33], ["FOXO1 activation", "PROBLEM", 53, 69], ["this phosphoproteomic study", "TEST", 77, 104], ["ANG", "TEST", 139, 142], ["FOXO1 phosphorylation and inhibition", "TREATMENT", 174, 210]]], ["Nevertheless, it is clear that other upstream players yet to be identified are responsible for FOXO1 dephosphorylation upon Mas activation.ANG-(1\u22127)/Mas and Alamandine/MrgD Induce NO Formation Via Different Signaling Pathways ::: NOVEL DOWNSTREAM PLAYERS OF ANG-(1\u22127)/MAS AND ALAMANDINE/MRGD SIGNALING NETWORKS IDENTIFIED BY PHOSPHOPROTEOMICSNO formation is a shared outcome of ANG-(1\u22127) and alamandine treatment.", [["Alamandine", "CHEMICAL", 157, 167], ["NO", "CHEMICAL", 180, 182], ["ANG", "CHEMICAL", 378, 381], ["alamandine", "CHEMICAL", 392, 402], ["Alamandine", "CHEMICAL", 157, 167], ["NO", "CHEMICAL", 180, 182], ["alamandine", "CHEMICAL", 392, 402], ["FOXO1", "GENE_OR_GENE_PRODUCT", 95, 100], ["Mas", "GENE_OR_GENE_PRODUCT", 124, 127], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 139, 148], ["Mas", "GENE_OR_GENE_PRODUCT", 149, 152], ["Alamandine", "SIMPLE_CHEMICAL", 157, 167], ["MrgD", "SIMPLE_CHEMICAL", 168, 172], ["NO", "SIMPLE_CHEMICAL", 180, 182], ["ANG-(1\u22127)", "SIMPLE_CHEMICAL", 378, 387], ["alamandine", "SIMPLE_CHEMICAL", 392, 402], ["FOXO1", "PROTEIN", 95, 100], ["MrgD", "PROTEIN", 168, 172], ["FOXO1 dephosphorylation", "PROBLEM", 95, 118], ["ANG", "TEST", 139, 142], ["Alamandine", "TREATMENT", 157, 167], ["ANG", "TEST", 378, 381], ["alamandine treatment", "TREATMENT", 392, 412]]], ["This event is associated with many beneficial effects observed for these peptides (45, 74).", [["these peptides", "TEST", 67, 81], ["associated with", "UNCERTAINTY", 14, 29]]], ["However, as mentioned above in alatensins, ANG-(1\u22127) and alamandine do not trigger a common pathway to activate NOS (Fig. 2).", [["alatensins", "CHEMICAL", 31, 41], ["ANG", "CHEMICAL", 43, 46], ["alamandine", "CHEMICAL", 57, 67], ["alatensins", "CHEMICAL", 31, 41], ["ANG-(1\u22127)", "CHEMICAL", 43, 52], ["alamandine", "CHEMICAL", 57, 67], ["alatensins", "SIMPLE_CHEMICAL", 31, 41], ["ANG", "SIMPLE_CHEMICAL", 43, 46], ["1\u22127", "SIMPLE_CHEMICAL", 48, 51], ["alamandine", "SIMPLE_CHEMICAL", 57, 67], ["NOS", "GENE_OR_GENE_PRODUCT", 112, 115], ["NOS", "PROTEIN", 112, 115], ["ANG", "TEST", 43, 46], ["alamandine", "TREATMENT", 57, 67]]], ["Although ANG-(1\u22127)/Mas induces NO production via the PI3K/Akt/eNOS pathway on endothelial cells and cardiomyocytes (29, 124), alamandine increases NO levels in a LKB1/AMPK-dependent manner in cardiomyocytes.", [["endothelial cells", "ANATOMY", 78, 95], ["cardiomyocytes", "ANATOMY", 100, 114], ["cardiomyocytes", "ANATOMY", 192, 206], ["NO", "CHEMICAL", 31, 33], ["alamandine", "CHEMICAL", 126, 136], ["NO", "CHEMICAL", 147, 149], ["NO", "CHEMICAL", 31, 33], ["alamandine", "CHEMICAL", 126, 136], ["NO", "CHEMICAL", 147, 149], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 9, 18], ["Mas", "GENE_OR_GENE_PRODUCT", 19, 22], ["NO", "SIMPLE_CHEMICAL", 31, 33], ["PI3K", "GENE_OR_GENE_PRODUCT", 53, 57], ["Akt", "GENE_OR_GENE_PRODUCT", 58, 61], ["eNOS", "GENE_OR_GENE_PRODUCT", 62, 66], ["endothelial cells", "CELL", 78, 95], ["cardiomyocytes", "CELL", 100, 114], ["alamandine", "SIMPLE_CHEMICAL", 126, 136], ["NO", "SIMPLE_CHEMICAL", 147, 149], ["LKB1", "GENE_OR_GENE_PRODUCT", 162, 166], ["AMPK", "GENE_OR_GENE_PRODUCT", 167, 171], ["cardiomyocytes", "CELL", 192, 206], ["PI3K", "PROTEIN", 53, 57], ["Akt", "PROTEIN", 58, 61], ["eNOS", "PROTEIN", 62, 66], ["endothelial cells", "CELL_TYPE", 78, 95], ["cardiomyocytes", "CELL_TYPE", 100, 114], ["LKB1", "PROTEIN", 162, 166], ["AMPK", "PROTEIN", 167, 171], ["cardiomyocytes", "CELL_TYPE", 192, 206], ["ANG", "TEST", 9, 12], ["production", "PROBLEM", 34, 44], ["the PI3K", "TEST", 49, 57], ["endothelial cells", "TEST", 78, 95], ["cardiomyocytes", "TEST", 100, 114], ["alamandine", "TEST", 126, 136], ["a LKB1", "TEST", 160, 166], ["cardiomyocytes", "PROBLEM", 192, 206], ["endothelial cells", "OBSERVATION", 78, 95], ["cardiomyocytes", "ANATOMY", 100, 114], ["cardiomyocytes", "ANATOMY", 192, 206]]], ["Using ventricular cardiomyocytes isolated from hearts of 10- to 12-wk-old male C57BL/6 mice, de Jesus and collaborators (61) showed that alamandine induced phosphorylation of AMPK-\u03b1 (Thr172) and its upstream effector LKB1 (Ser428).", [["ventricular cardiomyocytes", "ANATOMY", 6, 32], ["hearts", "ANATOMY", 47, 53], ["alamandine", "CHEMICAL", 137, 147], ["alamandine", "CHEMICAL", 137, 147], ["Thr", "CHEMICAL", 183, 186], ["ventricular cardiomyocytes", "CELL", 6, 32], ["hearts", "ORGAN", 47, 53], ["C57BL/6 mice", "ORGANISM", 79, 91], ["alamandine", "SIMPLE_CHEMICAL", 137, 147], ["AMPK-\u03b1", "GENE_OR_GENE_PRODUCT", 175, 181], ["Thr172", "AMINO_ACID", 183, 189], ["LKB1", "GENE_OR_GENE_PRODUCT", 217, 221], ["Ser428", "GENE_OR_GENE_PRODUCT", 223, 229], ["ventricular cardiomyocytes", "CELL_TYPE", 6, 32], ["AMPK", "PROTEIN", 175, 179], ["Thr172", "PROTEIN", 183, 189], ["upstream effector", "PROTEIN", 199, 216], ["LKB1", "PROTEIN", 217, 221], ["Ser428", "PROTEIN", 223, 229], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 87, 91], ["ventricular cardiomyocytes", "TEST", 6, 32], ["hearts", "TEST", 47, 53], ["AMPK", "TEST", 175, 179], ["Thr", "TEST", 183, 186], ["ventricular cardiomyocytes", "ANATOMY", 6, 32], ["hearts", "ANATOMY", 47, 53]]], ["Although ANG-(1\u22127) induced phosphorylation of Akt at its activation site (Ser473), the authors did not observe its phosphorylation using alamandine.", [["ANG-(1\u22127", "CHEMICAL", 9, 17], ["alamandine", "CHEMICAL", 137, 147], ["Ser473", "CHEMICAL", 74, 80], ["alamandine", "CHEMICAL", 137, 147], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 9, 18], ["Akt", "GENE_OR_GENE_PRODUCT", 46, 49], ["Ser473", "AMINO_ACID", 74, 80], ["alamandine", "SIMPLE_CHEMICAL", 137, 147], ["Akt", "PROTEIN", 46, 49], ["Ser473", "PROTEIN", 74, 80], ["ANG", "TEST", 9, 12], ["induced phosphorylation of Akt", "PROBLEM", 19, 49], ["alamandine", "TREATMENT", 137, 147]]], ["Using cardiomyocytes from Mas-deficient mice, the authors ruled out the contribution of Mas in LKB1 and AMPK-\u03b1 phosphorylation induced by alamandine (61).ANG-(1\u22127)/Mas and Alamandine/MrgD Induce NO Formation Via Different Signaling Pathways ::: NOVEL DOWNSTREAM PLAYERS OF ANG-(1\u22127)/MAS AND ALAMANDINE/MRGD SIGNALING NETWORKS IDENTIFIED BY PHOSPHOPROTEOMICSAlthough alamandine and ANG-(1\u22127) have 86% sequence identity (six of seven amino acid residues are the same), the replacement of the negatively charged residue (Asp) to the neutral one (Ala) in position 1 changes the physicochemical feature of alamandine, influencing its receptor affinity as alamandine activates MrgD but not Mas (74).", [["cardiomyocytes", "ANATOMY", 6, 20], ["alamandine", "CHEMICAL", 138, 148], ["Alamandine", "CHEMICAL", 172, 182], ["NO", "CHEMICAL", 195, 197], ["alamandine", "CHEMICAL", 366, 376], ["ANG", "CHEMICAL", 381, 384], ["amino acid", "CHEMICAL", 432, 442], ["Asp", "CHEMICAL", 518, 521], ["Ala", "CHEMICAL", 543, 546], ["alamandine", "CHEMICAL", 601, 611], ["alamandine", "CHEMICAL", 650, 660], ["alamandine", "CHEMICAL", 138, 148], ["Alamandine", "CHEMICAL", 172, 182], ["NO", "CHEMICAL", 195, 197], ["amino acid", "CHEMICAL", 432, 442], ["Asp", "CHEMICAL", 518, 521], ["Ala", "CHEMICAL", 543, 546], ["alamandine", "CHEMICAL", 601, 611], ["alamandine", "CHEMICAL", 650, 660], ["cardiomyocytes", "CELL", 6, 20], ["Mas-deficient mice", "ORGANISM", 26, 44], ["Mas", "GENE_OR_GENE_PRODUCT", 88, 91], ["LKB1", "GENE_OR_GENE_PRODUCT", 95, 99], ["AMPK-\u03b1", "GENE_OR_GENE_PRODUCT", 104, 110], ["alamandine", "SIMPLE_CHEMICAL", 138, 148], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 154, 163], ["Mas", "GENE_OR_GENE_PRODUCT", 164, 167], ["Alamandine", "SIMPLE_CHEMICAL", 172, 182], ["MrgD", "SIMPLE_CHEMICAL", 183, 187], ["NO", "SIMPLE_CHEMICAL", 195, 197], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 381, 390], ["amino acid", "AMINO_ACID", 432, 442], ["alamandine", "SIMPLE_CHEMICAL", 601, 611], ["alamandine", "SIMPLE_CHEMICAL", 650, 660], ["MrgD", "GENE_OR_GENE_PRODUCT", 671, 675], ["cardiomyocytes", "CELL_TYPE", 6, 20], ["Mas", "PROTEIN", 88, 91], ["LKB1", "PROTEIN", 95, 99], ["AMPK", "PROTEIN", 104, 108], ["\u03b1", "PROTEIN", 109, 110], ["MrgD", "PROTEIN", 183, 187], ["position 1", "PROTEIN", 551, 561], ["MrgD", "PROTEIN", 671, 675], ["Mas (74)", "PROTEIN", 684, 692], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 40, 44], ["cardiomyocytes", "PROBLEM", 6, 20], ["Mas in LKB1", "PROBLEM", 88, 99], ["AMPK", "TEST", 104, 108], ["phosphorylation", "TREATMENT", 111, 126], ["ANG", "TEST", 154, 157], ["Alamandine", "TREATMENT", 172, 182], ["ANG", "TEST", 381, 384], ["seven amino acid residues", "TREATMENT", 426, 451], ["the replacement of the negatively charged residue (Asp)", "TREATMENT", 467, 522], ["alamandine", "TREATMENT", 601, 611], ["its receptor affinity", "TREATMENT", 625, 646], ["cardiomyocytes", "ANATOMY", 6, 20]]], ["As reviewed here, by activating different receptors, alamandine and ANG-(1\u22127) induce the activation of different signaling pathways, adding new therapeutic clues and insights for the understanding of the RAS.Signaling of the AT2R and Cross-Talk With Mas ::: AT&!start&2&!end&Rs: FROM ENIGMA TO THERAPEUTICSThe mid-1990s brought a real breakthrough in the understanding of the AT2R.", [["alamandine", "CHEMICAL", 53, 63], ["ANG", "CHEMICAL", 68, 71], ["alamandine", "CHEMICAL", 53, 63], ["ANG-(1\u22127)", "CHEMICAL", 68, 77], ["alamandine", "SIMPLE_CHEMICAL", 53, 63], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 68, 77], ["RAS", "GENE_OR_GENE_PRODUCT", 204, 207], ["AT2R", "GENE_OR_GENE_PRODUCT", 225, 229], ["AT2R", "GENE_OR_GENE_PRODUCT", 376, 380], ["RAS", "PROTEIN", 204, 207], ["AT2R", "PROTEIN", 225, 229], ["AT2R", "PROTEIN", 376, 380], ["alamandine", "TREATMENT", 53, 63], ["ANG", "TREATMENT", 68, 71]]], ["Four groups independently discovered that activation of phosphatases seemed to be a major signaling mechanism of the AT2R, whereas the AT1R signals mainly through kinase-driven signaling cascades.", [["AT2R", "GENE_OR_GENE_PRODUCT", 117, 121], ["AT1R", "GENE_OR_GENE_PRODUCT", 135, 139], ["phosphatases", "PROTEIN", 56, 68], ["AT2R", "PROTEIN", 117, 121], ["AT1R", "PROTEIN", 135, 139], ["activation of phosphatases", "PROBLEM", 42, 68], ["the AT1R signals", "TEST", 131, 147], ["kinase", "TEST", 163, 169]]], ["Although Bottari et al. (9) found in 1992 that, in general, AT2R activation leads to tyrosine dephosphorylation, in subsequent years, the groups of Sumners, Dzau, and Nahmias identified protein phosphatase 2 (PP2A) (63), MAPK phosphatase 1 (165), and SHP-1 (92) as specific AT2R-stimulated phosphatases.", [["tyrosine", "CHEMICAL", 85, 93], ["tyrosine", "CHEMICAL", 85, 93], ["AT2R", "GENE_OR_GENE_PRODUCT", 60, 64], ["tyrosine", "AMINO_ACID", 85, 93], ["Dzau", "GENE_OR_GENE_PRODUCT", 157, 161], ["protein phosphatase 2", "GENE_OR_GENE_PRODUCT", 186, 207], ["PP2A", "GENE_OR_GENE_PRODUCT", 209, 213], ["MAPK phosphatase 1 (165)", "GENE_OR_GENE_PRODUCT", 221, 245], ["SHP-1", "GENE_OR_GENE_PRODUCT", 251, 256], ["AT2R", "GENE_OR_GENE_PRODUCT", 274, 278], ["AT2R", "PROTEIN", 60, 64], ["protein phosphatase 2", "PROTEIN", 186, 207], ["PP2A", "PROTEIN", 209, 213], ["MAPK phosphatase 1", "PROTEIN", 221, 239], ["SHP", "PROTEIN", 251, 254], ["AT2R", "PROTEIN", 274, 278], ["stimulated phosphatases", "PROTEIN", 279, 302], ["tyrosine dephosphorylation", "TREATMENT", 85, 111], ["protein phosphatase", "TEST", 186, 205], ["PP2A", "TEST", 209, 213], ["MAPK phosphatase", "TEST", 221, 237], ["SHP", "TEST", 251, 254], ["AT2R", "TEST", 274, 278]]], ["At the same time, it was excluded that the AT2R couples to \u201cconventional\u201d G proteins such as Gq or Gs proteins (10).", [["AT2R", "GENE_OR_GENE_PRODUCT", 43, 47], ["\u201d G proteins", "GENE_OR_GENE_PRODUCT", 72, 84], ["Gq", "GENE_OR_GENE_PRODUCT", 93, 95], ["Gs proteins", "GENE_OR_GENE_PRODUCT", 99, 110], ["AT2R", "PROTEIN", 43, 47], ["G proteins", "PROTEIN", 74, 84], ["Gq", "PROTEIN", 93, 95], ["Gs proteins", "PROTEIN", 99, 110], ["Gs proteins", "TEST", 99, 110]]], ["However, coupling to Gi proteins was demonstrated and shown to be involved in the modulation of ion channel currents and activation of PP2A (55, 63).", [["Gi proteins", "GENE_OR_GENE_PRODUCT", 21, 32], ["PP2A", "GENE_OR_GENE_PRODUCT", 135, 139], ["Gi proteins", "PROTEIN", 21, 32], ["PP2A", "PROTEIN", 135, 139], ["Gi proteins", "TEST", 21, 32], ["ion channel currents", "TREATMENT", 96, 116], ["PP2A", "TEST", 135, 139]]], ["The lack of conventional G protein coupling of the AT2R was elegantly explained by a Nature publication from 2017, which reported the crystalline structure of the AT2R (170).", [["G protein", "GENE_OR_GENE_PRODUCT", 25, 34], ["AT2R", "GENE_OR_GENE_PRODUCT", 51, 55], ["AT2R", "GENE_OR_GENE_PRODUCT", 163, 167], ["G protein", "PROTEIN", 25, 34], ["AT2R", "PROTEIN", 51, 55], ["AT2R (170)", "PROTEIN", 163, 173], ["conventional G protein coupling of the AT2R", "TREATMENT", 12, 55]]], ["Although this study confirmed that the AT2R displays all characteristics of a 7-transmembrane, class A G protein-coupled receptor, the authors unexpectedly discovered that upon activation of the AT2R, intracellular helix 8 changes its orientation in a way that it interacts with intracellular helixes III, V, and VI, thereby sterically blocking binding of conventional G proteins and \u03b2-arrestins.Signaling of the AT2R and Cross-Talk With Mas ::: AT&!start&2&!end&Rs: FROM ENIGMA TO THERAPEUTICSAlthough these newest findings explain the lack of conventional G protein coupling of the AT2R, the actual signaling mechanisms of the receptor are still only incompletely understood.", [["intracellular", "ANATOMY", 201, 214], ["intracellular", "ANATOMY", 279, 292], ["AT2R", "GENE_OR_GENE_PRODUCT", 39, 43], ["class A G protein-coupled receptor", "GENE_OR_GENE_PRODUCT", 95, 129], ["AT2R", "GENE_OR_GENE_PRODUCT", 195, 199], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 201, 214], ["helix 8", "GENE_OR_GENE_PRODUCT", 215, 222], ["intracellular helixes III", "GENE_OR_GENE_PRODUCT", 279, 304], ["V", "GENE_OR_GENE_PRODUCT", 306, 307], ["VI", "GENE_OR_GENE_PRODUCT", 313, 315], ["G proteins", "GENE_OR_GENE_PRODUCT", 369, 379], ["\u03b2-arrestins", "GENE_OR_GENE_PRODUCT", 384, 395], ["AT2R", "GENE_OR_GENE_PRODUCT", 413, 417], ["G protein", "GENE_OR_GENE_PRODUCT", 558, 567], ["AT2R", "GENE_OR_GENE_PRODUCT", 584, 588], ["AT2R", "PROTEIN", 39, 43], ["7-transmembrane, class A G protein-coupled receptor", "PROTEIN", 78, 129], ["AT2R", "PROTEIN", 195, 199], ["intracellular helix 8", "PROTEIN", 201, 222], ["intracellular helixes III, V, and VI", "PROTEIN", 279, 315], ["G proteins", "PROTEIN", 369, 379], ["\u03b2-arrestins", "PROTEIN", 384, 395], ["AT2R", "PROTEIN", 413, 417], ["G protein", "PROTEIN", 558, 567], ["AT2R", "PROTEIN", 584, 588], ["this study", "TEST", 9, 19], ["intracellular helix", "PROBLEM", 201, 220], ["conventional G proteins", "TREATMENT", 356, 379], ["\u03b2-arrestins", "PROBLEM", 384, 395], ["conventional G protein coupling", "TREATMENT", 545, 576], ["VI", "ANATOMY", 313, 315]]], ["This holds true, in particular, for the initiation of signaling upon receptor activation.", [["receptor activation", "TREATMENT", 69, 88]]], ["What is known, however, is that the third intracellular loop and COOH-terminal end of the AT2R seem crucial for AT2R signaling (114, 115).", [["intracellular", "ANATOMY", 42, 55], ["COOH", "CHEMICAL", 65, 69], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 55], ["AT2R", "GENE_OR_GENE_PRODUCT", 90, 94], ["AT2R", "GENE_OR_GENE_PRODUCT", 112, 116], ["COOH-terminal end", "PROTEIN", 65, 82], ["AT2R", "PROTEIN", 90, 94], ["AT2R", "PROTEIN", 112, 116], ["AT2R signaling", "TEST", 112, 126], ["loop", "OBSERVATION", 56, 60], ["COOH", "OBSERVATION_MODIFIER", 65, 69], ["terminal", "OBSERVATION_MODIFIER", 70, 78]]], ["In fact, some initial signaling molecules, such as SHP-1, PP2A, and AT2R-interacting protein, interact directly with the AT2R upon receptor activation: SHP-1 and PP2A (probably under involvement of Gi) with the third intracellular loop (64, 133) and AT2R-interacting protein with the COOH-terminal end (8).", [["intracellular", "ANATOMY", 217, 230], ["COOH", "CHEMICAL", 284, 288], ["SHP-1", "GENE_OR_GENE_PRODUCT", 51, 56], ["PP2A", "GENE_OR_GENE_PRODUCT", 58, 62], ["AT2R", "GENE_OR_GENE_PRODUCT", 68, 72], ["AT2R", "GENE_OR_GENE_PRODUCT", 121, 125], ["SHP-1", "GENE_OR_GENE_PRODUCT", 152, 157], ["PP2A", "GENE_OR_GENE_PRODUCT", 162, 166], ["Gi", "GENE_OR_GENE_PRODUCT", 198, 200], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 217, 230], ["AT2R", "GENE_OR_GENE_PRODUCT", 250, 254], ["signaling molecules", "PROTEIN", 22, 41], ["SHP", "PROTEIN", 51, 54], ["PP2A", "PROTEIN", 58, 62], ["AT2R", "PROTEIN", 68, 72], ["interacting protein", "PROTEIN", 73, 92], ["AT2R", "PROTEIN", 121, 125], ["SHP", "PROTEIN", 152, 155], ["PP2A", "PROTEIN", 162, 166], ["Gi", "PROTEIN", 198, 200], ["AT2R", "PROTEIN", 250, 254], ["interacting protein", "PROTEIN", 255, 274], ["COOH-terminal end", "PROTEIN", 284, 301], ["some initial signaling molecules", "PROBLEM", 9, 41], ["SHP", "TEST", 51, 54], ["PP2A", "TEST", 58, 62], ["SHP", "TEST", 152, 155], ["PP2A", "TEST", 162, 166], ["the third intracellular loop", "TEST", 207, 235], ["AT2R", "TEST", 250, 254], ["signaling molecules", "OBSERVATION", 22, 41], ["AT2R", "ANATOMY", 68, 72]]], ["Certain kinases may be involved, too, in this early initiation of signaling, such as tyrosine kinase c-Src (133).Signaling of the AT2R and Cross-Talk With Mas ::: AT&!start&2&!end&Rs: FROM ENIGMA TO THERAPEUTICSFrom a functional perspective, the lack of conventional G protein signaling and the activation of Gi and phosphatases, which again interfere with kinase-driven signaling in an inhibitory way, make sense and are in accordance with known AT2R actions, which oppose actions of cytokines, growth factors, and classical G protein-couple receptors such as the AT1R (22, 24, 25, 122, 151, 157).Signaling of the AT2R and Cross-Talk With Mas ::: AT&!start&2&!end&Rs: FROM ENIGMA TO THERAPEUTICSSignaling mechanisms of the AT2R and Mas have many similarities like, e.g., involvement of SHP-1/SHP-2 and signaling through PI3K/Akt/eNOS (Fig. 2).", [["tyrosine", "CHEMICAL", 85, 93], ["tyrosine", "CHEMICAL", 85, 93], ["c-Src", "GENE_OR_GENE_PRODUCT", 101, 106], ["AT2R", "GENE_OR_GENE_PRODUCT", 130, 134], ["G protein", "GENE_OR_GENE_PRODUCT", 267, 276], ["Gi", "GENE_OR_GENE_PRODUCT", 309, 311], ["AT2R", "GENE_OR_GENE_PRODUCT", 447, 451], ["G protein-couple receptors", "GENE_OR_GENE_PRODUCT", 526, 552], ["AT1R", "GENE_OR_GENE_PRODUCT", 565, 569], ["AT2R", "GENE_OR_GENE_PRODUCT", 615, 619], ["AT2R", "GENE_OR_GENE_PRODUCT", 724, 728], ["Mas", "GENE_OR_GENE_PRODUCT", 733, 736], ["SHP-1", "GENE_OR_GENE_PRODUCT", 787, 792], ["SHP-2", "GENE_OR_GENE_PRODUCT", 793, 798], ["PI3K", "GENE_OR_GENE_PRODUCT", 821, 825], ["Akt", "GENE_OR_GENE_PRODUCT", 826, 829], ["eNOS", "GENE_OR_GENE_PRODUCT", 830, 834], ["Fig. 2", "GENE_OR_GENE_PRODUCT", 836, 842], ["kinases", "PROTEIN", 8, 15], ["tyrosine kinase c", "PROTEIN", 85, 102], ["Src (133)", "PROTEIN", 103, 112], ["AT2R", "PROTEIN", 130, 134], ["G protein", "PROTEIN", 267, 276], ["Gi", "PROTEIN", 309, 311], ["phosphatases", "PROTEIN", 316, 328], ["kinase", "PROTEIN", 357, 363], ["AT2R", "PROTEIN", 447, 451], ["cytokines", "PROTEIN", 485, 494], ["growth factors", "PROTEIN", 496, 510], ["G protein-couple receptors", "PROTEIN", 526, 552], ["AT1R", "PROTEIN", 565, 569], ["AT2R", "PROTEIN", 615, 619], ["AT2R", "PROTEIN", 724, 728], ["Mas", "PROTEIN", 733, 736], ["SHP", "PROTEIN", 787, 790], ["SHP-2", "PROTEIN", 793, 798], ["PI3K", "PROTEIN", 821, 825], ["Akt", "PROTEIN", 826, 829], ["eNOS", "PROTEIN", 830, 834], ["Fig. 2", "PROTEIN", 836, 842], ["tyrosine kinase", "TEST", 85, 100], ["conventional G protein signaling", "PROBLEM", 254, 286], ["Gi and phosphatases", "TEST", 309, 328], ["kinase", "TEST", 357, 363], ["known AT2R actions", "TREATMENT", 441, 459], ["cytokines, growth factors", "PROBLEM", 485, 510], ["classical G protein-couple receptors", "TREATMENT", 516, 552], ["the AT1R", "TEST", 561, 569], ["SHP", "TEST", 787, 790], ["SHP", "TEST", 793, 796], ["PI3K", "TEST", 821, 825], ["may be", "UNCERTAINTY", 16, 22], ["AT2R", "ANATOMY", 724, 728], ["Akt", "ANATOMY", 826, 829]]], ["Moreover, the AT2R and Mas form heterodimers, at least in certain tissues, which may explain the shared signaling pathways and also the phenomenon that often effects of ANG-(1\u22127) can be inhibited by an AT2R antagonist and effects of an AT2R agonist by A779 (77, 101, 154).", [["tissues", "ANATOMY", 66, 73], ["ANG", "CHEMICAL", 169, 172], ["A779", "CHEMICAL", 252, 256], ["A779", "CHEMICAL", 252, 256], ["AT2R", "GENE_OR_GENE_PRODUCT", 14, 18], ["Mas", "GENE_OR_GENE_PRODUCT", 23, 26], ["tissues", "TISSUE", 66, 73], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 169, 178], ["AT2R", "GENE_OR_GENE_PRODUCT", 202, 206], ["AT2R", "GENE_OR_GENE_PRODUCT", 236, 240], ["AT2R", "PROTEIN", 14, 18], ["Mas", "PROTEIN", 23, 26], ["heterodimers", "PROTEIN", 32, 44], ["Mas form heterodimers", "PROBLEM", 23, 44], ["ANG", "TEST", 169, 172], ["an AT2R antagonist", "TREATMENT", 199, 217], ["an AT2R agonist", "TEST", 233, 248], ["certain tissues", "ANATOMY", 58, 73]]], ["Interestingly, when the AT2R and Mas dimerize, they seem to depend on each other functionally, because knockout of one of the receptors leads to loss of function of the other receptor in the respective cell or tissue (77).Physiological and Pathophysiological Actions of the AT2R ::: AT&!start&2&!end&Rs: FROM ENIGMA TO THERAPEUTICSIn the physiological situation, the AT2R is usually expressed at low levels and in most tissues appears to be dormant (25).", [["cell", "ANATOMY", 202, 206], ["tissue", "ANATOMY", 210, 216], ["tissues", "ANATOMY", 419, 426], ["AT2R", "GENE_OR_GENE_PRODUCT", 24, 28], ["Mas", "GENE_OR_GENE_PRODUCT", 33, 36], ["cell", "CELL", 202, 206], ["tissue", "TISSUE", 210, 216], ["AT2R", "GENE_OR_GENE_PRODUCT", 274, 278], ["AT2R", "GENE_OR_GENE_PRODUCT", 367, 371], ["tissues", "TISSUE", 419, 426], ["AT2R", "PROTEIN", 24, 28], ["Mas", "PROTEIN", 33, 36], ["AT2R", "PROTEIN", 274, 278], ["AT2R", "PROTEIN", 367, 371], ["respective cell", "OBSERVATION", 191, 206], ["low levels", "OBSERVATION_MODIFIER", 396, 406], ["most tissues", "OBSERVATION_MODIFIER", 414, 426]]], ["Exceptions seem to be a role in the central regulation of blood pressure (143), a weak vasodilation (160), a natriuretic effect (52), and an impact on cell differentiation, e.g., in neurons (86), uterus (26), or fetal tissue (18).Physiological and Pathophysiological Actions of the AT2R ::: AT&!start&2&!end&Rs: FROM ENIGMA TO THERAPEUTICSIn the pathophysiological situation, the AT2R mediates a variety of tissue protective actions, which again very much resemble the actions of ANG-(1\u22127) through Mas and which comprise, for example, anti-inflammation, immune modulation, antifibrosis, inhibition of sympathetic outflow, antiapoptosis, and neuroregeneration (91).", [["blood", "ANATOMY", 58, 63], ["cell", "ANATOMY", 151, 155], ["neurons", "ANATOMY", 182, 189], ["uterus", "ANATOMY", 196, 202], ["fetal tissue", "ANATOMY", 212, 224], ["tissue", "ANATOMY", 407, 413], ["sympathetic outflow", "ANATOMY", 601, 620], ["ANG", "CHEMICAL", 480, 483], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["cell", "CELL", 151, 155], ["neurons", "CELL", 182, 189], ["uterus", "ORGAN", 196, 202], ["fetal tissue", "TISSUE", 212, 224], ["AT2R", "GENE_OR_GENE_PRODUCT", 282, 286], ["AT2R", "GENE_OR_GENE_PRODUCT", 380, 384], ["tissue", "TISSUE", 407, 413], ["ANG", "GENE_OR_GENE_PRODUCT", 480, 483], ["1\u22127", "SIMPLE_CHEMICAL", 485, 488], ["Mas", "GENE_OR_GENE_PRODUCT", 498, 501], ["sympathetic outflow", "MULTI-TISSUE_STRUCTURE", 601, 620], ["AT2R", "PROTEIN", 282, 286], ["AT2R", "PROTEIN", 380, 384], ["blood pressure", "TEST", 58, 72], ["a weak vasodilation", "PROBLEM", 80, 99], ["a natriuretic effect", "PROBLEM", 107, 127], ["cell differentiation", "TEST", 151, 171], ["tissue protective actions", "TREATMENT", 407, 432], ["ANG", "TEST", 480, 483], ["anti-inflammation", "TREATMENT", 535, 552], ["immune modulation", "TREATMENT", 554, 571], ["antifibrosis", "PROBLEM", 573, 585], ["sympathetic outflow", "PROBLEM", 601, 620], ["antiapoptosis", "PROBLEM", 622, 635], ["neuroregeneration", "PROBLEM", 641, 658], ["central", "ANATOMY_MODIFIER", 36, 43], ["cell differentiation", "OBSERVATION", 151, 171], ["neurons", "ANATOMY", 182, 189], ["uterus", "ANATOMY", 196, 202], ["fetal tissue", "ANATOMY", 212, 224], ["sympathetic outflow", "OBSERVATION", 601, 620], ["antiapoptosis", "OBSERVATION_MODIFIER", 622, 635]]], ["In the context of HF, several of these actions work together in a well-orchestrated way.", [["HF", "DISEASE", 18, 20], ["HF", "PROBLEM", 18, 20], ["HF", "OBSERVATION", 18, 20]]], ["For example, in rats with HF caused by myocardial infarction, AT2R stimulation acts in an anti-inflammatory manner by reducing cytokine synthesis and in an antifibrotic manny by inhibition of transforming growth factor-\u03b2 generation, thus ameliorating peri-infarct remodeling, which again results in improved cardiac function (65, 73).", [["myocardial", "ANATOMY", 39, 49], ["peri-infarct", "ANATOMY", 251, 263], ["cardiac", "ANATOMY", 308, 315], ["HF", "DISEASE", 26, 28], ["myocardial infarction", "DISEASE", 39, 60], ["rats", "ORGANISM", 16, 20], ["myocardial", "MULTI-TISSUE_STRUCTURE", 39, 49], ["AT2R", "GENE_OR_GENE_PRODUCT", 62, 66], ["transforming growth factor-\u03b2", "GENE_OR_GENE_PRODUCT", 192, 220], ["cardiac", "ORGAN", 308, 315], ["AT2R", "PROTEIN", 62, 66], ["cytokine", "PROTEIN", 127, 135], ["transforming growth factor-\u03b2", "PROTEIN", 192, 220], ["rats", "SPECIES", 16, 20], ["HF", "PROBLEM", 26, 28], ["myocardial infarction", "PROBLEM", 39, 60], ["AT2R stimulation acts", "TREATMENT", 62, 83], ["an anti-inflammatory manner", "TREATMENT", 87, 114], ["cytokine synthesis", "TREATMENT", 127, 145], ["transforming growth factor", "PROBLEM", 192, 218], ["ameliorating peri-infarct remodeling", "PROBLEM", 238, 274], ["myocardial", "ANATOMY", 39, 49], ["infarction", "OBSERVATION", 50, 60], ["peri-infarct remodeling", "OBSERVATION", 251, 274], ["improved", "OBSERVATION_MODIFIER", 299, 307], ["cardiac", "ANATOMY", 308, 315]]], ["An antifibrotic effect was also seen in the right ventricles of rats with pulmonary hypertension (14).", [["right ventricles", "ANATOMY", 44, 60], ["pulmonary", "ANATOMY", 74, 83], ["pulmonary hypertension", "DISEASE", 74, 96], ["right ventricles", "MULTI-TISSUE_STRUCTURE", 44, 60], ["rats", "ORGANISM", 64, 68], ["pulmonary", "ORGAN", 74, 83], ["rats", "SPECIES", 64, 68], ["An antifibrotic effect", "PROBLEM", 0, 22], ["pulmonary hypertension", "PROBLEM", 74, 96], ["antifibrotic effect", "OBSERVATION", 3, 22], ["right ventricles", "ANATOMY", 44, 60], ["pulmonary", "ANATOMY", 74, 83], ["hypertension", "OBSERVATION", 84, 96]]], ["Right ventricular fibrosis leading to HF is in fact a major pathomechanism determining mortality in patients with pulmonary hypertension.", [["Right ventricular", "ANATOMY", 0, 17], ["pulmonary", "ANATOMY", 114, 123], ["fibrosis", "DISEASE", 18, 26], ["HF", "DISEASE", 38, 40], ["pulmonary hypertension", "DISEASE", 114, 136], ["Right ventricular", "MULTI-TISSUE_STRUCTURE", 0, 17], ["patients", "ORGANISM", 100, 108], ["pulmonary", "ORGAN", 114, 123], ["patients", "SPECIES", 100, 108], ["Right ventricular fibrosis", "PROBLEM", 0, 26], ["HF", "PROBLEM", 38, 40], ["pulmonary hypertension", "PROBLEM", 114, 136], ["ventricular", "ANATOMY", 6, 17], ["fibrosis", "OBSERVATION", 18, 26], ["pulmonary", "ANATOMY", 114, 123], ["hypertension", "OBSERVATION", 124, 136]]], ["In another model of ischemia-induced HF (coronary ligation model), central administration of the AT2R agonist C21 for 7 days by intracerebroventricular infusion significantly reduced sympathetic outflow and improved baroreceptor sensitivity, both mechanisms with a proven beneficial effect on HF (40).Physiological and Pathophysiological Actions of the AT2R ::: AT&!start&2&!end&Rs: FROM ENIGMA TO THERAPEUTICSThe protective effects of AT2R stimulation have been observed and associated with improved outcome in multiple other disease models. including cardiovascular disease, diabetic end-organ damage, autoimmune disease, neurological disease, etc. For more details on the protective actions of the AT2R in a broad spectrum of diseases, the reader is referred to recent review articles (22, 24, 25, 27, 122, 151, 157).Targeting the AT2R in Drug Development ::: AT&!start&2&!end&Rs: FROM ENIGMA TO THERAPEUTICSAs a result of the better understanding of AT2R actions and the realization that the receptor promotes tissue protection, repair, and regeneration in the context of several different pathologies, drug development projects have been initiated for the development of AT2R agonists.", [["coronary", "ANATOMY", 41, 49], ["cardiovascular", "ANATOMY", 553, 567], ["organ", "ANATOMY", 590, 595], ["neurological", "ANATOMY", 624, 636], ["tissue", "ANATOMY", 1014, 1020], ["HF", "DISEASE", 37, 39], ["C21", "CHEMICAL", 110, 113], ["HF", "DISEASE", 293, 295], ["cardiovascular disease", "DISEASE", 553, 575], ["diabetic end-organ damage", "DISEASE", 577, 602], ["autoimmune disease", "DISEASE", 604, 622], ["neurological disease", "DISEASE", 624, 644], ["start&2&!end&Rs", "CHEMICAL", 366, 381], ["coronary", "MULTI-TISSUE_STRUCTURE", 41, 49], ["AT2R", "GENE_OR_GENE_PRODUCT", 97, 101], ["C21", "SIMPLE_CHEMICAL", 110, 113], ["intracerebroventricular", "IMMATERIAL_ANATOMICAL_ENTITY", 128, 151], ["sympathetic outflow", "MULTI-TISSUE_STRUCTURE", 183, 202], ["baroreceptor", "ANATOMICAL_SYSTEM", 216, 228], ["AT2R", "GENE_OR_GENE_PRODUCT", 353, 357], ["AT2R", "GENE_OR_GENE_PRODUCT", 436, 440], ["cardiovascular", "ANATOMICAL_SYSTEM", 553, 567], ["organ", "ORGAN", 590, 595], ["AT2R", "GENE_OR_GENE_PRODUCT", 701, 705], ["AT2R", "GENE_OR_GENE_PRODUCT", 834, 838], ["AT2R", "GENE_OR_GENE_PRODUCT", 954, 958], ["tissue", "TISSUE", 1014, 1020], ["AT2R agonists", "GENE_OR_GENE_PRODUCT", 1176, 1189], ["AT2R", "PROTEIN", 97, 101], ["AT2R", "PROTEIN", 353, 357], ["AT2R", "PROTEIN", 436, 440], ["AT2R", "PROTEIN", 701, 705], ["AT2R", "PROTEIN", 834, 838], ["AT2R", "PROTEIN", 954, 958], ["ischemia-induced HF", "PROBLEM", 20, 39], ["coronary ligation model", "TREATMENT", 41, 64], ["the AT2R agonist C21", "TREATMENT", 93, 113], ["intracerebroventricular infusion", "TREATMENT", 128, 160], ["reduced sympathetic outflow", "PROBLEM", 175, 202], ["improved baroreceptor sensitivity", "PROBLEM", 207, 240], ["HF", "PROBLEM", 293, 295], ["AT2R stimulation", "TREATMENT", 436, 452], ["multiple other disease models", "PROBLEM", 512, 541], ["cardiovascular disease", "PROBLEM", 553, 575], ["diabetic end-organ damage", "PROBLEM", 577, 602], ["autoimmune disease", "PROBLEM", 604, 622], ["neurological disease", "PROBLEM", 624, 644], ["diseases", "PROBLEM", 729, 737], ["AT2R actions", "TREATMENT", 954, 966], ["the receptor promotes tissue protection", "TREATMENT", 992, 1031], ["repair", "TREATMENT", 1033, 1039], ["regeneration", "TREATMENT", 1045, 1057], ["several different pathologies", "PROBLEM", 1076, 1105], ["drug development projects", "TREATMENT", 1107, 1132], ["AT2R agonists", "TREATMENT", 1176, 1189], ["ischemia-induced", "OBSERVATION_MODIFIER", 20, 36], ["HF", "OBSERVATION", 37, 39], ["coronary", "ANATOMY", 41, 49], ["sympathetic outflow", "OBSERVATION", 183, 202], ["baroreceptor sensitivity", "OBSERVATION", 216, 240], ["cardiovascular", "ANATOMY", 553, 567], ["disease", "OBSERVATION", 568, 575], ["diabetic", "OBSERVATION_MODIFIER", 577, 585], ["organ", "ANATOMY", 590, 595], ["damage", "OBSERVATION", 596, 602], ["autoimmune disease", "OBSERVATION", 604, 622], ["neurological disease", "OBSERVATION", 624, 644], ["diseases", "OBSERVATION", 729, 737], ["AT2R", "ANATOMY", 834, 838], ["repair", "OBSERVATION", 1033, 1039], ["pathologies", "OBSERVATION", 1094, 1105]]], ["The nonpeptide AT2R agonist compound 21 (C21), a proprietary molecule of Vicore Pharma (https://vicorepharma.com/), has successfully undergone phase I clinical testing and will soon be forwarded into a phase IIa clinical study in patients with idiopathic pulmonary fibrosis.", [["pulmonary", "ANATOMY", 255, 264], ["compound 21", "CHEMICAL", 28, 39], ["idiopathic pulmonary fibrosis", "DISEASE", 244, 273], ["AT2R", "GENE_OR_GENE_PRODUCT", 15, 19], ["C21", "SIMPLE_CHEMICAL", 41, 44], ["patients", "ORGANISM", 230, 238], ["pulmonary", "ORGAN", 255, 264], ["patients", "SPECIES", 230, 238], ["The nonpeptide AT2R agonist compound", "TEST", 0, 36], ["clinical testing", "TEST", 151, 167], ["a phase IIa clinical study", "TEST", 200, 226], ["idiopathic pulmonary fibrosis", "PROBLEM", 244, 273], ["idiopathic", "OBSERVATION_MODIFIER", 244, 254], ["pulmonary", "ANATOMY", 255, 264], ["fibrosis", "OBSERVATION", 265, 273]]], ["The cyclic peptide MOR107 (Morphosys, https://www.morphosys.com/; previously LP-2 by Lanthio Pharma, https://www.lanthiopharma.com/) is currently being tested in a phase I clinical trial, whereas the clinical testing of MP-157 (Mitsubishi Tanabe, https://www.mt-pharma.co.jp/) has been discontinued.", [["MP-157", "CHEMICAL", 220, 226], ["MP-157", "CHEMICAL", 220, 226], ["MP-157", "SIMPLE_CHEMICAL", 220, 226], ["The cyclic peptide", "TEST", 0, 18], ["Morphosys", "TEST", 27, 36], ["LP", "TEST", 77, 79], ["the clinical testing", "TEST", 196, 216], ["MP", "TEST", 220, 222]]], ["The AT2R antagonist EMA401 (Novartis, https://www.novartisclinicaltrials.com/TrialConnectWeb/home.nov; previously Spinifex) has been successfully tested in a phase II trial for the treatment of neuropathic pain (120).", [["EMA401", "CHEMICAL", 20, 26], ["Spinifex", "CHEMICAL", 114, 122], ["neuropathic pain", "DISEASE", 194, 210], ["EMA401", "CHEMICAL", 20, 26], ["AT2R", "GENE_OR_GENE_PRODUCT", 4, 8], ["EMA401", "SIMPLE_CHEMICAL", 20, 26], ["The AT2R antagonist EMA401", "TREATMENT", 0, 26], ["a phase II trial", "TREATMENT", 156, 172], ["neuropathic pain", "PROBLEM", 194, 210], ["neuropathic", "OBSERVATION_MODIFIER", 194, 205]]], ["More phase II studies with EMA401 are currently being initiated.CONCLUSIONS AND FUTURE DIRECTIONSThe numerous beneficial actions of the novel RAS arms summarized in this review warrant clinical verification and therapeutic exploitation.CONCLUSIONS AND FUTURE DIRECTIONSACE2 has emerged as the dominant mechanism for negative regulation of the RAS by metabolizing ANG II into the beneficial peptide ANG-(1\u22127).", [["EMA401", "CHEMICAL", 27, 33], ["ANG II", "CHEMICAL", 363, 369], ["ANG", "CHEMICAL", 398, 401], ["EMA401", "CHEMICAL", 27, 33], ["EMA401", "SIMPLE_CHEMICAL", 27, 33], ["RAS", "GENE_OR_GENE_PRODUCT", 142, 145], ["RAS", "GENE_OR_GENE_PRODUCT", 343, 346], ["ANG II", "GENE_OR_GENE_PRODUCT", 363, 369], ["ANG", "GENE_OR_GENE_PRODUCT", 398, 401], ["1\u22127", "SIMPLE_CHEMICAL", 403, 406], ["RAS", "PROTEIN", 343, 346], ["ANG II", "PROTEIN", 363, 369], ["EMA401", "TREATMENT", 27, 33], ["clinical verification", "TEST", 185, 206], ["therapeutic exploitation", "TREATMENT", 211, 235]]], ["This heptapeptide has emerged as a major protective peptide in the cardiovascular system.", [["cardiovascular system", "ANATOMY", 67, 88], ["cardiovascular", "ANATOMICAL_SYSTEM", 67, 81], ["system", "ANATOMICAL_SYSTEM", 82, 88], ["This heptapeptide", "TREATMENT", 0, 17], ["a major protective peptide", "TREATMENT", 33, 59], ["cardiovascular system", "ANATOMY", 67, 88]]], ["Clinical and experimental findings have demonstrated that ACE2 and ANG-(1\u22127) comprise the dominant mechanism for protective regulation of the RAS in many types of HF.", [["HF", "DISEASE", 163, 165], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["ANG-(1\u22127", "GENE_OR_GENE_PRODUCT", 67, 75], ["RAS", "GENE_OR_GENE_PRODUCT", 142, 145], ["ACE2", "PROTEIN", 58, 62], ["ANG", "PROTEIN", 67, 70], ["RAS", "PROTEIN", 142, 145], ["ACE2", "TEST", 58, 62], ["ANG", "TEST", 67, 70], ["HF", "PROBLEM", 163, 165], ["HF", "OBSERVATION", 163, 165]]], ["ANG-(1\u22127) generated by ACE2-dependent conversion of ANG II is a crucial mediator of the cardioprotective effects, which makes ANG-(1\u22127) a promising therapy for HF.CONCLUSIONS AND FUTURE DIRECTIONSAfter a long period of preclinical research to understand AT2R signaling and function better, this knowledge is currently being translated into developments for a potential, future clinical use of drugs targeting the AT2R.", [["ANG II", "CHEMICAL", 52, 58], ["ANG", "CHEMICAL", 126, 129], ["HF", "DISEASE", 160, 162], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 0, 9], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["ANG II", "GENE_OR_GENE_PRODUCT", 52, 58], ["ANG-(1\u22127", "SIMPLE_CHEMICAL", 126, 134], ["AT2R", "GENE_OR_GENE_PRODUCT", 254, 258], ["AT2R", "GENE_OR_GENE_PRODUCT", 413, 417], ["ACE2", "PROTEIN", 23, 27], ["ANG II", "PROTEIN", 52, 58], ["AT2R", "PROTEIN", 254, 258], ["AT2R", "PROTEIN", 413, 417], ["ANG", "TEST", 0, 3], ["ANG", "TEST", 126, 129], ["a promising therapy", "TREATMENT", 136, 155], ["HF", "PROBLEM", 160, 162], ["drugs", "TREATMENT", 393, 398], ["cardioprotective effects", "OBSERVATION", 88, 112]]], ["Most of these drugs in development are AT2R agonists, with current primary indications being fibrotic diseases and diabetic nephropathy.", [["fibrotic diseases", "DISEASE", 93, 110], ["diabetic nephropathy", "DISEASE", 115, 135], ["AT2R", "GENE_OR_GENE_PRODUCT", 39, 43], ["these drugs", "TREATMENT", 8, 19], ["AT2R agonists", "TREATMENT", 39, 52], ["fibrotic diseases", "PROBLEM", 93, 110], ["diabetic nephropathy", "PROBLEM", 115, 135], ["fibrotic", "OBSERVATION", 93, 101], ["diabetic", "OBSERVATION_MODIFIER", 115, 123], ["nephropathy", "OBSERVATION", 124, 135]]], ["The AT2R antagonist EMA401 is being developed for the treatment of neuropathic pain.", [["EMA401", "CHEMICAL", 20, 26], ["neuropathic pain", "DISEASE", 67, 83], ["EMA401", "CHEMICAL", 20, 26], ["AT2R", "GENE_OR_GENE_PRODUCT", 4, 8], ["EMA401", "SIMPLE_CHEMICAL", 20, 26], ["The AT2R antagonist EMA401", "TREATMENT", 0, 26], ["neuropathic pain", "PROBLEM", 67, 83], ["neuropathic", "OBSERVATION_MODIFIER", 67, 78], ["pain", "OBSERVATION", 79, 83]]], ["Phase II clinical studies are currently being initiated and will provide information about the therapeutic potential of drugs targeting the AT2R.CONCLUSIONS AND FUTURE DIRECTIONSThe first compounds activating the Mas and AT2 axis are available, and clinical trials have been started.", [["AT2R", "GENE_OR_GENE_PRODUCT", 140, 144], ["Mas", "GENE_OR_GENE_PRODUCT", 213, 216], ["AT2", "GENE_OR_GENE_PRODUCT", 221, 224], ["AT2R", "PROTEIN", 140, 144], ["Phase II clinical studies", "TEST", 0, 25], ["drugs", "TREATMENT", 120, 125]]], ["For alatensins, the physiological and pathophysiological importance has still to be confirmed before therapeutic approaches can be initiated.", [["alatensins", "SIMPLE_CHEMICAL", 4, 14], ["alatensins", "PROBLEM", 4, 14], ["therapeutic approaches", "TREATMENT", 101, 123]]], ["However, it is quite likely that we will soon have novel therapies for cardiovascular and other diseases based on beneficial RAS peptides.", [["cardiovascular", "ANATOMY", 71, 85], ["cardiovascular and other diseases", "DISEASE", 71, 104], ["cardiovascular", "ANATOMICAL_SYSTEM", 71, 85], ["RAS peptides", "GENE_OR_GENE_PRODUCT", 125, 137], ["novel therapies", "TREATMENT", 51, 66], ["cardiovascular and other diseases", "PROBLEM", 71, 104], ["beneficial RAS peptides", "TREATMENT", 114, 137], ["is quite likely", "UNCERTAINTY", 12, 27]]], ["Indeed, a recent study has described the beneficial effects of an oral formulation of hydroxypropyl-\u03b2-cyclodextrin/ANG-(1\u22127) in volunteers submitted to isometric overload muscle damage (7).", [["oral", "ANATOMY", 66, 70], ["muscle", "ANATOMY", 171, 177], ["hydroxypropyl-\u03b2-cyclodextrin", "CHEMICAL", 86, 114], ["ANG", "CHEMICAL", 115, 118], ["muscle damage", "DISEASE", 171, 184], ["hydroxypropyl-\u03b2-cyclodextrin", "CHEMICAL", 86, 114], ["ANG-(1\u22127)", "CHEMICAL", 115, 124], ["oral", "ORGANISM_SUBDIVISION", 66, 70], ["hydroxypropyl-\u03b2-cyclodextrin", "SIMPLE_CHEMICAL", 86, 114], ["ANG-(1\u22127)", "SIMPLE_CHEMICAL", 115, 124], ["volunteers", "ORGANISM", 128, 138], ["muscle", "ORGAN", 171, 177], ["a recent study", "TEST", 8, 22], ["an oral formulation of hydroxypropyl", "TREATMENT", 63, 99], ["cyclodextrin/ANG", "TREATMENT", 102, 118], ["isometric overload muscle damage", "PROBLEM", 152, 184], ["muscle", "ANATOMY", 171, 177]]], ["This study, which is the first to test the effects of an oral formulation of ANG-(1\u22127) in humans, opens new possibilities for testing the actions of ANG-(1\u22127) and therapeutic effects in patients.CONCLUSIONS AND FUTURE DIRECTIONSFinally, this review highlights the potential of phosphoproteomics to investigate ANG-(1\u22127) and alamandine signaling in an unbiased way, allowing the identification of unanticipated downstream effectors of these signaling networks.GRANTSThis work was supported by the Canadian Institutes of Health Research and Heart and Stroke Foundation (to G. Oudit) and the Brazilian Funding Agencies CNPq (Grant 421021/2016-0, to T. Verano-Braga), FAPEMIG (Grant APQ-03139-16, to R. Santos, and Grant APQ-03242-16, to T. Verano-Braga), and CAPES (to R. Santos and T. Verano-Braga).DISCLOSURESNo conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONSR.A.S.S., G.Y.O., T.V.-B., and G.C. prepared figures; R.A.S.S., G.Y.O., T.V.-B., G.C., U.M.S., and M.B. drafted manuscript; R.A.S.S., G.Y.O., T.V.-B., G.C., U.M.S., and M.B. edited and revised manuscript; R.A.S.S., G.Y.O., T.V.-B., G.C., U.M.S., and M.B. approved final version of manuscript.", [["oral", "ANATOMY", 57, 61], ["ANG", "CHEMICAL", 77, 80], ["ANG", "CHEMICAL", 149, 152], ["alamandine", "CHEMICAL", 324, 334], ["Heart and Stroke", "DISEASE", 539, 555], ["alamandine", "CHEMICAL", 324, 334], ["oral", "ORGANISM_SUBDIVISION", 57, 61], ["ANG", "SIMPLE_CHEMICAL", 77, 80], ["1\u22127", "SIMPLE_CHEMICAL", 82, 85], ["humans", "ORGANISM", 90, 96], ["ANG", "SIMPLE_CHEMICAL", 149, 152], ["1\u22127", "SIMPLE_CHEMICAL", 154, 157], ["patients", "ORGANISM", 186, 194], ["ANG-(1\u22127)", "GENE_OR_GENE_PRODUCT", 310, 319], ["alamandine", "SIMPLE_CHEMICAL", 324, 334], ["humans", "SPECIES", 90, 96], ["patients", "SPECIES", 186, 194], ["humans", "SPECIES", 90, 96], ["This study", "TEST", 0, 10], ["an oral formulation", "TREATMENT", 54, 73], ["ANG", "TEST", 77, 80], ["testing", "TEST", 126, 133], ["ANG", "TEST", 149, 152], ["phosphoproteomics", "TEST", 277, 294], ["ANG", "TEST", 310, 313], ["alamandine signaling", "PROBLEM", 324, 344], ["Grant APQ", "TEST", 711, 720], ["CAPES", "TEST", 756, 761], ["Heart", "ANATOMY", 539, 544], ["Stroke", "OBSERVATION", 549, 555]]]], "38f5141c42798d03f9e466bfa6092581eedf1f43": [["mergency medical services (EMS) providers give medical and trauma care to patients.", [["trauma", "DISEASE", 59, 65], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82]]], ["They are the first line of care for those with urgent needs and often stabilize patients for transport to definitive care facilities.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88]]], ["1 In such situations, those first responders are at significant risk of injury and death.", [["death", "DISEASE", 83, 88], ["injury", "PROBLEM", 72, 78], ["death", "PROBLEM", 83, 88], ["injury", "OBSERVATION", 72, 78]]], ["For instance, during the severe acute respiratory syndrome (SARS) outbreak in Toronto, Canada, in 2003, of the 850 paramedics who responded, more than half were exposed to SARS and placed in quarantine, some of them developed SARS-like symptoms, and 4 of them were hospitalized.", [["acute respiratory syndrome", "DISEASE", 32, 58], ["SARS", "DISEASE", 60, 64], ["SARS", "DISEASE", 172, 176], ["SARS", "DISEASE", 226, 230], ["the severe acute respiratory syndrome", "PROBLEM", 21, 58], ["SARS", "PROBLEM", 172, 176], ["SARS", "PROBLEM", 226, 230], ["symptoms", "PROBLEM", 236, 244], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["respiratory syndrome", "OBSERVATION", 38, 58]]], ["1, 2 This incident resulted in a dramatic decrease in their workforces, which negatively affected the health-care system in the area by reducing its surge capacity.", [["a dramatic decrease in their workforces", "PROBLEM", 31, 70], ["dramatic", "OBSERVATION_MODIFIER", 33, 41], ["decrease", "OBSERVATION_MODIFIER", 42, 50]]], ["Moreover, the recent Ebola outbreak in 2014 has shown high infection and death rates among health-care professionals.", [["Ebola", "DISEASE", 21, 26], ["infection", "DISEASE", 59, 68], ["death", "DISEASE", 73, 78], ["high infection", "PROBLEM", 54, 68], ["Ebola", "OBSERVATION_MODIFIER", 21, 26], ["high", "OBSERVATION_MODIFIER", 54, 58], ["infection", "OBSERVATION", 59, 68]]], ["A report from the World Health Organization (WHO) shows that health-care workers are 21 to 32 times more likely to be infected with Ebola compared with the general population.", [["Ebola", "DISEASE", 132, 137], ["Ebola", "ORGANISM", 132, 137], ["Ebola", "PROBLEM", 132, 137], ["infected", "OBSERVATION", 118, 126], ["Ebola", "OBSERVATION", 132, 137]]], ["3 These disease outbreaks resurfaced the concern of willingness of health-care professionals to work during such pandemics.", [["These disease outbreaks", "PROBLEM", 2, 25], ["disease", "OBSERVATION", 8, 15]]]], "93785fd4792883daf90ad3983abbf8e6d76e308d": [["INTRODUCTIONRift Valley fever (RVF) is a disease of humans and livestock causing severe economic and human health impacts (Hartman, 2017) .", [["INTRODUCTIONRift Valley fever", "DISEASE", 0, 29], ["RVF", "DISEASE", 31, 34], ["humans", "ORGANISM", 52, 58], ["human", "ORGANISM", 101, 106], ["humans", "SPECIES", 52, 58], ["human", "SPECIES", 101, 106], ["RVF", "SPECIES", 31, 34], ["humans", "SPECIES", 52, 58], ["human", "SPECIES", 101, 106], ["Valley fever (RVF", "PROBLEM", 17, 34], ["a disease of humans", "PROBLEM", 39, 58], ["disease", "OBSERVATION", 41, 48], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["economic", "OBSERVATION_MODIFIER", 88, 96]]], ["Outbreaks of veterinary and human RVF occur throughout the Middle East and Africa with serosurveys indicating widespread human infection (LaBeaud et al., 2007 (LaBeaud et al., , 2008 (LaBeaud et al., , 2011 .", [["RVF", "DISEASE", 34, 37], ["human infection", "DISEASE", 121, 136], ["human", "ORGANISM", 28, 33], ["human", "ORGANISM", 121, 126], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 121, 126], ["veterinary and human RVF", "PROBLEM", 13, 37], ["serosurveys", "TREATMENT", 87, 98], ["widespread human infection", "PROBLEM", 110, 136], ["human", "OBSERVATION_MODIFIER", 28, 33], ["RVF", "OBSERVATION", 34, 37], ["widespread", "OBSERVATION_MODIFIER", 110, 120], ["human", "OBSERVATION_MODIFIER", 121, 126], ["infection", "OBSERVATION", 127, 136]]], ["In people, RVF spans a variety of clinical manifestations, ranging from an acute flu-like illness to a more severe and sometimes lethal form of disease (Laughlin et al., 1979) .", [["RVF", "DISEASE", 11, 14], ["flu-like illness", "DISEASE", 81, 97], ["people", "ORGANISM", 3, 9], ["people", "SPECIES", 3, 9], ["RVF", "PROBLEM", 11, 14], ["clinical manifestations", "PROBLEM", 34, 57], ["an acute flu-like illness", "PROBLEM", 72, 97], ["disease", "PROBLEM", 144, 151], ["RVF", "OBSERVATION", 11, 14], ["variety", "OBSERVATION_MODIFIER", 23, 30], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["flu", "OBSERVATION", 81, 84], ["more severe", "OBSERVATION_MODIFIER", 103, 114], ["disease", "OBSERVATION", 144, 151]]], ["The vast majority of human RVF virus (RVFV) infections result in self-limited febrile illnesses, but 10-20% of identified human cases progress to severe hepatitis, hemorrhagic fever, or encephalitis Strausbaugh et al., 1978; Nanyingi et al., 2015) .INTRODUCTIONThese large variations in human RVF disease progression and outcome are inadequately represented in the current small animal models.", [["RVF virus (RVFV) infections", "DISEASE", 27, 54], ["febrile illnesses", "DISEASE", 78, 95], ["hepatitis", "DISEASE", 153, 162], ["hemorrhagic fever", "DISEASE", 164, 181], ["encephalitis", "DISEASE", 186, 198], ["RVF disease", "DISEASE", 293, 304], ["human", "ORGANISM", 21, 26], ["RVF virus", "ORGANISM", 27, 36], ["RVFV", "ORGANISM", 38, 42], ["human", "ORGANISM", 122, 127], ["human", "ORGANISM", 287, 292], ["human", "SPECIES", 21, 26], ["RVF virus", "SPECIES", 27, 36], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 287, 292], ["human RVF virus", "SPECIES", 21, 36], ["RVFV", "SPECIES", 38, 42], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 287, 292], ["human RVF virus (RVFV) infections", "PROBLEM", 21, 54], ["self-limited febrile illnesses", "PROBLEM", 65, 95], ["severe hepatitis", "PROBLEM", 146, 162], ["hemorrhagic fever", "PROBLEM", 164, 181], ["encephalitis", "PROBLEM", 186, 198], ["large variations in human RVF disease progression", "PROBLEM", 267, 316], ["severe", "OBSERVATION_MODIFIER", 146, 152], ["hepatitis", "OBSERVATION", 153, 162], ["hemorrhagic", "OBSERVATION_MODIFIER", 164, 175], ["fever", "OBSERVATION", 176, 181], ["large", "OBSERVATION_MODIFIER", 267, 272], ["variations", "OBSERVATION_MODIFIER", 273, 283], ["human", "OBSERVATION_MODIFIER", 287, 292], ["RVF", "OBSERVATION", 293, 296]]], ["This lack of accurate recapitulation of human disease continues to limit our understanding of RVFV pathogenesis.INTRODUCTIONCurrently, the most faithful recapitulation of human disease is displayed in various non-human primate models (Peters and Linthicum, 1994; Ross et al., 2012; Lorenzo et al., 2015) .", [["RVFV", "DISEASE", 94, 98], ["human disease", "DISEASE", 171, 184], ["human", "ORGANISM", 40, 45], ["RVFV", "ORGANISM", 94, 98], ["human", "ORGANISM", 171, 176], ["primate", "ORGANISM", 219, 226], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 40, 45], ["RVFV", "SPECIES", 94, 98], ["human", "SPECIES", 171, 176], ["human disease", "PROBLEM", 40, 53], ["RVFV pathogenesis", "PROBLEM", 94, 111], ["human disease", "PROBLEM", 171, 184], ["human disease", "OBSERVATION", 40, 53], ["RVFV", "OBSERVATION", 94, 98], ["most faithful", "OBSERVATION_MODIFIER", 139, 152], ["human disease", "OBSERVATION", 171, 184]]], ["However, the use of non-human primate models is not feasible for large-scale or high-throughput studies.", [["primate", "ORGANISM", 30, 37]]], ["To date, all tested inbred mouse models are highly susceptible to wild-type RVFV and nearly all die of severe and early-onset hepatic disease.", [["hepatic", "ANATOMY", 126, 133], ["hepatic disease", "DISEASE", 126, 141], ["mouse", "ORGANISM", 27, 32], ["RVFV", "ORGANISM", 76, 80], ["hepatic", "ORGAN", 126, 133], ["mouse", "SPECIES", 27, 32], ["mouse", "SPECIES", 27, 32], ["RVFV", "SPECIES", 76, 80], ["type RVFV", "PROBLEM", 71, 80], ["early-onset hepatic disease", "PROBLEM", 114, 141], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["early", "OBSERVATION_MODIFIER", 114, 119], ["-onset", "OBSERVATION_MODIFIER", 119, 125], ["hepatic", "ANATOMY", 126, 133], ["disease", "OBSERVATION", 134, 141]]], ["A major exception to this are BALB/c mice that live longer following infection and are more prone to develop neurological disease (do Valle et al., 2010; Smith et al., 2010; Reed et al., 2013; Lathan et al., 2017) .", [["neurological", "ANATOMY", 109, 121], ["infection", "DISEASE", 69, 78], ["neurological disease", "DISEASE", 109, 129], ["BALB/c mice", "ORGANISM", 30, 41], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["infection", "PROBLEM", 69, 78], ["neurological disease", "PROBLEM", 109, 129], ["infection", "OBSERVATION", 69, 78]]], ["On the other side of the spectrum exist the highly susceptible MBT and C57BL/6J mice that exhibit 100% mortality in 3-4 days (do Valle et al., 2010; Gray et al., 2012; Lathan et al., 2017) .", [["C57BL/6J mice", "ORGANISM", 71, 84], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["C57BL/6J mice", "TREATMENT", 71, 84]]], ["Although these models demonstrate the existence of some variation in RVFV disease outcome in inbred mice, they are still overwhelmingly lethal unlike human RVFV disease.", [["RVFV disease", "DISEASE", 156, 168], ["RVFV", "ORGANISM", 69, 73], ["mice", "ORGANISM", 100, 104], ["human", "ORGANISM", 150, 155], ["RVFV", "ORGANISM", 156, 160], ["mice", "SPECIES", 100, 104], ["human", "SPECIES", 150, 155], ["RVFV", "SPECIES", 69, 73], ["mice", "SPECIES", 100, 104], ["human", "SPECIES", 150, 155], ["RVFV", "SPECIES", 156, 160], ["some variation in RVFV disease outcome", "PROBLEM", 51, 89], ["human RVFV disease", "PROBLEM", 150, 168], ["some", "OBSERVATION_MODIFIER", 51, 55], ["variation", "OBSERVATION_MODIFIER", 56, 65], ["RVFV disease", "OBSERVATION", 69, 81], ["RVFV disease", "OBSERVATION", 156, 168]]], ["Additionally, they only recapitulate severe hepatitis and inconsistently display lateonset encephalitis.", [["hepatitis", "DISEASE", 44, 53], ["encephalitis", "DISEASE", 91, 103], ["severe hepatitis", "PROBLEM", 37, 53], ["lateonset encephalitis", "PROBLEM", 81, 103], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["hepatitis", "OBSERVATION", 44, 53], ["encephalitis", "OBSERVATION", 91, 103]]], ["However, the notable differences in survival times and disease skewing between these strains do point to the possibility of identifying mice with additional RVFV phenotypes.INTRODUCTIONInbred rats have shown impressive differences in disease susceptibility to RVFV between strains.", [["RVFV", "DISEASE", 260, 264], ["mice", "ORGANISM", 136, 140], ["RVFV", "ORGANISM", 157, 161], ["rats", "ORGANISM", 192, 196], ["RVFV", "ORGANISM", 260, 264], ["mice", "SPECIES", 136, 140], ["rats", "SPECIES", 192, 196], ["mice", "SPECIES", 136, 140], ["RVFV", "SPECIES", 157, 161], ["RVFV", "SPECIES", 260, 264], ["disease skewing between these strains", "PROBLEM", 55, 92], ["disease susceptibility to RVFV between strains", "PROBLEM", 234, 280], ["notable", "OBSERVATION_MODIFIER", 13, 20], ["differences", "OBSERVATION_MODIFIER", 21, 32], ["RVFV", "OBSERVATION", 157, 161], ["impressive", "OBSERVATION_MODIFIER", 208, 218], ["differences", "OBSERVATION_MODIFIER", 219, 230], ["disease", "OBSERVATION", 234, 241]]], ["RVFV infection in rats ranges from extreme lethality in the highly susceptible Wistar-Furth (WF) rat to a complete absence of symptoms or death in subcutaneously infected Lewis rats (Peters and Anderson, 1981; Peters and Slone, 1982; Anderson et al., 1987) .", [["RVFV infection", "DISEASE", 0, 14], ["death", "DISEASE", 138, 143], ["RVFV", "ORGANISM", 0, 4], ["rats", "ORGANISM", 18, 22], ["Wistar-Furth (WF) rat", "ORGANISM", 79, 100], ["rats", "ORGANISM", 177, 181], ["rats", "SPECIES", 18, 22], ["rat", "SPECIES", 97, 100], ["rats", "SPECIES", 177, 181], ["RVFV", "SPECIES", 0, 4], ["Wistar-Furth (WF) rat", "SPECIES", 79, 100], ["RVFV infection in rats ranges", "PROBLEM", 0, 29], ["extreme lethality", "PROBLEM", 35, 52], ["symptoms", "PROBLEM", 126, 134], ["death", "PROBLEM", 138, 143], ["infection", "OBSERVATION", 5, 14], ["extreme", "OBSERVATION_MODIFIER", 35, 42], ["lethality", "OBSERVATION", 43, 52]]], ["Distinct clinical outcomes of RVFV infection also exist between inbred rat models, with WF rats dying of acute hepatitis while August-Copenhagen-Irish (ACI) rats die of a late-onset encephalitic disease (Bucci et al., 1981; Peters and Anderson, 1981; Peters and Slone, 1982; Anderson et al., 1987) .", [["RVFV infection", "DISEASE", 30, 44], ["acute hepatitis", "DISEASE", 105, 120], ["encephalitic disease", "DISEASE", 182, 202], ["RVFV", "ORGANISM", 30, 34], ["rat", "ORGANISM", 71, 74], ["WF rats", "ORGANISM", 88, 95], ["Copenhagen-Irish", "ORGANISM", 134, 150], ["rats", "ORGANISM", 157, 161], ["rat", "SPECIES", 71, 74], ["rats", "SPECIES", 91, 95], ["rats", "SPECIES", 157, 161], ["RVFV", "SPECIES", 30, 34], ["rat", "SPECIES", 71, 74], ["RVFV infection", "PROBLEM", 30, 44], ["inbred rat models", "PROBLEM", 64, 81], ["acute hepatitis", "PROBLEM", 105, 120], ["a late-onset encephalitic disease", "PROBLEM", 169, 202], ["RVFV", "OBSERVATION_MODIFIER", 30, 34], ["infection", "OBSERVATION", 35, 44], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["hepatitis", "OBSERVATION", 111, 120], ["encephalitic disease", "OBSERVATION", 182, 202]]], ["Interestingly, upon aerosol challenge, Lewis rats display a distinct phenotype, succumbing almost uniformly to encephalitis (Bales et al., 2012) .INTRODUCTIONDue to these divergent clinical outcomes from RVFV infection in both mice and rats, we deemed it useful to investigate other classically used inbred mouse strains for their susceptibility to and disease manifestations of RVFV.", [["encephalitis", "DISEASE", 111, 123], ["RVFV infection", "DISEASE", 204, 218], ["RVFV", "DISEASE", 379, 383], ["Lewis rats", "ORGANISM", 39, 49], ["RVFV", "ORGANISM", 204, 208], ["mice", "ORGANISM", 227, 231], ["rats", "ORGANISM", 236, 240], ["mouse", "ORGANISM", 307, 312], ["RVFV", "ORGANISM", 379, 383], ["rats", "SPECIES", 45, 49], ["mice", "SPECIES", 227, 231], ["rats", "SPECIES", 236, 240], ["mouse", "SPECIES", 307, 312], ["RVFV", "SPECIES", 204, 208], ["mice", "SPECIES", 227, 231], ["mouse", "SPECIES", 307, 312], ["RVFV", "SPECIES", 379, 383], ["aerosol challenge", "TREATMENT", 20, 37], ["a distinct phenotype", "PROBLEM", 58, 78], ["encephalitis", "PROBLEM", 111, 123], ["RVFV infection", "PROBLEM", 204, 218], ["inbred mouse strains", "TREATMENT", 300, 320], ["disease manifestations of RVFV", "PROBLEM", 353, 383], ["distinct", "OBSERVATION_MODIFIER", 60, 68], ["phenotype", "OBSERVATION", 69, 78], ["encephalitis", "OBSERVATION", 111, 123], ["RVFV", "OBSERVATION_MODIFIER", 204, 208], ["infection", "OBSERVATION", 209, 218]]], ["Three out of five of the chosen strains for this study had never been investigated in the context of wild-type RVFV infection and the 129S1/SvlmJ strain had only briefly been studied (do Valle et al., 2010) .", [["RVFV infection", "DISEASE", 111, 125], ["wild-type RVFV", "ORGANISM", 101, 115], ["SvlmJ", "GENE_OR_GENE_PRODUCT", 140, 145], ["RVFV", "SPECIES", 111, 115], ["the chosen strains", "PROBLEM", 21, 39], ["this study", "TEST", 44, 54], ["wild-type RVFV infection", "PROBLEM", 101, 125], ["the 129S1/SvlmJ strain", "PROBLEM", 130, 152], ["RVFV", "OBSERVATION_MODIFIER", 111, 115], ["infection", "OBSERVATION", 116, 125]]], ["Using the C57BL/6J mouse genome as a reference, the other four selected inbred mouse strains (129S1/SvlmJ, NOD/ShiLtJ, A/J, and NZO/ HILtJ) vary at 4 million single nucleotide polymorphisms (SNPs) (Keane et al., 2011) .", [["C57BL/6J mouse", "ORGANISM", 10, 24], ["mouse", "ORGANISM", 79, 84], ["SvlmJ", "GENE_OR_GENE_PRODUCT", 100, 105], ["C57BL/6J mouse genome", "DNA", 10, 31], ["NOD", "PROTEIN", 107, 110], ["ShiLtJ", "PROTEIN", 111, 117], ["NZO", "PROTEIN", 128, 131], ["HILtJ", "PROTEIN", 133, 138], ["mouse", "SPECIES", 19, 24], ["mouse", "SPECIES", 79, 84], ["mouse", "SPECIES", 19, 24], ["mouse", "SPECIES", 79, 84], ["the C57BL/6J mouse genome", "TREATMENT", 6, 31], ["inbred mouse strains", "TREATMENT", 72, 92], ["129S1/SvlmJ", "TREATMENT", 94, 105], ["NOD/ShiLtJ", "TREATMENT", 107, 117], ["A/J", "TREATMENT", 119, 122], ["NZO/ HILtJ)", "TREATMENT", 128, 139], ["single nucleotide polymorphisms (SNPs)", "TREATMENT", 158, 196]]], ["Due to this existing genetic variability between strains, these inbred mouse strains have been able to capture a range of human disease manifestations for other viral infections.", [["viral infections", "DISEASE", 161, 177], ["mouse", "ORGANISM", 71, 76], ["human", "ORGANISM", 122, 127], ["mouse", "SPECIES", 71, 76], ["human", "SPECIES", 122, 127], ["mouse", "SPECIES", 71, 76], ["human", "SPECIES", 122, 127], ["this existing genetic variability between strains", "PROBLEM", 7, 56], ["these inbred mouse strains", "PROBLEM", 58, 84], ["human disease manifestations", "PROBLEM", 122, 150], ["other viral infections", "PROBLEM", 155, 177], ["viral", "OBSERVATION_MODIFIER", 161, 166], ["infections", "OBSERVATION", 167, 177]]], ["Leist et al. (2016) discovered highly variable disease phenotypes, including survival, body weight, and viral load, across investigated mouse strains with even inbred strains showing clear divergence in their susceptibility to H3N2 infection.INTRODUCTIONSignificant differences in SARS-CoV pathogenesis and disease severity were also found by Gralinski et al. (2015) upon challenge of various inbred and outbred mice.", [["body", "ANATOMY", 87, 91], ["H3N2 infection", "DISEASE", 227, 241], ["SARS", "DISEASE", 281, 285], ["body", "ORGANISM_SUBDIVISION", 87, 91], ["mouse", "ORGANISM", 136, 141], ["H3N2", "ORGANISM", 227, 231], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 281, 289], ["mice", "ORGANISM", 412, 416], ["mouse", "SPECIES", 136, 141], ["mice", "SPECIES", 412, 416], ["mouse", "SPECIES", 136, 141], ["SARS-CoV", "SPECIES", 281, 289], ["mice", "SPECIES", 412, 416], ["highly variable disease phenotypes", "PROBLEM", 31, 65], ["survival", "TEST", 77, 85], ["body weight", "TEST", 87, 98], ["viral load", "PROBLEM", 104, 114], ["across investigated mouse strains", "PROBLEM", 116, 149], ["even inbred strains", "PROBLEM", 155, 174], ["clear divergence", "PROBLEM", 183, 199], ["H3N2 infection", "PROBLEM", 227, 241], ["SARS", "PROBLEM", 281, 285], ["CoV pathogenesis", "PROBLEM", 286, 302], ["disease severity", "PROBLEM", 307, 323], ["variable", "OBSERVATION_MODIFIER", 38, 46], ["disease", "OBSERVATION", 47, 54], ["viral load", "OBSERVATION", 104, 114], ["infection", "OBSERVATION", 232, 241], ["SARS", "OBSERVATION", 281, 285]]], ["While this paper found fascinating differences in the outbred mouse resource, they were even able to identify an expansion of SARS-CoV phenotypes within common inbred mouse strains.INTRODUCTIONThe study described here was undertaken to assess the susceptibility of five commonly used inbred laboratory mouse strains to wild-type RVFV.", [["SARS", "DISEASE", 126, 130], ["mouse", "ORGANISM", 62, 67], ["SARS-CoV", "ORGANISM", 126, 134], ["mouse", "ORGANISM", 167, 172], ["mouse", "ORGANISM", 302, 307], ["RVFV", "ORGANISM", 329, 333], ["mouse", "SPECIES", 62, 67], ["mouse", "SPECIES", 167, 172], ["mouse", "SPECIES", 302, 307], ["mouse", "SPECIES", 62, 67], ["SARS-CoV", "SPECIES", 126, 134], ["mouse", "SPECIES", 167, 172], ["mouse", "SPECIES", 302, 307], ["RVFV", "SPECIES", 329, 333], ["SARS", "PROBLEM", 126, 130], ["CoV phenotypes", "PROBLEM", 131, 145], ["common inbred mouse strains", "PROBLEM", 153, 180], ["The study", "TEST", 193, 202], ["inbred laboratory mouse strains", "PROBLEM", 284, 315]]], ["We investigated mouse strain, viral dose, sex, weight loss, and viral load following challenge with the wild-type ZH501 strain of RVFV.", [["weight loss", "DISEASE", 47, 58], ["RVFV", "DISEASE", 130, 134], ["mouse", "ORGANISM", 16, 21], ["ZH501", "ORGANISM", 114, 119], ["RVFV", "ORGANISM", 130, 134], ["mouse", "SPECIES", 16, 21], ["mouse", "SPECIES", 16, 21], ["RVFV", "SPECIES", 130, 134], ["mouse strain", "PROBLEM", 16, 28], ["viral dose", "TREATMENT", 30, 40], ["weight loss", "PROBLEM", 47, 58], ["viral load", "PROBLEM", 64, 74], ["RVFV", "PROBLEM", 130, 134], ["mouse strain", "OBSERVATION", 16, 28], ["viral load", "OBSERVATION", 64, 74]]], ["This report presents evidence for the overwhelming lethality of wild-type RVFV, down to a single virion, across C57BL/6J, 129S1/SvlmJ, NOD/ShiLtJ, A/J, and NZO/HILtJ inbred mouse strains, independent of sex.Ethics Statement and Biosafety InformationAll research in this study was conducted under the oversight of the University of Pittsburgh IACUC (protocol 19044158) .", [["wild-type RVFV", "ORGANISM", 64, 78], ["C57BL/6J", "ORGANISM", 112, 120], ["129S1", "GENE_OR_GENE_PRODUCT", 122, 127], ["SvlmJ", "GENE_OR_GENE_PRODUCT", 128, 133], ["NOD", "GENE_OR_GENE_PRODUCT", 135, 138], ["ShiLtJ", "GENE_OR_GENE_PRODUCT", 139, 145], ["NZO/HILtJ inbred mouse", "ORGANISM", 156, 178], ["NOD/ShiLtJ, A/J, and NZO/HILtJ inbred mouse strains", "CELL_LINE", 135, 186], ["mouse", "SPECIES", 173, 178], ["RVFV", "SPECIES", 74, 78], ["mouse", "SPECIES", 173, 178], ["the overwhelming lethality", "PROBLEM", 34, 60], ["type RVFV", "PROBLEM", 69, 78], ["ShiLtJ", "TREATMENT", 139, 145], ["A/J", "TREATMENT", 147, 150], ["NZO", "TREATMENT", 156, 159], ["HILtJ inbred mouse strains", "TREATMENT", 160, 186], ["this study", "TEST", 265, 275], ["mouse strains", "OBSERVATION", 173, 186]]], ["All experiments with wild-type RVFV ZH501 strain were performed in the University of Pittsburgh Regional Biocontainment Laboratory (RBL) Biosafety Level 3 (BSL-3) and Animal Biosafety Level 3 (ABSL-3) facilities.Virus Generation, Growth, and TiterThe wild-type ZH501 strain of RVFV was originally isolated from a febrile human during the 1977 Egyptian epidemic (Meegan, 1979) .", [["febrile", "DISEASE", 313, 320], ["RVFV", "ORGANISM", 31, 35], ["ZH501", "ORGANISM", 36, 41], ["Virus", "ORGANISM", 212, 217], ["wild-type ZH501 strain", "ORGANISM", 251, 273], ["RVFV", "ORGANISM", 277, 281], ["human", "ORGANISM", 321, 326], ["human", "SPECIES", 321, 326], ["RVFV", "SPECIES", 31, 35], ["RVFV", "SPECIES", 277, 281], ["human", "SPECIES", 321, 326], ["type RVFV ZH501 strain", "TREATMENT", 26, 48], ["Biosafety Level", "TEST", 137, 152], ["BSL", "TEST", 156, 159], ["Animal Biosafety Level", "TEST", 167, 189], ["ABSL", "TEST", 193, 197], ["RVFV", "PROBLEM", 277, 281], ["a febrile human", "PROBLEM", 311, 326], ["Growth", "OBSERVATION_MODIFIER", 230, 236]]], ["For this study, recombinant wild-type RVFV was generated using an established reverse-genetics system based on the ZH501 strain background (Bird et al., 2007a; Gerrard et al., 2007) .", [["RVFV", "ORGANISM", 38, 42], ["RVFV", "SPECIES", 38, 42], ["this study", "TEST", 4, 14]]], ["Virus stocks were fully sequence confirmed using next generation sequencing prior to use.", [["Virus", "ORGANISM", 0, 5], ["Virus stocks", "TREATMENT", 0, 12], ["next generation sequencing", "TREATMENT", 49, 75]]], ["Viral titer of the passage two stock was determined using a standard tissue culture infective dose 50 (TCID 50 ) assay.", [["tissue", "ANATOMY", 69, 75], ["Viral", "ORGANISM", 0, 5], ["Viral titer", "TEST", 0, 11], ["a standard tissue culture infective dose", "TREATMENT", 58, 98]]], ["Briefly, viral stocks were serially diluted in Dulbecco's Modified Eagle Medium (DMEM) then added to 96-well plates containing 1 \u00d7 10 4 Vero-E6 cells/well (eight replicates per viral dilution).", [["cells", "ANATOMY", 144, 149], ["E6", "ORGANISM", 141, 143], ["cells", "CELL", 144, 149], ["E6 cells", "CELL_LINE", 141, 149], ["viral stocks", "TREATMENT", 9, 21], ["Dulbecco's Modified Eagle Medium (DMEM", "TREATMENT", 47, 85], ["Vero-E6 cells", "TREATMENT", 136, 149], ["viral stocks", "OBSERVATION", 9, 21]]], ["Titers were determined through visualization by indirect fluorescent antibody assay (IFA) using a 1:500 dilution of a custom RVFV anti-N polyclonal #5584 (Genscript) as primary antibody and a 1:500 dilution of anti-rabbit 488 (Invitrogen) as secondary antibody.", [["anti-rabbit 488", "CHEMICAL", 210, 225], ["Genscript", "SIMPLE_CHEMICAL", 155, 164], ["anti-rabbit 488", "SIMPLE_CHEMICAL", 210, 225], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 227, 237], ["RVFV anti-N polyclonal #5584", "PROTEIN", 125, 153], ["Genscript", "PROTEIN", 155, 164], ["primary antibody", "PROTEIN", 169, 185], ["anti-rabbit 488", "PROTEIN", 210, 225], ["secondary antibody", "PROTEIN", 242, 260], ["anti-rabbit", "SPECIES", 210, 221], ["RVFV", "SPECIES", 125, 129], ["Titers", "TEST", 0, 6], ["indirect fluorescent antibody assay", "TEST", 48, 83], ["a custom RVFV anti", "TREATMENT", 116, 134], ["primary antibody", "TEST", 169, 185], ["a 1:500 dilution of anti-rabbit", "TREATMENT", 190, 221], ["secondary antibody", "PROBLEM", 242, 260]]], ["TCID 50 titers were calculated using the Reed and Muench calculations (Reed and Muench, 1938) .Mouse Study DesignSix to eight-week-old female and male A/J (stock #000646), C57BL/6J (stock #000664), 129S1/SvlmJ (stock #002448), NOD/ShiLtJ (stock #001976), and NZO/HILtJ (stock #002105) inbred mice were purchased from Jackson Laboratories.", [["Mouse", "ORGANISM", 95, 100], ["female", "ORGANISM", 135, 141], ["A/J (stock #000646", "ORGANISM", 151, 169], ["C57BL/6J", "ORGANISM", 172, 180], ["stock #000664", "ORGANISM", 182, 195], ["NOD/ShiLtJ", "ORGANISM", 227, 237], ["NZO/HILtJ (stock #002105", "ORGANISM", 259, 283], ["mice", "ORGANISM", 292, 296], ["Mouse", "SPECIES", 95, 100], ["mice", "SPECIES", 292, 296], ["mice", "SPECIES", 292, 296], ["NZO/HILtJ", "TREATMENT", 259, 268]]], ["All mice were housed in HEPA filtration racks in the RBL's ABSL-3 facility and provided ad lib access to food and water.", [["RBL", "ANATOMY", 53, 56], ["mice", "ORGANISM", 4, 8], ["RBL", "CELL", 53, 56], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["HEPA filtration", "TREATMENT", 24, 39]]], ["All mice were infected with recombinant wild-type RVFV ZH501 strain under isoflurane anesthesia via left rear footpad (FP) injection to imitate a mosquito bite.", [["isoflurane", "CHEMICAL", 74, 84], ["mosquito bite", "DISEASE", 146, 159], ["isoflurane", "CHEMICAL", 74, 84], ["mice", "ORGANISM", 4, 8], ["RVFV", "ORGANISM", 50, 54], ["ZH501", "ORGANISM", 55, 60], ["isoflurane", "SIMPLE_CHEMICAL", 74, 84], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["RVFV", "SPECIES", 50, 54], ["isoflurane anesthesia", "TREATMENT", 74, 95], ["left rear footpad (FP) injection", "TREATMENT", 100, 132], ["a mosquito bite", "PROBLEM", 144, 159], ["left", "ANATOMY_MODIFIER", 100, 104]]], ["Viral infection doses in these studies ranged from 0.2 to 2,000 TCID 50 per animal, which equates to doses ranging from 0.138 to 1,380 PFU per animal (0.69 TCID50 = 1 PFU; Poisson distribution based upon Reed and Muench, 1938) .", [["Viral infection", "DISEASE", 0, 15], ["Viral", "ORGANISM", 0, 5], ["Viral infection doses", "PROBLEM", 0, 21], ["these studies", "TEST", 25, 38], ["infection", "OBSERVATION", 6, 15]]], ["Mice received a 20 \u03bcl injection of virus diluted in sterile phosphate buffered saline (PBS).", [["phosphate", "CHEMICAL", 60, 69], ["phosphate", "CHEMICAL", 60, 69], ["Mice", "ORGANISM", 0, 4], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 60, 85], ["Mice", "SPECIES", 0, 4], ["a 20 \u03bcl injection of virus", "TREATMENT", 14, 40], ["sterile phosphate buffered saline (PBS", "TREATMENT", 52, 90]]], ["For all experiments, daily weights were recorded, and mice were evaluated at least once daily for clinical signs of disease.", [["mice", "ORGANISM", 54, 58], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 54, 58], ["daily weights", "TEST", 21, 34], ["disease", "PROBLEM", 116, 123], ["disease", "OBSERVATION", 116, 123]]], ["Mice were euthanized according to a predetermined clinical scoring method (Supplementary Table S1 ).", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4]]], ["At the time of euthanasia, mice were anesthetized with isoflurane and blood was collected via cardiac puncture.", [["blood", "ANATOMY", 70, 75], ["cardiac", "ANATOMY", 94, 101], ["isoflurane", "CHEMICAL", 55, 65], ["isoflurane", "CHEMICAL", 55, 65], ["mice", "ORGANISM", 27, 31], ["isoflurane", "SIMPLE_CHEMICAL", 55, 65], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["cardiac puncture", "MULTI-TISSUE_STRUCTURE", 94, 110], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["isoflurane", "TREATMENT", 55, 65], ["cardiac puncture", "TEST", 94, 110], ["euthanasia", "OBSERVATION", 15, 25], ["cardiac", "ANATOMY", 94, 101], ["puncture", "OBSERVATION", 102, 110]]], ["Following cervical dislocation, liver, spleen, brain, and testes (where applicable) were collected for subsequent RNA extraction and viral RNA load quantitation.RNA Extraction and Quantitative RT-PCRMouse liver, spleen, brain, and testes tissue samples were weighed and then homogenized in sterile PBS with 1X Antibiotic-Antimycotic (Gibco) using a D2400 Homogenizer (Benchmark Scientific).", [["cervical", "ANATOMY", 10, 18], ["liver", "ANATOMY", 32, 37], ["spleen", "ANATOMY", 39, 45], ["brain", "ANATOMY", 47, 52], ["testes", "ANATOMY", 58, 64], ["liver", "ANATOMY", 205, 210], ["spleen", "ANATOMY", 212, 218], ["brain", "ANATOMY", 220, 225], ["testes tissue samples", "ANATOMY", 231, 252], ["dislocation", "DISEASE", 19, 30], ["cervical", "ORGAN", 10, 18], ["liver", "ORGAN", 32, 37], ["spleen", "ORGAN", 39, 45], ["brain", "ORGAN", 47, 52], ["testes", "ORGAN", 58, 64], ["liver", "ORGAN", 205, 210], ["spleen", "ORGAN", 212, 218], ["brain", "ORGAN", 220, 225], ["testes tissue samples", "TISSUE", 231, 252], ["cervical dislocation, liver, spleen, brain, and testes", "PROBLEM", 10, 64], ["subsequent RNA extraction", "TREATMENT", 103, 128], ["viral RNA load quantitation", "PROBLEM", 133, 160], ["RNA Extraction", "TEST", 161, 175], ["Quantitative RT", "TEST", 180, 195], ["sterile PBS", "TREATMENT", 290, 301], ["1X Antibiotic", "TREATMENT", 307, 320], ["Antimycotic (Gibco)", "TREATMENT", 321, 340], ["a D2400 Homogenizer", "TREATMENT", 347, 366], ["cervical", "ANATOMY", 10, 18], ["dislocation", "OBSERVATION", 19, 30], ["liver", "ANATOMY", 32, 37], ["spleen", "ANATOMY", 39, 45], ["brain", "ANATOMY", 47, 52], ["testes", "ANATOMY", 58, 64], ["viral RNA load", "OBSERVATION", 133, 147], ["liver", "ANATOMY", 205, 210], ["spleen", "ANATOMY", 212, 218], ["brain", "ANATOMY", 220, 225], ["testes", "ANATOMY", 231, 237]]], ["RNA was extracted from liver, spleen, brain, and testes tissue samples with TRIzol reagent (Ambion) following the Direct-zol RNA purification protocol (Zymo Research).", [["liver", "ANATOMY", 23, 28], ["spleen", "ANATOMY", 30, 36], ["brain", "ANATOMY", 38, 43], ["testes tissue samples", "ANATOMY", 49, 70], ["liver", "ORGAN", 23, 28], ["spleen", "ORGAN", 30, 36], ["brain", "ORGAN", 38, 43], ["testes tissue samples", "TISSUE", 49, 70], ["RNA", "RNA", 0, 3], ["TRIzol reagent (Ambion", "TREATMENT", 76, 98], ["the Direct-zol RNA purification protocol", "TREATMENT", 110, 150], ["liver", "ANATOMY", 23, 28], ["spleen", "ANATOMY", 30, 36], ["brain", "ANATOMY", 38, 43], ["testes", "ANATOMY", 49, 55]]], ["Quantitative RT-PCR (qRT-PCR) targeting the L segment of RVFV (Bird et al., 2007b) was performed using the SuperScript III Platinum One-Step qRT-PCR kit (Thermofisher).", [["RVFV", "ORGANISM", 57, 61], ["L segment", "DNA", 44, 53], ["RVFV", "SPECIES", 57, 61], ["Quantitative RT-PCR", "TEST", 0, 19], ["qRT", "TEST", 21, 24], ["PCR", "TEST", 25, 28], ["the SuperScript III Platinum", "TREATMENT", 103, 131], ["L", "ANATOMY_MODIFIER", 44, 45], ["segment", "ANATOMY_MODIFIER", 46, 53]]], ["T7 driven RVFV L RNA template of known quantity was serially diluted to generate a RVFV RNA standard curve.", [["RVFV", "ORGANISM", 10, 14], ["T7", "DNA", 0, 2], ["RVFV L RNA template", "RNA", 10, 29], ["RVFV", "SPECIES", 10, 14], ["RVFV", "SPECIES", 83, 87], ["known quantity", "PROBLEM", 33, 47], ["RVFV", "OBSERVATION", 10, 14], ["quantity", "OBSERVATION_MODIFIER", 39, 47]]], ["This template RNA was made by In-Fusion cloning (Takara Bio), a fragment of the ZH501 RVFV L segment into pET-9a (Millipore Sigma).", [["pET-9a", "GENE_OR_GENE_PRODUCT", 106, 112], ["Millipore Sigma", "GENE_OR_GENE_PRODUCT", 114, 129], ["template RNA", "RNA", 5, 17], ["Takara Bio", "DNA", 49, 59], ["ZH501 RVFV L segment", "DNA", 80, 100], ["pET-9a", "DNA", 106, 112], ["Millipore Sigma", "PROTEIN", 114, 129], ["This template RNA", "TREATMENT", 0, 17], ["a fragment of the ZH501 RVFV L segment into pET", "TREATMENT", 62, 109], ["segment", "ANATOMY_MODIFIER", 93, 100]]], ["To generate linear pET-9a primers 5'-AATCCTCAAACTTCT GGGAAACCGTTGTGGTC-3' and 5'-TTCAAAGCTTATCATT CTAGAAATAATTTTGTTTAACTTTAAGAAGGA-3' were used.", [["pET", "DNA", 19, 22], ["linear pET-9a primers", "TREATMENT", 12, 33], ["AATCCTCAAACTTCT GGGAAACCGTTGTGGTC", "TREATMENT", 37, 70], ["5'-TTCAAAGCTTATCATT CTAGAAATAATTTTGTTTAACTTTAAGAAGGA", "TREATMENT", 78, 130], ["linear", "OBSERVATION_MODIFIER", 12, 18]]], ["To prepare the RVFV L segment fragment primers 5'-AA AATTATTTCTAGAATGATAAGCTTTGAAGAGATCCAT-3' and 5'-CCACAACGGTTTCCCAGAAGTTTGAGGATTGTATGA GG-3' were used.", [["RVFV L segment fragment primers", "DNA", 15, 46], ["RVFV", "SPECIES", 15, 19], ["the RVFV L segment fragment primers", "TREATMENT", 11, 46], ["AA AATTATTTCTAGAATGATAAGCTTTGAAGAGATCCAT", "TREATMENT", 50, 90], ["5'-CCACAACGGTTTCCCAGAAGTTTGAGGATTGTATGA GG-3'", "TREATMENT", 98, 143]]], ["The resultant plasmid, pLquant, was gel purified and linearized with XbaI (New England Biolabs), and then used as template in a TranscriptAid T7 High Yield in vitro transcription reaction (Thermo Scientific).", [["plasmid", "ANATOMY", 14, 21], ["XbaI", "GENE_OR_GENE_PRODUCT", 69, 73], ["Biolabs", "GENE_OR_GENE_PRODUCT", 87, 94], ["resultant plasmid", "DNA", 4, 21], ["pLquant", "DNA", 23, 30], ["XbaI", "DNA", 69, 73], ["The resultant plasmid", "TREATMENT", 0, 21], ["XbaI", "TREATMENT", 69, 73], ["New England Biolabs)", "TREATMENT", 75, 95], ["a TranscriptAid T7", "TREATMENT", 126, 144], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["plasmid", "OBSERVATION", 14, 21]]], ["Product RNA was purified using the GeneJET RNA Purification kit (Thermo Scientific), and then diluted to known copies/ml in RNase-free water for use as qRT-PCR standard curve template.", [["RNase", "GENE_OR_GENE_PRODUCT", 124, 129], ["Product RNA", "RNA", 0, 11], ["RNase", "PROTEIN", 124, 129], ["the GeneJET RNA", "TREATMENT", 31, 46], ["qRT", "TEST", 152, 155], ["PCR", "TEST", 156, 159]]], ["The assay was performed using a C1000 Touch Thermo Cycler/CFX96 Real-Time System (Bio-Rad) under the following reaction conditions: 50\u00b0C for 15 min, 95\u00b0C for 3 min, and then 40 cycles of 95\u00b0C for 15 s and 55\u00b0C for 1 min.", [["The assay", "TEST", 0, 9], ["a C1000 Touch Thermo Cycler", "TREATMENT", 30, 57]]], ["RNA copies for each unknown sample were normalized by tissue weight and are reported as log viral RNA copies per milligram of tissue.", [["sample", "ANATOMY", 28, 34], ["tissue", "ANATOMY", 54, 60], ["tissue", "ANATOMY", 126, 132], ["tissue", "TISSUE", 54, 60], ["tissue", "TISSUE", 126, 132], ["log viral RNA copies", "RNA", 88, 108], ["RNA copies", "TEST", 0, 10], ["tissue weight", "TEST", 54, 67]]], ["The lowest limit of detection of this assay was calculated as the highest Ct value detected in the standard curve multiplied by 50 to account for dilutions, and then divided by the average of all sampled tissue weights in mg.Enzyme-Linked Immunosorbent AssayMaxiSorp plates (Thermo Scientific) were coated with lysate, diluted 1:1,000 in PBS, from RVFV-infected Vero-E6 cells or with lysate from uninfected Vero-E6 cells to act as a negative control (McElroy et al., 2009) .", [["tissue", "ANATOMY", 204, 210], ["lysate", "ANATOMY", 311, 317], ["Vero-E6 cells", "ANATOMY", 362, 375], ["lysate", "ANATOMY", 384, 390], ["cells", "ANATOMY", 415, 420], ["tissue", "TISSUE", 204, 210], ["PBS", "SIMPLE_CHEMICAL", 338, 341], ["RVFV", "ORGANISM", 348, 352], ["Vero-E6 cells", "CELL", 362, 375], ["Vero-E6 cells", "CELL", 407, 420], ["E6 cells", "CELL_LINE", 367, 375], ["uninfected Vero-E6 cells", "CELL_LINE", 396, 420], ["RVFV", "SPECIES", 348, 352], ["Vero-E6", "SPECIES", 362, 369], ["Vero-E6", "SPECIES", 407, 414], ["this assay", "TEST", 33, 43], ["Ct value", "TEST", 74, 82], ["Enzyme", "TEST", 225, 231], ["Immunosorbent AssayMaxiSorp plates", "TREATMENT", 239, 273], ["lysate", "TREATMENT", 311, 317], ["RVFV", "TEST", 348, 352], ["lysate", "TEST", 384, 390], ["lowest limit", "OBSERVATION_MODIFIER", 4, 16]]], ["Plates were left at 4\u00b0C overnight, and then blocked in blocking buffer (5% non-fat milk in PBS-0.1% Tween 20) at 37\u00b0C for 1 h.", [["fat milk", "ANATOMY", 79, 87], ["Tween 20", "CHEMICAL", 100, 108], ["fat milk", "TISSUE", 79, 87], ["Plates", "TEST", 0, 6], ["blocking buffer", "TREATMENT", 55, 70], ["5% non-fat milk in PBS", "TREATMENT", 72, 94], ["left", "ANATOMY_MODIFIER", 12, 16]]], ["Terminal mouse serum samples were serially diluted in blocking buffer, and then incubated on blocked plates at 37\u00b0C for 2 h.", [["serum samples", "ANATOMY", 15, 28], ["mouse", "ORGANISM", 9, 14], ["serum samples", "ORGANISM_SUBSTANCE", 15, 28], ["mouse", "SPECIES", 9, 14], ["mouse", "SPECIES", 9, 14], ["Terminal mouse serum samples", "TEST", 0, 28], ["blocking buffer", "TREATMENT", 54, 69], ["blocked plates", "TREATMENT", 93, 107]]], ["All serum samples were assayed in duplicate alongside normal mouse serum as a negative control.", [["serum samples", "ANATOMY", 4, 17], ["serum", "ANATOMY", 67, 72], ["serum samples", "ORGANISM_SUBSTANCE", 4, 17], ["mouse", "ORGANISM", 61, 66], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["mouse", "SPECIES", 61, 66], ["mouse", "SPECIES", 61, 66], ["All serum samples", "TEST", 0, 17]]], ["After incubation with sera, plates were washed three times with PBS-0.1% Tween 20 (PBST), and then incubated for 1 h at 37\u00b0C in anti-mouse IgG-HRP (Jackson ImmunoResearch) diluted 1:5,000 in blocking buffer.", [["sera", "ANATOMY", 22, 26], ["Tween 20", "CHEMICAL", 73, 81], ["sera", "ORGANISM_SUBSTANCE", 22, 26], ["Tween 20", "SIMPLE_CHEMICAL", 73, 81], ["IgG-HRP", "GENE_OR_GENE_PRODUCT", 139, 146], ["anti-mouse IgG", "PROTEIN", 128, 142], ["HRP", "PROTEIN", 143, 146], ["Jackson ImmunoResearch", "PROTEIN", 148, 170], ["anti-mouse", "SPECIES", 128, 138], ["sera, plates", "TEST", 22, 34], ["PBS", "TEST", 64, 67], ["anti-mouse IgG", "TREATMENT", 128, 142], ["HRP (Jackson ImmunoResearch)", "TREATMENT", 143, 171]]], ["Following three PBST washes, the plates were incubated in tetramethylbenzidine (TMB) substrate, and then stopped with TMB stop solution.", [["tetramethylbenzidine", "CHEMICAL", 58, 78], ["TMB", "CHEMICAL", 80, 83], ["tetramethylbenzidine", "CHEMICAL", 58, 78], ["TMB", "CHEMICAL", 80, 83], ["TMB", "CHEMICAL", 118, 121], ["tetramethylbenzidine", "SIMPLE_CHEMICAL", 58, 78], ["TMB", "SIMPLE_CHEMICAL", 80, 83], ["TMB", "SIMPLE_CHEMICAL", 118, 121], ["three PBST washes", "TREATMENT", 10, 27], ["the plates", "TEST", 29, 39], ["tetramethylbenzidine", "TREATMENT", 58, 78], ["TMB stop solution", "TREATMENT", 118, 135]]], ["Plates were read at 450 nm and the raw data were analyzed in Excel by subtracting the negative control absolute values from those of the RVFV lysate plate.", [["RVFV", "ORGANISM", 137, 141], ["RVFV", "SPECIES", 137, 141], ["Plates", "TEST", 0, 6], ["the raw data", "TEST", 31, 43], ["the RVFV lysate plate", "TREATMENT", 133, 154], ["RVFV lysate plate", "OBSERVATION", 137, 154]]], ["The endpoint ELISA titer for each mouse was defined as the highest dilution of serum that resulted in an OD value at least two standard deviations above the average obtained from all negative mouse serum control wells.Statistical AnalysisAll data were entered into GraphPad Prism 8 for statistical analysis and generation of graphs.", [["serum", "ANATOMY", 79, 84], ["serum", "ANATOMY", 198, 203], ["mouse", "ORGANISM", 34, 39], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["mouse", "ORGANISM", 192, 197], ["serum", "ORGANISM_SUBSTANCE", 198, 203], ["mouse", "SPECIES", 34, 39], ["mouse", "SPECIES", 192, 197], ["mouse", "SPECIES", 34, 39], ["mouse", "SPECIES", 192, 197], ["The endpoint ELISA titer", "TEST", 0, 24], ["an OD value", "PROBLEM", 102, 113], ["all negative mouse serum control wells", "TREATMENT", 179, 217], ["Statistical Analysis", "TEST", 218, 238], ["statistical analysis", "TEST", 286, 306], ["graphs", "TEST", 325, 331]]], ["All survival curves were compared using a log rank (Mantel-Cox) test.", [["All survival curves", "TEST", 0, 19]]], ["The mixed-effects model with the Geisser-Greenhouse correction and Bonferroni's multiple comparisons test were used for weight loss comparisons between sexes and over time for each mouse strain.", [["weight loss", "DISEASE", 120, 131], ["mouse", "ORGANISM", 181, 186], ["mouse", "SPECIES", 181, 186], ["mouse", "SPECIES", 181, 186], ["Bonferroni's multiple comparisons test", "TEST", 67, 105], ["weight loss comparisons", "PROBLEM", 120, 143], ["each mouse strain", "PROBLEM", 176, 193], ["mixed", "OBSERVATION_MODIFIER", 4, 9]]], ["The mixed-effects model with the Geisser-Greenhouse was also run to compare weight data between mouse strains over time.", [["mouse", "ORGANISM", 96, 101], ["mouse", "SPECIES", 96, 101], ["mouse", "SPECIES", 96, 101], ["mouse strains", "PROBLEM", 96, 109], ["mixed", "OBSERVATION_MODIFIER", 4, 9]]], ["Viral RNA qRT-PCR data were analyzed in Excel.", [["Viral RNA qRT", "TEST", 0, 13], ["PCR data", "TEST", 14, 22]]], ["Comparison of viral RNA loads within each tissue for each strain across doses, with the exception of NZO/HILtJ mice, was performed using a one-way ANOVA.", [["tissue", "ANATOMY", 42, 48], ["tissue", "TISSUE", 42, 48], ["NZO/HILtJ mice", "ORGANISM", 101, 115], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["viral RNA loads", "PROBLEM", 14, 29], ["NZO/HILtJ mice", "TREATMENT", 101, 115], ["viral RNA loads", "OBSERVATION", 14, 29]]], ["For NZO/HILtJ mice, an unpaired t-test was used because there were only two challenge doses.", [["NZO/HILtJ mice", "ORGANISM", 4, 18], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["NZO/HILtJ mice", "TREATMENT", 4, 18], ["an unpaired t-test", "TEST", 20, 38]]], ["Two-way ANOVA, and an overall alpha of 0.05, was used to compare viral RNA loads within each tissue across strains and sex.", [["tissue", "ANATOMY", 93, 99], ["tissue", "TISSUE", 93, 99], ["an overall alpha", "TEST", 19, 35], ["viral RNA loads", "PROBLEM", 65, 80]]], ["Viral RNA load in testes was compared between strains using a one-way ANOVA.", [["testes", "ANATOMY", 18, 24], ["testes", "ORGAN", 18, 24], ["Viral RNA load in testes", "PROBLEM", 0, 24], ["strains", "PROBLEM", 46, 53], ["RNA load", "OBSERVATION", 6, 14], ["testes", "ANATOMY", 18, 24]]], ["A p \u2264 0.05 was considered statistically significant.Survival and Clinical ObservationsFemale and male mice of five genetically inbred mouse strains (C57BL/6J, 129S1/SvlmJ, NOD/ShiLtJ, A/J, and NZO/HILtJ) were infected by footpad injection with doses ranging from 0.2 to 2,000 TCID 50 of the wild-type ZH501 strain of RVFV.", [["C57BL/6J", "ANATOMY", 149, 157], ["NZO/HILtJ", "ANATOMY", 193, 202], ["footpad", "ANATOMY", 221, 228], ["RVFV", "DISEASE", 317, 321], ["mice", "ORGANISM", 102, 106], ["mouse", "ORGANISM", 134, 139], ["C57BL/6J, 129S1/SvlmJ, NOD/ShiLtJ, A/J", "ORGANISM", 149, 187], ["ZH501", "ORGANISM", 301, 306], ["RVFV", "ORGANISM", 317, 321], ["mice", "SPECIES", 102, 106], ["mouse", "SPECIES", 134, 139], ["mice", "SPECIES", 102, 106], ["mouse", "SPECIES", 134, 139], ["RVFV", "SPECIES", 317, 321], ["C57BL/6J", "TREATMENT", 149, 157], ["SvlmJ", "TREATMENT", 165, 170], ["NOD/ShiLtJ", "TREATMENT", 172, 182], ["A/J", "TREATMENT", 184, 187], ["NZO/HILtJ", "TREATMENT", 193, 202]]], ["Weight was recorded daily over the course of 28 days and mice were euthanized upon meeting predefined euthanasia criteria, as outlined in Supplementary Table S1, or at the end of the 28 days.", [["mice", "ORGANISM", 57, 61], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61], ["Weight", "TEST", 0, 6]]], ["Results from initial survival studies showed that RVFV was highly lethal in the evaluated inbred mouse strains, even down to an infection dose of 2 TCID 50 (Supplementary Figure S1) .", [["infection", "DISEASE", 128, 137], ["RVFV", "ORGANISM", 50, 54], ["mouse", "ORGANISM", 97, 102], ["mouse", "SPECIES", 97, 102], ["RVFV", "SPECIES", 50, 54], ["mouse", "SPECIES", 97, 102], ["initial survival studies", "TEST", 13, 37], ["RVFV", "PROBLEM", 50, 54], ["inbred mouse strains", "PROBLEM", 90, 110], ["an infection dose", "TREATMENT", 125, 142], ["infection", "OBSERVATION", 128, 137]]], ["Therefore, challenge doses were limited to 0.2 or 2 TCID 50 for subsequent experiments comparing all strains.", [["challenge doses", "TREATMENT", 11, 26], ["all strains", "PROBLEM", 97, 108]]], ["At the 0.2 TCID 50 challenge dose, there were mice that survived to day 28 across all five strains ( Figure 1A) .", [["mice", "ORGANISM", 46, 50], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50]]], ["As would be expected given the probability of delivering a live virus particle to each mouse when administering such a small dose, most of these \"survivor\" mice at this 0.2 TCID 50 challenge dose were confirmed to be uninfected by a negative terminal serum ELISA result and negative qRT-PCR of liver, spleen, brain, and testes tissues ( Figure 1B) .", [["serum", "ANATOMY", 251, 256], ["liver", "ANATOMY", 294, 299], ["spleen", "ANATOMY", 301, 307], ["brain", "ANATOMY", 309, 314], ["testes tissues", "ANATOMY", 320, 334], ["mouse", "ORGANISM", 87, 92], ["mice", "ORGANISM", 156, 160], ["serum", "ORGANISM_SUBSTANCE", 251, 256], ["liver", "ORGAN", 294, 299], ["spleen", "ORGAN", 301, 307], ["brain", "ORGAN", 309, 314], ["testes tissues", "TISSUE", 320, 334], ["mouse", "SPECIES", 87, 92], ["mice", "SPECIES", 156, 160], ["mouse", "SPECIES", 87, 92], ["mice", "SPECIES", 156, 160], ["a live virus particle", "TREATMENT", 57, 78], ["a small dose", "TREATMENT", 117, 129], ["terminal serum ELISA", "TEST", 242, 262], ["qRT", "TEST", 283, 286], ["PCR", "TEST", 287, 290], ["liver", "ANATOMY", 294, 299], ["spleen", "ANATOMY", 301, 307], ["brain", "ANATOMY", 309, 314], ["testes tissues", "ANATOMY", 320, 334]]], ["These mice were therefore excluded from subsequent data analysis.", [["mice", "ORGANISM", 6, 10], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["subsequent data analysis", "TEST", 40, 64]]], ["The only mouse that lived to the end of the study and was deemed a true survivor was one NZO/HILtJ female mouse.", [["mouse", "ORGANISM", 9, 14], ["mouse", "ORGANISM", 106, 111], ["mouse", "SPECIES", 9, 14], ["mouse", "SPECIES", 106, 111], ["mouse", "SPECIES", 9, 14], ["mouse", "SPECIES", 106, 111], ["the study", "TEST", 40, 49]]], ["This mouse showed high RVFV-specific terminal serum ELISA titers and detectable tissue viral RNA levels and thus was determined to have been successfully infected at the 0.2 TCID 50 dose ( Figure 1B) .", [["serum", "ANATOMY", 46, 51], ["tissue", "ANATOMY", 80, 86], ["mouse", "ORGANISM", 5, 10], ["RVFV", "ORGANISM", 23, 27], ["serum", "ORGANISM_SUBSTANCE", 46, 51], ["tissue", "TISSUE", 80, 86], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 5, 10], ["RVFV", "SPECIES", 23, 27], ["high RVFV-specific terminal serum ELISA titers", "PROBLEM", 18, 64], ["detectable tissue viral RNA levels", "PROBLEM", 69, 103], ["high", "OBSERVATION_MODIFIER", 18, 22], ["RVFV", "OBSERVATION", 23, 27], ["viral RNA", "OBSERVATION", 87, 96]]], ["This mouse was therefore not excluded from subsequent datasets.", [["mouse", "ORGANISM", 5, 10], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 5, 10], ["not excluded", "UNCERTAINTY", 25, 37]]], ["Apart from this one survivor, all other mice succumbed to RVFV infection from 2,000 TCID 50 down to the challenge dose of 0.2 TCID 50 across all five inbred mouse strains (Figure 2A and Supplementary Figure S1 ).", [["RVFV infection", "DISEASE", 58, 72], ["mice", "ORGANISM", 40, 44], ["RVFV", "ORGANISM", 58, 62], ["mouse", "ORGANISM", 157, 162], ["mice", "SPECIES", 40, 44], ["mouse", "SPECIES", 157, 162], ["mice", "SPECIES", 40, 44], ["RVFV", "SPECIES", 58, 62], ["mouse", "SPECIES", 157, 162], ["RVFV infection", "PROBLEM", 58, 72], ["all five inbred mouse strains", "TREATMENT", 141, 170], ["RVFV", "OBSERVATION_MODIFIER", 58, 62], ["infection", "OBSERVATION", 63, 72]]], ["These results demonstrate the lethality of RVFV down to a single virion in all five of the tested inbred mouse strains.", [["RVFV", "ORGANISM", 43, 47], ["mouse", "ORGANISM", 105, 110], ["mouse", "SPECIES", 105, 110], ["RVFV", "SPECIES", 43, 47], ["mouse", "SPECIES", 105, 110], ["the lethality of RVFV", "PROBLEM", 26, 47], ["a single virion", "TREATMENT", 56, 71], ["lethality", "OBSERVATION", 30, 39], ["RVFV", "OBSERVATION", 43, 47]]], ["With an LD 50 impossible to calculate, to the best we can estimate, the LD 100 of RVFV for all five of the tested inbred mouse strains is 1 infectious virus particle.Survival and Clinical ObservationsLog-rank (Mantel-Cox) tests revealed significant differences in the survival curves between challenge dose groups for all strains except for NOD/ShiLtJ mice (Figure 2A and Supplementary Figure S1 ).", [["RVFV", "DISEASE", 82, 86], ["RVFV", "ORGANISM", 82, 86], ["mouse", "ORGANISM", 121, 126], ["NOD/ShiLtJ mice", "ORGANISM", 341, 356], ["NOD", "PROTEIN", 341, 344], ["mouse", "SPECIES", 121, 126], ["mice", "SPECIES", 352, 356], ["RVFV", "SPECIES", 82, 86], ["mouse", "SPECIES", 121, 126], ["mice", "SPECIES", 352, 356], ["RVFV", "TREATMENT", 82, 86], ["the tested inbred mouse strains", "PROBLEM", 103, 134], ["1 infectious virus particle", "PROBLEM", 138, 165], ["Survival", "TREATMENT", 166, 174], ["Mantel-Cox) tests", "TEST", 210, 227], ["significant differences", "PROBLEM", 237, 260], ["the survival curves", "TREATMENT", 264, 283], ["challenge dose groups", "TREATMENT", 292, 313], ["all strains", "PROBLEM", 318, 329], ["NOD/ShiLtJ mice", "TREATMENT", 341, 356], ["significant", "OBSERVATION_MODIFIER", 237, 248], ["differences", "OBSERVATION_MODIFIER", 249, 260]]], ["All other strains succumbed to RVFV infection in a statistically significant dose-dependent manner with the 2 TCID 50 challenge group dying earlier than the 0.2 TCID 50 challenge group (Figure 2A; Supplementary Figure S1 ).", [["RVFV infection", "DISEASE", 31, 45], ["RVFV", "ORGANISM", 31, 35], ["RVFV", "SPECIES", 31, 35], ["All other strains", "PROBLEM", 0, 17], ["RVFV infection", "PROBLEM", 31, 45], ["RVFV", "OBSERVATION_MODIFIER", 31, 35], ["infection", "OBSERVATION", 36, 45]]], ["Across all mouse strains, the median time to death was increased at lower challenge doses.", [["death", "DISEASE", 45, 50], ["mouse", "ORGANISM", 11, 16], ["mouse", "SPECIES", 11, 16], ["mouse", "SPECIES", 11, 16], ["mouse strains", "OBSERVATION", 11, 24]]], ["Dose 2 TCID 50 was the challenge dose that infected 100% of mice while also extending the median time to death by 1 day as compared to higher challenge doses (for example, C57BL/6J mice had a median time to death of 3 days at dose 2 TCID 50 instead of 2 days at doses 20, 200, and 2,000 TCID 50 ).", [["TCID", "CHEMICAL", 7, 11], ["death", "DISEASE", 105, 110], ["death", "DISEASE", 207, 212], ["mice", "ORGANISM", 60, 64], ["C57BL/6J mice", "ORGANISM", 172, 185], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 181, 185], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 181, 185]]], ["Log-rank (Mantel-Cox) tests resulted in significance between strain survival curves (p = 0.0022) at dose 2 TCID 50 ( Figure 2B) .", [["Cox) tests", "TEST", 17, 27], ["strain survival curves", "TEST", 61, 83]]], ["However, the difference in time to death between strains is minimal as all inbred mouse strains succumb within 5 days of infection (apart from the one NOD/ShiLtJ female who died at day 10; Figure 2B ).", [["death", "DISEASE", 35, 40], ["infection", "DISEASE", 121, 130], ["mouse", "ORGANISM", 82, 87], ["mouse", "SPECIES", 82, 87], ["mouse", "SPECIES", 82, 87], ["strains", "PROBLEM", 49, 56], ["all inbred mouse strains", "PROBLEM", 71, 95], ["infection", "PROBLEM", 121, 130], ["minimal", "OBSERVATION_MODIFIER", 60, 67], ["infection", "OBSERVATION", 121, 130]]], ["Minimal but statistically significant differences in weight loss were observed between strains ( Figure 2C ).", [["weight loss", "DISEASE", 53, 64], ["weight loss", "PROBLEM", 53, 64], ["statistically", "OBSERVATION_MODIFIER", 12, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["differences", "OBSERVATION_MODIFIER", 38, 49], ["weight loss", "OBSERVATION", 53, 64]]], ["The greatest difference in weight trajectories was the NOD/ShiLt mouse that died of late-onset encephalitis.", [["encephalitis", "DISEASE", 95, 107], ["ShiLt mouse", "ORGANISM", 59, 70], ["mouse", "SPECIES", 65, 70], ["mouse", "SPECIES", 65, 70], ["late-onset encephalitis", "PROBLEM", 84, 107], ["greatest", "OBSERVATION_MODIFIER", 4, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["late", "OBSERVATION_MODIFIER", 84, 88], ["-onset", "OBSERVATION_MODIFIER", 88, 94], ["encephalitis", "OBSERVATION", 95, 107]]], ["This mouse lost weight consistently for 4 days, and then exhibited an abrupt increase in weight on the day leading up to its death ( Figure 2C) .Survival and Clinical ObservationsRVFV-induced death across all five inbred mouse strains tested at a dose of 2 TCID 50 was consistent with severe hepatic disease.", [["hepatic", "ANATOMY", 292, 299], ["death", "DISEASE", 125, 130], ["death", "DISEASE", 192, 197], ["hepatic disease", "DISEASE", 292, 307], ["mouse", "ORGANISM", 5, 10], ["mouse", "ORGANISM", 221, 226], ["hepatic", "ORGAN", 292, 299], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 221, 226], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 221, 226], ["an abrupt increase in weight", "PROBLEM", 67, 95], ["Survival", "TREATMENT", 145, 153], ["induced death", "PROBLEM", 184, 197], ["all five inbred mouse strains", "PROBLEM", 205, 234], ["severe hepatic disease", "PROBLEM", 285, 307], ["abrupt", "OBSERVATION_MODIFIER", 70, 76], ["increase", "OBSERVATION_MODIFIER", 77, 85], ["consistent with", "UNCERTAINTY", 269, 284], ["severe", "OBSERVATION_MODIFIER", 285, 291], ["hepatic", "ANATOMY", 292, 299], ["disease", "OBSERVATION", 300, 307]]], ["This was evidenced by gross liver pathology including hepatic enlargement and pale foci of necrosis as well as virologic A B FIGURE 1 | Nearly all \"survivor\" mice in the 0.2 TCID 50 challenge group were not infected with Rift Valley fever virus (RVFV).", [["liver", "ANATOMY", 28, 33], ["hepatic", "ANATOMY", 54, 61], ["pale foci", "ANATOMY", 78, 87], ["hepatic enlargement", "DISEASE", 54, 73], ["necrosis", "DISEASE", 91, 99], ["TCID", "CHEMICAL", 174, 178], ["Rift Valley fever", "DISEASE", 221, 238], ["liver", "ORGAN", 28, 33], ["hepatic", "ORGAN", 54, 61], ["mice", "ORGANISM", 158, 162], ["Rift Valley fever virus", "ORGANISM", 221, 244], ["RVFV", "ORGANISM", 246, 250], ["mice", "SPECIES", 158, 162], ["Rift Valley fever virus", "SPECIES", 221, 244], ["mice", "SPECIES", 158, 162], ["Rift Valley fever virus", "SPECIES", 221, 244], ["RVFV", "SPECIES", 246, 250], ["gross liver pathology", "PROBLEM", 22, 43], ["hepatic enlargement", "PROBLEM", 54, 73], ["pale foci of necrosis", "PROBLEM", 78, 99], ["Rift Valley fever virus", "PROBLEM", 221, 244], ["gross", "OBSERVATION_MODIFIER", 22, 27], ["liver", "ANATOMY", 28, 33], ["pathology", "OBSERVATION", 34, 43], ["hepatic", "ANATOMY", 54, 61], ["enlargement", "OBSERVATION", 62, 73], ["pale", "OBSERVATION_MODIFIER", 78, 82], ["foci", "OBSERVATION_MODIFIER", 83, 87], ["necrosis", "OBSERVATION", 91, 99]]], ["(A) Survival curve of five inbred mouse strains infected via footpad injection with wild-type RVFV at a dose of 0.2 TCID 50 shows \"survivor\" mice across all five strains.", [["footpad", "ANATOMY", 61, 68], ["mouse", "ORGANISM", 34, 39], ["footpad", "ORGANISM_SUBDIVISION", 61, 68], ["RVFV", "ORGANISM", 94, 98], ["mice", "ORGANISM", 141, 145], ["mouse", "SPECIES", 34, 39], ["mice", "SPECIES", 141, 145], ["mouse", "SPECIES", 34, 39], ["RVFV", "SPECIES", 94, 98], ["mice", "SPECIES", 141, 145], ["Survival curve", "TEST", 4, 18], ["five inbred mouse strains", "PROBLEM", 22, 47], ["footpad injection", "TREATMENT", 61, 78], ["wild-type RVFV", "TREATMENT", 84, 98]]], ["Each line represents the percent survival after infection of five female and five male mice.", [["infection", "DISEASE", 48, 57], ["mice", "ORGANISM", 87, 91], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 87, 91], ["Each line", "TREATMENT", 0, 9], ["infection", "PROBLEM", 48, 57], ["percent", "OBSERVATION_MODIFIER", 25, 32], ["survival", "OBSERVATION_MODIFIER", 33, 41], ["infection", "OBSERVATION", 48, 57]]], ["(B) Enzyme-linked immunosorbent assay (ELISA) and qRT-PCR analysis of \"survivor\" mice as well as early and late-death 0.2 TCID 50 -challenged mice as controls.", [["death", "DISEASE", 112, 117], ["mice", "ORGANISM", 81, 85], ["mice", "ORGANISM", 142, 146], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 142, 146], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 142, 146], ["Enzyme", "TEST", 4, 10], ["immunosorbent assay", "TEST", 18, 37], ["ELISA", "TEST", 39, 44], ["qRT", "TEST", 50, 53], ["PCR analysis", "TEST", 54, 66]]], ["Endpoint RVFV-specific ELISA titer in the serum of mice that survived to day 28 post-infection.", [["serum", "ANATOMY", 42, 47], ["infection", "DISEASE", 85, 94], ["RVFV", "ORGANISM", 9, 13], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["mice", "ORGANISM", 51, 55], ["mice", "SPECIES", 51, 55], ["RVFV", "SPECIES", 9, 13], ["mice", "SPECIES", 51, 55], ["Endpoint RVFV", "TEST", 0, 13], ["specific ELISA titer", "TEST", 14, 34], ["infection", "PROBLEM", 85, 94], ["infection", "OBSERVATION", 85, 94]]], ["Viral load per milligram of tissue in the liver, spleen, brain, and testes of mice that survived to day 28 post-infection was measured by qRT-PCR.", [["tissue", "ANATOMY", 28, 34], ["liver", "ANATOMY", 42, 47], ["spleen", "ANATOMY", 49, 55], ["brain", "ANATOMY", 57, 62], ["testes", "ANATOMY", 68, 74], ["infection", "DISEASE", 112, 121], ["tissue", "TISSUE", 28, 34], ["liver", "ORGAN", 42, 47], ["spleen", "ORGAN", 49, 55], ["brain", "ORGAN", 57, 62], ["testes", "ORGAN", 68, 74], ["mice", "ORGANISM", 78, 82], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 78, 82], ["Viral load", "TEST", 0, 10], ["infection", "PROBLEM", 112, 121], ["PCR", "TEST", 142, 145], ["liver", "ANATOMY", 42, 47], ["spleen", "ANATOMY", 49, 55], ["brain", "ANATOMY", 57, 62], ["testes", "ANATOMY", 68, 74], ["infection", "OBSERVATION", 112, 121]]], ["The limits of detection for these assays are indicated by dashed lines (ELISA limits of detection due to limited dilutions: lower limit of 100 and upper limit of 12,800; qRT-PCR limit of detection: 77.5 RNA copies/mg). data indicating the liver as the key target of RVFV at the time of death.", [["liver", "ANATOMY", 239, 244], ["death", "DISEASE", 286, 291], ["liver", "ORGAN", 239, 244], ["RVFV", "ORGANISM", 266, 270], ["dashed lines", "CELL_LINE", 58, 70], ["RVFV", "SPECIES", 266, 270], ["these assays", "TEST", 28, 40], ["qRT", "TEST", 170, 173], ["death", "PROBLEM", 286, 291], ["liver", "ANATOMY", 239, 244]]], ["The only exception to this in the 2 TCID 50 challenge dose was one late-onset NOD/ShiLtJ death.", [["death", "DISEASE", 89, 94], ["NOD", "ORGANISM", 78, 81], ["ShiLtJ death", "PROBLEM", 82, 94]]], ["This mouse cleared most virus from its liver and spleen but died at day 10 of late-onset encephalitis as evidenced by clinical symptoms (tremor) and virologic data.", [["liver", "ANATOMY", 39, 44], ["spleen", "ANATOMY", 49, 55], ["encephalitis", "DISEASE", 89, 101], ["tremor", "DISEASE", 137, 143], ["mouse", "ORGANISM", 5, 10], ["liver", "ORGAN", 39, 44], ["spleen", "ORGAN", 49, 55], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 5, 10], ["late-onset encephalitis", "PROBLEM", 78, 101], ["clinical symptoms", "PROBLEM", 118, 135], ["tremor", "PROBLEM", 137, 143], ["virologic data", "TEST", 149, 163], ["liver", "ANATOMY", 39, 44], ["spleen", "ANATOMY", 49, 55], ["encephalitis", "OBSERVATION", 89, 101]]], ["Late-onset encephalitis was also seen in the 0.2 and 20 TCID 50 dose groups and was the reason for euthanasia for all deaths after day 6.", [["encephalitis", "DISEASE", 11, 23], ["deaths", "DISEASE", 118, 124], ["Late-onset encephalitis", "PROBLEM", 0, 23], ["euthanasia", "PROBLEM", 99, 109], ["-onset", "OBSERVATION_MODIFIER", 4, 10], ["encephalitis", "OBSERVATION", 11, 23]]], ["Not all mice showed symptoms of disease before death due to the extremely fast progression of disease.", [["death", "DISEASE", 47, 52], ["mice", "ORGANISM", 8, 12], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["symptoms", "PROBLEM", 20, 28], ["disease", "PROBLEM", 32, 39], ["death", "PROBLEM", 47, 52], ["disease", "PROBLEM", 94, 101], ["disease", "OBSERVATION", 32, 39], ["disease", "OBSERVATION", 94, 101]]], ["Symptoms, when present before death, were similar among all five inbred mouse strains.", [["death", "DISEASE", 30, 35], ["mouse", "ORGANISM", 72, 77], ["mouse", "SPECIES", 72, 77], ["mouse", "SPECIES", 72, 77], ["Symptoms", "PROBLEM", 0, 8]]], ["Observed symptoms include hunched posture, ruffled fur, piloerection, huddling behavior, eye squinting, and poor response to stimuli.", [["eye", "ANATOMY", 89, 92], ["piloerection", "DISEASE", 56, 68], ["eye squinting", "DISEASE", 89, 102], ["eye", "ORGAN", 89, 92], ["symptoms", "PROBLEM", 9, 17], ["hunched posture", "PROBLEM", 26, 41], ["ruffled fur", "PROBLEM", 43, 54], ["ruffled fur", "OBSERVATION", 43, 54], ["eye", "ANATOMY", 89, 92]]], ["Mice that succumbed or were euthanized past day 6 post-infection displayed symptoms of encephalitis including hind limb paralysis and tremor.Sex DifferencesMales and females of all five strains of mice succumbed equally to RVFV infection with 100% lethality at the dose 2 TCID 50 , regardless of sex.", [["hind limb", "ANATOMY", 110, 119], ["infection", "DISEASE", 55, 64], ["encephalitis", "DISEASE", 87, 99], ["paralysis", "DISEASE", 120, 129], ["tremor", "DISEASE", 134, 140], ["RVFV infection", "DISEASE", 223, 237], ["Mice", "ORGANISM", 0, 4], ["hind limb", "ORGANISM_SUBDIVISION", 110, 119], ["mice", "ORGANISM", 197, 201], ["RVFV", "ORGANISM", 223, 227], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 197, 201], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 197, 201], ["RVFV", "SPECIES", 223, 227], ["infection", "PROBLEM", 55, 64], ["symptoms", "PROBLEM", 75, 83], ["encephalitis", "PROBLEM", 87, 99], ["hind limb paralysis", "PROBLEM", 110, 129], ["tremor", "PROBLEM", 134, 140], ["RVFV infection", "PROBLEM", 223, 237], ["encephalitis", "OBSERVATION", 87, 99], ["hind limb", "ANATOMY", 110, 119], ["paralysis", "OBSERVATION", 120, 129], ["tremor", "OBSERVATION", 134, 140], ["RVFV", "OBSERVATION_MODIFIER", 223, 227], ["infection", "OBSERVATION", 228, 237]]], ["Upon comparing female and male mice within each inbred strain using Log-rank (Mantel-Cox) tests, a significant difference in survival curves was only found for A/J mice, with males dying approximately 1 day later than females ( Figure 3A) .", [["mice", "ORGANISM", 31, 35], ["A/J mice", "ORGANISM", 160, 168], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 164, 168], ["mice", "SPECIES", 31, 35], ["A/J mice", "SPECIES", 160, 168], ["tests", "TEST", 90, 95], ["a significant difference in survival curves", "PROBLEM", 97, 140]]], ["For all other strains (C57BL/6J, 129S1/SvlmJ, NOD/ShiLtJ, and NZO/HILtJ) no significant sex-dependent difference was observed between survival curves ( Figure 3A) .", [["C57BL/6J", "ORGANISM", 23, 31], ["SvlmJ", "GENE_OR_GENE_PRODUCT", 39, 44], ["ShiLtJ", "GENE_OR_GENE_PRODUCT", 50, 56], ["NOD", "PROTEIN", 46, 49], ["NZO", "PROTEIN", 62, 65], ["all other strains", "PROBLEM", 4, 21], ["C57BL/6J", "TREATMENT", 23, 31], ["SvlmJ", "TREATMENT", 39, 44], ["NOD/ShiLtJ", "TREATMENT", 46, 56], ["NZO/HILtJ", "TREATMENT", 62, 71], ["dependent difference", "PROBLEM", 92, 112], ["survival curves", "TEST", 134, 149]]], ["Interestingly, only 129S1/SvlmJ and NOD/ShiLtJ mice displayed even a slight sex-specific significant difference in weight loss while showing no sex-specific difference in time to death ( Figure 3B) .", [["weight loss", "DISEASE", 115, 126], ["death", "DISEASE", 179, 184], ["SvlmJ", "GENE_OR_GENE_PRODUCT", 26, 31], ["NOD/ShiLtJ mice", "ORGANISM", 36, 51], ["129S1", "PROTEIN", 20, 25], ["SvlmJ", "PROTEIN", 26, 31], ["NOD", "PROTEIN", 36, 39], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51], ["a slight sex", "PROBLEM", 67, 79], ["weight loss", "PROBLEM", 115, 126], ["slight", "OBSERVATION_MODIFIER", 69, 75], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["difference", "OBSERVATION", 101, 111], ["weight loss", "OBSERVATION", 115, 126]]], ["Paradoxically, 129S1/SvlmJ mice and female NOD/ShiLtJ mice actually gained weight leading up to death ( Figure 3B ).", [["death", "DISEASE", 96, 101], ["129S1/SvlmJ mice", "ORGANISM", 15, 31], ["female NOD/ShiLtJ mice", "ORGANISM", 36, 58], ["129S1", "PROTEIN", 15, 20], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 54, 58], ["Paradoxically", "TEST", 0, 13]]], ["All NOD/ShiLtJ female mice gained weight before death; however, the one mouse that succumbed to late-onset encephalitis in this group gained weight suddenly at day 3 post-infection, and then slowly dropped weight until finally gaining weight on the day leading up to euthanasia at day 10.Viral TitersLiver, spleen, and brain tissue samples were harvested from all mice for viral RNA level analysis by qRT-PCR.", [["spleen", "ANATOMY", 307, 313], ["brain tissue samples", "ANATOMY", 319, 339], ["death", "DISEASE", 48, 53], ["encephalitis", "DISEASE", 107, 119], ["infection", "DISEASE", 171, 180], ["NOD/ShiLtJ female mice", "ORGANISM", 4, 26], ["mouse", "ORGANISM", 72, 77], ["spleen", "ORGAN", 307, 313], ["brain tissue samples", "TISSUE", 319, 339], ["mice", "ORGANISM", 364, 368], ["viral RNA", "RNA", 373, 382], ["mice", "SPECIES", 22, 26], ["mouse", "SPECIES", 72, 77], ["mice", "SPECIES", 364, 368], ["mice", "SPECIES", 22, 26], ["mouse", "SPECIES", 72, 77], ["mice", "SPECIES", 364, 368], ["death", "PROBLEM", 48, 53], ["encephalitis", "PROBLEM", 107, 119], ["infection", "PROBLEM", 171, 180], ["Viral TitersLiver", "TEST", 288, 305], ["viral RNA level analysis", "TEST", 373, 397], ["qRT", "TEST", 401, 404], ["PCR", "TEST", 405, 408], ["encephalitis", "OBSERVATION", 107, 119], ["infection", "OBSERVATION", 171, 180], ["spleen", "ANATOMY", 307, 313], ["brain tissue", "ANATOMY", 319, 331]]], ["RVFV challenge dose did not significantly affect the viral RNA levels in the liver, spleen, or brain of mice at the time of death/euthanasia ( Figure 4A ).", [["liver", "ANATOMY", 77, 82], ["spleen", "ANATOMY", 84, 90], ["brain", "ANATOMY", 95, 100], ["death", "DISEASE", 124, 129], ["RVFV", "ORGANISM", 0, 4], ["liver", "ORGAN", 77, 82], ["spleen", "ORGAN", 84, 90], ["brain", "ORGAN", 95, 100], ["mice", "ORGANISM", 104, 108], ["mice", "SPECIES", 104, 108], ["RVFV", "SPECIES", 0, 4], ["mice", "SPECIES", 104, 108], ["the viral RNA levels", "TEST", 49, 69], ["death", "PROBLEM", 124, 129], ["euthanasia", "PROBLEM", 130, 140], ["viral RNA", "OBSERVATION", 53, 62], ["liver", "ANATOMY", 77, 82], ["spleen", "ANATOMY", 84, 90], ["brain", "ANATOMY", 95, 100], ["euthanasia", "OBSERVATION", 130, 140]]], ["An assessment of viral load in different tissues as a function of sex or strain was performed The mixed-effects model with the Geisser-Greenhouse correction were used for weight loss comparisons between mouse strains over time.Viral Titersusing the 2 TCID 50 dose.", [["tissues", "ANATOMY", 41, 48], ["weight loss", "DISEASE", 171, 182], ["tissues", "TISSUE", 41, 48], ["mouse", "ORGANISM", 203, 208], ["mouse", "SPECIES", 203, 208], ["mouse", "SPECIES", 203, 208], ["An assessment", "TEST", 0, 13], ["viral load in different tissues", "PROBLEM", 17, 48], ["strain", "PROBLEM", 73, 79], ["the Geisser-Greenhouse correction", "TREATMENT", 123, 156], ["weight loss comparisons between mouse strains", "PROBLEM", 171, 216], ["Viral Titersusing", "TREATMENT", 227, 244], ["viral load", "OBSERVATION", 17, 27], ["mixed", "OBSERVATION_MODIFIER", 98, 103]]], ["This dose was chosen since it uniformly resulted in 100% of the mice being infected. qRT-PCR data are presented as the viral RNA levels in tissues at the time of death for both female and male mice of all five inbred strains ( Figure 4B) .", [["tissues", "ANATOMY", 139, 146], ["death", "DISEASE", 162, 167], ["mice", "ORGANISM", 64, 68], ["tissues", "TISSUE", 139, 146], ["mice", "ORGANISM", 193, 197], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 193, 197], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 193, 197], ["PCR data", "TEST", 89, 97], ["the viral RNA levels", "TEST", 115, 135], ["all five inbred strains", "PROBLEM", 201, 224], ["infected", "OBSERVATION", 75, 83], ["viral RNA", "OBSERVATION", 119, 128]]], ["For male mice, testes were collected to investigate any differences in viral RNA load between strains.", [["testes", "ANATOMY", 15, 21], ["mice", "ORGANISM", 9, 13], ["testes", "ORGAN", 15, 21], ["viral RNA", "RNA", 71, 80], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["viral RNA load between strains", "PROBLEM", 71, 101], ["testes", "ANATOMY", 15, 21], ["viral RNA load", "OBSERVATION", 71, 85]]], ["There were no significant differences in RNA levels in the liver, spleen, or brain when comparing between the five inbred mouse strains either with sexes combined or separate ( Figure 4B) .", [["liver", "ANATOMY", 59, 64], ["spleen", "ANATOMY", 66, 72], ["brain", "ANATOMY", 77, 82], ["liver", "ORGAN", 59, 64], ["spleen", "ORGAN", 66, 72], ["brain", "ORGAN", 77, 82], ["mouse", "ORGANISM", 122, 127], ["mouse", "SPECIES", 122, 127], ["mouse", "SPECIES", 122, 127], ["significant differences in RNA levels in the liver, spleen, or brain", "PROBLEM", 14, 82], ["the five inbred mouse strains", "PROBLEM", 106, 135], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37], ["RNA levels", "OBSERVATION", 41, 51], ["liver", "ANATOMY", 59, 64], ["spleen", "ANATOMY", 66, 72], ["brain", "ANATOMY", 77, 82]]], ["Although there appeared to be sex-specific trends in liver viral load for C57BL/6J, 129S1/SvlmJ, and A/J mouse strains, none are statistically significant by two-way ANOVA ( Figure 4B ).", [["liver", "ANATOMY", 53, 58], ["liver", "ORGAN", 53, 58], ["C57BL/6J", "ORGANISM", 74, 82], ["129S1", "GENE_OR_GENE_PRODUCT", 84, 89], ["SvlmJ", "GENE_OR_GENE_PRODUCT", 90, 95], ["A/J mouse", "ORGANISM", 101, 110], ["mouse", "SPECIES", 105, 110], ["A/J mouse", "SPECIES", 101, 110], ["liver viral load", "TEST", 53, 69], ["C57BL", "TEST", 74, 79], ["SvlmJ", "TEST", 90, 95], ["A/J mouse strains", "PROBLEM", 101, 118], ["liver", "ANATOMY", 53, 58], ["viral load", "OBSERVATION", 59, 69]]], ["No significant difference in viral RNA in testes was found between mouse strains when compared using one-way ANOVA.", [["testes", "ANATOMY", 42, 48], ["testes", "ORGAN", 42, 48], ["mouse", "ORGANISM", 67, 72], ["viral RNA", "RNA", 29, 38], ["mouse", "SPECIES", 67, 72], ["mouse", "SPECIES", 67, 72], ["significant difference in viral RNA in testes", "PROBLEM", 3, 48], ["mouse strains", "PROBLEM", 67, 80], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION_MODIFIER", 15, 25], ["viral RNA", "OBSERVATION", 29, 38], ["testes", "ANATOMY", 42, 48]]], ["The two low data points that appear on the graph represent the liver and spleen RNA levels from the late-onset NOD/ShiLtJ encephalitis death.", [["liver", "ANATOMY", 63, 68], ["spleen", "ANATOMY", 73, 79], ["encephalitis", "DISEASE", 122, 134], ["death", "DISEASE", 135, 140], ["liver", "ORGAN", 63, 68], ["spleen", "ORGAN", 73, 79], ["NOD", "ORGANISM", 111, 114], ["RNA levels", "TEST", 80, 90], ["ShiLtJ encephalitis death", "PROBLEM", 115, 140], ["two", "OBSERVATION_MODIFIER", 4, 7], ["low", "OBSERVATION_MODIFIER", 8, 11], ["liver", "ANATOMY", 63, 68], ["spleen", "ANATOMY", 73, 79], ["RNA levels", "OBSERVATION", 80, 90], ["late", "OBSERVATION_MODIFIER", 100, 104], ["ShiLtJ", "OBSERVATION_MODIFIER", 115, 121], ["encephalitis", "OBSERVATION", 122, 134]]], ["The consistency of these RNA load data across both strain and sex are remarkable but logical due to the similarity of disease manifestations and survival timeframes.", [["these RNA load data", "TEST", 19, 38], ["both strain and sex", "TEST", 46, 65], ["disease manifestations", "PROBLEM", 118, 140], ["RNA load", "OBSERVATION", 25, 33], ["disease", "OBSERVATION", 118, 125]]], ["All strains consistently carry the highest viral load in the liver and the lowest viral load in the brain withDISCUSSIONThis study evaluated the consequences of RVFV infection in five common inbred laboratory mouse strains: C57BL/6J, 129S1/ SvlmJ, NOD/ShiLtJ, A/J, and NZO/HILtJ.", [["liver", "ANATOMY", 61, 66], ["brain", "ANATOMY", 100, 105], ["RVFV infection", "DISEASE", 161, 175], ["liver", "ORGAN", 61, 66], ["brain", "ORGAN", 100, 105], ["RVFV", "ORGANISM", 161, 165], ["mouse", "ORGANISM", 209, 214], ["C57BL/6J", "ORGANISM", 224, 232], ["SvlmJ", "GENE_OR_GENE_PRODUCT", 241, 246], ["mouse", "SPECIES", 209, 214], ["RVFV", "SPECIES", 161, 165], ["mouse", "SPECIES", 209, 214], ["All strains", "PROBLEM", 0, 11], ["the highest viral load in the liver", "PROBLEM", 31, 66], ["the lowest viral load in the brain", "PROBLEM", 71, 105], ["RVFV infection", "PROBLEM", 161, 175], ["SvlmJ", "TREATMENT", 241, 246], ["NOD", "TREATMENT", 248, 251], ["ShiLtJ", "TREATMENT", 252, 258], ["A/J", "TREATMENT", 260, 263], ["NZO/HILtJ", "TREATMENT", 269, 278], ["viral load", "OBSERVATION", 43, 53], ["liver", "ANATOMY", 61, 66], ["viral load", "OBSERVATION", 82, 92], ["brain", "ANATOMY", 100, 105], ["RVFV", "OBSERVATION_MODIFIER", 161, 165], ["infection", "OBSERVATION", 166, 175]]], ["RVFV pathogenicity was studied in these strains with challenge doses ranging from 0.2 to 2,000 TCID 50 .", [["RVFV", "ORGANISM", 0, 4], ["RVFV", "SPECIES", 0, 4], ["RVFV pathogenicity", "PROBLEM", 0, 18], ["challenge doses", "TREATMENT", 53, 68]]], ["Complete lethality was observed in all five inbred mouse strains down to a dose of 2 TCID 50 .", [["mouse", "ORGANISM", 51, 56], ["mouse", "SPECIES", 51, 56], ["mouse", "SPECIES", 51, 56], ["Complete lethality", "PROBLEM", 0, 18], ["lethality", "OBSERVATION", 9, 18]]], ["This is consistent with other published studies using different strains of inbred mice (do Valle et al., 2010; Smith et al., 2010; Gray et al., 2012) .", [["mice", "ORGANISM", 82, 86], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 82, 86], ["consistent with", "UNCERTAINTY", 8, 23]]], ["It is not possible to infect a mouse with a portion of a virus particle, therefore, mice in the 0.2 TCID 50 dose group were either infected with 0, 1, or more virus particles depending on the distribution of virions in the 10 TCID 50 /ml dilution stock.", [["virions", "ANATOMY", 208, 215], ["TCID", "CHEMICAL", 100, 104], ["mouse", "ORGANISM", 31, 36], ["mice", "ORGANISM", 84, 88], ["mouse", "SPECIES", 31, 36], ["mice", "SPECIES", 84, 88], ["mouse", "SPECIES", 31, 36], ["mice", "SPECIES", 84, 88], ["a virus particle", "PROBLEM", 55, 71], ["more virus particles", "PROBLEM", 154, 174], ["virions", "TREATMENT", 208, 215], ["not possible", "UNCERTAINTY", 6, 18], ["virus", "OBSERVATION", 57, 62]]], ["Mice in this dose group that \"survived\" until day 28 and had negative terminal serum ELISA and tissue qRT-PCR were determined to have not been infected.", [["serum", "ANATOMY", 79, 84], ["tissue", "ANATOMY", 95, 101], ["Mice", "ORGANISM", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["tissue", "TISSUE", 95, 101], ["Mice", "SPECIES", 0, 4], ["terminal serum ELISA", "TEST", 70, 90], ["tissue qRT", "TEST", 95, 105], ["PCR", "TEST", 106, 109], ["infected", "OBSERVATION", 143, 151]]], ["It is interesting to note that these mice were co-housed with sick and dying animals from the same 0.2 TCID 50 infection group, revealing a lack of RVFV transmission between animals.", [["infection", "DISEASE", 111, 120], ["mice", "ORGANISM", 37, 41], ["RVFV", "ORGANISM", 148, 152], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["RVFV", "SPECIES", 148, 152], ["RVFV", "OBSERVATION", 148, 152]]], ["This is consistent with the reported absence of person to person transmission (Al-Hamdan et al., 2015) .", [["person", "SPECIES", 48, 54], ["person", "SPECIES", 58, 64], ["consistent with", "UNCERTAINTY", 8, 23]]], ["All mice that were successfully infected in the 0.2 TCID 50 dose group succumbed to disease with the exception of one NZO/HILtJ female mouse that was determined to be a true survivor.", [["TCID", "CHEMICAL", 52, 56], ["mice", "ORGANISM", 4, 8], ["mouse", "ORGANISM", 135, 140], ["mice", "SPECIES", 4, 8], ["mouse", "SPECIES", 135, 140], ["mice", "SPECIES", 4, 8], ["mouse", "SPECIES", 135, 140], ["disease", "PROBLEM", 84, 91]]], ["From these results, we conclude that one infectious virion is sufficient to cause lethal RVFV disease in C57BL/6J, 129S1/SvlmJ, NOD/ShiLtJ, A/J, and NZO/HILtJ mice.", [["RVFV disease", "DISEASE", 89, 101], ["RVFV", "ORGANISM", 89, 93], ["C57BL/6J", "ORGANISM", 105, 113], ["129S1/SvlmJ", "ORGANISM", 115, 126], ["NOD/ShiLtJ, A/J", "ORGANISM", 128, 143], ["NZO/HILtJ mice", "ORGANISM", 149, 163], ["mice", "SPECIES", 159, 163], ["RVFV", "SPECIES", 89, 93], ["mice", "SPECIES", 159, 163], ["one infectious virion", "PROBLEM", 37, 58], ["lethal RVFV disease", "PROBLEM", 82, 101], ["SvlmJ", "TREATMENT", 121, 126], ["ShiLtJ", "TREATMENT", 132, 138], ["A/J", "TREATMENT", 140, 143], ["NZO/HILtJ mice", "TREATMENT", 149, 163]]], ["(B) Viral load per milligram of tissue in the liver, spleen, brain, and testes of mice that succumbed to infection with 2 TCID 50 RVFV was measured by qRT-PCR.", [["tissue", "ANATOMY", 32, 38], ["liver", "ANATOMY", 46, 51], ["spleen", "ANATOMY", 53, 59], ["brain", "ANATOMY", 61, 66], ["testes", "ANATOMY", 72, 78], ["infection", "DISEASE", 105, 114], ["Viral", "ORGANISM", 4, 9], ["tissue", "TISSUE", 32, 38], ["liver", "ORGAN", 46, 51], ["spleen", "ORGAN", 53, 59], ["brain", "ORGAN", 61, 66], ["testes", "ORGAN", 72, 78], ["mice", "ORGANISM", 82, 86], ["RVFV", "ORGANISM", 130, 134], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 82, 86], ["RVFV", "SPECIES", 130, 134], ["Viral load", "TEST", 4, 14], ["infection", "PROBLEM", 105, 114], ["PCR", "TEST", 155, 158], ["Viral load", "OBSERVATION", 4, 14], ["liver", "ANATOMY", 46, 51], ["spleen", "ANATOMY", 53, 59], ["brain", "ANATOMY", 61, 66], ["testes", "ANATOMY", 72, 78], ["infection", "OBSERVATION", 105, 114]]], ["A one-way ANOVA was used to compare viral RNA loads within each tissue for each strain across doses.", [["tissue", "ANATOMY", 64, 70], ["tissue", "TISSUE", 64, 70], ["viral RNA loads", "PROBLEM", 36, 51]]], ["For NZO/HILtJ mice an unpaired t-test was used since there were only two challenge doses.", [["NZO/HILtJ mice", "ORGANISM", 4, 18], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["NZO/HILtJ mice", "TREATMENT", 4, 18]]], ["A two-way ANOVA was used to compare viral RNA loads within each tissue across strains and sex.", [["tissue", "ANATOMY", 64, 70], ["tissue", "TISSUE", 64, 70], ["viral RNA loads", "PROBLEM", 36, 51]]], ["A one-way ANOVA was used to compare viral RNA loads within the testes across strains.", [["testes", "ANATOMY", 63, 69], ["testes", "ORGAN", 63, 69], ["viral RNA loads within the testes across strains", "PROBLEM", 36, 84], ["viral RNA loads", "OBSERVATION", 36, 51], ["testes", "ANATOMY", 63, 69]]], ["The limit of detection of these assays (77.5 RNA copies/mg) is indicated by a dashed line.DISCUSSIONFrontiers in Microbiology | www.frontiersin.org 8 August 2020 | Volume 11 | Article 1962DISCUSSIONThroughout the execution of this work consistency in lethality and time to death using a recombinant reverse-genetics generated strain of RVFV was noted.", [["death", "DISEASE", 273, 278], ["RVFV", "DISEASE", 336, 340], ["RVFV", "ORGANISM", 336, 340], ["RVFV", "SPECIES", 336, 340], ["these assays", "TEST", 26, 38], ["a dashed line", "TREATMENT", 76, 89], ["RVFV", "PROBLEM", 336, 340]]], ["Fully sequence confirmed, early passage recombinant RVFV (rRVFV) strains made through reverse genetics offer far greater reproducibility.", [["recombinant RVFV", "ORGANISM", 40, 56], ["RVFV", "SPECIES", 52, 56], ["rRVFV", "SPECIES", 58, 63], ["early passage recombinant RVFV (rRVFV) strains", "TREATMENT", 26, 72]]], ["This is especially important when evaluating novel mouse strains for their susceptibility to RVFV.", [["RVFV", "DISEASE", 93, 97], ["mouse", "ORGANISM", 51, 56], ["RVFV", "ORGANISM", 93, 97], ["mouse", "SPECIES", 51, 56], ["mouse", "SPECIES", 51, 56], ["RVFV", "SPECIES", 93, 97], ["novel mouse strains", "PROBLEM", 45, 64]]], ["Even at a dose of 2 TCID 50 , all mice were successfully infected and time to death was remarkably consistent within each strain.", [["death", "DISEASE", 78, 83], ["mice", "ORGANISM", 34, 38], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 34, 38]]], ["This is likely related to the lack of significant numbers of defective-interfering (DI) particles or viral subpopulations that would accumulate over repeated passaging.", [["defective-interfering (DI) particles", "PROBLEM", 61, 97], ["viral subpopulations", "PROBLEM", 101, 121], ["repeated passaging", "TREATMENT", 149, 167], ["likely related to", "UNCERTAINTY", 8, 25], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["numbers", "OBSERVATION_MODIFIER", 50, 57], ["defective", "OBSERVATION", 61, 70], ["interfering", "OBSERVATION_MODIFIER", 71, 82], ["viral subpopulations", "OBSERVATION", 101, 121]]], ["In fact, the importance of using recombinant RVFV strains was noted in a recent publication (Ikegami et al., 2017) .", [["RVFV", "ORGANISM", 45, 49], ["RVFV", "SPECIES", 45, 49], ["recombinant RVFV strains", "PROBLEM", 33, 57]]], ["Ikegami et al. (2017) found that several genetic lineages of RVFV exhibited differences in virulence in outbred CD1 mice.", [["RVFV", "ORGANISM", 61, 65], ["outbred CD1 mice", "ORGANISM", 104, 120], ["mice", "SPECIES", 116, 120], ["RVFV", "SPECIES", 61, 65], ["mice", "SPECIES", 116, 120], ["RVFV", "PROBLEM", 61, 65], ["RVFV", "OBSERVATION", 61, 65]]], ["Specific to the ZH501 strain of RVFV, it was found that the ZH501 isolate might contain two distinct viral subpopulations, M847-G and M847-A (Morrill et al., 2010) .", [["ZH501", "GENE_OR_GENE_PRODUCT", 16, 21], ["RVFV", "ORGANISM", 32, 36], ["ZH501", "GENE_OR_GENE_PRODUCT", 60, 65], ["M847-G", "CELL", 123, 129], ["RVFV", "SPECIES", 32, 36], ["RVFV", "PROBLEM", 32, 36], ["the ZH501 isolate", "TEST", 56, 73], ["two", "OBSERVATION_MODIFIER", 88, 91], ["distinct", "OBSERVATION_MODIFIER", 92, 100], ["viral subpopulations", "OBSERVATION", 101, 121]]], ["The two subpopulations were found in a stock of wild-type ZH501 acquired from the CDC, although the authors note that there is no way to determine when the subpopulations arose or if they were present in the infected patient from which the isolate came (Morrill et al., 2010) .", [["ZH501", "CELL", 58, 63], ["patient", "ORGANISM", 217, 224], ["patient", "SPECIES", 217, 224], ["two", "OBSERVATION_MODIFIER", 4, 7], ["subpopulations", "OBSERVATION_MODIFIER", 8, 22]]], ["Infection of mice with the mixture of viral populations was found to be less virulent than the reverse-genetics derived rRVFV M847-A viral variant (Morrill et al., 2010) .", [["mice", "ORGANISM", 13, 17], ["rRVFV M847-A viral", "ORGANISM", 120, 138], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["Infection of mice", "PROBLEM", 0, 17], ["viral populations", "PROBLEM", 38, 55], ["viral variant", "OBSERVATION", 133, 146]]], ["The increased lethality and reliability obtained by using rRVFV was reflected in our mouse challenge studies.DISCUSSIONThe inbred mouse strains investigated in this paper were extremely susceptible to RVFV but revealed a significant difference in time to death corresponding to viral dose, with mice challenged at lower doses surviving longer.", [["RVFV", "DISEASE", 201, 205], ["death", "DISEASE", 255, 260], ["rRVFV", "GENE_OR_GENE_PRODUCT", 58, 63], ["mouse", "ORGANISM", 85, 90], ["mouse", "ORGANISM", 130, 135], ["RVFV", "ORGANISM", 201, 205], ["mice", "ORGANISM", 295, 299], ["rRVFV", "PROTEIN", 58, 63], ["mouse", "SPECIES", 85, 90], ["mouse", "SPECIES", 130, 135], ["mice", "SPECIES", 295, 299], ["mouse", "SPECIES", 85, 90], ["mouse", "SPECIES", 130, 135], ["RVFV", "SPECIES", 201, 205], ["mice", "SPECIES", 295, 299], ["The increased lethality", "PROBLEM", 0, 23], ["our mouse challenge studies", "TEST", 81, 108], ["The inbred mouse strains", "PROBLEM", 119, 143], ["RVFV", "PROBLEM", 201, 205], ["viral dose", "TREATMENT", 278, 288], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["lethality", "OBSERVATION", 14, 23], ["significant", "OBSERVATION_MODIFIER", 221, 232], ["difference", "OBSERVATION", 233, 243]]], ["In this study, the dose of 2 TCID 50 RVFV was found to be the lowest dose that reliably infects 100% of the tested inbred mice.", [["RVFV", "ORGANISM", 37, 41], ["mice", "ORGANISM", 122, 126], ["mice", "SPECIES", 122, 126], ["RVFV", "SPECIES", 37, 41], ["mice", "SPECIES", 122, 126], ["this study", "TEST", 3, 13]]], ["The 2 TCID 50 dose was also found to result in the longest median time to death, for C57BL/6J, 129S1/SvlmJ, NOD/ShiLtJ, and A/J mouse strains, as compared to all higher challenge doses.", [["TCID 50", "CHEMICAL", 6, 13], ["death", "DISEASE", 74, 79], ["C57BL/6J", "ORGANISM", 85, 93], ["129S1", "GENE_OR_GENE_PRODUCT", 95, 100], ["SvlmJ", "GENE_OR_GENE_PRODUCT", 101, 106], ["ShiLtJ", "GENE_OR_GENE_PRODUCT", 112, 118], ["A/J mouse", "ORGANISM", 124, 133], ["mouse", "SPECIES", 128, 133], ["mouse", "SPECIES", 128, 133], ["The 2 TCID", "TREATMENT", 0, 10], ["C57BL/6J", "TREATMENT", 85, 93], ["SvlmJ", "TREATMENT", 101, 106], ["NOD/ShiLtJ", "TREATMENT", 108, 118], ["A/J mouse strains", "TREATMENT", 124, 141]]], ["Therefore, this dose allows for the possibility of dilution errors while still challenging mice with at least one virion of lethal RVFV and extends the survival time by 1 day.", [["RVFV", "DISEASE", 131, 135], ["mice", "ORGANISM", 91, 95], ["RVFV", "ORGANISM", 131, 135], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["RVFV", "SPECIES", 131, 135], ["dilution errors", "PROBLEM", 51, 66], ["lethal RVFV", "TREATMENT", 124, 135]]], ["Doses higher than 2 TCID 50 were not used to challenge NZO/HILtJ mice; however, it can be hypothesized that this strain would follow the same trend.", [["NZO/HILtJ mice", "ORGANISM", 55, 69], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 65, 69], ["this strain", "PROBLEM", 108, 119]]], ["The acute hepatic inbred mouse challenge models described in this paper, therefore, permit the reliable administration of a low dose of virus, while also consistently extending the intervention window for post-exposure studies or serial euthanasia.", [["hepatic", "ANATOMY", 10, 17], ["mouse", "ORGANISM", 25, 30], ["mouse", "SPECIES", 25, 30], ["mouse", "SPECIES", 25, 30], ["The acute hepatic inbred mouse challenge models", "TREATMENT", 0, 47], ["a low dose of virus", "TREATMENT", 122, 141], ["post-exposure studies", "TEST", 205, 226], ["serial euthanasia", "PROBLEM", 230, 247], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["hepatic", "ANATOMY", 10, 17], ["inbred mouse challenge", "OBSERVATION", 18, 40], ["euthanasia", "OBSERVATION", 237, 247]]], ["These models could be used alongside the highly established BALB/c mouse model, which is undoubtably a useful model for post-exposure studies due to its longer time to death and greater resiliency to RVFV infection.", [["death", "DISEASE", 168, 173], ["RVFV infection", "DISEASE", 200, 214], ["BALB/c mouse", "ORGANISM", 60, 72], ["RVFV", "ORGANISM", 200, 204], ["mouse", "SPECIES", 67, 72], ["mouse", "SPECIES", 67, 72], ["RVFV", "SPECIES", 200, 204], ["BALB/c mouse model", "TREATMENT", 60, 78], ["exposure studies", "TEST", 125, 141], ["RVFV infection", "PROBLEM", 200, 214], ["RVFV", "OBSERVATION_MODIFIER", 200, 204], ["infection", "OBSERVATION", 205, 214]]], ["However, time to death in BALB/c mice is varied as well as their course of disease.", [["death", "DISEASE", 17, 22], ["BALB/c mice", "ORGANISM", 26, 37], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["disease", "PROBLEM", 75, 82], ["disease", "OBSERVATION", 75, 82]]], ["Therefore, for the study of RVFV hepatic disease, the presented five inbred mouse models represent a consistent model for pathogenesis and intervention studies.DISCUSSIONInterestingly, RVFV challenge dose did not affect viral RNA load in mouse tissues at the time of death or euthanasia.", [["hepatic", "ANATOMY", 33, 40], ["tissues", "ANATOMY", 244, 251], ["RVFV hepatic disease", "DISEASE", 28, 48], ["death", "DISEASE", 267, 272], ["RVFV", "ORGANISM", 28, 32], ["hepatic", "ORGAN", 33, 40], ["mouse", "ORGANISM", 76, 81], ["RVFV", "ORGANISM", 185, 189], ["mouse", "ORGANISM", 238, 243], ["tissues", "TISSUE", 244, 251], ["mouse", "SPECIES", 76, 81], ["mouse", "SPECIES", 238, 243], ["RVFV", "SPECIES", 28, 32], ["mouse", "SPECIES", 76, 81], ["RVFV", "SPECIES", 185, 189], ["mouse", "SPECIES", 238, 243], ["the study", "TEST", 15, 24], ["RVFV hepatic disease", "PROBLEM", 28, 48], ["intervention studies", "TEST", 139, 159], ["RVFV challenge dose", "TREATMENT", 185, 204], ["viral RNA load in mouse tissues", "PROBLEM", 220, 251], ["death", "PROBLEM", 267, 272], ["euthanasia", "PROBLEM", 276, 286], ["RVFV", "OBSERVATION", 28, 32], ["hepatic", "ANATOMY", 33, 40], ["disease", "OBSERVATION", 41, 48], ["euthanasia", "OBSERVATION", 276, 286]]], ["This result is comparable to work performed in rats showing no correlation between the dose of administered virus and the amount of infectious virus (PFU) at the time of death (Bales et al., 2012) .", [["death", "DISEASE", 170, 175], ["rats", "ORGANISM", 47, 51], ["infectious virus", "ORGANISM", 132, 148], ["rats", "SPECIES", 47, 51], ["administered virus", "TREATMENT", 95, 113], ["infectious virus", "PROBLEM", 132, 148], ["infectious", "OBSERVATION_MODIFIER", 132, 142]]], ["A lower challenge dose of virus could be slower at establishing infection; however, a maximal viral set point is reached by the time of death/euthanasia regardless of challenge dose.", [["infection", "DISEASE", 64, 73], ["death", "DISEASE", 136, 141], ["A lower challenge dose of virus", "TREATMENT", 0, 31], ["establishing infection", "PROBLEM", 51, 73], ["a maximal viral set point", "PROBLEM", 84, 109], ["euthanasia", "PROBLEM", 142, 152], ["lower", "OBSERVATION_MODIFIER", 2, 7], ["infection", "OBSERVATION", 64, 73]]], ["Serial sacrifice studies at early time points post-infection would likely reveal initial differences in viral establishment between infection doses.DISCUSSIONMice from all five strains died of disease consistent with severe acute hepatitis, typically within 5 days of infection at a dose of 2 TCID 50 .", [["infection", "DISEASE", 132, 141], ["acute hepatitis", "DISEASE", 224, 239], ["infection", "DISEASE", 268, 277], ["Serial sacrifice studies", "TEST", 0, 24], ["initial differences in viral establishment between infection doses", "PROBLEM", 81, 147], ["disease", "PROBLEM", 193, 200], ["severe acute hepatitis", "PROBLEM", 217, 239], ["infection", "PROBLEM", 268, 277], ["viral establishment", "OBSERVATION", 104, 123], ["disease", "OBSERVATION", 193, 200], ["consistent with", "UNCERTAINTY", 201, 216], ["severe", "OBSERVATION_MODIFIER", 217, 223], ["acute", "OBSERVATION_MODIFIER", 224, 229], ["hepatitis", "OBSERVATION", 230, 239], ["infection", "OBSERVATION", 268, 277]]], ["Clinical symptoms, gross liver pathology, virologic level trends in key tissues, and time to death were all consistent with the acute RVFV hepatic disease phenotype previously described in BALB/c, C57BL/6J, and MBT mouse models (do Valle et al., 2010; Smith et al., 2010; Gray et al., 2012; Lathan et al., 2017) .", [["liver", "ANATOMY", 25, 30], ["tissues", "ANATOMY", 72, 79], ["hepatic", "ANATOMY", 139, 146], ["C57BL/6J", "ANATOMY", 197, 205], ["death", "DISEASE", 93, 98], ["RVFV hepatic disease", "DISEASE", 134, 154], ["liver", "ORGAN", 25, 30], ["tissues", "TISSUE", 72, 79], ["hepatic", "ORGAN", 139, 146], ["BALB/c, C57BL/6J", "ORGANISM", 189, 205], ["mouse", "ORGANISM", 215, 220], ["mouse", "SPECIES", 215, 220], ["RVFV", "SPECIES", 134, 138], ["mouse", "SPECIES", 215, 220], ["Clinical symptoms", "PROBLEM", 0, 17], ["gross liver pathology", "PROBLEM", 19, 40], ["virologic level trends", "PROBLEM", 42, 64], ["the acute RVFV hepatic disease phenotype", "PROBLEM", 124, 164], ["liver", "ANATOMY", 25, 30], ["pathology", "OBSERVATION", 31, 40], ["consistent with", "UNCERTAINTY", 108, 123], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["RVFV", "OBSERVATION", 134, 138], ["hepatic", "ANATOMY", 139, 146], ["disease", "OBSERVATION", 147, 154]]], ["The only other disease manifestations observed in the infected mice were hind limb paralysis and tremor in the three mice that died after day 6 in the 0.2 and 2 TCID 50 dose groups.", [["hind limb", "ANATOMY", 73, 82], ["paralysis", "DISEASE", 83, 92], ["tremor", "DISEASE", 97, 103], ["mice", "ORGANISM", 63, 67], ["hind limb", "ORGANISM_SUBDIVISION", 73, 82], ["mice", "ORGANISM", 117, 121], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 117, 121], ["other disease manifestations", "PROBLEM", 9, 37], ["hind limb paralysis", "PROBLEM", 73, 92], ["tremor", "PROBLEM", 97, 103], ["disease", "OBSERVATION", 15, 22], ["infected", "OBSERVATION_MODIFIER", 54, 62], ["hind limb", "ANATOMY", 73, 82], ["paralysis", "OBSERVATION", 83, 92], ["tremor", "OBSERVATION", 97, 103]]], ["These mice displayed clear encephalitic disease with viral titers appearing highest in the brain while viral RNA was nearly cleared from all other organs, mirroring RVFV encephalitic presentation in other mouse models (Smith et al., 2010; Reed et al., 2013) .DISCUSSIONIt is known that genetic variability exists between commonly used laboratory inbred mouse strains and that these genetic differences have substantial influence on mouse phenotypes.", [["brain", "ANATOMY", 91, 96], ["organs", "ANATOMY", 147, 153], ["encephalitic disease", "DISEASE", 27, 47], ["mice", "ORGANISM", 6, 10], ["brain", "ORGAN", 91, 96], ["organs", "ORGAN", 147, 153], ["RVFV", "ORGANISM", 165, 169], ["mouse", "ORGANISM", 205, 210], ["mouse", "ORGANISM", 353, 358], ["mouse", "ORGANISM", 432, 437], ["viral RNA", "RNA", 103, 112], ["mice", "SPECIES", 6, 10], ["mouse", "SPECIES", 205, 210], ["mouse", "SPECIES", 353, 358], ["mouse", "SPECIES", 432, 437], ["mice", "SPECIES", 6, 10], ["RVFV", "SPECIES", 165, 169], ["mouse", "SPECIES", 205, 210], ["mouse", "SPECIES", 353, 358], ["mouse", "SPECIES", 432, 437], ["clear encephalitic disease", "PROBLEM", 21, 47], ["viral titers", "PROBLEM", 53, 65], ["viral RNA", "PROBLEM", 103, 112], ["mirroring RVFV encephalitic presentation", "PROBLEM", 155, 195], ["genetic variability", "PROBLEM", 286, 305], ["laboratory inbred mouse strains", "TREATMENT", 335, 366], ["substantial influence on mouse phenotypes", "PROBLEM", 407, 448], ["clear", "OBSERVATION_MODIFIER", 21, 26], ["encephalitic disease", "OBSERVATION", 27, 47], ["viral titers", "OBSERVATION", 53, 65], ["highest", "OBSERVATION_MODIFIER", 76, 83], ["brain", "ANATOMY", 91, 96], ["viral RNA", "OBSERVATION", 103, 112], ["organs", "ANATOMY", 147, 153], ["RVFV", "OBSERVATION_MODIFIER", 165, 169], ["encephalitic", "OBSERVATION_MODIFIER", 170, 182]]], ["These genetic differences are also present between the strains used in this study and influence such things as the skewing of C57BL/6J mice toward a Th1 response, the development of polygenic obesity in NZO/HILtJ mice or the predisposition of NOD/ShiLtJ mice to develop type 1 diabetes.", [["polygenic obesity", "DISEASE", 182, 199], ["type 1 diabetes", "DISEASE", 270, 285], ["C57BL/6J mice", "ORGANISM", 126, 139], ["NZO/HILtJ mice", "ORGANISM", 203, 217], ["NOD/ShiLtJ mice", "ORGANISM", 243, 258], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 213, 217], ["mice", "SPECIES", 254, 258], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 213, 217], ["the strains", "PROBLEM", 51, 62], ["this study", "TEST", 71, 81], ["C57BL/6J mice", "TREATMENT", 126, 139], ["polygenic obesity", "PROBLEM", 182, 199], ["NZO/HILtJ mice", "TREATMENT", 203, 217], ["NOD/ShiLtJ mice", "TREATMENT", 243, 258], ["type 1 diabetes", "PROBLEM", 270, 285], ["polygenic", "OBSERVATION_MODIFIER", 182, 191], ["obesity", "OBSERVATION", 192, 199], ["diabetes", "OBSERVATION", 277, 285]]], ["However, it is clear that the five inbred mouse strains used in this study do not contain adequate genetic diversity to elicit increased resistance to RVFV infection or a skewing toward different manifestations of RVF disease.", [["infection", "DISEASE", 156, 165], ["RVF disease", "DISEASE", 214, 225], ["mouse", "ORGANISM", 42, 47], ["RVFV", "ORGANISM", 151, 155], ["mouse", "SPECIES", 42, 47], ["mouse", "SPECIES", 42, 47], ["RVFV", "SPECIES", 151, 155], ["RVF", "SPECIES", 214, 217], ["the five inbred mouse strains", "PROBLEM", 26, 55], ["this study", "TEST", 64, 74], ["increased resistance", "PROBLEM", 127, 147], ["RVFV infection", "PROBLEM", 151, 165], ["RVF disease", "PROBLEM", 214, 225], ["increased", "OBSERVATION_MODIFIER", 127, 136], ["resistance", "OBSERVATION", 137, 147], ["RVFV", "OBSERVATION_MODIFIER", 151, 155], ["infection", "OBSERVATION", 156, 165], ["RVF", "OBSERVATION", 214, 217]]], ["The one exception to the universal death caused by RVFV in this study was a female NZO/HILtJ mouse that survived to the end of the study and was determined to have been successfully infected from a dose of 0.2 TCID 50 .", [["death", "DISEASE", 35, 40], ["RVFV", "DISEASE", 51, 55], ["RVFV", "ORGANISM", 51, 55], ["mouse", "ORGANISM", 93, 98], ["mouse", "SPECIES", 93, 98], ["RVFV", "SPECIES", 51, 55], ["mouse", "SPECIES", 93, 98], ["the universal death", "PROBLEM", 21, 40], ["this study", "TEST", 59, 69], ["HILtJ mouse", "TREATMENT", 87, 98], ["the study", "TEST", 127, 136], ["RVFV", "OBSERVATION", 51, 55], ["infected", "OBSERVATION", 182, 190]]], ["Although this mouse did not show symptoms or die by day 28, it is possible that it would have died of late-onset encephalitis if the study had been prolonged.", [["encephalitis", "DISEASE", 113, 125], ["mouse", "ORGANISM", 14, 19], ["mouse", "SPECIES", 14, 19], ["mouse", "SPECIES", 14, 19], ["symptoms", "PROBLEM", 33, 41], ["late-onset encephalitis", "PROBLEM", 102, 125], ["the study", "TEST", 129, 138], ["encephalitis", "OBSERVATION", 113, 125]]], ["Although not a direct comparison, encephalitis deaths in CD4-depleted inbred mice have been seen as late as 36 days post-infection with \u2206NSs RVFV (Dodd et al., 2013) .", [["encephalitis", "DISEASE", 34, 46], ["deaths", "DISEASE", 47, 53], ["CD4", "GENE_OR_GENE_PRODUCT", 57, 60], ["mice", "ORGANISM", 77, 81], ["CD4", "PROTEIN", 57, 60], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["RVFV", "SPECIES", 141, 145], ["encephalitis deaths", "PROBLEM", 34, 53], ["CD4", "TEST", 57, 60], ["encephalitis", "OBSERVATION", 34, 46]]], ["However, it is also distinctly possible that this mouse did survive productive wild-type RVFV infection.", [["infection", "DISEASE", 94, 103], ["mouse", "ORGANISM", 50, 55], ["wild-type", "ORGANISM", 79, 88], ["RVFV", "ORGANISM", 89, 93], ["mouse", "SPECIES", 50, 55], ["mouse", "SPECIES", 50, 55], ["RVFV", "SPECIES", 89, 93], ["type RVFV infection", "PROBLEM", 84, 103], ["also distinctly possible", "UNCERTAINTY", 15, 39], ["RVFV", "OBSERVATION_MODIFIER", 89, 93], ["infection", "OBSERVATION", 94, 103]]], ["It is interesting to note that NZO/ HILtJ mice are the only strain in this study with a fully functional Mx1 locus (human homologue MxA), which has been shown to have antiviral activity against multiple viruses (Staeheli et al., 1988; Frese et al., 1996; Ferris et al., 2013; Verhelst et al., 2013; Leist et al., 2016) .", [["NZO/ HILtJ mice", "ORGANISM", 31, 46], ["Mx1", "GENE_OR_GENE_PRODUCT", 105, 108], ["human", "ORGANISM", 116, 121], ["MxA", "GENE_OR_GENE_PRODUCT", 132, 135], ["Mx1 locus", "DNA", 105, 114], ["MxA", "PROTEIN", 132, 135], ["mice", "SPECIES", 42, 46], ["human", "SPECIES", 116, 121], ["mice", "SPECIES", 42, 46], ["human", "SPECIES", 116, 121], ["NZO/ HILtJ mice", "TREATMENT", 31, 46], ["this study", "TEST", 70, 80]]], ["However, as only one out of all challenged NZO/HILtJ mice survived, it is clear that Mx1 is not the main host genetic factor responsible for mouse susceptibility to RVFV.DISCUSSIONIt is widely accepted that sex significantly influences infectious disease pathogenesis and severity across multiple species Klein, 2016, 2017) .", [["RVFV", "DISEASE", 165, 169], ["infectious disease", "DISEASE", 236, 254], ["NZO/HILtJ mice", "ORGANISM", 43, 57], ["Mx1", "GENE_OR_GENE_PRODUCT", 85, 88], ["mouse", "ORGANISM", 141, 146], ["RVFV", "ORGANISM", 165, 169], ["Mx1", "PROTEIN", 85, 88], ["mice", "SPECIES", 53, 57], ["mouse", "SPECIES", 141, 146], ["mice", "SPECIES", 53, 57], ["mouse", "SPECIES", 141, 146], ["RVFV", "SPECIES", 165, 169], ["mouse susceptibility to RVFV", "PROBLEM", 141, 169], ["infectious disease pathogenesis", "PROBLEM", 236, 267], ["multiple", "OBSERVATION_MODIFIER", 288, 296], ["species Klein", "OBSERVATION", 297, 310]]], ["Males and females of numerous species differ in disease severity to various viral pathogens due to differences in their hormone environments and immune response potentials Roberts, 2010, 2015) .DISCUSSIONFrontiers in Microbiology | www.frontiersin.org 9 August 2020 | Volume 11 | Article 1962DISCUSSIONThese sex influences on viral disease severity are complex and thus must be investigated for each individual pathogen.", [["numerous species", "PROBLEM", 21, 37], ["disease severity", "PROBLEM", 48, 64], ["various viral pathogens", "PROBLEM", 68, 91], ["Volume", "TEST", 268, 274], ["viral disease severity", "PROBLEM", 326, 348], ["each individual pathogen", "PROBLEM", 395, 419], ["viral disease", "OBSERVATION", 326, 339]]], ["Although in general males are more susceptible to infection by viral pathogens, there are viruses, such as human Papillomavirus and Influenza A virus, that do not follow this rule and are instead higher risk infections in females (Chan et al., 1989; Lorenzo et al., 2011; Hoffmann et al., 2015; vom Steeg and Klein, 2016) .", [["infection", "DISEASE", 50, 59], ["viral pathogens", "DISEASE", 63, 78], ["human Papillomavirus", "DISEASE", 107, 127], ["Influenza A virus", "DISEASE", 132, 149], ["infections", "DISEASE", 208, 218], ["human", "ORGANISM", 107, 112], ["Papillomavirus", "ORGANISM", 113, 127], ["Influenza A virus", "ORGANISM", 132, 149], ["human", "SPECIES", 107, 112], ["Papillomavirus", "SPECIES", 113, 127], ["Influenza A virus", "SPECIES", 132, 149], ["human Papillomavirus", "SPECIES", 107, 127], ["Influenza A virus", "SPECIES", 132, 149], ["infection", "PROBLEM", 50, 59], ["viral pathogens", "PROBLEM", 63, 78], ["viruses", "PROBLEM", 90, 97], ["human Papillomavirus", "PROBLEM", 107, 127], ["Influenza A virus", "PROBLEM", 132, 149], ["more susceptible", "OBSERVATION_MODIFIER", 30, 46], ["infection", "OBSERVATION", 50, 59], ["viral pathogens", "OBSERVATION", 63, 78], ["viruses", "OBSERVATION", 90, 97]]], ["However, little data exist on the importance of sex in the context of RVFV infection in mice.", [["RVFV infection", "DISEASE", 70, 84], ["RVFV", "ORGANISM", 70, 74], ["mice", "ORGANISM", 88, 92], ["mice", "SPECIES", 88, 92], ["RVFV", "SPECIES", 70, 74], ["mice", "SPECIES", 88, 92], ["RVFV infection", "PROBLEM", 70, 84], ["RVFV", "OBSERVATION_MODIFIER", 70, 74], ["infection", "OBSERVATION", 75, 84]]], ["Historic RVFV studies have used both sexes of mice, but few have directly compared females and males in the same study.DISCUSSIONIn this study, both females and males of the five inbred mouse strains were challenged with the same doses of RVFV.", [["RVFV", "DISEASE", 239, 243], ["mice", "ORGANISM", 46, 50], ["mouse", "ORGANISM", 186, 191], ["RVFV", "ORGANISM", 239, 243], ["mice", "SPECIES", 46, 50], ["mouse", "SPECIES", 186, 191], ["RVFV", "SPECIES", 9, 13], ["mice", "SPECIES", 46, 50], ["mouse", "SPECIES", 186, 191], ["RVFV", "SPECIES", 239, 243], ["Historic RVFV studies", "TEST", 0, 21], ["this study", "TEST", 132, 142], ["the five inbred mouse strains", "TREATMENT", 170, 199], ["RVFV", "PROBLEM", 239, 243]]], ["There was no significant difference in survival curves or time to death between female and male mice except for a 1-day difference in time to death for A/J mice.", [["death", "DISEASE", 66, 71], ["death", "DISEASE", 142, 147], ["mice", "ORGANISM", 96, 100], ["A/J mice", "ORGANISM", 152, 160], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 156, 160], ["mice", "SPECIES", 96, 100], ["A/J mice", "SPECIES", 152, 160], ["significant difference in survival curves", "PROBLEM", 13, 54], ["A/J mice", "TREATMENT", 152, 160], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["Although weight loss was found to be statistically different between sexes for 129S1/SvlmJ, A/J, and NZO/HILtJ mice, this is not felt to be of clinical importance given the overall lethality.", [["weight loss", "DISEASE", 9, 20], ["SvlmJ", "GENE_OR_GENE_PRODUCT", 85, 90], ["A/J", "GENE_OR_GENE_PRODUCT", 92, 95], ["NZO", "GENE_OR_GENE_PRODUCT", 101, 104], ["HILtJ", "GENE_OR_GENE_PRODUCT", 105, 110], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["weight loss", "PROBLEM", 9, 20], ["A/J", "TREATMENT", 92, 95], ["NZO/HILtJ mice", "TREATMENT", 101, 115], ["the overall lethality", "PROBLEM", 169, 190], ["lethality", "OBSERVATION", 181, 190]]], ["Additionally, viral RNA load in the liver, spleen, and brain was not found to be significantly different when comparing females and males of any of the five inbred mouse strains.", [["liver", "ANATOMY", 36, 41], ["spleen", "ANATOMY", 43, 49], ["brain", "ANATOMY", 55, 60], ["liver", "ORGAN", 36, 41], ["spleen", "ORGAN", 43, 49], ["brain", "ORGAN", 55, 60], ["mouse", "ORGANISM", 164, 169], ["mouse", "SPECIES", 164, 169], ["mouse", "SPECIES", 164, 169], ["viral RNA load in the liver, spleen, and brain", "PROBLEM", 14, 60], ["the five inbred mouse strains", "PROBLEM", 148, 177], ["viral RNA load", "OBSERVATION", 14, 28], ["liver", "ANATOMY", 36, 41], ["spleen", "ANATOMY", 43, 49], ["brain", "ANATOMY", 55, 60]]], ["This failure to identify any significant sex difference in percent survival or viral burden and the extremely modest influence of sex on time to death and weight loss is qualified by the relatively low number of animals challenged in these studies.", [["death", "DISEASE", 145, 150], ["weight loss", "DISEASE", 155, 166], ["This failure", "PROBLEM", 0, 12], ["viral burden", "PROBLEM", 79, 91], ["weight loss", "PROBLEM", 155, 166], ["these studies", "TEST", 234, 247], ["relatively", "OBSERVATION_MODIFIER", 187, 197], ["low number", "OBSERVATION_MODIFIER", 198, 208]]], ["Five mice per group are not of sufficient power to conclude a total absence of sex differences in RVFV infection.", [["RVFV infection", "DISEASE", 98, 112], ["mice", "ORGANISM", 5, 9], ["RVFV", "ORGANISM", 98, 102], ["mice", "SPECIES", 5, 9], ["mice", "SPECIES", 5, 9], ["RVFV", "SPECIES", 98, 102], ["RVFV infection", "PROBLEM", 98, 112], ["RVFV", "OBSERVATION_MODIFIER", 98, 102], ["infection", "OBSERVATION", 103, 112]]], ["However, even with small sample sizes, the almost uniform lethality seen in both sexes suggests that it would be a reasonable approach to use only one sex for initial survival studies in future experiments, saving both time and resources.", [["small sample sizes", "PROBLEM", 19, 37], ["initial survival studies", "TEST", 159, 183], ["small", "OBSERVATION_MODIFIER", 19, 24], ["sample", "OBSERVATION_MODIFIER", 25, 31], ["sizes", "OBSERVATION_MODIFIER", 32, 37], ["almost", "OBSERVATION_MODIFIER", 43, 49], ["uniform", "OBSERVATION_MODIFIER", 50, 57], ["lethality", "OBSERVATION", 58, 67]]], ["In the context of vaccine and therapeutic studies, however, it would still be advisable to evaluate both sexes for potential subtle variation in responses that could be revealed with a more highly powered study.DISCUSSIONThese data differ from that presented by Tokuda et al. (2015) who found that sex influenced susceptibility to RVFV in MBT (n = 90) and BALB/c (n = 96) mice as determined by log-rank tests of survival curves.", [["RVFV", "DISEASE", 331, 335], ["RVFV", "ORGANISM", 331, 335], ["BALB/c (n = 96)", "ORGANISM", 356, 371], ["mice", "ORGANISM", 372, 376], ["mice", "SPECIES", 372, 376], ["RVFV", "SPECIES", 331, 335], ["mice", "SPECIES", 372, 376], ["vaccine", "TREATMENT", 18, 25], ["therapeutic studies", "TEST", 30, 49], ["RVFV", "TEST", 331, 335], ["MBT", "TEST", 339, 342], ["BALB/c", "TEST", 356, 362], ["survival curves", "TEST", 412, 427]]], ["The authors found that males were more susceptible to infection than females, concluding that MBT susceptibility is controlled by multiple genes, of which sex is a contributing factor (Tokuda et al., 2015) .", [["infection", "DISEASE", 54, 63], ["infection", "PROBLEM", 54, 63], ["MBT susceptibility", "PROBLEM", 94, 112], ["infection", "OBSERVATION", 54, 63]]], ["These include the mouse strains used, the age of the mice, the RVFV challenge strain, the power of the study, and whether reversegenetics derived virus or passaged isolate is used for challenge.", [["mouse", "ORGANISM", 18, 23], ["mice", "ORGANISM", 53, 57], ["RVFV", "ORGANISM", 63, 67], ["mouse", "SPECIES", 18, 23], ["mice", "SPECIES", 53, 57], ["mouse", "SPECIES", 18, 23], ["mice", "SPECIES", 53, 57], ["RVFV", "SPECIES", 63, 67], ["the mouse strains", "PROBLEM", 14, 31], ["the RVFV challenge strain", "PROBLEM", 59, 84], ["the study", "TEST", 99, 108], ["reversegenetics derived virus", "PROBLEM", 122, 151]]], ["Additionally, environmental factors between research facilities could affect such things as the mouse microbiome, which has been shown to influence severity of various infectious diseases (Villarino et al., 2016; Li et al., 2019; Robinson et al., 2019) .DISCUSSIONIn summary, C57BL/6J, 129S1/SvlmJ, NOD/ShiLtJ, A/J, and NZO/HILtJ mice are highly susceptible to lethal RVFV infection.", [["infectious diseases", "DISEASE", 168, 187], ["RVFV infection", "DISEASE", 368, 382], ["mouse", "ORGANISM", 96, 101], ["C57BL/6J", "ORGANISM", 276, 284], ["129S1", "GENE_OR_GENE_PRODUCT", 286, 291], ["SvlmJ", "GENE_OR_GENE_PRODUCT", 292, 297], ["NOD", "GENE_OR_GENE_PRODUCT", 299, 302], ["ShiLtJ", "GENE_OR_GENE_PRODUCT", 303, 309], ["NZO/HILtJ mice", "ORGANISM", 320, 334], ["RVFV", "ORGANISM", 368, 372], ["mouse", "SPECIES", 96, 101], ["mice", "SPECIES", 330, 334], ["mouse", "SPECIES", 96, 101], ["mice", "SPECIES", 330, 334], ["RVFV", "SPECIES", 368, 372], ["various infectious diseases", "PROBLEM", 160, 187], ["SvlmJ", "TREATMENT", 292, 297], ["ShiLtJ", "TREATMENT", 303, 309], ["A/J", "TREATMENT", 311, 314], ["NZO/HILtJ mice", "TREATMENT", 320, 334], ["lethal RVFV infection", "PROBLEM", 361, 382], ["infectious", "OBSERVATION", 168, 178], ["lethal", "OBSERVATION_MODIFIER", 361, 367], ["RVFV", "OBSERVATION_MODIFIER", 368, 372], ["infection", "OBSERVATION", 373, 382]]], ["In this study, the dose of 2 TCID 50 wild-type RVFV was found to be the lowest dose that reliably infected 100% of inbred mice tested.", [["RVFV", "ORGANISM", 47, 51], ["mice", "ORGANISM", 122, 126], ["mice", "SPECIES", 122, 126], ["RVFV", "SPECIES", 47, 51], ["mice", "SPECIES", 122, 126], ["this study", "TEST", 3, 13]]], ["All inbred mice that were tested uniformly died of 2 TCID 50 RVFV challenge, regardless of sex or inbred strain.", [["RVFV", "DISEASE", 61, 65], ["mice", "ORGANISM", 11, 15], ["RVFV", "ORGANISM", 61, 65], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["RVFV", "SPECIES", 61, 65], ["All inbred mice", "TREATMENT", 0, 15], ["inbred strain", "PROBLEM", 98, 111]]], ["No substantial differences in disease phenotype or susceptibility were found between the five chosen inbred mouse strains as most died of acute hepatic disease.", [["hepatic", "ANATOMY", 144, 151], ["acute hepatic disease", "DISEASE", 138, 159], ["mouse", "ORGANISM", 108, 113], ["hepatic", "ORGAN", 144, 151], ["mouse", "SPECIES", 108, 113], ["mouse", "SPECIES", 108, 113], ["substantial differences in disease phenotype", "PROBLEM", 3, 47], ["susceptibility", "PROBLEM", 51, 65], ["acute hepatic disease", "PROBLEM", 138, 159], ["substantial", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION_MODIFIER", 15, 26], ["disease", "OBSERVATION", 30, 37], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["hepatic", "ANATOMY", 144, 151], ["disease", "OBSERVATION", 152, 159]]], ["Therefore, all of these models could be useful for the study of acute lethal hepatitis caused by RVFV.", [["hepatitis", "DISEASE", 77, 86], ["RVFV", "DISEASE", 97, 101], ["RVFV", "ORGANISM", 97, 101], ["RVFV", "SPECIES", 97, 101], ["the study", "TEST", 51, 60], ["acute lethal hepatitis", "PROBLEM", 64, 86], ["RVFV", "PROBLEM", 97, 101], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["hepatitis", "OBSERVATION", 77, 86], ["RVFV", "OBSERVATION", 97, 101]]], ["From these studies, it is clear that the five chosen mouse strains do not contain adequate genetic diversity to identify increased resistance to RVFV in mice.", [["RVFV", "DISEASE", 145, 149], ["mouse", "ORGANISM", 53, 58], ["RVFV", "ORGANISM", 145, 149], ["mice", "ORGANISM", 153, 157], ["mouse", "SPECIES", 53, 58], ["mice", "SPECIES", 153, 157], ["mouse", "SPECIES", 53, 58], ["RVFV", "SPECIES", 145, 149], ["mice", "SPECIES", 153, 157], ["these studies", "TEST", 5, 18], ["the five chosen mouse strains", "PROBLEM", 37, 66], ["increased resistance", "PROBLEM", 121, 141], ["increased resistance", "OBSERVATION", 121, 141]]], ["Additional studies aimed at assessing mice for divergent RVFV phenotypes that better recapitulate human disease could focus on mice with additional genetic diversity.DATA AVAILABILITY STATEMENTAll datasets presented in this study are included in the article/Supplementary Material.ETHICS STATEMENTThe animal study was reviewed and approved by the University of Pittsburgh IACUC (protocol number 19044158).AUTHOR CONTRIBUTIONSAM: conceptualization, methodology, investigation, writing and review, and funding acquisition.", [["mice", "ORGANISM", 38, 42], ["RVFV", "ORGANISM", 57, 61], ["human", "ORGANISM", 98, 103], ["mice", "ORGANISM", 127, 131], ["mice", "SPECIES", 38, 42], ["human", "SPECIES", 98, 103], ["mice", "SPECIES", 127, 131], ["mice", "SPECIES", 38, 42], ["RVFV", "SPECIES", 57, 61], ["human", "SPECIES", 98, 103], ["mice", "SPECIES", 127, 131], ["Additional studies", "TEST", 0, 18], ["divergent RVFV phenotypes", "PROBLEM", 47, 72], ["human disease", "PROBLEM", 98, 111], ["this study", "TEST", 219, 229], ["The animal study", "TEST", 297, 313]]], ["All authors contributed to the article and approved the submitted version.FUNDINGThis project was supported by a grant from the National Institute of Allergy and Infectious Diseases, (R21AI145352).", [["Allergy and Infectious Diseases", "DISEASE", 150, 181], ["Infectious", "OBSERVATION", 162, 172]]], ["AM was also supported in part by Children's Hospital of Pittsburgh of the UPMC Health System and Burroughs Wellcome (CAMS 1013362.01) during the conduct of this work.ACKNOWLEDGMENTSThe authors would like to thank Dr. Cesar Albarino from the US CDC Viral Special Pathogens Branch for sharing the RVFV reverse genetics system.", [["Children", "SPECIES", 33, 41], ["RVFV", "SPECIES", 295, 299]]], ["The authors also thank the University of Pittsburgh Clinical and Translational Science Institute (CTSI) Biostatistics, Epidemiology, and Research Design (BERD) Core for providing statistical consultation (supported by NIH grant UL1 TR001857) as well as the Division of Laboratory Animal Resources of University of Pittsburgh staff for their assistance throughout the project.SUPPLEMENTARY MATERIALThe Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2020.01962/ full#supplementary-material", [["SUPPLEMENTARY", "DISEASE", 375, 388], ["full#supplementary-material", "PROBLEM", 528, 555]]]], "f375536dd8e3671b71cade567b99cc0a2ff16020": [["The nuclear receptor heterodimers of liver X receptors (LXRs) are recently identified as key transcriptional regulators of genes involved in lipid homeostasis and inflammation.", [["nuclear", "ANATOMY", 4, 11], ["inflammation", "DISEASE", 163, 175], ["liver X receptors", "GENE_OR_GENE_PRODUCT", 37, 54], ["LXRs", "GENE_OR_GENE_PRODUCT", 56, 60], ["lipid", "SIMPLE_CHEMICAL", 141, 146], ["nuclear receptor heterodimers", "PROTEIN", 4, 33], ["liver X receptors", "PROTEIN", 37, 54], ["LXRs", "PROTEIN", 56, 60], ["transcriptional regulators", "PROTEIN", 93, 119], ["lipid homeostasis", "PROBLEM", 141, 158], ["inflammation", "PROBLEM", 163, 175], ["liver", "ANATOMY", 37, 42], ["lipid homeostasis", "OBSERVATION", 141, 158], ["inflammation", "OBSERVATION", 163, 175]]], ["LXRs and their ligands are negative regulators of macrophage inflammatory gene expression.", [["macrophage", "ANATOMY", 50, 60], ["LXRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["macrophage", "CELL", 50, 60], ["LXRs", "PROTEIN", 0, 4], ["macrophage inflammatory gene expression", "PROBLEM", 50, 89], ["macrophage", "OBSERVATION_MODIFIER", 50, 60], ["inflammatory", "OBSERVATION_MODIFIER", 61, 73]]], ["Multiple sclerosis (MS), a demyelinating disease of the central nervous system of unknown cause, is characterized by recurrent inflammation involving macrophages and their inflammatory mediators.", [["central nervous system", "ANATOMY", 56, 78], ["macrophages", "ANATOMY", 150, 161], ["Multiple sclerosis", "DISEASE", 0, 18], ["MS", "DISEASE", 20, 22], ["demyelinating disease of the central nervous system", "DISEASE", 27, 78], ["inflammation", "DISEASE", 127, 139], ["central nervous system", "ANATOMICAL_SYSTEM", 56, 78], ["macrophages", "CELL", 150, 161], ["macrophages", "CELL_TYPE", 150, 161], ["inflammatory mediators", "PROTEIN", 172, 194], ["Multiple sclerosis (MS)", "PROBLEM", 0, 23], ["a demyelinating disease of the central nervous system", "PROBLEM", 25, 78], ["recurrent inflammation involving macrophages", "PROBLEM", 117, 161], ["sclerosis", "OBSERVATION", 9, 18], ["demyelinating disease", "OBSERVATION", 27, 48], ["central", "ANATOMY_MODIFIER", 56, 63], ["nervous system", "ANATOMY", 64, 78], ["recurrent", "OBSERVATION_MODIFIER", 117, 126], ["inflammation", "OBSERVATION", 127, 139], ["macrophages", "OBSERVATION_MODIFIER", 150, 161], ["inflammatory", "OBSERVATION_MODIFIER", 172, 184]]], ["Sweden belongs to the countries with a high MS incidence.", [["MS", "DISEASE", 44, 46], ["a high MS incidence", "PROBLEM", 37, 56]]], ["In Italy, incidence is lower, with an exception for Sardinia where the incidence is even higher than that in Sweden.", [["lower", "OBSERVATION_MODIFIER", 23, 28], ["higher", "OBSERVATION_MODIFIER", 89, 95]]], ["We studied LXRs and their related molecules of blood mononuclear cells (MNCs) from female patients with untreated relapsing-remitting MS from Sassari, Sardinia and Stockholm, Sweden.", [["blood mononuclear cells", "ANATOMY", 47, 70], ["MNCs", "ANATOMY", 72, 76], ["relapsing-remitting MS", "DISEASE", 114, 136], ["LXRs", "GENE_OR_GENE_PRODUCT", 11, 15], ["blood mononuclear cells", "CELL", 47, 70], ["MNCs", "CELL", 72, 76], ["patients", "ORGANISM", 90, 98], ["LXRs", "PROTEIN", 11, 15], ["blood mononuclear cells", "CELL_TYPE", 47, 70], ["MNCs", "CELL_TYPE", 72, 76], ["patients", "SPECIES", 90, 98], ["blood mononuclear cells", "PROBLEM", 47, 70], ["untreated relapsing-remitting MS", "PROBLEM", 104, 136], ["blood mononuclear cells", "OBSERVATION", 47, 70], ["relapsing", "OBSERVATION_MODIFIER", 114, 123]]], ["Sex-and age-matched healthy controls (HCs) were from both areas. mRNA expression was evaluated by real-time PCR.", [["controls", "ORGANISM", 28, 36], ["mRNA", "RNA", 65, 69], ["mRNA expression", "PROBLEM", 65, 80]]], ["LXR-a was lower (P < 0.05) in MS (mean AE SEM: 3.1 AE 0.2; n \u00bc 37) compared to HC (3.6 AE 0.1; n \u00bc 37).", [["MS", "DISEASE", 30, 32], ["LXR", "GENE_OR_GENE_PRODUCT", 0, 3], ["LXR", "PROTEIN", 0, 3], ["LXR", "TEST", 0, 3], ["MS", "TEST", 30, 32], ["mean AE SEM", "TEST", 34, 45], ["AE", "TEST", 51, 53], ["n \u00bc", "TEST", 59, 62], ["HC", "TEST", 79, 81]]], ["LXR-a was lower in MS from Stockholm (2.6 AE 0.2; n \u00bc 22) compared to corresponding HC (3.4 AE 0.1; n \u00bc 22; P < 0.01) and compared to MS (3.8 AE 0.2; n \u00bc 15; P < 0.001) and HC (4 AE 0.2; n \u00bc 15; P < 0.001) from Sardinia.", [["MS", "DISEASE", 19, 21], ["MS", "DISEASE", 134, 136], ["LXR", "GENE_OR_GENE_PRODUCT", 0, 3], ["LXR", "PROTEIN", 0, 3], ["LXR", "TEST", 0, 3], ["AE", "TEST", 42, 44], ["HC", "TEST", 84, 86], ["AE", "TEST", 92, 94], ["n \u00bc", "TEST", 100, 103], ["P", "TEST", 108, 109], ["MS", "TEST", 134, 136], ["AE", "TEST", 142, 144], ["n", "TEST", 150, 151], ["\u00bc", "TEST", 152, 153], ["P", "TEST", 158, 159], ["HC", "TEST", 173, 175], ["AE", "TEST", 179, 181], ["n \u00bc", "TEST", 187, 190], ["P", "TEST", 195, 196], ["Sardinia", "PROBLEM", 211, 219], ["lower", "OBSERVATION_MODIFIER", 10, 15]]], ["MS patients from Stockholm, but not from Sassari, also expressed lower (P < 0.05) LXR-b (\u00c04.1 AE 0.4) compared to corresponding HC (\u00c02.9 AE 0.3).", [["MS", "DISEASE", 0, 2], ["patients", "ORGANISM", 3, 11], ["LXR-b", "GENE_OR_GENE_PRODUCT", 82, 87], ["LXR", "PROTEIN", 82, 85], ["patients", "SPECIES", 3, 11], ["LXR-b (\u00c04.1 AE", "TEST", 82, 96], ["HC", "TEST", 128, 130]]], ["MS from Stockholm was associated with higher ABCA-1 (6.1 AE 0.4 versus 5.0 AE 0.3; P < 0.05) and higher estrogen receptor-b-Cx (2.4 AE 0.4 versus 0.8 AE 0.4; P < 0.01) compared to corresponding HC.", [["MS", "DISEASE", 0, 2], ["estrogen", "CHEMICAL", 104, 112], ["estrogen", "CHEMICAL", 104, 112], ["ABCA-1", "GENE_OR_GENE_PRODUCT", 45, 51], ["estrogen receptor-b-Cx", "GENE_OR_GENE_PRODUCT", 104, 126], ["estrogen receptor", "PROTEIN", 104, 121], ["ABCA", "TEST", 45, 49], ["AE", "TEST", 57, 59], ["AE", "TEST", 75, 77], ["P", "TEST", 83, 84], ["higher estrogen receptor", "TEST", 97, 121], ["Cx", "TEST", 124, 126], ["AE", "TEST", 132, 134], ["AE", "TEST", 150, 152], ["P", "TEST", 158, 159]]], ["The HC from Sassari had higher androgen receptor (2.9 AE 0.2) compared to MS from Sassari (1.4 AE 0.3; P < 0.01), MS (1.3 AE 0.4; P < 0.01) and HC from Stockholm (1.2 AE 0.3; P < 0.01).", [["MS", "DISEASE", 74, 76], ["MS", "DISEASE", 114, 116], ["androgen", "CHEMICAL", 31, 39], ["androgen receptor", "GENE_OR_GENE_PRODUCT", 31, 48], ["androgen receptor", "PROTEIN", 31, 48], ["The HC", "TEST", 0, 6], ["Sassari", "TEST", 12, 19], ["higher androgen receptor", "PROBLEM", 24, 48], ["MS", "TEST", 74, 76], ["Sassari", "TEST", 82, 89], ["AE", "TEST", 95, 97], ["P", "TEST", 103, 104], ["MS", "TEST", 114, 116], ["AE", "TEST", 122, 124], ["P", "TEST", 130, 131], ["HC", "TEST", 144, 146], ["Stockholm", "TEST", 152, 161], ["AE", "TEST", 167, 169], ["P", "TEST", 175, 176]]], ["MS from Sassari had lower cyclooxygenase-1 compared to corresponding HC (5.1 AE 0.4 versus 6.6 AE 0.3; P < 0.01) and lower prostaglandin-E (\u00c00.03 AE 0.5) compared to the HC (1.4 AE 0.5; P < 0.05) and MS (2.7 AE 0.4; P < 0.05) and HC from Stockholm (1.9 AE 0.4, P < 0.001).", [["MS", "DISEASE", 0, 2], ["prostaglandin-E", "CHEMICAL", 123, 138], ["prostaglandin-E", "CHEMICAL", 123, 138], ["cyclooxygenase-1", "GENE_OR_GENE_PRODUCT", 26, 42], ["prostaglandin-E", "SIMPLE_CHEMICAL", 123, 138], ["cyclooxygenase-1", "PROTEIN", 26, 42], ["lower cyclooxygenase", "PROBLEM", 20, 40], ["HC", "TEST", 69, 71], ["AE", "TEST", 77, 79], ["AE", "TEST", 95, 97], ["P", "TEST", 103, 104], ["lower prostaglandin", "TEST", 117, 136], ["AE", "TEST", 146, 148], ["the HC", "TEST", 166, 172], ["AE", "TEST", 178, 180], ["P", "TEST", 186, 187], ["MS", "TEST", 200, 202], ["AE", "TEST", 208, 210], ["P", "TEST", 216, 217], ["HC", "TEST", 230, 232], ["Stockholm", "TEST", 238, 247], ["AE", "TEST", 253, 255], ["P", "TEST", 261, 262]]], ["Our findings identify LXRs and their related molecules as being involved in MS from Stockholm but not from Sassari, while sex hormone receptors seem to be involved in MS in Sassari.A U T O I M M U N I T Y 5Multiple Sclerosis: IFN-b Induces CD123 + BDCA2 -Dendritic Cells that Produce IL-6 and IL-10 and have No Enhanced Type I Interferon Production Y. M. Huang, 1 S. Adikari, 1 U. B\u00e5ve, 2 A. Sanna 1,3 & G. Alm 4 DC antigens (BDCA) and investigate their ability to produce Type I IFN in response to virus stimulation.", [["Cells", "ANATOMY", 265, 270], ["MS", "DISEASE", 76, 78], ["MS", "DISEASE", 167, 169], ["Sclerosis", "DISEASE", 215, 224], ["LXRs", "GENE_OR_GENE_PRODUCT", 22, 26], ["sex hormone receptors", "GENE_OR_GENE_PRODUCT", 122, 143], ["CD123", "GENE_OR_GENE_PRODUCT", 240, 245], ["IL-6", "GENE_OR_GENE_PRODUCT", 284, 288], ["IL-10", "GENE_OR_GENE_PRODUCT", 293, 298], ["Alm 4 DC antigens", "GENE_OR_GENE_PRODUCT", 407, 424], ["BDCA", "CELL", 426, 430], ["Type I IFN", "GENE_OR_GENE_PRODUCT", 473, 483], ["LXRs", "PROTEIN", 22, 26], ["sex hormone receptors", "PROTEIN", 122, 143], ["IFN", "PROTEIN", 226, 229], ["CD123", "PROTEIN", 240, 245], ["BDCA2", "PROTEIN", 248, 253], ["Dendritic Cells", "CELL_TYPE", 255, 270], ["IL-6", "PROTEIN", 284, 288], ["IL", "PROTEIN", 293, 295], ["DC antigens", "PROTEIN", 413, 424], ["BDCA", "PROTEIN", 426, 430], ["Type I IFN", "PROTEIN", 473, 483], ["Sassari", "TREATMENT", 107, 114], ["Sclerosis", "PROBLEM", 215, 224], ["IFN-b", "TEST", 226, 231], ["CD123", "TEST", 240, 245], ["BDCA2", "TEST", 248, 253], ["Dendritic Cells", "PROBLEM", 255, 270], ["IL", "TEST", 284, 286], ["IL", "TEST", 293, 295], ["Adikari", "TEST", 367, 374], ["Sanna", "TEST", 392, 397], ["Type I IFN", "PROBLEM", 473, 483], ["virus stimulation", "TREATMENT", 499, 516], ["Sclerosis", "OBSERVATION", 215, 224], ["Dendritic Cells", "OBSERVATION", 255, 270], ["No", "UNCERTAINTY", 308, 310]]], ["We show that IFN-b induces development of CD123 \u00fe DC from human blood monocytes, which coexpress BDCA4 \u00fe but are negative for BDCA2 -, a specific marker for plasmacytoid DC.", [["CD123 \u00fe DC", "ANATOMY", 42, 52], ["blood monocytes", "ANATOMY", 64, 79], ["plasmacytoid DC", "ANATOMY", 157, 172], ["IFN-b", "GENE_OR_GENE_PRODUCT", 13, 18], ["CD123 \u00fe DC", "CELL", 42, 52], ["human", "ORGANISM", 58, 63], ["blood monocytes", "CELL", 64, 79], ["BDCA4", "GENE_OR_GENE_PRODUCT", 97, 102], ["BDCA2", "GENE_OR_GENE_PRODUCT", 126, 131], ["plasmacytoid DC", "CELL", 157, 172], ["IFN", "PROTEIN", 13, 16], ["CD123 \u00fe DC", "CELL_TYPE", 42, 52], ["human blood monocytes", "CELL_TYPE", 58, 79], ["BDCA4", "PROTEIN", 97, 102], ["BDCA2", "PROTEIN", 126, 131], ["plasmacytoid DC", "CELL_TYPE", 157, 172], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["human blood monocytes", "TEST", 58, 79], ["BDCA2", "PROBLEM", 126, 131], ["plasmacytoid DC", "TREATMENT", 157, 172]]], ["Such IFN-b-modulated DC produce large amounts of IL-6 and IL-10, but no IL-12p40 and have no enhanced IFN-b and IFN-b production.", [["DC", "ANATOMY", 21, 23], ["IFN", "CHEMICAL", 5, 8], ["IFN-b-", "GENE_OR_GENE_PRODUCT", 5, 11], ["DC", "CELL", 21, 23], ["IL-6", "GENE_OR_GENE_PRODUCT", 49, 53], ["IL-10", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 72, 80], ["IFN-b", "GENE_OR_GENE_PRODUCT", 102, 107], ["IFN-b", "GENE_OR_GENE_PRODUCT", 112, 117], ["IFN", "PROTEIN", 5, 8], ["DC", "CELL_TYPE", 21, 23], ["IL-12p40", "PROTEIN", 72, 80], ["IFN", "PROTEIN", 102, 105], ["IFN", "PROTEIN", 112, 115], ["IL", "TEST", 49, 51], ["IL", "TEST", 58, 60], ["IL", "TEST", 72, 74], ["enhanced IFN", "PROBLEM", 93, 105], ["IFN", "PROBLEM", 112, 115], ["large", "OBSERVATION_MODIFIER", 32, 37], ["amounts", "OBSERVATION_MODIFIER", 38, 45], ["no", "UNCERTAINTY", 90, 92]]], ["The findings indicate that IFN-bmodulated DC represent a myeloid DC subset with diminished CD11c, BDCA-1 and CD1a expression, having potent Th2-promoting function but lacking antiviral capacity.", [["DC", "ANATOMY", 42, 44], ["myeloid DC", "ANATOMY", 57, 67], ["IFN", "GENE_OR_GENE_PRODUCT", 27, 30], ["DC", "CELL", 42, 44], ["myeloid DC", "CELL", 57, 67], ["CD11c", "GENE_OR_GENE_PRODUCT", 91, 96], ["BDCA-1", "GENE_OR_GENE_PRODUCT", 98, 104], ["CD1a", "GENE_OR_GENE_PRODUCT", 109, 113], ["IFN", "PROTEIN", 27, 30], ["bmodulated DC", "CELL_TYPE", 31, 44], ["myeloid DC subset", "CELL_TYPE", 57, 74], ["CD11c", "PROTEIN", 91, 96], ["BDCA", "PROTEIN", 98, 102], ["CD1a", "PROTEIN", 109, 113], ["IFN", "PROBLEM", 27, 30], ["diminished CD11c", "PROBLEM", 80, 96], ["BDCA", "TEST", 98, 102], ["lacking antiviral capacity", "PROBLEM", 167, 193], ["myeloid", "OBSERVATION", 57, 64], ["diminished", "OBSERVATION_MODIFIER", 80, 90], ["CD11c", "OBSERVATION", 91, 96], ["antiviral capacity", "OBSERVATION", 175, 193]]], ["The association of psoriasis with throat infections by streptococcus pyogenes suggests a potential antigenic target for the T cells that are known to infiltrate dermis and epidermis of psoriatic skin.", [["throat", "ANATOMY", 34, 40], ["T cells", "ANATOMY", 124, 131], ["infiltrate dermis", "ANATOMY", 150, 167], ["epidermis", "ANATOMY", 172, 181], ["psoriatic skin", "ANATOMY", 185, 199], ["psoriasis", "DISEASE", 19, 28], ["throat infections", "DISEASE", 34, 51], ["streptococcus pyogenes", "DISEASE", 55, 77], ["throat", "ORGANISM_SUBDIVISION", 34, 40], ["streptococcus pyogenes", "ORGANISM", 55, 77], ["T cells", "CELL", 124, 131], ["dermis", "TISSUE", 161, 167], ["epidermis", "TISSUE", 172, 181], ["skin", "ORGAN", 195, 199], ["T cells", "CELL_TYPE", 124, 131], ["streptococcus pyogenes", "SPECIES", 55, 77], ["streptococcus pyogenes", "SPECIES", 55, 77], ["psoriasis", "PROBLEM", 19, 28], ["throat infections", "PROBLEM", 34, 51], ["streptococcus pyogenes", "PROBLEM", 55, 77], ["the T cells", "PROBLEM", 120, 131], ["infiltrate dermis", "PROBLEM", 150, 167], ["epidermis of psoriatic skin", "PROBLEM", 172, 199], ["psoriasis", "OBSERVATION", 19, 28], ["throat", "ANATOMY", 34, 40], ["infections", "OBSERVATION", 41, 51], ["streptococcus pyogenes", "OBSERVATION", 55, 77], ["known to", "UNCERTAINTY", 141, 149], ["infiltrate", "OBSERVATION", 150, 160], ["epidermis", "OBSERVATION_MODIFIER", 172, 181], ["psoriatic", "OBSERVATION_MODIFIER", 185, 194], ["skin", "ANATOMY", 195, 199]]], ["Streptococcal M protein shares an extensive sequence homology with human epidermal keratins.", [["epidermal keratins", "ANATOMY", 73, 91], ["Streptococcal M protein", "GENE_OR_GENE_PRODUCT", 0, 23], ["human", "ORGANISM", 67, 72], ["epidermal keratins", "GENE_OR_GENE_PRODUCT", 73, 91], ["Streptococcal M protein", "PROTEIN", 0, 23], ["human epidermal keratins", "PROTEIN", 67, 91], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["Streptococcal M protein", "TEST", 0, 23], ["human epidermal keratins", "TREATMENT", 67, 91], ["epidermal keratins", "OBSERVATION", 73, 91]]], ["Keratins 16 (K16) and 17 (K17) are mostly absent from uninvolved skin but are upregulated in psoriatic lesions.", [["skin", "ANATOMY", 65, 69], ["psoriatic lesions", "ANATOMY", 93, 110], ["psoriatic lesions", "DISEASE", 93, 110], ["Keratins 16", "GENE_OR_GENE_PRODUCT", 0, 11], ["K16", "GENE_OR_GENE_PRODUCT", 13, 16], ["17", "GENE_OR_GENE_PRODUCT", 22, 24], ["K17", "GENE_OR_GENE_PRODUCT", 26, 29], ["skin", "ORGAN", 65, 69], ["psoriatic lesions", "PATHOLOGICAL_FORMATION", 93, 110], ["K16", "PROTEIN", 13, 16], ["K17", "PROTEIN", 26, 29], ["Keratins", "TEST", 0, 8], ["psoriatic lesions", "PROBLEM", 93, 110], ["skin", "ANATOMY", 65, 69], ["upregulated", "OBSERVATION_MODIFIER", 78, 89], ["psoriatic", "OBSERVATION_MODIFIER", 93, 102], ["lesions", "OBSERVATION", 103, 110]]], ["There is increasing evidence that CD8 \u00fe T cells play an important effector role in psoriasis and M proteinprimed T cells may recognize these shared epitopes in skin via molecular mimicry.", [["CD8 \u00fe T cells", "ANATOMY", 34, 47], ["T cells", "ANATOMY", 113, 120], ["skin", "ANATOMY", 160, 164], ["psoriasis", "DISEASE", 83, 92], ["CD8", "GENE_OR_GENE_PRODUCT", 34, 37], ["T cells", "CELL", 40, 47], ["M proteinprimed T cells", "CELL", 97, 120], ["skin", "ORGAN", 160, 164], ["CD8 \u00fe T cells", "CELL_TYPE", 34, 47], ["T cells", "CELL_TYPE", 113, 120], ["CD8 \u00fe T cells", "PROBLEM", 34, 47], ["psoriasis", "PROBLEM", 83, 92], ["M proteinprimed T cells", "TREATMENT", 97, 120], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["skin", "ANATOMY", 160, 164], ["molecular mimicry", "OBSERVATION", 169, 186]]], ["To identify candidate epitopes, peptides with sequences from K17 were selected on the basis of predicted binding to HLA-Cw6 and sequence similarities with M6 protein.", [["K17", "GENE_OR_GENE_PRODUCT", 61, 64], ["HLA-Cw6", "GENE_OR_GENE_PRODUCT", 116, 123], ["K17", "DNA", 61, 64], ["Cw6", "DNA", 120, 123], ["M6 protein", "PROTEIN", 155, 165], ["sequences from K17", "TEST", 46, 64], ["HLA", "TEST", 116, 119]]], ["Matched peptides from the sequence of M6 protein and a set of peptides with poor predicted binding were also selected.", [["M6 protein", "PROTEIN", 38, 48], ["Matched peptides", "PROBLEM", 0, 16], ["M6 protein", "TEST", 38, 48], ["poor predicted binding", "PROBLEM", 76, 98]]], ["Cw6 \u00fe individuals with psoriasis and Cw6 \u00fe healthy controls, having a family history of psoriasis, were recruited.", [["psoriasis", "DISEASE", 23, 32], ["psoriasis", "DISEASE", 88, 97], ["Cw6", "GENE_OR_GENE_PRODUCT", 0, 3], ["psoriasis", "PROBLEM", 23, 32], ["psoriasis", "PROBLEM", 88, 97], ["psoriasis", "OBSERVATION", 23, 32], ["psoriasis", "OBSERVATION", 88, 97]]], ["PBMCs were incubated with the peptide antigens.", [["PBMCs", "ANATOMY", 0, 5], ["PBMCs", "CELL", 0, 5], ["PBMCs", "CELL_TYPE", 0, 5], ["PBMCs", "TREATMENT", 0, 5], ["the peptide antigens", "TEST", 26, 46]]], ["T-cell activation in the CD4 \u00fe , CD8 \u00fe and later the skin-homing cutaneous lymphocyteassociated antigen (CLA)-expressing subset of CD8 \u00fe T cells was evaluated by CD69 expression and intracellular IFN-g accumulation using flow cytometry.", [["T-cell", "ANATOMY", 0, 6], ["CD4 \u00fe", "ANATOMY", 25, 30], ["CD8 \u00fe", "ANATOMY", 33, 38], ["skin", "ANATOMY", 53, 57], ["CD8 \u00fe T cells", "ANATOMY", 131, 144], ["intracellular", "ANATOMY", 182, 195], ["T-cell", "CELL", 0, 6], ["CD4", "GENE_OR_GENE_PRODUCT", 25, 28], ["CD8", "GENE_OR_GENE_PRODUCT", 33, 36], ["skin", "ORGAN", 53, 57], ["cutaneous lymphocyteassociated antigen", "GENE_OR_GENE_PRODUCT", 65, 103], ["CLA", "GENE_OR_GENE_PRODUCT", 105, 108], ["CD8", "GENE_OR_GENE_PRODUCT", 131, 134], ["CD69", "GENE_OR_GENE_PRODUCT", 162, 166], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 182, 195], ["IFN-g", "GENE_OR_GENE_PRODUCT", 196, 201], ["CD4", "PROTEIN", 25, 28], ["CD8", "PROTEIN", 33, 36], ["skin-homing cutaneous lymphocyteassociated antigen (CLA)-expressing subset of CD8 \u00fe T cells", "CELL_TYPE", 53, 144], ["CD69", "PROTEIN", 162, 166], ["IFN", "PROTEIN", 196, 199], ["T-cell activation", "TEST", 0, 17], ["the CD4", "TEST", 21, 28], ["CD8", "TEST", 33, 36], ["homing cutaneous lymphocyteassociated antigen", "PROBLEM", 58, 103], ["T cells", "PROBLEM", 137, 144], ["CD69 expression", "TEST", 162, 177], ["intracellular IFN", "TEST", 182, 199], ["flow cytometry", "TEST", 221, 235], ["cell activation", "OBSERVATION", 2, 17], ["CD4", "ANATOMY", 25, 28], ["skin", "ANATOMY", 53, 57], ["homing", "ANATOMY_MODIFIER", 58, 64], ["cutaneous", "ANATOMY", 65, 74], ["flow cytometry", "OBSERVATION", 221, 235]]], ["We demonstrate that Cw6 \u00fe psoriasis patients had significant CD8 \u00fe T-cell IFN-g responses to peptides from K17 and M6 protein selected on the basis of sequence homology and predicted HLA-Cw1501 and HLA-B1501 and HLA-B0204 was measured by a radioimmunoassay (RIA).", [["CD8 \u00fe T-cell", "ANATOMY", 61, 73], ["psoriasis", "DISEASE", 26, 35], ["Cw6", "GENE_OR_GENE_PRODUCT", 20, 23], ["patients", "ORGANISM", 36, 44], ["CD8", "GENE_OR_GENE_PRODUCT", 61, 64], ["K17", "GENE_OR_GENE_PRODUCT", 107, 110], ["HLA-B1501", "GENE_OR_GENE_PRODUCT", 198, 207], ["HLA-B0204", "GENE_OR_GENE_PRODUCT", 212, 221], ["CD8", "PROTEIN", 61, 64], ["IFN", "PROTEIN", 74, 77], ["M6 protein", "PROTEIN", 115, 125], ["HLA-Cw1501", "DNA", 183, 193], ["HLA-B1501 and HLA-B0204", "DNA", 198, 221], ["patients", "SPECIES", 36, 44], ["Cw6 \u00fe psoriasis", "PROBLEM", 20, 35], ["IFN", "TEST", 74, 77], ["peptides", "TEST", 93, 101], ["K17", "TEST", 107, 110], ["M6 protein", "TEST", 115, 125], ["sequence homology", "TEST", 151, 168], ["HLA", "TEST", 183, 186], ["HLA", "TEST", 198, 201], ["HLA", "TEST", 212, 215], ["a radioimmunoassay (RIA", "TEST", 238, 261]]], ["This data was used to develop multiple first generation ANNs, which formed a virtual committee.", [["multiple first generation ANNs", "PROBLEM", 30, 60]]], ["This committee was used to screen (or 'queried') for peptides, where the ANNs agreed ('low-QBC'), or disagreed ('high-QBC'), on their HLA-binding potential.", [["peptides", "PROBLEM", 53, 61]]], ["Seventeen low-QBC peptides and 17 high-QBC peptides were synthesized and tested.", [["QBC peptides", "TEST", 14, 26]]], ["The high-or low-QBC data were added to the original data, and new high-or low-QBC second generation ANNs were developed, respectively.", [["the original data", "TEST", 39, 56], ["new high-or low-QBC second generation ANNs", "PROBLEM", 62, 104], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["This procedure was repeated 40 times.Results:The high-QBC-enriched ANN performed significantly better than the low-QBC-enriched ANN in 37 of the 40 tests.", [["QBC", "DNA", 115, 118], ["This procedure", "TREATMENT", 0, 14], ["the 40 tests", "TEST", 141, 153]]], ["Conclusion: These results demonstrate that high-QBCenriched networks perform better than low-QBC-enriched networks in selecting informative data for developing peptide-MHC-binding predictors.", [["QBC", "PROTEIN", 93, 96], ["MHC", "PROTEIN", 168, 171], ["high-QBCenriched networks", "PROBLEM", 43, 68]]], ["This improvement in selecting data is not due to differences in network training performance but due to the difference in information content in the high-QBC experiment and in the low-QBC experiment.", [["selecting data", "TEST", 20, 34], ["the difference in information content", "PROBLEM", 104, 141]]], ["Finally, it should be noted that this strategy could be used in many contexts where generation of data is difficult and costly.", [["this strategy", "TREATMENT", 33, 46]]], ["Interleukin-18 (IL-18), a pro-inflammatory cytokine that is produced by both lymphoid and nonlymphoid cells, has a critical role in modulation of innate and adaptive immunity.", [["lymphoid", "ANATOMY", 77, 85], ["nonlymphoid cells", "ANATOMY", 90, 107], ["Interleukin-18", "GENE_OR_GENE_PRODUCT", 0, 14], ["IL-18", "GENE_OR_GENE_PRODUCT", 16, 21], ["lymphoid", "CELL", 77, 85], ["nonlymphoid cells", "CELL", 90, 107], ["Interleukin-18 (IL-18", "PROTEIN", 0, 21], ["pro-inflammatory cytokine", "PROTEIN", 26, 51], ["lymphoid and nonlymphoid cells", "CELL_TYPE", 77, 107], ["Interleukin", "TEST", 0, 11], ["IL", "TEST", 16, 18], ["a pro-inflammatory cytokine", "TEST", 24, 51], ["innate and adaptive immunity", "TREATMENT", 146, 174], ["both lymphoid", "OBSERVATION", 72, 85], ["nonlymphoid cells", "OBSERVATION", 90, 107]]], ["Its primary function in stimulation of IFN-g production and stimulation of NK-cell-cytotoxic activities makes this cytokine a candidate for cancer immunotherapy.", [["NK", "ANATOMY", 75, 77], ["cell", "ANATOMY", 78, 82], ["cancer", "ANATOMY", 140, 146], ["cancer", "DISEASE", 140, 146], ["IFN-g", "GENE_OR_GENE_PRODUCT", 39, 44], ["NK-cell", "CELL", 75, 82], ["cancer", "CANCER", 140, 146], ["IFN", "PROTEIN", 39, 42], ["cytokine", "PROTEIN", 115, 123], ["IFN-g production", "TREATMENT", 39, 55], ["NK", "TEST", 75, 77], ["cytotoxic activities", "PROBLEM", 83, 103], ["cancer immunotherapy", "TREATMENT", 140, 160]]], ["In oral cavity, this cytokine is produced by oral epithelia and carcinoma cells and is related to tumour regression in nude mice bearing salivary adenocarcinoma.", [["oral cavity", "ANATOMY", 3, 14], ["oral epithelia", "ANATOMY", 45, 59], ["carcinoma cells", "ANATOMY", 64, 79], ["tumour", "ANATOMY", 98, 104], ["salivary adenocarcinoma", "ANATOMY", 137, 160], ["carcinoma", "DISEASE", 64, 73], ["tumour", "DISEASE", 98, 104], ["salivary adenocarcinoma", "DISEASE", 137, 160], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 3, 14], ["oral epithelia", "CELL", 45, 59], ["carcinoma cells", "CELL", 64, 79], ["tumour", "CANCER", 98, 104], ["nude mice", "ORGANISM", 119, 128], ["salivary adenocarcinoma", "CANCER", 137, 160], ["cytokine", "PROTEIN", 21, 29], ["carcinoma cells", "CELL_TYPE", 64, 79], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 124, 128], ["oral epithelia", "PROBLEM", 45, 59], ["carcinoma cells", "PROBLEM", 64, 79], ["tumour regression in nude mice bearing salivary adenocarcinoma", "PROBLEM", 98, 160], ["oral cavity", "ANATOMY", 3, 14], ["carcinoma cells", "OBSERVATION", 64, 79], ["related to", "UNCERTAINTY", 87, 97], ["tumour regression", "OBSERVATION", 98, 115], ["salivary adenocarcinoma", "OBSERVATION", 137, 160]]], ["However, direct effects of this cytokine on oral cancer cells have not been elucidated.", [["oral cancer cells", "ANATOMY", 44, 61], ["oral cancer", "DISEASE", 44, 55], ["oral cancer cells", "CELL", 44, 61], ["cytokine", "PROTEIN", 32, 40], ["oral cancer cells", "CELL_TYPE", 44, 61], ["this cytokine", "TREATMENT", 27, 40], ["oral cancer cells", "PROBLEM", 44, 61]]], ["In this project, we investigated IL-18 effect on an oral carcinoma (KB) cell line.", [["oral carcinoma (KB) cell line", "ANATOMY", 52, 81], ["oral carcinoma", "DISEASE", 52, 66], ["IL-18", "GENE_OR_GENE_PRODUCT", 33, 38], ["oral carcinoma (KB) cell line", "CELL", 52, 81], ["IL-18", "PROTEIN", 33, 38], ["oral carcinoma (KB) cell line", "CELL_LINE", 52, 81], ["IL", "TEST", 33, 35], ["an oral carcinoma", "PROBLEM", 49, 66], ["cell line", "TREATMENT", 72, 81], ["oral", "ANATOMY", 52, 56], ["carcinoma", "OBSERVATION", 57, 66], ["cell line", "OBSERVATION", 72, 81]]], ["With RT-PCR technique, KB-cell line was found to express IL-18 receptors (IL-18Ra and IL-18Rb), indicating that this oral carcinoma line is a target for IL-18 study.", [["KB-cell line", "ANATOMY", 23, 35], ["oral carcinoma line", "ANATOMY", 117, 136], ["oral carcinoma", "DISEASE", 117, 131], ["KB-cell line", "CELL", 23, 35], ["IL-18 receptors", "GENE_OR_GENE_PRODUCT", 57, 72], ["IL-18Ra", "GENE_OR_GENE_PRODUCT", 74, 81], ["IL-18Rb", "GENE_OR_GENE_PRODUCT", 86, 93], ["oral carcinoma line", "CELL", 117, 136], ["IL-18", "GENE_OR_GENE_PRODUCT", 153, 158], ["KB-cell line", "CELL_LINE", 23, 35], ["IL-18 receptors", "PROTEIN", 57, 72], ["IL", "PROTEIN", 74, 76], ["18Ra", "PROTEIN", 77, 81], ["IL", "PROTEIN", 86, 88], ["18Rb", "PROTEIN", 89, 93], ["oral carcinoma line", "CELL_LINE", 117, 136], ["IL", "PROTEIN", 153, 155], ["RT-PCR technique", "TREATMENT", 5, 21], ["KB-cell line", "TREATMENT", 23, 35], ["IL", "TEST", 57, 59], ["IL", "TEST", 74, 76], ["IL", "TREATMENT", 86, 88], ["this oral carcinoma line", "PROBLEM", 112, 136], ["IL-18 study", "TEST", 153, 164], ["cell line", "OBSERVATION", 26, 35], ["carcinoma", "OBSERVATION", 122, 131]]], ["We showed that recombinant human IL-18 inhibited KB-cell proliferation by 17% at concentration of 100 ng/ml (P < 0.05), whereas LDH release by these cells in treatment group and control groups was comparable, indicating that IL-18 suppression of cell proliferation was not mediated by the induction of cell death.", [["KB-cell", "ANATOMY", 49, 56], ["cells", "ANATOMY", 149, 154], ["cell", "ANATOMY", 246, 250], ["cell", "ANATOMY", 302, 306], ["death", "DISEASE", 307, 312], ["human", "ORGANISM", 27, 32], ["IL-18", "GENE_OR_GENE_PRODUCT", 33, 38], ["KB-cell", "CELL", 49, 56], ["LDH", "SIMPLE_CHEMICAL", 128, 131], ["cells", "CELL", 149, 154], ["IL-18", "GENE_OR_GENE_PRODUCT", 225, 230], ["cell", "CELL", 246, 250], ["cell", "CELL", 302, 306], ["recombinant human IL-18", "PROTEIN", 15, 38], ["KB-cell", "CELL_LINE", 49, 56], ["LDH", "PROTEIN", 128, 131], ["IL-18", "PROTEIN", 225, 230], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["recombinant human IL", "TEST", 15, 35], ["KB", "TEST", 49, 51], ["cell proliferation", "TEST", 52, 70], ["LDH release", "TEST", 128, 139], ["treatment group and control groups", "TREATMENT", 158, 192], ["IL", "TEST", 225, 227], ["cell proliferation", "PROBLEM", 246, 264], ["cell death", "PROBLEM", 302, 312], ["cell proliferation", "OBSERVATION", 52, 70], ["cell proliferation", "OBSERVATION", 246, 264]]], ["To further address this hypothesis, we found that IL-18 treatment did not induce apoptotic cell death, as studied by DNA laddering and TUNEL assays.", [["cell", "ANATOMY", 91, 95], ["IL-18", "GENE_OR_GENE_PRODUCT", 50, 55], ["cell", "CELL", 91, 95], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["IL", "PROTEIN", 50, 52], ["IL-18 treatment", "TREATMENT", 50, 65], ["apoptotic cell death", "PROBLEM", 81, 101], ["TUNEL assays", "TEST", 135, 147], ["apoptotic cell death", "OBSERVATION", 81, 101]]], ["In addition, expression pattern of cell death-controlling genes (bcl-2 and bax) was not altered by this cytokine.", [["cell", "ANATOMY", 35, 39], ["cell", "CELL", 35, 39], ["bcl-2", "GENE_OR_GENE_PRODUCT", 65, 70], ["bax", "GENE_OR_GENE_PRODUCT", 75, 78], ["bcl", "DNA", 65, 68], ["bax", "DNA", 75, 78], ["cytokine", "PROTEIN", 104, 112], ["cell death", "PROBLEM", 35, 45], ["bcl", "TEST", 65, 68], ["cell death", "OBSERVATION", 35, 45]]], ["Findings in these studies indicated that suppression of KB-cell proliferation may be attributed to control of cell cycle, growth arrest or induction of cell differentiation.", [["KB-cell", "ANATOMY", 56, 63], ["cell", "ANATOMY", 110, 114], ["cell", "ANATOMY", 152, 156], ["KB-cell", "CELL", 56, 63], ["cell", "CELL", 110, 114], ["cell", "CELL", 152, 156], ["these studies", "TEST", 12, 25], ["KB-cell proliferation", "PROBLEM", 56, 77], ["cell cycle", "PROBLEM", 110, 120], ["growth arrest", "PROBLEM", 122, 135], ["cell differentiation", "PROBLEM", 152, 172], ["cell proliferation", "OBSERVATION", 59, 77], ["cell cycle", "OBSERVATION", 110, 120], ["cell differentiation", "OBSERVATION", 152, 172]]], ["The data presented in this project could provide an insight of how cancer cell directly responds to IL-18, as this cytokine is an important regulator of anticancer mechanisms.Results:Aloe emodin (AE) is a naturally occurring compound with wide spectrum of biological properties, including antimicrobial, vasorelaxant, immunosuppressive and anticancer actions.", [["cancer cell", "ANATOMY", 67, 78], ["anticancer", "ANATOMY", 153, 163], ["anticancer", "ANATOMY", 340, 350], ["cancer", "DISEASE", 67, 73], ["Aloe emodin", "CHEMICAL", 183, 194], ["AE", "CHEMICAL", 196, 198], ["emodin", "CHEMICAL", 188, 194], ["cancer cell", "CELL", 67, 78], ["IL-18", "GENE_OR_GENE_PRODUCT", 100, 105], ["anticancer", "CANCER", 153, 163], ["Aloe emodin", "SIMPLE_CHEMICAL", 183, 194], ["AE", "SIMPLE_CHEMICAL", 196, 198], ["anticancer", "CANCER", 340, 350], ["cancer cell", "CELL_TYPE", 67, 78], ["IL-18", "PROTEIN", 100, 105], ["cytokine", "PROTEIN", 115, 123], ["how cancer cell", "PROBLEM", 63, 78], ["Aloe emodin", "TREATMENT", 183, 194], ["antimicrobial", "TREATMENT", 289, 302], ["vasorelaxant", "TREATMENT", 304, 316], ["immunosuppressive", "TREATMENT", 318, 335], ["anticancer actions", "TREATMENT", 340, 358], ["Aloe emodin", "OBSERVATION_MODIFIER", 183, 194]]], ["This anthraquinone induces apoptosis in several tumour cell lines with special affinity to tumours of neuroectodermal origin.", [["tumour cell lines", "ANATOMY", 48, 65], ["tumours", "ANATOMY", 91, 98], ["neuroectodermal", "ANATOMY", 102, 117], ["anthraquinone", "CHEMICAL", 5, 18], ["tumour", "DISEASE", 48, 54], ["anthraquinone", "CHEMICAL", 5, 18], ["anthraquinone", "SIMPLE_CHEMICAL", 5, 18], ["tumour cell lines", "CELL", 48, 65], ["tumours", "CANCER", 91, 98], ["neuroectodermal", "CANCER", 102, 117], ["tumour cell lines", "CELL_LINE", 48, 65], ["This anthraquinone", "TREATMENT", 0, 18], ["apoptosis", "PROBLEM", 27, 36], ["several tumour cell lines", "TREATMENT", 40, 65], ["apoptosis", "OBSERVATION_MODIFIER", 27, 36], ["several", "OBSERVATION_MODIFIER", 40, 47], ["tumour cell lines", "OBSERVATION", 48, 65], ["neuroectodermal origin", "OBSERVATION", 102, 124]]], ["High amounts of nitric oxide (NO) released by activated macrophages induce tumour cell death.", [["macrophages", "ANATOMY", 56, 67], ["tumour cell", "ANATOMY", 75, 86], ["nitric oxide", "CHEMICAL", 16, 28], ["NO", "CHEMICAL", 30, 32], ["tumour", "DISEASE", 75, 81], ["death", "DISEASE", 87, 92], ["nitric oxide", "CHEMICAL", 16, 28], ["NO", "CHEMICAL", 30, 32], ["nitric oxide", "SIMPLE_CHEMICAL", 16, 28], ["NO", "SIMPLE_CHEMICAL", 30, 32], ["macrophages", "CELL", 56, 67], ["tumour cell", "CELL", 75, 86], ["activated macrophages", "CELL_TYPE", 46, 67], ["nitric oxide", "TREATMENT", 16, 28], ["tumour cell death", "PROBLEM", 75, 92], ["tumour cell death", "OBSERVATION", 75, 92]]], ["Therefore, we explored the capacity of AE to modulate NO-mediated antitumour response in vitro.", [["NO", "CHEMICAL", 54, 56], ["NO", "CHEMICAL", 54, 56], ["AE", "SIMPLE_CHEMICAL", 39, 41], ["NO", "SIMPLE_CHEMICAL", 54, 56], ["antitumour", "CANCER", 66, 76]]], ["Interestingly, while AE markedly suppressed NO release from macrophages alone, it significantly potentiated NO production in cocultures of macrophages and C6 cells, after 48 h of cultivation.", [["macrophages", "ANATOMY", 60, 71], ["macrophages", "ANATOMY", 139, 150], ["C6 cells", "ANATOMY", 155, 163], ["NO", "CHEMICAL", 44, 46], ["NO", "CHEMICAL", 108, 110], ["NO", "CHEMICAL", 44, 46], ["NO", "CHEMICAL", 108, 110], ["AE", "SIMPLE_CHEMICAL", 21, 23], ["NO", "SIMPLE_CHEMICAL", 44, 46], ["macrophages", "CELL", 60, 71], ["NO", "SIMPLE_CHEMICAL", 108, 110], ["macrophages", "CELL", 139, 150], ["C6 cells", "CELL", 155, 163], ["macrophages", "CELL_TYPE", 60, 71], ["macrophages", "CELL_TYPE", 139, 150], ["C6 cells", "CELL_LINE", 155, 163], ["macrophages", "PROBLEM", 139, 150], ["C6 cells", "PROBLEM", 155, 163], ["cultivation", "TREATMENT", 179, 190], ["macrophages", "OBSERVATION", 60, 71]]], ["Accordingly, the viability of C6 cells cocultivated with macrophages was reduced in the presence of AE.", [["C6 cells", "ANATOMY", 30, 38], ["macrophages", "ANATOMY", 57, 68], ["C6 cells", "CELL", 30, 38], ["macrophages", "CELL", 57, 68], ["C6 cells", "CELL_LINE", 30, 38], ["macrophages", "CELL_TYPE", 57, 68], ["the viability of C6 cells", "TEST", 13, 38], ["macrophages", "PROBLEM", 57, 68], ["C6 cells", "OBSERVATION", 30, 38], ["macrophages", "OBSERVATION", 57, 68]]], ["Moreover, the observed AE-imposed potentiation of NO production in macrophages was closely related to macrophage culture cell density.", [["macrophages", "ANATOMY", 67, 78], ["macrophage culture cell", "ANATOMY", 102, 125], ["NO", "CHEMICAL", 50, 52], ["NO", "CHEMICAL", 50, 52], ["NO", "SIMPLE_CHEMICAL", 50, 52], ["macrophages", "CELL", 67, 78], ["macrophage culture cell", "CELL", 102, 125], ["macrophages", "CELL_TYPE", 67, 78], ["production in macrophages", "PROBLEM", 53, 78], ["macrophage culture cell density", "TEST", 102, 133], ["NO", "UNCERTAINTY", 50, 52], ["production", "OBSERVATION_MODIFIER", 53, 63], ["cell density", "OBSERVATION", 121, 133]]], ["According to these data, we proposed that NO modulator capacity of AE strongly depended on intercellular contact, indicating that macrophage antitumour response was not compromised but even potentiated by AE.Results:Immunotherapy represents an attractive fourth-modality therapeutic approach, especially in the light of the shortcomings of conventional surgery, radiation and chemotherapies in the management of metastatic cancer.", [["intercellular", "ANATOMY", 91, 104], ["macrophage", "ANATOMY", 130, 140], ["metastatic cancer", "ANATOMY", 412, 429], ["NO", "CHEMICAL", 42, 44], ["cancer", "DISEASE", 423, 429], ["NO", "CHEMICAL", 42, 44], ["NO", "SIMPLE_CHEMICAL", 42, 44], ["AE", "SIMPLE_CHEMICAL", 67, 69], ["macrophage", "CELL", 130, 140], ["metastatic cancer", "CANCER", 412, 429], ["Immunotherapy", "TREATMENT", 216, 229], ["an attractive fourth-modality therapeutic approach", "TREATMENT", 241, 291], ["conventional surgery", "TREATMENT", 340, 360], ["radiation", "TREATMENT", 362, 371], ["chemotherapies", "TREATMENT", 376, 390], ["the management", "TREATMENT", 394, 408], ["metastatic cancer", "PROBLEM", 412, 429], ["metastatic", "OBSERVATION_MODIFIER", 412, 422], ["cancer", "OBSERVATION", 423, 429]]], ["To this end, a large number of peptide antigens derived from TAA have been applied in immunotherapeutic trials for the treatment of various malignancies, e.g. cancers of the breast, prostate and kidney, in addition to haematological cancers.", [["malignancies", "ANATOMY", 140, 152], ["cancers", "ANATOMY", 159, 166], ["breast", "ANATOMY", 174, 180], ["prostate", "ANATOMY", 182, 190], ["kidney", "ANATOMY", 195, 201], ["haematological cancers", "ANATOMY", 218, 240], ["TAA", "DISEASE", 61, 64], ["malignancies", "DISEASE", 140, 152], ["cancers of the breast, prostate and kidney", "DISEASE", 159, 201], ["haematological cancers", "DISEASE", 218, 240], ["TAA", "SIMPLE_CHEMICAL", 61, 64], ["malignancies", "CANCER", 140, 152], ["cancers", "CANCER", 159, 166], ["breast", "CANCER", 174, 180], ["prostate", "CANCER", 182, 190], ["kidney", "ORGAN", 195, 201], ["haematological cancers", "CANCER", 218, 240], ["peptide antigens", "PROTEIN", 31, 47], ["peptide antigens", "TREATMENT", 31, 47], ["TAA", "TREATMENT", 61, 64], ["immunotherapeutic trials", "TREATMENT", 86, 110], ["the treatment", "TREATMENT", 115, 128], ["various malignancies", "PROBLEM", 132, 152], ["e.g. cancers of the breast, prostate and kidney", "PROBLEM", 154, 201], ["haematological cancers", "PROBLEM", 218, 240], ["large", "OBSERVATION_MODIFIER", 15, 20], ["various", "OBSERVATION_MODIFIER", 132, 139], ["malignancies", "OBSERVATION", 140, 152], ["breast", "ANATOMY", 174, 180], ["prostate", "ANATOMY", 182, 190], ["kidney", "ANATOMY", 195, 201], ["haematological", "ANATOMY", 218, 232], ["cancers", "OBSERVATION", 233, 240]]], ["In some cases the response rates have been impressive and no adverse autoimmunity have been observed.", [["autoimmunity", "DISEASE", 69, 81], ["adverse autoimmunity", "PROBLEM", 61, 81], ["no", "UNCERTAINTY", 58, 60]]], ["A major strategic difficulty associated with these trials relates to the choice of best-suited peptide antigens.", [["A major strategic difficulty", "PROBLEM", 0, 28]]], ["The vast majority of the antigens described thus far is not vital for survival and growth of the tumour cells, and immunoselection of antigen-loss variants may therefore prove to be an additional obstacle for the clinical applicability of most of the known peptide epitopes.", [["tumour cells", "ANATOMY", 97, 109], ["tumour", "DISEASE", 97, 103], ["tumour cells", "CELL", 97, 109], ["antigen", "GENE_OR_GENE_PRODUCT", 134, 141], ["antigens", "PROTEIN", 25, 33], ["tumour cells", "CELL_TYPE", 97, 109], ["the tumour cells", "PROBLEM", 93, 109], ["antigen-loss variants", "PROBLEM", 134, 155], ["the known peptide epitopes", "PROBLEM", 247, 273], ["tumour cells", "OBSERVATION", 97, 109]]], ["In this respect, the development of acquired antigen loss during immunotherapy has been demonstrated in several cases.", [["antigen loss", "DISEASE", 45, 57], ["antigen", "GENE_OR_GENE_PRODUCT", 45, 52], ["acquired antigen loss", "PROBLEM", 36, 57], ["immunotherapy", "TREATMENT", 65, 78], ["antigen loss", "OBSERVATION", 45, 57]]], ["Obviously, the development of loss-variant tumour cells implies that these cells acquire a pronounced growth advantage and are left unaffected by further treatment.", [["loss-variant tumour cells", "ANATOMY", 30, 55], ["cells", "ANATOMY", 75, 80], ["tumour", "DISEASE", 43, 49], ["tumour cells", "CELL", 43, 55], ["cells", "CELL", 75, 80], ["loss-variant tumour cells", "CELL_TYPE", 30, 55], ["loss-variant tumour cells", "PROBLEM", 30, 55], ["these cells", "PROBLEM", 69, 80], ["a pronounced growth advantage", "PROBLEM", 89, 118], ["further treatment", "TREATMENT", 146, 163], ["loss", "OBSERVATION", 30, 34], ["variant", "OBSERVATION_MODIFIER", 35, 42], ["tumour cells", "OBSERVATION", 43, 55], ["pronounced", "OBSERVATION_MODIFIER", 91, 101], ["growth", "OBSERVATION_MODIFIER", 102, 108], ["left", "ANATOMY_MODIFIER", 127, 131]]], ["Ideally, target antigens should be derived from proteins required for survival and growth of tumour cells, as antigens with these characteristics would not be inflicted by the development of loss-variant tumour cells.", [["tumour cells", "ANATOMY", 93, 105], ["loss-variant tumour cells", "ANATOMY", 191, 216], ["tumour", "DISEASE", 93, 99], ["tumour", "DISEASE", 204, 210], ["tumour cells", "CELL", 93, 105], ["tumour cells", "CELL", 204, 216], ["tumour cells", "CELL_TYPE", 93, 105], ["loss-variant tumour cells", "CELL_TYPE", 191, 216], ["survival", "TREATMENT", 70, 78], ["tumour cells", "PROBLEM", 93, 105], ["loss-variant tumour cells", "PROBLEM", 191, 216], ["tumour cells", "OBSERVATION", 93, 105], ["tumour cells", "OBSERVATION", 204, 216]]], ["In this respect, several inhibitors of apoptosis proteins (IAPs) are universally expressed among tumours and play an important role in tumour cell escape from apoptosis.", [["tumours", "ANATOMY", 97, 104], ["tumour cell", "ANATOMY", 135, 146], ["tumour", "DISEASE", 135, 141], ["IAPs", "GENE_OR_GENE_PRODUCT", 59, 63], ["tumours", "CANCER", 97, 104], ["tumour cell", "CELL", 135, 146], ["apoptosis proteins", "PROTEIN", 39, 57], ["IAPs", "PROTEIN", 59, 63], ["apoptosis proteins", "PROBLEM", 39, 57], ["apoptosis", "PROBLEM", 159, 168], ["tumour cell escape", "OBSERVATION", 135, 153]]], ["We have characterized spontaneous T-cell reactivity against IAPderived peptides in cancer patients.", [["T-cell", "ANATOMY", 34, 40], ["cancer", "ANATOMY", 83, 89], ["cancer", "DISEASE", 83, 89], ["T-cell", "CELL", 34, 40], ["cancer", "CANCER", 83, 89], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["spontaneous T-cell reactivity", "PROBLEM", 22, 51], ["IAPderived peptides in cancer patients", "PROBLEM", 60, 98], ["spontaneous", "OBSERVATION_MODIFIER", 22, 33], ["T-cell reactivity", "OBSERVATION", 34, 51], ["cancer", "OBSERVATION", 83, 89]]], ["From the IAP survivin, we have characterized peptides restricted to the Class I molecules HLA-A1, A2, A3, A11, B7 and B35.", [["IAP", "GENE_OR_GENE_PRODUCT", 9, 12], ["survivin", "GENE_OR_GENE_PRODUCT", 13, 21], ["HLA-A1", "GENE_OR_GENE_PRODUCT", 90, 96], ["A2", "GENE_OR_GENE_PRODUCT", 98, 100], ["A3", "GENE_OR_GENE_PRODUCT", 102, 104], ["A11", "GENE_OR_GENE_PRODUCT", 106, 109], ["B7", "GENE_OR_GENE_PRODUCT", 111, 113], ["B35", "GENE_OR_GENE_PRODUCT", 118, 121], ["IAP survivin", "PROTEIN", 9, 21], ["Class I molecules", "PROTEIN", 72, 89], ["HLA", "PROTEIN", 90, 93], ["A1", "PROTEIN", 94, 96], ["A2", "PROTEIN", 98, 100], ["A3", "PROTEIN", 102, 104], ["A11", "PROTEIN", 106, 109], ["B7", "PROTEIN", 111, 113], ["B35", "PROTEIN", 118, 121], ["the IAP survivin", "TREATMENT", 5, 21], ["HLA", "TEST", 90, 93], ["A2", "TEST", 98, 100], ["A11", "TEST", 106, 109], ["A2", "ANATOMY", 98, 100], ["A3", "ANATOMY", 102, 104]]], ["Furthermore, we have demonstrated that survivin-specific T cells infiltrate metastatic lesions and that isolated survivinspecific CTLs are capable of killing HLA-matched tumour cells.", [["T cells", "ANATOMY", 57, 64], ["metastatic lesions", "ANATOMY", 76, 94], ["CTLs", "ANATOMY", 130, 134], ["tumour cells", "ANATOMY", 170, 182], ["tumour", "DISEASE", 170, 176], ["survivin", "GENE_OR_GENE_PRODUCT", 39, 47], ["T cells", "CELL", 57, 64], ["metastatic lesions", "CANCER", 76, 94], ["CTLs", "CELL", 130, 134], ["tumour cells", "CELL", 170, 182], ["survivin", "PROTEIN", 39, 47], ["T cells", "CELL_TYPE", 57, 64], ["survivinspecific CTLs", "CELL_TYPE", 113, 134], ["HLA-matched tumour cells", "CELL_TYPE", 158, 182], ["survivin-specific T cells infiltrate metastatic lesions", "PROBLEM", 39, 94], ["isolated survivinspecific CTLs", "PROBLEM", 104, 134], ["killing HLA-matched tumour cells", "PROBLEM", 150, 182], ["metastatic", "OBSERVATION_MODIFIER", 76, 86], ["tumour cells", "OBSERVATION", 170, 182]]], ["Survivin-derived peptides are now in clinical trial, and continued work in our lab has demonstrated that other IAPs are targets for spontaneous T-cell reactivity in cancer patients.", [["T-cell", "ANATOMY", 144, 150], ["cancer", "ANATOMY", 165, 171], ["cancer", "DISEASE", 165, 171], ["Survivin", "GENE_OR_GENE_PRODUCT", 0, 8], ["IAPs", "GENE_OR_GENE_PRODUCT", 111, 115], ["T-cell", "CELL", 144, 150], ["cancer", "CANCER", 165, 171], ["patients", "ORGANISM", 172, 180], ["Survivin", "PROTEIN", 0, 8], ["IAPs", "PROTEIN", 111, 115], ["patients", "SPECIES", 172, 180], ["Survivin", "TREATMENT", 0, 8], ["other IAPs", "TEST", 105, 115], ["spontaneous T-cell reactivity", "PROBLEM", 132, 161]]], ["We previously reported that in mice with large progressing T-cell lymphoma tumours, dysfunctions in the antitumour CTL activity occur, associated with an accumulation of splenic arginase-producing myeloid suppressor cells (MSCs).", [["T-cell lymphoma tumours", "ANATOMY", 59, 82], ["splenic", "ANATOMY", 170, 177], ["myeloid suppressor cells", "ANATOMY", 197, 221], ["MSCs", "ANATOMY", 223, 227], ["T-cell lymphoma tumours", "DISEASE", 59, 82], ["mice", "ORGANISM", 31, 35], ["T-cell lymphoma tumours", "CANCER", 59, 82], ["antitumour", "CANCER", 104, 114], ["arginase", "GENE_OR_GENE_PRODUCT", 178, 186], ["myeloid suppressor cells", "CELL", 197, 221], ["MSCs", "CELL", 223, 227], ["splenic arginase-producing myeloid suppressor cells", "CELL_TYPE", 170, 221], ["MSCs", "CELL_TYPE", 223, 227], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["large progressing T-cell lymphoma tumours", "PROBLEM", 41, 82], ["dysfunctions", "PROBLEM", 84, 96], ["the antitumour CTL activity", "PROBLEM", 100, 127], ["an accumulation of splenic arginase", "PROBLEM", 151, 186], ["myeloid suppressor cells", "PROBLEM", 197, 221], ["large", "OBSERVATION_MODIFIER", 41, 46], ["progressing", "OBSERVATION_MODIFIER", 47, 58], ["T-cell lymphoma tumours", "OBSERVATION", 59, 82], ["antitumour CTL activity", "OBSERVATION", 104, 127], ["accumulation", "OBSERVATION_MODIFIER", 154, 166], ["splenic", "ANATOMY", 170, 177], ["arginase", "OBSERVATION", 178, 186], ["myeloid suppressor cells", "OBSERVATION", 197, 221]]], ["In this study, we first demonstrate that both the presence and the activation state of these MSC depends on tumour evolution.", [["MSC", "ANATOMY", 93, 96], ["tumour", "ANATOMY", 108, 114], ["tumour", "DISEASE", 108, 114], ["MSC", "CELL", 93, 96], ["tumour", "CANCER", 108, 114], ["MSC", "CELL_TYPE", 93, 96], ["this study", "TEST", 3, 13], ["tumour", "OBSERVATION", 108, 114]]], ["While in tumour regressors hardly any arginase-producing MSC can be found, both the amount and the arginase activity of this population expands from early over late progressors.", [["tumour", "ANATOMY", 9, 15], ["MSC", "ANATOMY", 57, 60], ["tumour", "DISEASE", 9, 15], ["tumour", "CANCER", 9, 15], ["arginase", "GENE_OR_GENE_PRODUCT", 38, 46], ["MSC", "CELL", 57, 60], ["arginase", "GENE_OR_GENE_PRODUCT", 99, 107], ["arginase", "PROTEIN", 38, 46], ["MSC", "CELL_TYPE", 57, 60], ["arginase", "PROTEIN", 99, 107], ["any arginase", "PROBLEM", 34, 46], ["MSC", "PROBLEM", 57, 60], ["arginase activity", "OBSERVATION", 99, 116]]], ["This gradual induction of MSCs is paralleled by an increasing suppression of CTL activity and Th1, but not Th2, cytokine production.", [["MSCs", "ANATOMY", 26, 30], ["MSCs", "CELL", 26, 30], ["CTL", "GENE_OR_GENE_PRODUCT", 77, 80], ["Th1", "GENE_OR_GENE_PRODUCT", 94, 97], ["Th2", "GENE_OR_GENE_PRODUCT", 107, 110], ["MSCs", "CELL_TYPE", 26, 30], ["cytokine", "PROTEIN", 112, 120], ["This gradual induction of MSCs", "TREATMENT", 0, 30], ["MSCs", "OBSERVATION", 26, 30]]], ["Upon analysing the molecular repertoire of MSC in vitro, we found, besides arginase1, a well-established marker for alternatively activated myeloid cells or M2, a strong upregulation of FIZZ1 and Ym, two additional recently identified markers for M2.", [["MSC", "ANATOMY", 43, 46], ["myeloid cells", "ANATOMY", 140, 153], ["MSC", "CELL", 43, 46], ["arginase1", "GENE_OR_GENE_PRODUCT", 75, 84], ["myeloid cells", "CELL", 140, 153], ["M2", "CELL", 157, 159], ["FIZZ1", "GENE_OR_GENE_PRODUCT", 186, 191], ["Ym", "GENE_OR_GENE_PRODUCT", 196, 198], ["M2", "GENE_OR_GENE_PRODUCT", 247, 249], ["MSC", "CELL_TYPE", 43, 46], ["arginase1", "PROTEIN", 75, 84], ["myeloid cells", "CELL_TYPE", 140, 153], ["M2", "PROTEIN", 157, 159], ["FIZZ1", "PROTEIN", 186, 191], ["Ym", "PROTEIN", 196, 198], ["M2", "PROTEIN", 247, 249], ["activated myeloid cells", "PROBLEM", 130, 153], ["myeloid cells", "OBSERVATION", 140, 153]]], ["Further evaluation of molecular markers by microarray analysis in MSC yielded genes involved in wound healing (e.g. coagulation factor XIIIa), anti-inflammation (e.g. selenoprotein P), immunomodulation (e.g. PD-L2) and fat and sugar metabolism (e.g. leptin receptor).", [["MSC", "ANATOMY", 66, 69], ["wound", "ANATOMY", 96, 101], ["fat", "ANATOMY", 219, 222], ["sugar", "CHEMICAL", 227, 232], ["MSC", "CELL", 66, 69], ["wound", "PATHOLOGICAL_FORMATION", 96, 101], ["coagulation factor XIIIa", "GENE_OR_GENE_PRODUCT", 116, 140], ["selenoprotein P", "GENE_OR_GENE_PRODUCT", 167, 182], ["PD-L2", "GENE_OR_GENE_PRODUCT", 208, 213], ["fat", "TISSUE", 219, 222], ["sugar", "SIMPLE_CHEMICAL", 227, 232], ["leptin receptor", "GENE_OR_GENE_PRODUCT", 250, 265], ["MSC", "CELL_TYPE", 66, 69], ["coagulation factor XIIIa", "PROTEIN", 116, 140], ["selenoprotein P", "PROTEIN", 167, 182], ["leptin receptor", "PROTEIN", 250, 265], ["Further evaluation", "TEST", 0, 18], ["molecular markers", "TEST", 22, 39], ["microarray analysis", "TEST", 43, 62], ["wound healing", "PROBLEM", 96, 109], ["coagulation factor XIIIa", "TEST", 116, 140], ["anti-inflammation", "PROBLEM", 143, 160], ["immunomodulation (e.g. PD", "TEST", 185, 210], ["fat and sugar metabolism", "PROBLEM", 219, 243], ["leptin receptor", "TREATMENT", 250, 265], ["wound healing", "OBSERVATION_MODIFIER", 96, 109], ["fat", "ANATOMY", 219, 222]]], ["Of note, many of these genes are regulated by type 2 cytokines (IL-4, IL-13 and IL-10) and are therefore rather M2 associated.", [["IL-4", "GENE_OR_GENE_PRODUCT", 64, 68], ["IL-13", "GENE_OR_GENE_PRODUCT", 70, 75], ["IL-10", "GENE_OR_GENE_PRODUCT", 80, 85], ["M2", "GENE_OR_GENE_PRODUCT", 112, 114], ["type 2 cytokines", "PROTEIN", 46, 62], ["IL", "PROTEIN", 64, 66], ["IL", "PROTEIN", 70, 72], ["IL", "PROTEIN", 80, 82], ["M2", "PROTEIN", 112, 114], ["IL", "TEST", 64, 66], ["IL", "TEST", 70, 72], ["rather M2", "OBSERVATION_MODIFIER", 105, 114]]], ["Overall, our data provide new markers for MSC in cancer and further establish their M2 activation state. study.", [["MSC", "ANATOMY", 42, 45], ["cancer", "ANATOMY", 49, 55], ["cancer", "DISEASE", 49, 55], ["MSC", "CELL", 42, 45], ["cancer", "CANCER", 49, 55], ["M2", "GENE_OR_GENE_PRODUCT", 84, 86], ["MSC", "CELL_TYPE", 42, 45], ["M2", "PROTEIN", 84, 86], ["our data", "TEST", 9, 17], ["new markers", "TEST", 26, 37], ["MSC in cancer", "PROBLEM", 42, 55], ["study", "TEST", 105, 110], ["cancer", "OBSERVATION", 49, 55]]], ["Only SP-A showed a significant expression in normal mucosa which was downregulated in CRC.", [["mucosa", "ANATOMY", 52, 58], ["CRC", "ANATOMY", 86, 89], ["CRC", "DISEASE", 86, 89], ["SP-A", "GENE_OR_GENE_PRODUCT", 5, 9], ["mucosa", "MULTI-TISSUE_STRUCTURE", 52, 58], ["CRC", "CANCER", 86, 89], ["SP", "PROTEIN", 5, 7], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["expression", "OBSERVATION", 31, 41], ["normal mucosa", "OBSERVATION", 45, 58], ["CRC", "OBSERVATION", 86, 89]]], ["As the absolute signal level was below the noise threshold, these results have to be interpreted with caution and require confirmation by direct measurenment of the proteins.", [["the absolute signal level", "TEST", 3, 28], ["confirmation", "TEST", 122, 134]]], ["Our results suggest that there is no major role for the human collectins in colorectal cancer.", [["colorectal cancer", "ANATOMY", 76, 93], ["colorectal cancer", "DISEASE", 76, 93], ["human", "ORGANISM", 56, 61], ["collectins", "CELL", 62, 72], ["colorectal cancer", "CANCER", 76, 93], ["human collectins", "PROTEIN", 56, 72], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["colorectal cancer", "PROBLEM", 76, 93], ["no major", "UNCERTAINTY", 34, 42], ["colorectal", "ANATOMY", 76, 86], ["cancer", "OBSERVATION", 87, 93]]]], "e1d48bc9752153571a832f416e12a0d13a4fcd32": [["J o u r n a l P r e -p r o o fTo the editor:J o u r n a l P r e -p r o o fThe public health threat posed by the coronavirus disease 2019 (COVID-19) may negatively impact on mental wellbeing of the population and significantly increase the risk of mental health problems [1] .", [["coronavirus disease", "DISEASE", 112, 131], ["COVID-19", "CHEMICAL", 138, 146], ["coronavirus", "ORGANISM", 112, 123], ["the coronavirus disease", "PROBLEM", 108, 131], ["COVID", "TEST", 138, 143], ["mental health problems", "PROBLEM", 247, 269], ["coronavirus disease", "OBSERVATION", 112, 131]]], ["In this regard, there are regional differences in mental health which may be affected by sociocultural, economic and environmental factors.", [["regional", "OBSERVATION_MODIFIER", 26, 34], ["differences", "OBSERVATION_MODIFIER", 35, 46], ["may be", "UNCERTAINTY", 70, 76]]], ["In China, the prevalence of mental health problems has been generally higher in the rural areas than their urban counterparts [2, 3] .", [["mental health problems", "PROBLEM", 28, 50], ["generally", "OBSERVATION_MODIFIER", 60, 69], ["higher", "OBSERVATION_MODIFIER", 70, 76]]], ["However, little is known about the urban-rural disparities in the occurrence of mental health problems associated with the COVID-19 pandemic.J o u r n a l P r e -p r o o f.", [["mental health problems", "PROBLEM", 80, 102], ["the COVID", "TEST", 119, 128], ["pandemic", "PROBLEM", 132, 140]]], ["Understanding the regional differences in mental health is essential for planning and implementing targeted intervention and prevention for the general population in the urban and rural areas.", [["targeted intervention", "TREATMENT", 99, 120], ["prevention", "TREATMENT", 125, 135], ["the general population", "PROBLEM", 140, 162]]], ["Therefore, we conducted a cross-sectional study from Feb 25 to Mar 17, 2020 among the outpatients in West China Hospital of Sichuan University.", [["outpatients", "ORGANISM", 86, 97], ["a cross-sectional study", "TEST", 24, 47]]], ["A semi-structured questionnaire was used to collect information pertaining to socio-demographic and clinical characteristics, with three specific questions to assess the symptoms of anxiety, depression and insomnia related to COVID-19.", [["anxiety", "DISEASE", 182, 189], ["depression", "DISEASE", 191, 201], ["insomnia", "DISEASE", 206, 214], ["the symptoms", "PROBLEM", 166, 178], ["anxiety", "PROBLEM", 182, 189], ["depression", "PROBLEM", 191, 201], ["insomnia", "PROBLEM", 206, 214], ["COVID", "TEST", 226, 231]]], ["For those with an affirmative response to any of these items, they were further assessed by the following questionnaires: 7-item Generalized Anxiety Disorder (GAD-7), 9-item Patient Health Questionnaire (PHQ-9), and Insomnia Severity Index (ISI).J o u r n a l P r e -p r o o fJ o u r n a l P r e -p r o o f the pandemic was 25.9%, 14.2%, and 27.9%, respectively.", [["Anxiety Disorder", "DISEASE", 141, 157], ["Insomnia", "DISEASE", 216, 224], ["Patient", "SPECIES", 174, 181], ["Generalized Anxiety Disorder", "PROBLEM", 129, 157], ["GAD", "TEST", 159, 162], ["PHQ", "TEST", 204, 207], ["Insomnia Severity Index", "PROBLEM", 216, 239], ["J", "TEST", 246, 247], ["a l P r e", "TEST", 286, 295], ["the pandemic", "TEST", 307, 319]]], ["Notably, there was a significantly higher prevalence of mental health problems in the urban patients compared to their rural counterparts (anxiety: 27.5% vs. 23.2%, depression: 15.3% vs. 12.4%, insomnia: 29.5% vs.J o u r n a l P r e -p r o o f25.5%, all p<0.05).", [["anxiety", "DISEASE", 139, 146], ["depression", "DISEASE", 165, 175], ["insomnia", "DISEASE", 194, 202], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["mental health problems", "PROBLEM", 56, 78], ["anxiety", "TEST", 139, 146], ["depression", "PROBLEM", 165, 175], ["insomnia", "PROBLEM", 194, 202], ["a l P r e -p r o o f", "TEST", 223, 243]]], ["There were no significant differences between the urban and rural participants in terms of age, sex, marital status, and medical comorbidities, except for higher education level and family income, and being more likely to live alone in the urban participants ( Figure 1 ).", [["participants", "SPECIES", 66, 78], ["participants", "SPECIES", 246, 258], ["medical comorbidities", "PROBLEM", 121, 142], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25]]], ["There were 369 out of 1,110 participants (33.2%) with mental symptoms who reported not being able to receive timely diagnosis and treatment.", [["participants", "SPECIES", 28, 40], ["mental symptoms", "PROBLEM", 54, 69], ["treatment", "TREATMENT", 130, 139]]], ["In particular, rural patients were more affected by the transportation restriction (53% vs. 29.5%, p<0.001), while urban patients were more likely to express fear of cross-infection in hospitals (48.2% vs. 37.6%, p<0.05).", [["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 121, 129]]], ["In addition, rural patients were more likely to face the challenges of the drug shortage (9.9% vs. 7.8%, p<0.05; Supplemental Table 1 ).", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27]]], ["Logistic regression analysis showed that living with others was a risk factor of anxiety in the urban patients, while being married was associated with a reduced risk of depression in the rural patients.", [["anxiety", "DISEASE", 81, 88], ["depression", "DISEASE", 170, 180], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 194, 202], ["Logistic regression analysis", "TEST", 0, 28], ["anxiety", "PROBLEM", 81, 88], ["depression", "PROBLEM", 170, 180], ["depression", "OBSERVATION", 170, 180]]], ["Higher family income and drug shortage were significantly associated with the risk of insomnia in the urban patients, while failing to receive timely diagnosis and treatment was a risk factor of insomnia in the rural patients (Supplemental Table 2", [["insomnia", "DISEASE", 86, 94], ["insomnia", "DISEASE", 195, 203], ["patients", "ORGANISM", 108, 116], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 217, 225], ["insomnia", "PROBLEM", 86, 94], ["treatment", "TREATMENT", 164, 173], ["insomnia", "PROBLEM", 195, 203]]]], "5ec3a6d38cf3ecf0b59898945b3233f0a3715403": [["IntroductionWhile the age dependency in clinical severity of COVID-19 has been well documented (1-5), there is limited information on how transmission risk vary with age, clinical presentation, and contact types (6) (7) (8) (9) (10) (11) (12) .", [["COVID", "TEST", 61, 66]]], ["Individual-based interventions such as case isolation, contact tracing and quarantine have been shown to accelerate case detection and interrupt transmission chains (13) .", [["Individual-based interventions", "TREATMENT", 0, 30], ["case isolation", "TREATMENT", 39, 53], ["contact tracing", "TEST", 55, 70]]], ["However, these interventions are typically implemented in conjunction with population-level physical distancing measures, and their effects on contact patterns and transmission risk remain difficult to separate (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) .", [["16) (17) (18) (19) (20) (21) (22", "SIMPLE_CHEMICAL", 222, 254], ["transmission risk", "TEST", 164, 181]]], ["A better understanding of the factors driving SARS-CoV-2 transmission is key to achieve epidemic control while minimizing societal cost, particularly as countries relax physical distancing measures.IntroductionHunan, a province in China adjacent to Hubei where the COVID-19 pandemic began, experienced sustained SARS-CoV-2 transmission in late January and early February 2020, but the outbreak was swiftly suppressed thereafter.", [["SARS", "DISEASE", 46, 50], ["SARS-CoV-2", "ORGANISM", 46, 56], ["CoV-2", "ORGANISM", 317, 322], ["SARS-CoV", "SPECIES", 46, 54], ["CoV-2 transmission", "TREATMENT", 51, 69], ["epidemic control", "TREATMENT", 88, 104], ["the COVID", "TEST", 261, 270], ["pandemic", "PROBLEM", 274, 282], ["sustained SARS", "PROBLEM", 302, 316]]], ["As in many other provinces in China, epidemic control was achieved by a combination of individual-based interventions targeting cases and their contacts and population-level physical distancing measures.", [["epidemic control", "TREATMENT", 37, 53], ["individual-based interventions", "TREATMENT", 87, 117]]], ["In this study, we reconstruct transmission chains for all identified SARS-CoV-2 infections in Hunan, as of April 3, 2020, based on granular epidemiological information collected through extensive surveillance and contact tracing efforts.", [["SARS-CoV-2 infections", "DISEASE", 69, 90], ["SARS-CoV-2", "ORGANISM", 69, 79], ["SARS-CoV-2", "SPECIES", 69, 79], ["this study", "TEST", 3, 13], ["extensive surveillance", "TEST", 186, 208]]], ["We identify the demographic, clinical and behavioral factors that drive transmission heterogeneities and evaluate how interventions modulate the topology of the transmission network.", [["the demographic, clinical and behavioral factors", "PROBLEM", 12, 60], ["transmission heterogeneities", "PROBLEM", 72, 100]]], ["Further, we reconstruct the infectiousness profile of SARS-CoV-2 over the course of a typical infection and estimate the feasibility of epidemic control by individual and population-based interventions.IntroductionWe analyze detailed epidemiological records for 1,178 SARS-CoV-2 infected individuals and their 15,648 close contacts, representing 19,227 separate exposure events, compiled by the Hunan Provincial Center for Disease Control and Prevention.", [["SARS", "DISEASE", 54, 58], ["infection", "DISEASE", 94, 103], ["SARS-CoV-2 infected", "DISEASE", 268, 287], ["SARS-CoV-2", "ORGANISM", 54, 64], ["SARS-CoV-2", "ORGANISM", 268, 278], ["individuals", "ORGANISM", 288, 299], ["CoV-", "SPECIES", 273, 277], ["SARS-CoV", "SPECIES", 54, 62], ["SARS-CoV", "SPECIES", 268, 276], ["the infectiousness profile", "TEST", 24, 50], ["SARS", "TEST", 54, 58], ["CoV", "TEST", 59, 62], ["a typical infection", "PROBLEM", 84, 103], ["epidemic control", "TREATMENT", 136, 152], ["based interventions", "TREATMENT", 182, 201], ["SARS", "TEST", 268, 272], ["CoV", "TEST", 273, 276], ["Disease Control", "TREATMENT", 423, 438], ["infection", "OBSERVATION", 94, 103]]], ["Cases were identified between January 16 and April 2, 2020; index cases were captured by passive surveillance and laboratory confirmed by RT-PCR.", [["passive surveillance", "TEST", 89, 109], ["RT", "TEST", 138, 140], ["PCR", "TEST", 141, 144]]], ["Individuals who were close contacts of the index cases were followed for at least 2 weeks after the last exposure to the infected individual.", [["infected", "OBSERVATION", 121, 129]]], ["Prior to February 7, 2020, contacts were tested if they developed symptoms during the quarantine period.", [["symptoms", "PROBLEM", 66, 74]]], ["After February 7, 2020, RT-PCR testing was required for all contacts, and specimens were collected at least once from each contact during quarantine, regardless of symptoms.", [["specimens", "ANATOMY", 74, 83], ["RT-PCR testing", "TEST", 24, 38], ["specimens", "TEST", 74, 83], ["symptoms", "PROBLEM", 164, 172]]], ["Upon positive RT-PCR test results, infected individuals were isolated in dedicated hospitals, regardless of their clinical severity, while their contacts were quarantined in medical observation facilities.IntroductionThe dataset includes 210 epidemiological clusters representing 831 cases, with additional 347 sporadic cases (29%) unlinked to any cluster (detailed in Materials & Methods).", [["individuals", "ORGANISM", 44, 55], ["positive RT-PCR test", "TEST", 5, 25], ["infected individuals", "PROBLEM", 35, 55]]], ["For each cluster, we stochastically reconstruct transmission chains and estimate the timing of infection most compatible with each patient's exposure history.", [["infection", "DISEASE", 95, 104], ["patient", "ORGANISM", 131, 138], ["patient", "SPECIES", 131, 138], ["infection", "PROBLEM", 95, 104], ["infection", "OBSERVATION", 95, 104]]], ["We observe between 0 and 4 generations of transmission, with the largest cluster involving 20 SARS-CoV-2-infected individuals.", [["SARS-CoV-2-infected", "DISEASE", 94, 113], ["CoV-2", "ORGANISM", 99, 104], ["individuals", "ORGANISM", 114, 125], ["CoV", "TEST", 99, 102], ["infected individuals", "PROBLEM", 105, 125]]], ["The number of secondary infections ranges from 0 to 10, with a distribution of secondary infections best characterized by a negative binomial distribution with mean \u00b5 = 0.40 (95% CI, 0.39 to 0.41) and variance \u00b5(1 + \u00b5/k) = 0.95 (95% CI, 0.92 to 0.97), where = 0.30 (95% CI, 0.29 to 0.30) is the dispersion parameter (Fig. 1) .", [["infections", "DISEASE", 24, 34], ["infections", "DISEASE", 89, 99], ["secondary infections", "PROBLEM", 14, 34], ["secondary infections", "PROBLEM", 79, 99], ["mean", "TEST", 160, 164], ["CI", "TEST", 179, 181], ["variance", "TEST", 201, 209], ["CI", "TEST", 233, 235], ["CI", "TEST", 270, 272], ["the dispersion parameter", "TEST", 291, 315], ["number", "OBSERVATION_MODIFIER", 4, 10], ["secondary", "OBSERVATION_MODIFIER", 14, 23], ["infections", "OBSERVATION", 24, 34], ["secondary", "OBSERVATION_MODIFIER", 79, 88], ["infections", "OBSERVATION", 89, 99], ["negative", "OBSERVATION_MODIFIER", 124, 132], ["binomial distribution", "OBSERVATION", 133, 154]]], ["This suggests 80% of secondary infection can be traced back to 14% of SARS-CoV-2 infected individuals, indicating substantial transmission heterogeneities at the individual-level.Characterizing SARS-CoV-2 transmission heterogeneities at the individual levelTo dissect the individual transmission heterogeneities and identify predictors of transmission, we analyze the infection risk among a subset of 14,622 individuals who were close contacts of 870 SARS-CoV-2 patients.", [["infection", "DISEASE", 31, 40], ["SARS-CoV-2 infected", "DISEASE", 70, 89], ["infection", "DISEASE", 368, 377], ["SARS", "DISEASE", 451, 455], ["SARS-CoV-2", "ORGANISM", 70, 80], ["individuals", "ORGANISM", 90, 101], ["individuals", "ORGANISM", 408, 419], ["SARS-CoV-2", "ORGANISM", 451, 461], ["patients", "ORGANISM", 462, 470], ["patients", "SPECIES", 462, 470], ["SARS-CoV", "SPECIES", 70, 78], ["SARS-CoV", "SPECIES", 451, 459], ["secondary infection", "PROBLEM", 21, 40], ["SARS", "TEST", 70, 74], ["CoV", "TEST", 75, 78], ["2 infected individuals", "PROBLEM", 79, 101], ["substantial transmission heterogeneities", "PROBLEM", 114, 154], ["SARS", "PROBLEM", 194, 198], ["CoV", "PROBLEM", 199, 202], ["2 transmission heterogeneities", "PROBLEM", 203, 233], ["the infection risk", "PROBLEM", 364, 382], ["80%", "OBSERVATION_MODIFIER", 14, 17], ["secondary", "OBSERVATION_MODIFIER", 21, 30], ["infection", "OBSERVATION", 31, 40], ["substantial", "OBSERVATION_MODIFIER", 114, 125], ["transmission", "OBSERVATION_MODIFIER", 126, 138], ["heterogeneities", "OBSERVATION", 139, 154], ["CoV", "OBSERVATION_MODIFIER", 199, 202], ["infection", "OBSERVATION", 368, 377]]], ["The dataset represents 74% of all SARS-CoV-2 cases in the Hunan epidemic, for whom contacts have been carefully monitored, capturing 17,750 independent exposure events.Characterizing SARS-CoV-2 transmission heterogeneities at the individual levelWe start by characterizing variation in transmission risk across the diverse set of 17,750 exposures.", [["SARS", "DISEASE", 34, 38], ["SARS-CoV", "SPECIES", 34, 42], ["The dataset", "TEST", 0, 11], ["all SARS", "TEST", 30, 38], ["CoV", "TEST", 39, 42], ["SARS", "PROBLEM", 183, 187], ["CoV", "PROBLEM", 188, 191], ["2 transmission heterogeneities", "PROBLEM", 192, 222], ["CoV", "OBSERVATION_MODIFIER", 188, 191]]], ["We also stratify exposures by the date of occurrence, with January 25, 2020 marking the beginning of enhanced physical distancing measures in Hunan (based on Baidu Qianxi mobility index (25) , Fig. S1A insert).", [["S1A", "GENE_OR_GENE_PRODUCT", 198, 201], ["S1A insert", "DNA", 198, 208]]], ["To address putative variation in infectiousness over the course of infection, we distinguish exposures based on whether the exposure window contains the time of symptom onset of the primary case, a period associated with high viral shedding.", [["infection", "DISEASE", 67, 76], ["putative variation", "PROBLEM", 11, 29], ["infectiousness", "PROBLEM", 33, 47], ["infection", "PROBLEM", 67, 76], ["high viral shedding", "PROBLEM", 221, 240], ["infection", "OBSERVATION", 67, 76]]], ["We use a mixed effects multiple logistic regression model (GLMM-logit) to quantify the effects of these factors on transmission (see Fig. S1A for regression results, and Table S3 for a detailed definition of all risk factors and summary statistics).Characterizing SARS-CoV-2 transmission heterogeneities at the individual levelWe find a marked gradient of transmission risk scales positively with closeness of social interactions (Fig. S1A ): household contacts pose the highest risk of transmission (see also (12) ), followed by contacts in the extended family, social and community settings.", [["S1A", "GENE_OR_GENE_PRODUCT", 138, 141], ["SARS-CoV-2", "ORGANISM", 264, 274], ["S1A", "PROTEIN", 138, 141], ["a mixed effects multiple logistic regression model (GLMM-logit)", "TREATMENT", 7, 70], ["regression results", "TEST", 146, 164], ["SARS", "PROBLEM", 264, 268], ["2 transmission heterogeneities", "PROBLEM", 273, 303], ["a marked gradient of transmission risk scales", "PROBLEM", 335, 380], ["marked", "OBSERVATION_MODIFIER", 337, 343], ["gradient", "OBSERVATION_MODIFIER", 344, 352]]], ["Contacts in the healthcare setting have the lowest risk, suggesting that adequate protective measures were adopted by patients and healthcare staff in Hunan, China.", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["adequate protective measures", "TREATMENT", 73, 101]]], ["Interestingly, the impact of physical distancing differs by transmission setting (Table 1) : enhanced physical distancing measures elevates the risk of transmission in the household, likely due to increased contact frequency at home as a result of physical confinement during the \"lockdown\".", [["increased contact frequency", "PROBLEM", 197, 224], ["likely due to", "UNCERTAINTY", 183, 196], ["increased", "OBSERVATION_MODIFIER", 197, 206], ["contact", "OBSERVATION", 207, 214]]], ["In contrast, reduced within-city mobility is associated with a reduction in transmission risk per contact opportunity in the community and social settings, possibly caused by adoption of prudent behaviors such as mask wearing, hand washing and coughing/sneezing etiquette.", [["hand", "ANATOMY", 227, 231], ["hand", "ORGANISM_SUBDIVISION", 227, 231], ["mask wearing", "TREATMENT", 213, 225], ["hand washing", "TREATMENT", 227, 239], ["coughing", "PROBLEM", 244, 252], ["sneezing", "PROBLEM", 253, 261], ["reduced", "OBSERVATION_MODIFIER", 13, 20], ["reduction", "OBSERVATION_MODIFIER", 63, 72]]], ["We also find that longer exposure window is a significant risk factor, with one additional day of exposure increasing the transmission risk by 10% (95% CI, 5% to 15%).", [["CI", "TEST", 152, 154], ["significant", "OBSERVATION_MODIFIER", 46, 57]]], ["Transmission risk is higher around the time of symptom presentation of the primary case (Table 1) .", [["Transmission risk", "PROBLEM", 0, 17], ["higher", "OBSERVATION_MODIFIER", 21, 27]]], ["And while susceptibility to SARS-CoV-2 gradually increases with age, we find no statistical support for age differences in infectivity (Fig. S1A ), in agreement with previous findings (12) .Characterizing SARS-CoV-2 transmission heterogeneities at the individual levelFor each of the 17,750 contact exposure events, we estimate the probability of transmission using the point estimate of the baseline odds and odds ratios from the GLMM-logit regression (Fig. S1A ).", [["SARS", "DISEASE", 28, 32], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 38], ["SARS-CoV", "SPECIES", 28, 36], ["SARS", "TEST", 28, 32], ["CoV", "TEST", 33, 36], ["SARS", "PROBLEM", 205, 209], ["CoV", "PROBLEM", 210, 213], ["2 transmission heterogeneities", "PROBLEM", 214, 244], ["odds ratios", "TEST", 410, 421], ["the GLMM", "TEST", 427, 435], ["CoV", "OBSERVATION_MODIFIER", 210, 213]]], ["The average \"per-contact\" transmission probability is highest in the household (7.1%, 95% CI, 1.2% to 19.3%), followed by family (1.7%, 95% CI, 0.4% to 5.7%) and social settings (0.9% with 95% CI, 0.3% to 2.7%), and lowest in the community (0.4% with 95% CI, 0.1% to 1.1%).", [["CI", "TEST", 90, 92], ["CI", "TEST", 140, 142], ["CI", "TEST", 193, 195], ["CI", "TEST", 255, 257]]], ["The gradient of transmission probabilities across settings is the joint effects of increasing duration of exposure with closeness of social interactions (Fig. 2B) , superimposed on setting-specific risk differences (Fig. S1A ).", [["gradient", "OBSERVATION_MODIFIER", 4, 12], ["joint", "ANATOMY", 66, 71], ["increasing", "OBSERVATION_MODIFIER", 83, 93]]], ["It is worth noting that these \"per-contact\" transmission probabilities were evaluated in a situation of intense interventions measures and high population awareness of the disease, and thus, they may be not generalizable elsewhere.Characterizing SARS-CoV-2 transmission heterogeneities at the individual levelThe number of contacts is also a key driver of individual transmission potential and varies by transmission setting.", [["intense interventions measures", "TREATMENT", 104, 134], ["the disease", "PROBLEM", 168, 179], ["SARS", "PROBLEM", 246, 250], ["CoV", "PROBLEM", 251, 254], ["2 transmission heterogeneities", "PROBLEM", 255, 285], ["disease", "OBSERVATION", 172, 179], ["CoV", "OBSERVATION_MODIFIER", 251, 254]]], ["Fig. 2C presents the contact degree distribution, defined as the number of unique contacts per individual.", [["contact degree", "OBSERVATION_MODIFIER", 21, 35]]], ["We find that the distributions of individual contact degree are overdispersed with dispersion parameter 0 < < 1 across all settings.", [["individual contact degree", "PROBLEM", 34, 59], ["dispersion parameter", "TEST", 83, 103], ["individual", "OBSERVATION_MODIFIER", 34, 44], ["contact degree", "OBSERVATION", 45, 59]]], ["Fig. 2D visualizes the age-specific contact patterns between the primary cases and their contacts, demonstrating diverse mixing patterns across settings.", [["diverse", "OBSERVATION_MODIFIER", 113, 120], ["mixing patterns", "OBSERVATION", 121, 136]]], ["Specifically, household contacts present the canonical \"three-bands\" pattern with the diagonal representing age-assortative interactions and the two off-diagonals representing intergenerational mixing (26, 27) .", [["diagonal", "ANATOMY_MODIFIER", 86, 94], ["intergenerational", "OBSERVATION_MODIFIER", 176, 193], ["mixing", "OBSERVATION_MODIFIER", 194, 200]]], ["Other settings display more diffusive mixing patterns by age.Characterizing SARS-CoV-2 transmission heterogeneities at the individual levelNext, we summarize the overall transmission potential of an individual by calculating the cumulative contact rate (CCR) of the primary case.", [["SARS", "PROBLEM", 76, 80], ["CoV", "PROBLEM", 81, 84], ["2 transmission heterogeneities", "PROBLEM", 85, 115], ["diffusive mixing", "OBSERVATION", 28, 44], ["CoV", "OBSERVATION_MODIFIER", 81, 84]]], ["The CCR captures how contact opportunities vary with demography, temporal variation in the infectiousness profile, an individual's contact degree, and interventions.", [["CCR", "PROTEIN", 4, 7], ["temporal variation in the infectiousness profile", "PROBLEM", 65, 113], ["interventions", "TREATMENT", 151, 164], ["temporal variation", "OBSERVATION", 65, 83]]], ["Through regression analysis, we focus on how the overall transmission opportunity of an infected individual is affected by different intervention measures across transmission settings.", [["regression analysis", "TEST", 8, 27], ["an infected individual", "PROBLEM", 85, 107], ["infected", "OBSERVATION", 88, 96]]], ["In contrast, faster case isolation (measured as the time between isolation, or pre-symptomatic quarantine, and symptom onset) universally reduces CCRs, decreasing transmission opportunities across all settings (Fig. 2E ).Characterizing the natural history of SARS-CoV-2 infectionWe have characterized the SARS-CoV-2 transmission risk factors and have shown that individual and population-based interventions have a differential impact on contact patterns and transmission potential.", [["SARS", "DISEASE", 259, 263], ["SARS-CoV-2", "ORGANISM", 259, 269], ["CoV-2", "ORGANISM", 310, 315], ["SARS-CoV-2", "SPECIES", 259, 269], ["faster case isolation", "TREATMENT", 13, 34], ["isolation", "TREATMENT", 65, 74], ["pre-symptomatic quarantine", "PROBLEM", 79, 105], ["SARS", "PROBLEM", 259, 263], ["CoV-2 infectionWe", "PROBLEM", 264, 281], ["the SARS", "PROBLEM", 301, 309], ["SARS", "OBSERVATION", 259, 263]]], ["Next, we use our probabilistic reconstruction of infector-infectee pairs to further dissect transmission kinetics and project the impact of interventions on SARS-CoV-2 dynamics and control.", [["SARS", "DISEASE", 157, 161], ["infector-infectee pairs", "DNA", 49, 72], ["SARS-CoV", "SPECIES", 157, 165], ["our probabilistic reconstruction of infector", "TREATMENT", 13, 57], ["SARS", "TEST", 157, 161], ["CoV", "TEST", 162, 165]]], ["Based on the reconstructed transmission chains, we estimate a median serial interval of 5.7 days, with an inter-quartile range (IQR) of 2.8 to 8.7 days, which represents the time interval between symptom onset of an infector and his/her infectee (Fig. S2B) .", [["an infector", "PROBLEM", 213, 224]]], ["The median generation interval, defined as the interval between the infection times of an infector and his/her infectee, is 5.3 days, with an IQR of 3.1 to 8.7 days (Fig. S2A ).", [["infection", "DISEASE", 68, 77], ["the infection", "PROBLEM", 64, 77], ["an infector", "PROBLEM", 87, 98], ["an IQR", "TEST", 139, 145], ["median", "OBSERVATION_MODIFIER", 4, 10], ["infection", "OBSERVATION", 68, 77]]], ["We estimate that 63.2% (95% CI, 59.6% to 66.4%) of all transmission events occur before symptom onset, which is comparable with findings from other studies (6-8, 10-13, 19, 28) .", [["CI", "TEST", 28, 30], ["all transmission events", "PROBLEM", 51, 74], ["other studies", "TEST", 142, 155]]], ["However, these estimates are impacted by the intensity of interventions, as we will show later.", [["interventions", "TREATMENT", 58, 71]]], ["In Hunan, interventions including case isolation, contact tracing, and close-contact quarantine were in place throughout the epidemic.Characterizing the natural history of SARS-CoV-2 infectionCase isolation and contact quarantine are meant to prevent potentially infectious individuals from contacting susceptible individuals, effectively shortening the infectious period.", [["SARS", "DISEASE", 172, 176], ["SARS-CoV-2", "ORGANISM", 172, 182], ["SARS-CoV", "SPECIES", 172, 180], ["interventions", "TREATMENT", 10, 23], ["case isolation", "TREATMENT", 34, 48], ["contact tracing", "TEST", 50, 65], ["SARS", "PROBLEM", 172, 176], ["CoV-2 infectionCase isolation", "TREATMENT", 177, 206], ["contact quarantine", "TREATMENT", 211, 229], ["potentially infectious individuals", "PROBLEM", 251, 285], ["infectious", "OBSERVATION", 263, 273], ["infectious", "OBSERVATION_MODIFIER", 354, 364]]], ["As a result, we would expect right censoring of the generation and serial interval distributions (29).", [["right censoring of the generation and serial interval distributions", "PROBLEM", 29, 96], ["right", "ANATOMY_MODIFIER", 29, 34], ["censoring", "OBSERVATION", 35, 44], ["distributions", "OBSERVATION_MODIFIER", 83, 96]]], ["Symptomatic cases represent 86.5% of all SARS-CoV-2 infections in our data; among these patients, we observe longer generation intervals for cases isolated later in the course of their infection (Fig. 3A) .", [["SARS", "DISEASE", 41, 45], ["infections", "DISEASE", 52, 62], ["infection", "DISEASE", 185, 194], ["SARS-CoV-2", "ORGANISM", 41, 51], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["SARS-CoV", "SPECIES", 41, 49], ["Symptomatic cases", "PROBLEM", 0, 17], ["all SARS", "TEST", 37, 45], ["2 infections", "PROBLEM", 50, 62], ["their infection", "PROBLEM", 179, 194], ["infection", "OBSERVATION", 185, 194]]], ["The median generation interval increases from 4.1 days (IQR, 1.9 to 7.2 days) for cases isolated 2 day since symptom onset, to 7.0 days (IQR, 3.6 to 11.1 days) for those isolated more than 6 days after symptom onset (p<0.001, Mann-Whitney U test).", [["symptom onset", "PROBLEM", 202, 215], ["Whitney U test", "TEST", 231, 245], ["increases", "OBSERVATION_MODIFIER", 31, 40]]], ["We observe similar tends for the serial interval distributions (Fig. 3B) .", [["the serial interval distributions", "PROBLEM", 29, 62]]], ["The median serial interval increases from 1.7 days (IQR, -1.5 to 4.7 days) for cases isolated less than 2 day after symptom onset, to 7.3 days (IQR, 3.4 to10.9 days) for those isolated more than 6 days after symptom onset (p<0.001, Mann-Whitney U test).Characterizing the natural history of SARS-CoV-2 infectionFaster case isolation restricts transmission to the earlier stages of infection, thus inflating the contribution of pre-symptomatic transmission (Fig. 3C) .", [["SARS", "DISEASE", 291, 295], ["infection", "DISEASE", 381, 390], ["SARS-CoV-2", "ORGANISM", 291, 301], ["SARS-CoV", "SPECIES", 291, 299], ["symptom onset", "PROBLEM", 208, 221], ["SARS", "PROBLEM", 291, 295], ["CoV-2 infectionFaster case isolation", "TREATMENT", 296, 332], ["infection", "PROBLEM", 381, 390], ["increases", "OBSERVATION_MODIFIER", 27, 36], ["infection", "OBSERVATION", 381, 390]]], ["The proportion of pre-symptomatic transmission is estimated at 86.6% (95% CI, 80.8% to 92.3%) if cases are isolated within 2 day of symptom onset, while this proportion decreases to 47.5% (95% CI, 41.4% to 53.3%) if cases are isolated more than 6 days after symptom onset (p<0.001, Mann-Whitney U test).Characterizing the natural history of SARS-CoV-2 infectionTo adjust for censoring due to case isolation and reconstruct the infectiousness profile of a SARS-CoV-2 infection in the absence of intervention, we characterize the changes in the speed of case isolation over time in Hunan.", [["SARS-CoV-2 infection", "DISEASE", 341, 361], ["SARS", "DISEASE", 455, 459], ["infection", "DISEASE", 466, 475], ["SARS-CoV-2", "ORGANISM", 341, 351], ["SARS-CoV-2", "ORGANISM", 455, 465], ["CoV-2", "SPECIES", 460, 465], ["SARS-CoV", "SPECIES", 341, 349], ["SARS-CoV-2", "SPECIES", 455, 465], ["pre-symptomatic transmission", "PROBLEM", 18, 46], ["CI", "TEST", 74, 76], ["CI", "TEST", 193, 195], ["symptom onset", "TEST", 258, 271], ["Whitney U test", "TEST", 287, 301], ["SARS", "PROBLEM", 341, 345], ["CoV", "PROBLEM", 346, 349], ["2 infection", "PROBLEM", 350, 361], ["censoring", "TREATMENT", 375, 384], ["case isolation", "TREATMENT", 392, 406], ["a SARS", "PROBLEM", 453, 459], ["CoV-2 infection", "PROBLEM", 460, 475], ["intervention", "TREATMENT", 494, 506], ["infection", "OBSERVATION", 466, 475]]], ["Fig. S4 shows the distributions of time from symptom onset to isolation during three different phases of epidemic control, coinciding with major changes in COVID-19 case definition (Phase I: before Jan. 27 th ; Phase II: Jan. 27 th -Feb.", [["symptom", "PROBLEM", 45, 52], ["epidemic control", "TREATMENT", 105, 121], ["COVID", "TEST", 156, 161], ["Jan.", "TEST", 198, 202], ["distributions", "OBSERVATION_MODIFIER", 18, 31]]], ["In Phase I, 78% of cases were detected through passive surveillance; as a result, most cases were isolated after symptom onset (median time from onset to isolation 5.4 days, IQR (2.7, 8.2) days, Fig. S4A ).", [["passive surveillance", "TEST", 47, 67]]], ["Phase II is intermediate.", [["intermediate", "OBSERVATION_MODIFIER", 12, 24]]], ["We use mathematical models (detailed in Materials and Methods) to dynamically adjust the serial interval distribution for censoring and apply the same approach to the time interval between a primary case's symptom onset and onward transmission ( Fig. S6A-B) .", [["mathematical models", "TREATMENT", 7, 26], ["the serial interval distribution", "TREATMENT", 85, 117], ["censoring", "PROBLEM", 122, 131]]], ["These censoring-adjusted distributions can be rescaled by the basic reproduction number ! to reflect the risk of transmission of a typical SARS-CoV-2 case since the time of infection or since symptom onset (Fig 3D-E) .", [["SARS", "DISEASE", 139, 143], ["infection", "DISEASE", 173, 182], ["SARS-CoV", "ORGANISM", 139, 147], ["SARS-CoV", "SPECIES", 139, 147], ["infection", "PROBLEM", 173, 182], ["infection", "OBSERVATION", 173, 182]]], ["Assuming no interventions were in place, we estimated that infectiousness peaks near the time of symptoms onset (Fig. S6B) , consistent with our regression estimates that transmission risk is higher if the onset of the primary case occurred within the window of exposure (Table 1) .Characterizing the natural history of SARS-CoV-2 infectionrepresents a typical scenario of unmitigated SARS-CoV-2 transmissibility in an urban setting.", [["SARS", "DISEASE", 320, 324], ["SARS", "DISEASE", 385, 389], ["SARS-CoV-2", "ORGANISM", 320, 330], ["CoV-2", "ORGANISM", 390, 395], ["SARS-CoV", "SPECIES", 320, 328], ["interventions", "TREATMENT", 12, 25], ["infectiousness peaks", "PROBLEM", 59, 79], ["symptoms", "PROBLEM", 97, 105], ["transmission risk", "PROBLEM", 171, 188], ["SARS", "PROBLEM", 320, 324], ["consistent with", "UNCERTAINTY", 125, 140], ["SARS", "OBSERVATION", 320, 324]]], ["The reconstructed infectiousness profile in the absence of control is shown in solid red lines in Fig. 3D -E, with respect to time of infection and symptom onset respectively.", [["solid red lines", "ANATOMY", 79, 94], ["infection", "DISEASE", 134, 143], ["solid red lines", "CELL", 79, 94], ["solid red lines", "CELL_LINE", 79, 94], ["The reconstructed infectiousness profile", "TEST", 0, 40], ["solid red lines in Fig", "PROBLEM", 79, 101], ["infection", "PROBLEM", 134, 143], ["symptom onset", "PROBLEM", 148, 161], ["infectiousness", "OBSERVATION", 18, 32], ["solid red lines", "OBSERVATION", 79, 94], ["Fig", "OBSERVATION_MODIFIER", 98, 101], ["infection", "OBSERVATION", 134, 143]]], ["Notably, SARS-CoV-2 infectiousness peaks slightly before symptom onset (-0.1 days on average), with 86% of the overall infectiousness concentrated within \u00b15 days of symptom onset and 52% of the overall infectiousness in the pre-symptomatic phase (Fig. 3E ).Characterizing the natural history of SARS-CoV-2 infectionNext, we evaluate the impact of case isolation on transmission by considering three different intervention scenarios mimicking the speed of isolation in the three phases of the Hunan epidemic control.", [["SARS", "DISEASE", 295, 299], ["SARS-CoV-2", "ORGANISM", 295, 305], ["SARS-CoV", "SPECIES", 9, 17], ["SARS-CoV", "SPECIES", 295, 303], ["SARS", "TEST", 9, 13], ["CoV", "TEST", 14, 17], ["2 infectiousness", "PROBLEM", 18, 34], ["symptom onset", "PROBLEM", 57, 70], ["symptom onset", "PROBLEM", 165, 178], ["SARS", "PROBLEM", 295, 299], ["CoV-2 infectionNext", "PROBLEM", 300, 319], ["case isolation", "TREATMENT", 347, 361], ["the Hunan epidemic control", "TREATMENT", 488, 514], ["infectiousness", "OBSERVATION", 119, 133], ["SARS", "OBSERVATION", 295, 299]]], ["We first assume that 100% of infections are detected and isolated and that isolation is fully protective (i.e., there is no onward transmission after the patient has been isolated/quarantined).", [["infections", "DISEASE", 29, 39], ["patient", "ORGANISM", 154, 161], ["patient", "SPECIES", 154, 161], ["infections", "PROBLEM", 29, 39], ["infections", "OBSERVATION", 29, 39]]], ["The infectiousness profiles of the three intervention scenarios are shown in dashed lines in Fig. 3D -E.", [["lines", "CELL", 84, 89], ["dashed lines", "CELL_LINE", 77, 89], ["The infectiousness profiles", "PROBLEM", 0, 27], ["dashed lines", "OBSERVATION", 77, 89], ["Fig", "OBSERVATION_MODIFIER", 93, 96]]], ["We find that the basic reproduction number decreases in all intervention scenarios, but the projected decrease is not sufficient to interrupt transmission (Fig. 3D , ! \" = 1.77 for Phase I, ! \" = 1.54 for Phase II, and ! \" = 1.10 for Phase III).Characterizing the natural history of SARS-CoV-2 infectionWe further relax the assumption of 100% case detection and isolation and relate changes in the basic reproduction number to the efficacy of surveillance and compliance with case isolation and contact quarantine (measured as the fraction of total infections isolated) as well as the speed of isolation (delay from symptom onset to isolation, phase diagram in Fig. 3F ).", [["SARS", "DISEASE", 283, 287], ["infections", "DISEASE", 549, 559], ["SARS-CoV-2", "ORGANISM", 283, 293], ["SARS-CoV", "SPECIES", 283, 291], ["all intervention scenarios", "TREATMENT", 56, 82], ["Phase II", "TEST", 205, 213], ["SARS", "PROBLEM", 283, 287], ["CoV-2 infectionWe", "PROBLEM", 288, 305], ["isolation", "TREATMENT", 362, 371], ["surveillance", "TEST", 443, 455], ["case isolation", "TREATMENT", 476, 490], ["total infections", "PROBLEM", 543, 559], ["symptom", "PROBLEM", 616, 623], ["reproduction", "OBSERVATION_MODIFIER", 23, 35], ["number", "OBSERVATION_MODIFIER", 36, 42], ["decreases", "OBSERVATION_MODIFIER", 43, 52], ["SARS", "OBSERVATION", 283, 287]]], ["Dashed lines in Fig. 3F illustrate 30%, 40% and 50% of reduction in ! .", [["Dashed lines", "CELL", 0, 12], ["Dashed lines", "CELL_LINE", 0, 12], ["Dashed lines in Fig", "TREATMENT", 0, 19], ["lines", "OBSERVATION", 7, 12], ["Fig", "OBSERVATION_MODIFIER", 16, 19]]], ["To reduce the ! in half (the minimum amount of transmission reduction required to achieve control for a baseline !~2 ), 100% of infections would need to be isolated even if individuals are isolated as early as the day of symptom onset.", [["infections", "DISEASE", 128, 138], ["individuals", "ORGANISM", 173, 184], ["transmission reduction", "TREATMENT", 47, 69], ["infections", "PROBLEM", 128, 138]]], ["In practice, epidemic control is unrealistic to achieve if case isolation and quarantine of close contacts are the only measures in place.Characterizing the natural history of SARS-CoV-2 infectionIndividual-based interventions are unlikely to be the sole mode of SARS-CoV-2 control in the months ahead.", [["SARS", "DISEASE", 176, 180], ["infection", "DISEASE", 187, 196], ["SARS", "DISEASE", 263, 267], ["SARS-CoV-2", "ORGANISM", 176, 186], ["SARS-CoV", "SPECIES", 176, 184], ["epidemic control", "TREATMENT", 13, 29], ["case isolation", "TREATMENT", 59, 73], ["SARS", "PROBLEM", 176, 180], ["CoV", "PROBLEM", 181, 184], ["2 infection", "PROBLEM", 185, 196], ["based interventions", "TREATMENT", 207, 226]]], ["Layering additional physical distancing measures (e.g. through increased teleworking, reduced operation in the service industry, or broader adoption of face mask wearing), could provide substantial relief on the burden of case isolation and contact quarantine.", [["Layering additional physical distancing measures", "PROBLEM", 0, 48], ["face mask wearing", "TREATMENT", 152, 169], ["case isolation", "TREATMENT", 222, 236], ["additional", "OBSERVATION_MODIFIER", 9, 19], ["physical", "OBSERVATION_MODIFIER", 20, 28], ["distancing", "OBSERVATION", 29, 39]]], ["The synergistic effects of these interventions are illustrated in Fig. 3G .", [["these interventions", "TREATMENT", 27, 46]]], ["We find that a 30% reduction in transmission from population-level measures would require a 70% case detection rate to achieve epidemic control, assuming that cases can be promptly isolated on average upon symptom presentation.", [["a 30% reduction", "TREATMENT", 13, 28], ["epidemic control", "TREATMENT", 127, 143]]], ["Of note, a 30% reduction in transmission could be achieved in various ways and does not necessarily require physical distancing measures.", [["a 30% reduction in transmission", "TREATMENT", 9, 40], ["physical distancing measures", "TREATMENT", 108, 136]]], ["It could also encompass the benefits of residual population-level immunity from the first wave of COVID-19, especially in hard-hit regions (32, 33).", [["COVID-19", "DNA", 98, 106], ["residual population", "PROBLEM", 40, 59], ["COVID", "TEST", 98, 103], ["residual", "OBSERVATION_MODIFIER", 40, 48], ["population", "OBSERVATION", 49, 59], ["hit", "ANATOMY", 127, 130], ["regions", "ANATOMY_MODIFIER", 131, 138]]], ["As a sensitivity analysis, we further consider a more optimistic scenario with a lower baseline ! = 1.59, corresponding to an epidemic growth rate of 0.08 day -1 (95% CI, 0.06 to 0.10) in Wuhan (30), which is adjusted for reporting changes.", [["a sensitivity analysis", "TEST", 3, 25], ["an epidemic growth rate", "TEST", 123, 146], ["CI", "TEST", 167, 169]]], ["As expected, control is much easier to achieve in this scenario: if detected SARS-CoV-2 infections are effectively isolated on average 2 days after symptom onset, a 25% population-level reduction in transmission coupled with a 43% infection isolation rate is able to achieve control (Fig. 3H ).DiscussionTo our knowledge, our study is the most comprehensive analysis of contact tracing data so far.", [["SARS", "DISEASE", 77, 81], ["infections", "DISEASE", 88, 98], ["infection", "DISEASE", 231, 240], ["SARS-CoV-2", "ORGANISM", 77, 87], ["SARS-CoV", "SPECIES", 77, 85], ["SARS", "PROBLEM", 77, 81], ["CoV", "PROBLEM", 82, 85], ["2 infections", "PROBLEM", 86, 98], ["symptom onset", "PROBLEM", 148, 161], ["a 25% population-level reduction", "TREATMENT", 163, 195], ["a 43% infection isolation rate", "TREATMENT", 225, 255], ["our study", "TEST", 322, 331], ["contact tracing data", "TEST", 370, 390]]], ["Detailed information on 1,178 SARS-CoV-2 infected individuals along with their 15,648 contacts has allowed us to dissect the behavioral and clinical drivers of SARS-CoV-2 transmission; to evaluate how transmission opportunities are modulated by individual and population-level interventions, and to characterize the typical infectiousness profile of a case.", [["SARS-CoV-2 infected", "DISEASE", 30, 49], ["SARS", "DISEASE", 160, 164], ["SARS-CoV-2", "ORGANISM", 30, 40], ["individuals", "ORGANISM", 50, 61], ["SARS-CoV-2", "ORGANISM", 160, 170], ["CoV-", "SPECIES", 35, 39], ["SARS-CoV", "SPECIES", 160, 168], ["CoV", "TEST", 35, 38], ["level interventions", "TREATMENT", 271, 290]]], ["Informed by this understanding, particularly the importance of pre-symptomatic transmission, we have evaluated the plausibility of SARS-CoV-2 control through individual and population-based interventions.DiscussionContacts in healthcare settings pose the lowest risk of transmission in Hunan, suggesting that adequate protective measures against SARS-CoV-2 were taken in hospitals and medical observation centers (Table 1 ).", [["SARS", "DISEASE", 346, 350], ["SARS-CoV-2", "ORGANISM", 346, 356], ["SARS-CoV", "SPECIES", 346, 354], ["SARS", "PROBLEM", 131, 135], ["CoV", "TEST", 136, 139], ["population-based interventions", "TREATMENT", 173, 203], ["adequate protective measures", "TREATMENT", 309, 337]]], ["The transmission risk associated with household exposures is further elevated when intense physical distancing is enforced, and for contacts that last longer.", [["household exposures", "PROBLEM", 38, 57], ["further elevated", "PROBLEM", 61, 77], ["elevated", "OBSERVATION_MODIFIER", 69, 77]]], ["These lines of evidence support that SARS-CoV-2 transmission is facilitated by close proximity, confined settings, and high frequency of contacts.", [["SARS", "DISEASE", 37, 41], ["SARS-CoV-2", "ORGANISM", 37, 47]]], ["We cannot evaluate the relative risks of transmission in other settings such as schools, workplaces, conferences, prisons, or factories, as no contacts in these settings were reported in the Hunan dataset.DiscussionRegression analysis indicates a higher risk of transmission when an individual is exposed to a SARS-CoV-2 patient around the time of symptom onset, in line with our reconstructed infectiousness profile that peaks just before symptom onset.", [["SARS", "DISEASE", 310, 314], ["SARS-CoV", "ORGANISM", 310, 318], ["patient", "ORGANISM", 321, 328], ["patient", "SPECIES", 321, 328], ["DiscussionRegression analysis", "TEST", 205, 234], ["a SARS", "TEST", 308, 314], ["symptom onset", "PROBLEM", 348, 361]]], ["These epidemiological findings are in agreement with viral shedding studies (6, 34, 35) .", [["viral shedding studies", "TEST", 53, 75]]], ["We estimate that overall in Hunan, ~63% of all transmission events were from pre-symptomatic individuals, in line with estimates from other modeling studies (6, 7, 10, 12, 36) .", [["pre-symptomatic individuals", "PROBLEM", 77, 104], ["other modeling studies", "TEST", 134, 156], ["overall", "OBSERVATION_MODIFIER", 17, 24]]], ["However, this proportion is inflated by case isolation and contact quarantine measures, with right-censoring affecting transmission primarily in the symptomatic phase.", [["case isolation", "TREATMENT", 40, 54], ["inflated", "OBSERVATION", 28, 36], ["right", "ANATOMY_MODIFIER", 93, 98], ["symptomatic phase", "OBSERVATION_MODIFIER", 149, 166]]], ["We estimate that the relative contribution of pre-symptomatic transmission drops to ~52% in an uncontrolled scenario where case-based interventions are absent.DiscussionCase isolation reduces the \"effective\" infectious period of SARS-CoV-2 infected individuals by blocking contacts with susceptible individuals.", [["SARS-CoV-2 infected", "DISEASE", 229, 248], ["SARS-CoV-2", "ORGANISM", 229, 239], ["individuals", "ORGANISM", 249, 260], ["CoV-2", "SPECIES", 234, 239], ["SARS-CoV", "SPECIES", 229, 237], ["pre-symptomatic transmission drops", "PROBLEM", 46, 80], ["SARS", "PROBLEM", 229, 233], ["susceptible individuals", "PROBLEM", 287, 310], ["infectious", "OBSERVATION_MODIFIER", 208, 218]]], ["We observe that faster isolation significantly reduces CCRs across settings (Fig. 2E ).", [["CCRs", "PROTEIN", 55, 59], ["faster isolation", "PROBLEM", 16, 32]]], ["As a result, strict physical distancing confines the epidemic mostly to families and households (see also Fig. S7 ).", [["S7", "GENE_OR_GENE_PRODUCT", 111, 113], ["S7", "PROTEIN", 111, 113]]], ["The precise impact of physical distancing on transmission is difficult to separate from that of individual-based interventions.", [["individual-based interventions", "TREATMENT", 96, 126], ["precise", "OBSERVATION_MODIFIER", 4, 11], ["impact", "OBSERVATION_MODIFIER", 12, 18]]], ["However, our analysis suggests that physical distancing changes the topology of the transmission network by affecting the number and duration of interactions.", [["our analysis", "TEST", 9, 21]]], ["Interestingly, the topological structure of the household contact network is highly clustered (37), and high clustering is expected to hinder epidemic spread (38, 39).", [["highly", "OBSERVATION_MODIFIER", 77, 83], ["clustered", "OBSERVATION_MODIFIER", 84, 93], ["high", "OBSERVATION_MODIFIER", 104, 108], ["epidemic", "OBSERVATION_MODIFIER", 142, 150], ["spread", "OBSERVATION_MODIFIER", 151, 157]]], ["Thus, these higher-order topological changes could contribute to reducing transmission beyond the effects expected from an overall reduction in CCRs.", [["CCRs", "PROTEIN", 144, 148], ["an overall reduction in CCRs", "PROBLEM", 120, 148], ["overall", "OBSERVATION_MODIFIER", 123, 130], ["reduction", "OBSERVATION_MODIFIER", 131, 140]]], ["Observationally, the effectiveness of physical distancing measures on reducing COVID-19 transmission has been demonstrated in China (16, 40) and elsewhere (41).DiscussionWe have explored the feasibility of SARS-CoV-2 epidemic control against two important metrics related to case isolation and contact quarantine: the speed of isolation and the infection isolation proportion (Fig. 3F ).", [["infection", "DISEASE", 345, 354], ["reducing COVID", "TREATMENT", 70, 84], ["SARS", "PROBLEM", 206, 210], ["CoV-2 epidemic control", "TREATMENT", 211, 233], ["case isolation", "TREATMENT", 275, 289], ["isolation", "TREATMENT", 327, 336], ["the infection isolation proportion", "TREATMENT", 341, 375], ["infection", "OBSERVATION", 345, 354]]], ["For a baseline transmission scenario compatible with the initial growth phase of the epidemic in Wuhan, we find that epidemic control solely relying on case isolation and quarantine of close contact is difficult to achieve.", [["a baseline transmission scenario", "PROBLEM", 4, 36]]], ["Layering case isolation and quarantine of close contact with moderate physical distancing makes control more likely over a range of plausible parameters -a situation that could be further improved by residual immunity from the first wave of SARS-CoV-2 circulation (32, 33).", [["SARS", "DISEASE", 241, 245], ["SARS-CoV", "SPECIES", 241, 249], ["Layering case isolation", "PROBLEM", 0, 23], ["residual immunity", "PROBLEM", 200, 217], ["SARS", "TEST", 241, 245], ["CoV", "TEST", 246, 249]]], ["Successful implementation of contact tracing requires a low-level of active infections in the community, as the number of contacts to be monitored is several folds the number of infections (~13 contacts were being traced per SARS-CoV-2 infected individual in Hunan).", [["infections", "DISEASE", 76, 86], ["infections", "DISEASE", 178, 188], ["SARS-CoV-2 infected", "DISEASE", 225, 244], ["contact tracing", "TEST", 29, 44], ["active infections", "PROBLEM", 69, 86], ["infections", "PROBLEM", 178, 188], ["active", "OBSERVATION_MODIFIER", 69, 75], ["infections", "OBSERVATION", 76, 86], ["infections", "OBSERVATION", 178, 188]]], ["The timing of easing of lockdown measures should align with the capacities of testing and contact tracing efforts, relative to the number of active infections in the community.", [["infections", "DISEASE", 148, 158], ["easing of lockdown measures", "TREATMENT", 14, 41], ["testing", "TEST", 78, 85], ["active infections", "PROBLEM", 141, 158], ["active", "OBSERVATION_MODIFIER", 141, 147], ["infections", "OBSERVATION", 148, 158]]], ["Our study is likely underpowered to assess the transmission potential of asymptomatic infections given the relatively small fraction of these infections in our data (13.5% overall and 22.1% of infections captured through contact tracing).", [["infections", "DISEASE", 86, 96], ["infections", "DISEASE", 142, 152], ["infections", "DISEASE", 193, 203], ["Our study", "TEST", 0, 9], ["asymptomatic infections", "PROBLEM", 73, 96], ["these infections", "PROBLEM", 136, 152], ["our data", "TEST", 156, 164], ["infections", "PROBLEM", 193, 203], ["contact tracing", "TEST", 221, 236], ["asymptomatic", "OBSERVATION_MODIFIER", 73, 85], ["infections", "OBSERVATION", 86, 96], ["relatively", "OBSERVATION_MODIFIER", 107, 117], ["small", "OBSERVATION_MODIFIER", 118, 123], ["fraction", "OBSERVATION_MODIFIER", 124, 132], ["infections", "OBSERVATION", 142, 152]]], ["There is no statistical support for decreased transmission from asymptomatic individuals (Fig. S1A) , although we observe a positive, but non-significant trend in transmission risk scaling with disease severity.", [["statistical support", "TREATMENT", 12, 31], ["decreased transmission", "PROBLEM", 36, 58], ["asymptomatic individuals", "PROBLEM", 64, 88], ["a positive", "PROBLEM", 122, 132], ["transmission risk scaling", "PROBLEM", 163, 188], ["disease severity", "PROBLEM", 194, 210], ["no", "UNCERTAINTY", 9, 11], ["disease", "OBSERVATION", 194, 201]]], ["There is conflicting evidence from viral shedding studies; viral load appears independent of clinical severity in some studies (6, 23, 35, 43) while others suggest faster viral clearance in asymptomatic individuals (44) .", [["viral shedding studies", "TEST", 35, 57], ["viral load", "TEST", 59, 69], ["clinical severity", "PROBLEM", 93, 110], ["some studies", "TEST", 114, 126], ["faster viral clearance in asymptomatic individuals", "PROBLEM", 164, 214], ["conflicting evidence from", "UNCERTAINTY", 9, 34], ["viral", "OBSERVATION", 35, 40]]], ["Before February 7 in Hunan, a fraction of contacts were only tested upon symptom presentation, which may affect our estimates on age-specific susceptibility, as younger individuals are less likely to develop symptom (45) .", [["symptom", "PROBLEM", 208, 215]]], ["The rate of asymptomatic infections and their impact on transmission have profound implications on the feasibility of control through individual-based interventions.", [["infections", "DISEASE", 25, 35], ["asymptomatic infections", "PROBLEM", 12, 35], ["individual-based interventions", "TREATMENT", 134, 164], ["asymptomatic", "OBSERVATION_MODIFIER", 12, 24], ["infections", "OBSERVATION", 25, 35]]], ["Careful serological studies combined with virologic testing in households and other controlled settings will be needed to fully resolve the role of asymptomatic infections and viral shedding on transmission.DiscussionIn conclusion, detailed contact tracing data illuminate important heterogeneities in SARS-CoV-2 transmission driven by biological and behavioral factors and modulated by the impact of interventions.", [["infections", "DISEASE", 161, 171], ["SARS", "DISEASE", 302, 306], ["CoV-2", "ORGANISM", 307, 312], ["SARS-CoV", "SPECIES", 302, 310], ["Careful serological studies", "TEST", 0, 27], ["virologic testing", "TEST", 42, 59], ["other controlled settings", "TREATMENT", 78, 103], ["asymptomatic infections", "PROBLEM", 148, 171], ["viral shedding on transmission", "PROBLEM", 176, 206], ["SARS", "PROBLEM", 302, 306], ["interventions", "TREATMENT", 401, 414], ["asymptomatic", "OBSERVATION_MODIFIER", 148, 160], ["infections", "OBSERVATION", 161, 171]]], ["Crucially, and in contrast to SARS-CoV-1, the ability of SARS-CoV-2 to transmit during the host's pre-symptomatic phase makes it particularly difficult to achieve epidemic control (46) .", [["SARS", "DISEASE", 30, 34], ["SARS-CoV-1", "ORGANISM", 30, 40], ["SARS-CoV-2", "ORGANISM", 57, 67], ["SARS-CoV-1", "SPECIES", 30, 40], ["SARS", "TEST", 30, 34], ["CoV", "TEST", 35, 38], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65]]], ["Our risk factor estimates can provide useful evidence to guide the design of more targeted and sustainable mitigation strategies, while our reconstructed transmission kinetics will help calibrate further modeling efforts.", [["sustainable mitigation strategies", "TREATMENT", 95, 128]]], ["Moving forward, it will be particularly important to intensify collection and analysis of rich contact tracing data to monitor how transmission risk changes over time with growing population immunity, waxing and waning of interventions, and reactive changes in human behavior and contact opportunities. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted August 13, 2020.", [["human", "ORGANISM", 261, 266], ["human", "SPECIES", 261, 266], ["human", "SPECIES", 261, 266], ["tracing data", "TEST", 103, 115], ["interventions", "TREATMENT", 222, 235], ["reactive", "OBSERVATION_MODIFIER", 241, 249], ["med", "ANATOMY", 382, 385]]], ["All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.", [["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21]]], ["Data and materials availability: the datasets generated during and/or analyzed during the current study are not publicly available due to privacy concerns but are available from the corresponding authors on reasonable request. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted August 13, 2020. .", [["the current study", "TEST", 86, 103], ["med", "ANATOMY", 306, 309]]], ["(E) Rate ratios of negative binomial regression of the cumulative contact rates (CCRs) against predictors including the infector's age, sex, presence of fever/cough, Wuhan travel history, whether symptom onset occurred before social distancing was in place (before or after Jan. 25, 2020), and time from isolation to symptom onset.", [["fever", "DISEASE", 153, 158], ["cough", "DISEASE", 159, 164], ["Rate ratios", "TEST", 4, 15], ["fever", "PROBLEM", 153, 158], ["cough", "PROBLEM", 159, 164], ["symptom", "PROBLEM", 196, 203], ["fever", "OBSERVATION", 153, 158]]], ["CCRs represent the sum of relevant contacts over a one-week window centered at the date of the primary case's symptom onset.", [["CCRs", "PROTEIN", 0, 4]]], ["Dots and lines indicate point estimates and 95% confidence interval of the rate ratios, numbers below the dots indicate the numerical value of the point estimates; Ref. stands for reference category; * indicates p-value<0.05, ** indicates p-value<0.01, *** indicates p-value<0.001.", [["lines", "CELL", 9, 14], ["the rate ratios", "TEST", 71, 86], ["p-value", "TEST", 212, 219], ["p-value", "TEST", 239, 246], ["p-value", "TEST", 267, 274]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted August 13, 2020.MildPatients with mild symptoms and no radiographic evidence of pneumonia Moderate Patients with fever, or respiratory symptoms, and radiographic evidence of pneumonia SevereMildPatients who have any of the following: a. respiratory distress, breathing rate \u226530 beats/min; or b. finger oxygen saturation \u226493% during resting state; or c.", [["respiratory", "ANATOMY", 373, 384], ["pneumonia", "DISEASE", 330, 339], ["fever", "DISEASE", 363, 368], ["respiratory symptoms", "DISEASE", 373, 393], ["pneumonia", "DISEASE", 424, 433], ["respiratory distress", "DISEASE", 487, 507], ["oxygen", "CHEMICAL", 552, 558], ["oxygen", "CHEMICAL", 552, 558], ["Patients", "ORGANISM", 349, 357], ["Patients", "ORGANISM", 444, 452], ["finger", "ORGANISM_SUBDIVISION", 545, 551], ["oxygen", "SIMPLE_CHEMICAL", 552, 558], ["Patients", "SPECIES", 349, 357], ["Patients", "SPECIES", 444, 452], ["mild symptoms", "PROBLEM", 284, 297], ["pneumonia", "PROBLEM", 330, 339], ["fever", "PROBLEM", 363, 368], ["respiratory symptoms", "PROBLEM", 373, 393], ["pneumonia", "PROBLEM", 424, 433], ["a. respiratory distress", "PROBLEM", 484, 507], ["breathing rate", "TEST", 509, 523], ["b. finger oxygen saturation", "TEST", 542, 569], ["med", "ANATOMY", 125, 128], ["mild", "OBSERVATION_MODIFIER", 284, 288], ["symptoms", "OBSERVATION", 289, 297], ["no radiographic evidence of", "UNCERTAINTY", 302, 329], ["pneumonia", "OBSERVATION", 330, 339], ["Moderate", "OBSERVATION_MODIFIER", 340, 348], ["fever", "OBSERVATION", 363, 368], ["pneumonia", "OBSERVATION", 424, 433], ["respiratory", "ANATOMY", 487, 498], ["distress", "OBSERVATION", 499, 507]]], ["PaO2/FiO2 \u2264300mmHg (1mmHg = 0.133kPa).", [["PaO2", "TEST", 0, 4], ["FiO2", "TEST", 5, 9]]], ["Patients whose pulmonary imaging have obvious progress of lesions (>50%) within 24~48 hours are managed as severe case.CriticalPatients who have any of the following: a. respiratory failure that requires mechanical ventilation; or b. shock; or c. other organ failures that requires ICU admission.CriticalAll rights reserved.", [["pulmonary", "ANATOMY", 15, 24], ["lesions", "ANATOMY", 58, 65], ["organ", "ANATOMY", 253, 258], ["respiratory failure", "DISEASE", 170, 189], ["b. shock", "DISEASE", 231, 239], ["Patients", "ORGANISM", 0, 8], ["pulmonary", "ORGAN", 15, 24], ["lesions", "PATHOLOGICAL_FORMATION", 58, 65], ["organ", "ORGAN", 253, 258], ["Patients", "SPECIES", 0, 8], ["pulmonary imaging", "TEST", 15, 32], ["lesions", "PROBLEM", 58, 65], ["a. respiratory failure", "PROBLEM", 167, 189], ["mechanical ventilation", "TREATMENT", 204, 226], ["b. shock", "PROBLEM", 231, 239], ["c. other organ failures", "PROBLEM", 244, 267], ["CriticalAll rights", "TREATMENT", 296, 314], ["pulmonary", "ANATOMY", 15, 24], ["lesions", "OBSERVATION", 58, 65], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["respiratory", "ANATOMY", 170, 181], ["failure", "OBSERVATION", 182, 189], ["mechanical ventilation", "OBSERVATION", 204, 226], ["shock", "OBSERVATION", 234, 239], ["organ", "ANATOMY", 253, 258], ["failures", "OBSERVATION", 259, 267]]], ["No reuse allowed without permission.Critical(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.CriticalThe copyright holder for this preprint this version posted August 13, 2020. .Dates of key events in the course of exposure and infection:For each SARS-CoV-2 positive individual in the database, information is compiled on the start/end date of exposure, along with the date of symptom onset (for symptomatic individuals) and laboratory confirmation.", [["infection", "DISEASE", 314, 323], ["The copyright holder", "TREATMENT", 187, 207], ["infection", "PROBLEM", 314, 323], ["each SARS", "TEST", 328, 337], ["CoV", "TEST", 338, 341], ["symptomatic individuals", "PROBLEM", 482, 505], ["laboratory confirmation", "TEST", 511, 534], ["med", "ANATOMY", 123, 126], ["infection", "OBSERVATION", 314, 323]]], ["Biologically, the time of infection should occur before the onset of symptom or a positive RT-PCR test.", [["infection", "DISEASE", 26, 35], ["infection", "PROBLEM", 26, 35], ["symptom", "PROBLEM", 69, 76], ["a positive RT-PCR test", "PROBLEM", 80, 102], ["infection", "OBSERVATION", 26, 35]]], ["Thus, we update the patient's end date of putative exposures in the database as the earliest of the reported exposure end date, date of symptom onset, or date of laboratory confirmation.", [["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27], ["laboratory confirmation", "TEST", 162, 185]]], ["If the start date of exposure is later than the date of symptom onset or positive RT-PCR test, it likely reflects recall error and we update the exposure start date as missing (1.9% of the records).Contact tracing databaseWe collected data on 15,648 individuals in close contact with the 1,178 confirmed SARS-CoV-2 infections identified in Hunan Province, China, representing 19,227 unique exposure events following the national protocol (1).", [["SARS-CoV-2 infections", "DISEASE", 304, 325], ["SARS-CoV-2", "ORGANISM", 304, 314], ["CoV-", "SPECIES", 309, 313], ["SARS-CoV-2", "SPECIES", 304, 314], ["symptom", "PROBLEM", 56, 63], ["positive RT-PCR test", "TEST", 73, 93], ["SARS", "PROBLEM", 304, 308], ["2 infections", "PROBLEM", 313, 325], ["the national protocol", "TREATMENT", 416, 437]]], ["If the contact was confirmed with SARS-CoV-2 by RT-PCR, a unique identifier mapping the individual to the SARS-CoV-2 patient database was provided.Contact Type Definition HouseholdA household member living with a SARS-CoV-2 infected individual.Extended familyA family member not residing in the same household but who has been in close contact with the primary SARS-CoV-2 infected individual.SocialFriends, coworkers and classmates who study, work or are in close contact with the primary infected individual.CommunityStaff who interact with SARS-CoV-2-infected individuals in restaurants, entertainment venues, or other service settings; passengers seated in close proximity to a SARS-CoV-2 infected individual.HealthcareHealthcare workers who provide diagnosis, treat or nurse a SARS-CoV-2 patient or other patients and caregivers in the same ward as a SARS-CoV-2 infected individual.", [["SARS-CoV-2 infected", "DISEASE", 213, 232], ["SARS-CoV-2 infected", "DISEASE", 361, 380], ["primary infected", "DISEASE", 481, 497], ["SARS-CoV-2-infected", "DISEASE", 542, 561], ["SARS-CoV-2 infected", "DISEASE", 681, 700], ["SARS", "DISEASE", 781, 785], ["SARS-CoV-2 infected", "DISEASE", 855, 874], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 34, 44], ["patient", "ORGANISM", 117, 124], ["SARS-CoV-2", "ORGANISM", 213, 223], ["SARS-CoV-2", "ORGANISM", 361, 371], ["SARS-CoV-2", "ORGANISM", 542, 552], ["individuals", "ORGANISM", 562, 573], ["SARS-CoV-2", "ORGANISM", 681, 691], ["patient", "ORGANISM", 792, 799], ["patients", "ORGANISM", 809, 817], ["SARS-CoV-2", "ORGANISM", 855, 865], ["SARS-CoV-2", "DNA", 34, 44], ["SARS-CoV-2 patient database", "DNA", 106, 133], ["patient", "SPECIES", 117, 124], ["CoV-", "SPECIES", 218, 222], ["CoV-", "SPECIES", 366, 370], ["CoV-2", "SPECIES", 547, 552], ["patient", "SPECIES", 792, 799], ["patients", "SPECIES", 809, 817], ["SARS-CoV", "SPECIES", 34, 42], ["SARS-CoV", "TEST", 34, 42], ["RT-PCR", "TEST", 48, 54], ["a unique identifier mapping", "TEST", 56, 83], ["the SARS", "TEST", 102, 110], ["CoV", "TEST", 111, 114], ["a SARS", "PROBLEM", 679, 685]]], ["Any individual reporting encounters as described in Table S2 and occurring within <1m of a SARS-CoV-2 infected individual (irrespective of displaying symptom) was considered a close contact, at risk of SARS-CoV-2 infection.", [["SARS-CoV-2 infected", "DISEASE", 91, 110], ["SARS-CoV-2 infection", "DISEASE", 202, 222], ["SARS-CoV-2", "ORGANISM", 91, 101], ["SARS-CoV-2", "ORGANISM", 202, 212], ["SARS-CoV-2", "SPECIES", 202, 212], ["a SARS", "TEST", 89, 95], ["SARS", "PROBLEM", 202, 206], ["CoV", "PROBLEM", 207, 210], ["2 infection", "PROBLEM", 211, 222], ["infection", "OBSERVATION", 213, 222]]], ["All records were extracted from the electronic database managed by Hunan Provincial Center for Disease Control and Prevention.", [["Disease Control", "TREATMENT", 95, 110]]], ["All individual records were anonymized and de-identified before analysis.Definition of a SARS-CoV-2 clusterBased on the contact tracing database, we define a SARS-CoV-2 cluster as a group of two or more confirmed SARS-CoV-2 cases or asymptomatic infections with an epidemiological link, i.e. occurring in the same setting (e.g. home, work, community, healthcare, or other) and for which a direct contact between successive cases can be established within two weeks of symptom onset of the most recent case (alternatively, the date of RT-PCR test for asymptomatic infections).", [["SARS", "DISEASE", 89, 93], ["infections", "DISEASE", 246, 256], ["infections", "DISEASE", 563, 573], ["SARS-CoV", "SPECIES", 213, 221], ["analysis", "TEST", 64, 72], ["a SARS", "TEST", 87, 93], ["a SARS", "TEST", 156, 162], ["asymptomatic infections", "PROBLEM", 233, 256], ["RT-PCR test", "TEST", 534, 545], ["asymptomatic infections", "PROBLEM", 550, 573], ["asymptomatic", "OBSERVATION_MODIFIER", 233, 245], ["infections", "OBSERVATION", 246, 256]]], ["In total, there are 210 clusters recorded in the database, for a total of 831 SARS-COV-2 infections.Definition of a SARS-CoV-2 clusterWhile clusters of cases are grouped together based on shared exposures, a subset of cases report additional exposures outside the cluster as possible causes of infection as well.", [["SARS", "DISEASE", 78, 82], ["infections", "DISEASE", 89, 99], ["SARS", "DISEASE", 116, 120], ["infection", "DISEASE", 294, 303], ["SARS-CoV", "SPECIES", 116, 124], ["the database", "TEST", 45, 57], ["COV-2 infections", "PROBLEM", 83, 99], ["a SARS", "TEST", 114, 120], ["CoV", "TEST", 121, 124], ["infection", "PROBLEM", 294, 303], ["possible causes of", "UNCERTAINTY", 275, 293], ["infection", "OBSERVATION", 294, 303]]], ["In addition, for cases that only report exposures within the cluster, a unique infector cannot always be identified, given simultaneous SARS-CoV-2 exposures within the same cluster.Definition of a SARS-CoV-2 clusterA sporadic case is defined as a laboratory-confirmed SARS-CoV-2 individual who does not belong to any of the reported clusters (i.e. a singleton who has no epidemiological link to other infections identified).", [["SARS", "DISEASE", 197, 201], ["infections", "DISEASE", 401, 411], ["SARS-CoV-2", "ORGANISM", 197, 207], ["SARS-CoV-2", "ORGANISM", 268, 278], ["SARS-CoV", "SPECIES", 197, 205], ["simultaneous SARS", "PROBLEM", 123, 140], ["a SARS", "TEST", 195, 201], ["CoV", "TEST", 202, 205], ["SARS", "PROBLEM", 268, 272], ["other infections", "PROBLEM", 395, 411], ["infections", "OBSERVATION", 401, 411]]], ["In total, there are 347 sporadic cases recorded in the database.Definition of a SARS-CoV-2 clusterSince the source and direction of transmission within a cluster cannot always be defined based on epidemiological grounds alone, we next turn to a modeling approach to probabilistically reconstruct possible infector-infectee transmission chains and further evaluate predictors of transmission.Reconstruction of SARS-CoV-2 transmission chainsAll rights reserved.", [["SARS", "DISEASE", 80, 84], ["SARS", "DISEASE", 409, 413], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 409, 419], ["SARS-CoV-2 transmission chains", "PROTEIN", 409, 439], ["a SARS", "PROBLEM", 78, 84], ["a modeling approach", "TREATMENT", 243, 262], ["infector", "PROBLEM", 305, 313], ["infectee transmission chains", "PROBLEM", 314, 342], ["SARS", "TEST", 409, 413], ["SARS", "OBSERVATION", 409, 413]]], ["No reuse allowed without permission.Reconstruction of SARS-CoV-2 transmission chains(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Reconstruction of SARS-CoV-2 transmission chainsThe copyright holder for this preprint this version posted August 13, 2020. . https://doi.org/10.1101/2020.08.09.20171132 doi: medRxiv preprintSampling algorithmFor each cluster and each patient in the cluster, the time of infection t ! !\"# is stochastically sampled by randomly drawing from the incubation period distribution and subtracting this value from the reported time of symptom onset, i.e. t ! !\"# = t ! $%& \u2212 \u03c4 ! !\"'( , where \u03c4 ! !\"'( is the sampled incubation period and t ! $%& the date of symptom onset (2) .", [["SARS", "DISEASE", 54, 58], ["SARS", "DISEASE", 237, 241], ["infection", "DISEASE", 490, 499], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 237, 247], ["patient", "ORGANISM", 454, 461], ["SARS-CoV-2 transmission chains", "PROTEIN", 237, 267], ["patient", "SPECIES", 454, 461], ["SARS", "TEST", 54, 58], ["SARS", "TEST", 237, 241], ["The copyright holder", "TREATMENT", 267, 287], ["medRxiv", "TREATMENT", 394, 401], ["Sampling algorithm", "TEST", 410, 428], ["infection", "PROBLEM", 490, 499], ["symptom onset", "PROBLEM", 770, 783], ["SARS", "OBSERVATION", 54, 58], ["med", "ANATOMY", 163, 166], ["SARS", "OBSERVATION", 237, 241], ["infection", "OBSERVATION", 490, 499]]], ["The incubation period follows a Weibull distribution:Sampling algorithm)0 must satisfy the following constrains:Sampling algorithm\u2022 t ! !\"# must fall within the start and end dates of the exposures identified by epidemiological investigation.", [["epidemiological investigation", "TEST", 212, 241]]], ["We remove all singletons from the reconstruction of transmission chains, since they are not epidemiologically linked to other cases, but we consider these singletons when we analyze the distribution of secondary cases and when we represent the transmission network in Fig. 1.Distribution of the number of secondary infections among transmission chainsNext, we calculate the number of secondary infections for each of the 1,178 SARS-CoV-2 individuals based on the 100 reconstructed transmission chains among 831 cluster cases, and the 347 singletons.", [["infections", "DISEASE", 315, 325], ["infections", "DISEASE", 394, 404], ["SARS", "DISEASE", 427, 431], ["SARS-CoV", "ORGANISM", 427, 435], ["SARS-CoV", "SPECIES", 427, 435], ["all singletons", "TREATMENT", 10, 24], ["the reconstruction of transmission chains", "TREATMENT", 30, 71], ["secondary infections", "PROBLEM", 305, 325], ["transmission chains", "PROBLEM", 332, 351], ["secondary infections", "PROBLEM", 384, 404], ["CoV", "TEST", 432, 435], ["number", "OBSERVATION_MODIFIER", 295, 301], ["secondary", "OBSERVATION_MODIFIER", 305, 314], ["infections", "OBSERVATION", 315, 325], ["chains", "OBSERVATION_MODIFIER", 345, 351], ["secondary", "OBSERVATION_MODIFIER", 384, 393], ["infections", "OBSERVATION", 394, 404]]], ["The distribution of secondary infections is shown in Fig. 1 We fit a negative binomial distribution to these data using package \"pystan\" version v2.19.1.1 with uniform prior.", [["infections", "DISEASE", 30, 40], ["secondary infections", "PROBLEM", 20, 40], ["package \"pystan\" version", "TREATMENT", 120, 144], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["secondary", "OBSERVATION_MODIFIER", 20, 29], ["infections", "OBSERVATION", 30, 40], ["uniform", "OBSERVATION_MODIFIER", 160, 167]]], ["We estimated mean = 0.40, 95% CI 0.39 to 0.41 and dispersion parameter = 0.30, 95%CI 0.29 to 0.30.Kinetics of SARS-CoV-2 transmission 3.1 Generation interval and serial interval distributionThe generation interval is defined as the time interval between the dates of infections in the infector and the infectee.", [["infections", "DISEASE", 267, 277], ["mean", "TEST", 13, 17], ["CI", "TEST", 30, 32], ["dispersion parameter", "TEST", 50, 70], ["CI", "TEST", 82, 84], ["SARS", "TEST", 110, 114], ["CoV", "TEST", 115, 118], ["serial interval distribution", "TREATMENT", 162, 190], ["infections", "PROBLEM", 267, 277], ["SARS", "OBSERVATION", 110, 114], ["distribution", "OBSERVATION_MODIFIER", 178, 190], ["infections", "OBSERVATION", 267, 277]]], ["We calculate the generation intervals of all the infector-infectee pairs based on 100 realization of the reconstructed transmission chains.", [["infector-infectee pairs", "DNA", 49, 72], ["infectee pairs", "PROBLEM", 58, 72]]], ["The distribution of the generation interval is shown in Fig. S2A .", [["S2A", "GENE_OR_GENE_PRODUCT", 61, 64], ["S2A", "PROTEIN", 61, 64], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["The observed serial interval is defined as the time interval between dates of symptom onsets in the infector and the infectee.", [["symptom onsets", "PROBLEM", 78, 92]]], ["We calculate the serial interval of all the infector-infectee pairs based on 100 realizations of the reconstructed transmission chains with known dates of symptom onset.", [["infector-infectee pairs", "DNA", 44, 67], ["infectee pairs", "PROBLEM", 53, 67], ["the reconstructed transmission chains", "TREATMENT", 97, 134], ["symptom onset", "PROBLEM", 155, 168]]], ["The distribution of the serial interval is shown in Fig. S2B .Gauging the impact of case isolation on the distribution of the serial and generation intervals.We select all infector-infectee pairs for which the infector has been isolated during the course of his/her infection, date of symptom onset is available, and times of infection have been estimated.", [["infection", "DISEASE", 266, 275], ["infection", "DISEASE", 326, 335], ["S2B", "GENE_OR_GENE_PRODUCT", 57, 60], ["infector", "CANCER", 210, 218], ["S2B", "PROTEIN", 57, 60], ["infector-infectee pairs", "DNA", 172, 195], ["case isolation", "TREATMENT", 84, 98], ["all infector-infectee pairs", "PROBLEM", 168, 195], ["her infection", "PROBLEM", 262, 275], ["symptom", "PROBLEM", 285, 292], ["infection", "PROBLEM", 326, 335], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["infection", "OBSERVATION", 266, 275], ["infection", "OBSERVATION", 326, 335]]], ["We stratify the data by the infector's time interval between onset and isolation, \u03c4 !. observations of >? given 3) without intervention ) ( )63 ).", [["intervention", "TREATMENT", 123, 135]]], ["Thus, we denote the sampling weight adjusted for case isolation as )63 = / 9 ! \"#$. .", [["the sampling weight", "TREATMENT", 16, 35]]], ["The overall resampling weight of generation interval )) between infector and infectee considering both incubation period distribution and censoring due to case isolation is given byDistribution of time interval between symptom onset and transmission, adjusted for case isolation.In contrast to the generation interval distribution, which characterize the relative infectiousness of a SARS-CoV-2 infection over time with respect to the time of infection, we now focus on the interval between symptom onset and transmission.", [["SARS", "DISEASE", 384, 388], ["infection", "DISEASE", 395, 404], ["infection", "DISEASE", 443, 452], ["SARS-CoV-2", "ORGANISM", 384, 394], ["SARS-CoV-2", "SPECIES", 384, 394], ["case isolation", "TREATMENT", 155, 169], ["case isolation", "TREATMENT", 264, 278], ["a SARS-CoV-2 infection", "PROBLEM", 382, 404], ["infection", "PROBLEM", 443, 452], ["distribution", "OBSERVATION_MODIFIER", 318, 330], ["relative", "OBSERVATION_MODIFIER", 355, 363], ["infectiousness", "OBSERVATION_MODIFIER", 364, 378], ["SARS", "OBSERVATION", 384, 388], ["infection", "OBSERVATION", 395, 404], ["infection", "OBSERVATION", 443, 452]]], ["This shifts the reference point of the infectiousness profile from the time of infection to the time of symptom onset.", [["infection", "DISEASE", 79, 88], ["the infectiousness profile", "PROBLEM", 35, 61], ["infection", "PROBLEM", 79, 88], ["symptom onset", "PROBLEM", 104, 117], ["infection", "OBSERVATION", 79, 88]]], ["Namely the distribution of symptom onset to transmission adjusted for case isolation { AH B:8. } represents the population-average relative infectiousness profile over time since the onset of symptom.", [["symptom", "PROBLEM", 27, 34], ["case isolation", "TEST", 70, 84], ["symptom", "PROBLEM", 192, 199], ["infectiousness", "OBSERVATION", 140, 154]]], ["Of note, since we observe substantial pre-symptomatic transmission for SARS-CoV-2, negative values of AH B:8. are allowed.Distribution of time interval between symptom onset and transmission, adjusted for case isolation.Similarly to the previous section, we resample from { AH ( , )} with sampling weights 6BC9D1 ( , ) until a sample of size = 10000 is reached to obtain the distribution of symptom onset to transmission { AH B:8. }.", [["SARS", "DISEASE", 71, 75], ["AH ( , )}", "CHEMICAL", 274, 283], ["SARS-CoV", "SPECIES", 71, 79], ["SARS", "TEST", 71, 75], ["CoV", "TEST", 76, 79], ["symptom onset", "PROBLEM", 160, 173], ["case isolation", "TREATMENT", 205, 219], ["sampling weights", "TEST", 289, 305], ["a sample of size", "TEST", 325, 341]]], ["The resampled distribution represents the infector's relative infectiousness (population average) with respect to the infector's symptom onset (Fig. S6B) .", [["the infector's relative infectiousness", "PROBLEM", 38, 76], ["the infector's symptom", "PROBLEM", 114, 136], ["distribution", "OBSERVATION_MODIFIER", 14, 26]]], ["The best-fit distribution is a normal distribution: A recent study (6) estimated the initial growth rate of the epidemic in Wuhan at 0.15 day -1 95% CI (95% CI, 0.14 to 0.17) ahead of the lockdown.", [["A recent study", "TEST", 52, 66], ["CI", "TEST", 149, 151], ["CI", "TEST", 157, 159], ["fit distribution", "OBSERVATION", 9, 25], ["normal", "OBSERVATION", 31, 37], ["distribution", "OBSERVATION_MODIFIER", 38, 50]]], ["The estimate is based on the daily rise in reported cases by onset date; adjustment for increased reporting due to a broadening case definition places the growth rate at 0.08 day -1 (6).", [["a broadening case definition", "PROBLEM", 115, 143], ["the growth rate", "TEST", 151, 166]]], ["The Euler-Lotka equation (7) describes the relationship between the basic reproduction number N , the epidemic growth rate , and the generation interval distribution ( ):Distribution of time interval between symptom onset and transmission, adjusted for case isolation.We assume that no effective intervention had been implemented in Wuhan by the time of the lockdown (Jan. 23).", [["the epidemic growth rate", "TEST", 98, 122], ["symptom onset", "PROBLEM", 208, 221], ["case isolation", "TREATMENT", 253, 267], ["effective intervention", "TREATMENT", 286, 308], ["no", "UNCERTAINTY", 283, 285], ["effective", "OBSERVATION_MODIFIER", 286, 295]]], ["Using the generation time distribution adjusted for \"censoring\" due to quarantine and case isolation >?", [["quarantine and case isolation", "TREATMENT", 71, 100]]], ["B:8. ( ) described in the previous section, we estimate the basic reproduction number in Wuhan during the exponential growth phase atEvaluating the impact of case isolation and quarantine on SARS-CoV-2 transmission.To The corresponding basic reproduction number assuming 100% SARS-CoV-2 infection detection rate is given by: Similarly, following Section 3.3.1, 3) 8 ( ) gives the probability that transmission is blocked after time since symptom onset in the infector, for the 3 phases of epidemic control \u2208 { , , }.", [["SARS", "DISEASE", 191, 195], ["SARS", "DISEASE", 276, 280], ["infection", "DISEASE", 287, 296], ["\u2208 { , , }.", "CHEMICAL", 506, 516], ["CoV-2", "ORGANISM", 196, 201], ["SARS-CoV", "SPECIES", 191, 199], ["case isolation", "TREATMENT", 158, 172], ["% SARS", "TEST", 274, 280], ["CoV", "TEST", 281, 284], ["symptom", "PROBLEM", 438, 445]]], ["No reuse allowed without permission.Evaluating the impact of case isolation and quarantine on SARS-CoV-2 transmission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Evaluating the impact of case isolation and quarantine on SARS-CoV-2 transmission.The copyright holder for this preprint this version posted August 13, 2020. .", [["SARS", "DISEASE", 94, 98], ["SARS", "DISEASE", 311, 315], ["CoV-2", "ORGANISM", 99, 104], ["CoV-2", "ORGANISM", 316, 321], ["SARS-CoV", "SPECIES", 94, 102], ["SARS-CoV", "SPECIES", 311, 319], ["case isolation", "TREATMENT", 61, 75], ["case isolation", "TREATMENT", 278, 292], ["The copyright holder", "TREATMENT", 335, 355], ["med", "ANATOMY", 197, 200]]], ["In Fig. 3E , we visualize the transmission profile with respect to symptom onset time AH +3*243D (8) for all three phases of epidemic control (dashed lines).Evaluating synergistic effects of individual-level and population-level interventions on SARS-CoV-2 transmission.We start by characterizing the controllability of SARS-CoV-2 (measured as N under control measures) as a function of infection isolation rate and the speed of case isolation/pre-symptomatic quarantine.", [["SARS", "DISEASE", 246, 250], ["SARS", "DISEASE", 320, 324], ["infection", "DISEASE", 387, 396], ["lines", "CELL", 150, 155], ["SARS-CoV-2", "ORGANISM", 246, 256], ["SARS-CoV", "SPECIES", 246, 254], ["AH", "TEST", 86, 88], ["epidemic control (dashed lines", "TREATMENT", 125, 155], ["population-level interventions", "TREATMENT", 212, 242], ["SARS", "TEST", 246, 250], ["SARS", "PROBLEM", 320, 324], ["infection isolation rate", "TREATMENT", 387, 411], ["pre-symptomatic quarantine", "TREATMENT", 444, 470], ["infection", "OBSERVATION", 387, 396]]], ["In Fig. 3F , we plot the phase diagram of N as a function of infection detection proportion (fraction of all SARS-CoV-2 infections detected) and the mean time from symptom onset to isolation/quarantine )63 .", [["infection", "DISEASE", 61, 70], ["infections", "DISEASE", 120, 130], ["SARS-CoV", "SPECIES", 109, 117], ["infection detection proportion", "PROBLEM", 61, 91], ["all SARS", "PROBLEM", 105, 113], ["CoV", "TEST", 114, 117], ["2 infections", "PROBLEM", 118, 130], ["infection", "OBSERVATION", 61, 70]]], ["Contour lines indicates reductions in R0 from baseline non-intervention conditions.", [["Contour lines", "TREATMENT", 0, 13], ["lines", "OBSERVATION", 8, 13], ["reductions", "OBSERVATION_MODIFIER", 24, 34]]], ["It is worth noting that we do not know the precise prevalence of truly asymptomatic infections as well as their role in transmission.", [["infections", "DISEASE", 84, 94], ["truly asymptomatic infections", "PROBLEM", 65, 94], ["asymptomatic", "OBSERVATION_MODIFIER", 71, 83], ["infections", "OBSERVATION", 84, 94]]], ["Here we assume that asymptomatic cases have a similar shape of infectiousness profile over the course of infection as symptomatic cases, and a peak of infectiousness corresponding to the time of symptom onset in symptomatic cases, as shown in Fig. S6 .", [["infection", "DISEASE", 105, 114], ["S6", "GENE_OR_GENE_PRODUCT", 248, 250], ["S6", "PROTEIN", 248, 250], ["asymptomatic cases", "PROBLEM", 20, 38], ["infectiousness profile", "PROBLEM", 63, 85], ["infection", "PROBLEM", 105, 114], ["symptomatic cases", "PROBLEM", 118, 135], ["infectiousness", "PROBLEM", 151, 165], ["symptom onset in symptomatic cases", "PROBLEM", 195, 229], ["infectiousness", "OBSERVATION", 63, 77], ["infection", "OBSERVATION", 105, 114]]], ["The corresponding )63 for asymptomatic cases is measured as time from peak infectiousness to isolation.", [["asymptomatic cases", "PROBLEM", 26, 44], ["peak infectiousness", "PROBLEM", 70, 89]]], ["Here we assume that the distribution of symptom onset/peak infectiousness to isolation follows a normal distribution with mean )63 and standard deviation of 2 days.", [["symptom", "PROBLEM", 40, 47], ["peak infectiousness", "PROBLEM", 54, 73]]], ["We further consider the synergic effects of layering individual-based intervention (case isolation, contact tracing, and quarantine) with population-based interventions (ie, via physical distancing, measured as a reduction in effective contact rates).", [["layering individual-based intervention", "TREATMENT", 44, 82], ["contact tracing", "TEST", 100, 115], ["a reduction in effective contact rates", "TREATMENT", 211, 249], ["layering", "OBSERVATION_MODIFIER", 44, 52]]], ["In Fig. 3G , we plot the phase diagram of N as a function of the proportion of population-level contact reduction and infection isolation rate, with the average speed of isolation 0 days after symptom onset/peak infectiousness and standard deviation of 2 days.", [["infection", "DISEASE", 118, 127], ["level contact reduction", "TREATMENT", 90, 113], ["infection isolation rate", "PROBLEM", 118, 142], ["symptom onset", "PROBLEM", 193, 206], ["peak infectiousness", "PROBLEM", 207, 226], ["Fig", "OBSERVATION", 3, 6], ["infection", "OBSERVATION", 118, 127]]], ["The blue area indicates the region below the epidemic threshold, where control is achieved, and the red area indicates region above the epidemic threshold.Evaluating synergistic effects of individual-level and population-level interventions on SARS-CoV-2 transmission.Last, we consider a sensitivity analysis with a lower base N = 1.59, using the growth rate of = 0.08 observed in Wuhan data with adjustment for changes in reporting (Section 3.4).", [["SARS", "DISEASE", 244, 248], ["SARS-CoV-2", "ORGANISM", 244, 254], ["SARS-CoV", "SPECIES", 244, 252], ["The blue area", "PROBLEM", 0, 13], ["the red area", "PROBLEM", 96, 108], ["population-level interventions", "TREATMENT", 210, 240], ["SARS", "TEST", 244, 248], ["a sensitivity analysis", "TEST", 286, 308], ["a lower base N", "TEST", 314, 328], ["the growth rate", "TEST", 343, 358], ["blue", "OBSERVATION_MODIFIER", 4, 8], ["area", "OBSERVATION_MODIFIER", 9, 13], ["region", "ANATOMY_MODIFIER", 28, 34], ["epidemic threshold", "OBSERVATION", 45, 63], ["region", "ANATOMY_MODIFIER", 119, 125], ["epidemic threshold", "OBSERVATION", 136, 154]]], ["In Fig. 3F , we plot the phase diagram of N as a function of % population-level contact reduction (i.e. through physical distancing) and isolation rate, assuming that SARS-CoV-2 infections are isolated 2 days after symptom onset/peak infectiousness on average with a standard deviation of 2 days.", [["SARS", "DISEASE", 167, 171], ["infections", "DISEASE", 178, 188], ["SARS-CoV-2", "ORGANISM", 167, 177], ["SARS-CoV", "SPECIES", 167, 175], ["level contact reduction", "TREATMENT", 74, 97], ["isolation rate", "TEST", 137, 151], ["SARS", "PROBLEM", 167, 171], ["CoV", "PROBLEM", 172, 175], ["2 infections", "PROBLEM", 176, 188], ["symptom onset", "PROBLEM", 215, 228], ["peak infectiousness", "PROBLEM", 229, 248]]], ["The blue area indicates the region below the epidemic threshold and the red area indicates region above the epidemic threshold.Evaluating individual-level transmission heterogeneity of SARS-CoV-2 4.1 Regression analysis to evaluate the \"per-exposure\" risk of SARS-CoV-2 transmission as a function of demographical, epidemiological, clinical, and behavioral predictors.In this section, we use a mixed effects multiple logistic regression model to evaluate the risk of SARS-CoV-2 transmission for each exposure reported in the contact tracing database.", [["SARS", "DISEASE", 185, 189], ["SARS", "DISEASE", 259, 263], ["SARS", "DISEASE", 467, 471], ["CoV-2", "ORGANISM", 264, 269], ["SARS-CoV", "SPECIES", 185, 193], ["SARS-CoV", "SPECIES", 259, 267], ["SARS-CoV", "SPECIES", 467, 475], ["The blue area", "PROBLEM", 0, 13], ["SARS", "TEST", 185, 189], ["CoV", "TEST", 190, 193], ["Regression analysis", "TEST", 200, 219], ["SARS", "PROBLEM", 259, 263], ["a mixed effects multiple logistic regression model", "TREATMENT", 392, 442], ["SARS", "PROBLEM", 467, 471], ["CoV", "TEST", 472, 475], ["blue", "OBSERVATION_MODIFIER", 4, 8], ["area", "OBSERVATION_MODIFIER", 9, 13], ["region", "ANATOMY_MODIFIER", 28, 34], ["epidemic threshold", "OBSERVATION", 45, 63], ["red", "OBSERVATION_MODIFIER", 72, 75], ["area", "OBSERVATION_MODIFIER", 76, 80], ["region", "ANATOMY_MODIFIER", 91, 97], ["epidemic threshold", "OBSERVATION", 108, 126]]], ["Each entry in the database represents a contact exposure between a SARS-CoV-2 infected individual and his/her contact.", [["SARS-CoV-2 infected", "DISEASE", 67, 86], ["entry", "OBSERVATION_MODIFIER", 5, 10]]], ["For individuals who were in contact with SARS-CoV-2 infected individual, the contact individual's age, sex, type of contact, the start/end dates of exposure, as well as the infection status (whether the exposed individuals was eventually infected with SARS-CoV-2) are carefully documented (Section 1.2).", [["SARS-CoV-2 infected", "DISEASE", 41, 60], ["infection", "DISEASE", 173, 182], ["SARS", "DISEASE", 252, 256], ["SARS-CoV-2", "ORGANISM", 41, 51], ["the infection status", "PROBLEM", 169, 189], ["the exposed individuals", "PROBLEM", 199, 222], ["SARS", "PROBLEM", 252, 256], ["CoV", "TEST", 257, 260], ["infection", "OBSERVATION", 173, 182]]], ["All SARS-CoV-2 infected individual (both primary cases and secondary infections via contact exposures) have unique identifiers that can be mapped to the SARS-CoV-2 patient line-list database, where additional information about the course of infection is also available (see Section 1.1 for detailed information).", [["SARS-CoV-2 infected", "DISEASE", 4, 23], ["infections", "DISEASE", 69, 79], ["infection", "DISEASE", 241, 250], ["SARS-CoV-2", "ORGANISM", 4, 14], ["patient", "ORGANISM", 164, 171], ["CoV-", "SPECIES", 9, 13], ["patient", "SPECIES", 164, 171], ["SARS-CoV", "SPECIES", 4, 12], ["All SARS", "TEST", 0, 8], ["secondary infections", "PROBLEM", 59, 79], ["infection", "PROBLEM", 241, 250], ["infection", "OBSERVATION", 241, 250]]], ["An individual in the contact tracing database can be exposed to multiple SARS-CoV-2 cases; further, an individual in the contact tracing database can be exposed to the same SARS-CoV-2 case through multiple independent exposures.", [["SARS", "DISEASE", 73, 77], ["SARS", "DISEASE", 173, 177], ["SARS-CoV", "SPECIES", 73, 81], ["multiple SARS", "TEST", 64, 77]]], ["All exposures are recorded independently.Evaluating individual-level transmission heterogeneity of SARS-CoV-2 4.1 Regression analysis to evaluate the \"per-exposure\" risk of SARS-CoV-2 transmission as a function of demographical, epidemiological, clinical, and behavioral predictors.For each exposure in the contact-tracing database, the regression outcome is coded as 1 if the contact eventually becomes infected and 0 if not infected.", [["SARS", "DISEASE", 99, 103], ["SARS", "DISEASE", 173, 177], ["CoV-2", "ORGANISM", 178, 183], ["SARS-CoV", "SPECIES", 99, 107], ["SARS-CoV", "SPECIES", 173, 181], ["SARS", "TEST", 99, 103], ["CoV", "TEST", 104, 107], ["Regression analysis", "TEST", 114, 133], ["SARS", "PROBLEM", 173, 177], ["infected", "PROBLEM", 426, 434]]], ["For each exposure, a list of independent variables, their definitions, and corresponding values are shown in Table S3 (fixed effects in the mixed model): (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Evaluating individual-level transmission heterogeneity of SARS-CoV-2 4.1 Regression analysis to evaluate the \"per-exposure\" risk of SARS-CoV-2 transmission as a function of demographical, epidemiological, clinical, and behavioral predictors.The copyright holder for this preprint this version posted August 13, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Evaluating individual-level transmission heterogeneity of SARS-CoV-2 4.1 Regression analysis to evaluate the \"per-exposure\" risk of SARS-CoV-2 transmission as a function of demographical, epidemiological, clinical, and behavioral predictors.The copyright holder for this preprint this version posted August 13, 2020 We also introduce random effects for each SARS-CoV-2 case, representing the individual-level infectiousness heterogeneity that is not explained by the independent variables representing fixed effects.", [["SARS", "DISEASE", 347, 351], ["SARS", "DISEASE", 421, 425], ["SARS", "DISEASE", 799, 803], ["SARS", "DISEASE", 873, 877], ["SARS", "DISEASE", 1099, 1103], ["CoV-2", "ORGANISM", 426, 431], ["CoV-2", "ORGANISM", 878, 883], ["SARS-CoV", "SPECIES", 347, 355], ["SARS-CoV", "SPECIES", 421, 429], ["SARS-CoV", "SPECIES", 799, 807], ["SARS-CoV", "SPECIES", 873, 881], ["SARS", "TEST", 347, 351], ["CoV", "TEST", 352, 355], ["Regression analysis", "TEST", 362, 381], ["SARS", "PROBLEM", 421, 425], ["The copyright holder", "TREATMENT", 530, 550], ["SARS", "TEST", 799, 803], ["CoV", "TEST", 804, 807], ["Regression analysis", "TEST", 814, 833], ["SARS", "PROBLEM", 873, 877], ["each SARS", "TEST", 1094, 1103], ["the individual-level infectiousness heterogeneity", "PROBLEM", 1129, 1178], ["fixed effects", "PROBLEM", 1243, 1256], ["med", "ANATOMY", 233, 236], ["med", "ANATOMY", 685, 688], ["infectiousness", "OBSERVATION", 1150, 1164], ["not explained", "UNCERTAINTY", 1187, 1200], ["fixed effects", "OBSERVATION", 1243, 1256]]], ["If the contact eventually becomes infected, however, only one of the many exposures will be the actual source of infection.", [["infection", "DISEASE", 113, 122], ["infected", "PROBLEM", 34, 42], ["infection", "PROBLEM", 113, 122], ["infected", "OBSERVATION", 34, 42], ["infection", "OBSERVATION", 113, 122]]], ["In this case, if we denote the number of exposures as 1U93 , for each of the contact's 1U93 exposure entries in the database with two different outcomes, either the contact became infected (1 as regression outcome) with regression weight 1/ 1U93 or the contact avoided infection from the same exposure (0 as regression outcome) with regression weight ( 1U93 \u2212 1)/ 1U93 .", [["infection", "DISEASE", 269, 278], ["regression weight", "TEST", 220, 237], ["infection", "PROBLEM", 269, 278], ["regression weight", "TEST", 333, 350]]], ["We remove contacts who become infected but also have travel history to Wuhan (81/15646, <1%), as the infection could possibility originate from exposures in Wuhan in addition to exposure to local cases in Hunan.Evaluating individual-level transmission heterogeneity of SARS-CoV-2 4.1 Regression analysis to evaluate the \"per-exposure\" risk of SARS-CoV-2 transmission as a function of demographical, epidemiological, clinical, and behavioral predictors.A fraction of the regression variables has missing values in the contact-tracing database (see Table S3 , column 3).", [["infection", "DISEASE", 101, 110], ["SARS", "DISEASE", 269, 273], ["SARS", "DISEASE", 343, 347], ["CoV-2", "ORGANISM", 348, 353], ["SARS-CoV", "SPECIES", 269, 277], ["SARS-CoV", "SPECIES", 343, 351], ["the infection", "PROBLEM", 97, 110], ["SARS", "TEST", 269, 273], ["CoV", "TEST", 274, 277], ["Regression analysis", "TEST", 284, 303], ["SARS", "PROBLEM", 343, 347], ["the regression variables", "PROBLEM", 466, 490], ["missing values", "PROBLEM", 495, 509], ["infection", "OBSERVATION", 101, 110], ["fraction", "OBSERVATION_MODIFIER", 454, 462]]], ["We adopted the state-of-the-art \"Multivariate Imputation by Chained Equations\" algorithm (8) (implemented in R package \"MICE\" version 3.9.1 https://cran.r-project.org/web/packages/mice/index.html) to impute missing values in the database.", [["missing values in the database", "PROBLEM", 207, 237]]], ["All independent variables in Table S3 are used as predictors for data imputation.", [["data imputation", "TEST", 65, 80]]], ["The number of multiple imputations is set as 10 with each imputation running 10 realizations.", [["multiple", "OBSERVATION_MODIFIER", 14, 22], ["imputations", "OBSERVATION", 23, 34]]], ["For each of the 5 realizations of imputed contacttracing databases, we independently perform mixed effects multiple logistic regression of the risk of SARS-CoV-2 transmission with all exposures and variables described in Table S3 as covariates.", [["SARS", "DISEASE", 151, 155], ["SARS-CoV", "SPECIES", 151, 159], ["SARS", "PROBLEM", 151, 155]]], ["The regression is performed using R package \"lme4\" (9) version v1.1-23 function \"glmer\" (https://cran.r-project.org/web/packages/lme4/index.html).", [["version v", "TEST", 55, 64]]], ["The final odds-ratio estimates are pooled from the 5 independent regressions on 5 imputed databases using \"MICE\" package's \"pool\" function, based on Rubin's rule (8) .", [["the 5 independent regressions", "PROBLEM", 47, 76], ["Rubin's rule", "TEST", 149, 161]]], ["The odds ratios of independent variables, their 95%CIs, and the baseline odds (intercept) are reported in Fig. S1A .Evaluating individual-level transmission heterogeneity of SARS-CoV-2 4.1 Regression analysis to evaluate the \"per-exposure\" risk of SARS-CoV-2 transmission as a function of demographical, epidemiological, clinical, and behavioral predictors.To examine the model's fit to the data, we explore (i) how well the model reproduces the age profiles of infectorinfectee pairs and (ii) whether the model captures the amount of transmission that occurs in different settings (household, family, transportation, etc).", [["SARS", "DISEASE", 174, 178], ["SARS", "DISEASE", 248, 252], ["S1A", "GENE_OR_GENE_PRODUCT", 111, 114], ["CoV-2", "ORGANISM", 253, 258], ["S1A", "PROTEIN", 111, 114], ["SARS-CoV", "SPECIES", 174, 182], ["SARS-CoV", "SPECIES", 248, 256], ["SARS", "TEST", 174, 178], ["CoV", "TEST", 179, 182], ["Regression analysis", "TEST", 189, 208], ["SARS", "PROBLEM", 248, 252]]], ["For each exposure entry in the imputed contact-tracing database, we calculate the model predicted risk of infection based on all fixed variables in the regression.", [["infection", "DISEASE", 106, 115], ["infection", "PROBLEM", 106, 115], ["infection", "OBSERVATION", 106, 115]]], ["We simulate the infection status of the contact according to the predicted risk by drawing from a binomial distribution.", [["infection", "DISEASE", 16, 25], ["the infection status", "PROBLEM", 12, 32], ["infection", "OBSERVATION", 16, 25], ["binomial distribution", "OBSERVATION", 98, 119]]], ["We repeat the process for all contacts, and further simulate 100 realizations of projected infection databases to gauge variability.", [["infection", "DISEASE", 91, 100], ["projected infection", "PROBLEM", 81, 100], ["infection", "OBSERVATION", 91, 100]]], ["Fig. S1C shows the observed age distribution of the infector-infectee pairs in the original data, and Fig. S1B visualizes the projected age distribution based on the regression model, averaged over 100 realizations.", [["S1B", "GENE_OR_GENE_PRODUCT", 107, 110], ["infector-infectee pairs", "DNA", 52, 75], ["S1B", "PROTEIN", 107, 110], ["the infector", "PROBLEM", 48, 60], ["infectee pairs", "PROBLEM", 61, 75]]], ["Violin plots in Fig. S1D show the relative fraction (with projection uncertainties) of transmission that is explained by each type of contacts, based on the model, while the dots in Fig. S1D represents the empirical observations.", [["S1D", "GENE_OR_GENE_PRODUCT", 21, 24], ["S1D", "GENE_OR_GENE_PRODUCT", 187, 190], ["S1D", "PROTEIN", 21, 24], ["S1D", "PROTEIN", 187, 190]]], ["Further, the model reproduces the relative contribution of different types of contacts seen in the empirical data (Fig. S1D) .Evaluating individual-level transmission heterogeneity of SARS-CoV-2 4.1 Regression analysis to evaluate the \"per-exposure\" risk of SARS-CoV-2 transmission as a function of demographical, epidemiological, clinical, and behavioral predictors.As a sensitivity analysis of imputing missing data (especially addressing the issue of imputing \"onset within exposure\" for SARS-CoV-2 infected individuals that are asymptomatic), we perform a GLMM-logit regression with entries of missing data removed.", [["SARS", "DISEASE", 184, 188], ["SARS", "DISEASE", 258, 262], ["SARS-CoV-2 infected", "DISEASE", 491, 510], ["CoV-2", "ORGANISM", 263, 268], ["individuals", "ORGANISM", 511, 522], ["SARS-CoV", "SPECIES", 184, 192], ["SARS-CoV", "SPECIES", 258, 266], ["the empirical data", "TEST", 95, 113], ["SARS", "TEST", 184, 188], ["CoV", "TEST", 189, 192], ["Regression analysis", "TEST", 199, 218], ["SARS", "PROBLEM", 258, 262], ["a sensitivity analysis", "TEST", 370, 392], ["SARS", "PROBLEM", 491, 495], ["infected individuals", "PROBLEM", 502, 522], ["a GLMM", "TEST", 558, 564], ["missing data", "PROBLEM", 598, 610]]], ["We remove the predictor of \"onset within exposure\", however, for predictor \"clinical severity (case)\", we break down the category \"mild & moderate\", and \"severe & critical\" based on the whether onset of the primary case occurred within the exposure time window. \"(-)\" indicate symptom onset outside the exposure time window, while \"(+)\" indicate symptom onset within the exposure time window.", [["symptom", "PROBLEM", 277, 284]]], ["The results of the regression are shown in Fig. S8 .Regression analysis evaluating predictors of individual contact patterns among SARS-CoV-2 cases and the impact of interventionsWhile Section 4.1 addresses predictors of \"per-contact\" transmission risk heterogeneity, in this section we aim to characterize variation in individual contact patterns of SARS-CoV-2 cases by type of contact.", [["SARS", "DISEASE", 131, 135], ["SARS", "DISEASE", 351, 355], ["S8", "GENE_OR_GENE_PRODUCT", 48, 50], ["S8", "PROTEIN", 48, 50], ["SARS-CoV", "SPECIES", 131, 139], ["SARS-CoV", "SPECIES", 351, 359], ["the regression", "TEST", 15, 29], ["Regression analysis", "TEST", 52, 71], ["interventions", "TREATMENT", 166, 179]]], ["Intuitively, the overall transmission rate of an infectious individual can be interpreted as the sum of contact rates across contact categories weighted by the \"per-contact\" transmission risk.", [["infectious", "OBSERVATION", 49, 59]]], ["Thus, conditioning on all other predictors, higher contact rates would translate to higher transmission rates.Regression analysis evaluating predictors of individual contact patterns among SARS-CoV-2 cases and the impact of interventionsWe use regression analysis to model the individual contact patterns of each symptomatic SARS-CoV-2 case, whose contacts are traced and documented in the contact-tracing database.", [["SARS", "DISEASE", 189, 193], ["SARS", "DISEASE", 325, 329], ["SARS-CoV", "SPECIES", 189, 197], ["SARS-CoV", "SPECIES", 325, 333], ["Regression analysis", "TEST", 110, 129], ["interventions", "TREATMENT", 224, 237], ["regression analysis", "TEST", 244, 263]]], ["We focus on symptomatic cases (the majority of our data) because we are particularly interested in contacts near the time of symptom onset, since we have previously shown that transmission risk is highest near symptom onset.", [["symptomatic cases", "PROBLEM", 12, 29]]], ["We first define a time window 6VC9. of peak infectiousness as \u00b15 days before and after each case's symptom onset 6VC9. .", [["6VC9", "DNA", 30, 34], ["a time window 6VC9", "TREATMENT", 16, 34], ["peak infectiousness", "PROBLEM", 39, 58], ["peak", "OBSERVATION_MODIFIER", 39, 43], ["infectiousness", "OBSERVATION", 44, 58]]], ["This time window accounts for a majority (86%) of the total infection risk of a typical symptomatic SARS-CoV-2 infection (Fig. S6B ).", [["infection", "DISEASE", 60, 69], ["SARS-CoV-2 infection", "DISEASE", 100, 120], ["CoV-2", "ORGANISM", 105, 110], ["CoV-", "SPECIES", 105, 109], ["SARS-CoV-2", "SPECIES", 100, 110], ["the total infection risk", "PROBLEM", 50, 74], ["a typical symptomatic SARS", "PROBLEM", 78, 104], ["CoV-2 infection", "PROBLEM", 105, 120], ["total", "OBSERVATION_MODIFIER", 54, 59], ["infection", "OBSERVATION", 60, 69], ["typical", "OBSERVATION_MODIFIER", 80, 87], ["symptomatic", "OBSERVATION_MODIFIER", 88, 99], ["SARS", "OBSERVATION", 100, 104]]], ["For each symptomatic SARS-CoV-2 case and contact type , we denote the number of contacts on day as ) 6 .", [["SARS", "DISEASE", 21, 25], ["each symptomatic SARS", "PROBLEM", 4, 25]]], ["6 within the time window 6VC9. for a given case is given by:Regression analysis evaluating predictors of individual contact patterns among SARS-CoV-2 cases and the impact of interventionsHere ( ) is the infectiousness profile with respect to symptom onset (Fig. S6B) .", [["SARS", "DISEASE", 139, 143], ["6VC9", "DNA", 25, 29], ["SARS-CoV", "SPECIES", 139, 147], ["interventions", "TREATMENT", 174, 187], ["the infectiousness profile", "PROBLEM", 199, 225]]], ["Clearly, case isolation will impact an infected individual's contact rate, irrespective of whether the case is symptomatic.", [["symptomatic", "PROBLEM", 111, 122], ["symptomatic", "OBSERVATION_MODIFIER", 111, 122]]], ["However here we restrict our analysis to symptomatic cases as the speed of case isolation and pre-symptomatic quarantine can be quantitatively measured as the time from isolation/pre-symptomatic quarantine to symptom onset.Regression analysis evaluating predictors of individual contact patterns among SARS-CoV-2 cases and the impact of interventionsTo quantify the impact of socio-demographic factors and interventions on < #012.", [["SARS", "DISEASE", 302, 306], ["SARS-CoV", "SPECIES", 302, 310], ["our analysis", "TEST", 25, 37], ["case isolation", "TREATMENT", 75, 89], ["pre-symptomatic quarantine", "TREATMENT", 94, 120], ["Regression analysis", "TEST", 223, 242], ["interventions", "TREATMENT", 337, 350]]], ["6Regression analysis evaluating predictors of individual contact patterns among SARS-CoV-2 cases and the impact of interventions, we consider a negative binomial regression with < #012.", [["SARS", "DISEASE", 80, 84], ["SARS-CoV", "SPECIES", 80, 88], ["6Regression analysis", "TEST", 0, 20], ["interventions", "TREATMENT", 115, 128]]], ["6 as the dependent variable and proxies of interventions intensities as independent variables in the regression.", [["interventions intensities", "TREATMENT", 43, 68], ["dependent", "OBSERVATION_MODIFIER", 9, 18], ["variable", "OBSERVATION_MODIFIER", 19, 27]]], ["Specifically, we use a within-city mobility index as a proxy for the intensity of populationlevel social distancing, while we use time between isolation and symptom onset to measure the intensity of individuallevel interventions (here, case isolation).", [["symptom", "PROBLEM", 157, 164], ["individuallevel interventions", "TREATMENT", 199, 228]]], ["A full description of all regression variables is shown in Table S4 : All rights reserved.", [["all regression variables", "PROBLEM", 22, 46]]], ["No reuse allowed without permission.Regression analysis evaluating predictors of individual contact patterns among SARS-CoV-2 cases and the impact of interventions(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Regression analysis evaluating predictors of individual contact patterns among SARS-CoV-2 cases and the impact of interventionsThe copyright holder for this preprint this version posted August 13, 2020. . https://doi.org/10.1101/2020.08.09.20171132 doi: medRxiv preprintSymptom fever (Y/N)Whether the SARS-CoV-2 case had \"fever\".", [["SARS", "DISEASE", 115, 119], ["SARS", "DISEASE", 377, 381], ["preprintSymptom fever", "DISEASE", 560, 581], ["SARS", "DISEASE", 599, 603], ["fever", "DISEASE", 620, 625], ["SARS-CoV", "ORGANISM", 599, 607], ["SARS-CoV", "SPECIES", 115, 123], ["SARS-CoV", "SPECIES", 377, 385], ["Regression analysis", "TEST", 36, 55], ["interventions", "TREATMENT", 150, 163], ["Regression analysis", "TEST", 298, 317], ["interventions", "TREATMENT", 412, 425], ["The copyright holder", "TREATMENT", 425, 445], ["fever", "PROBLEM", 576, 581], ["the SARS", "PROBLEM", 595, 603], ["fever", "PROBLEM", 620, 625], ["med", "ANATOMY", 242, 245]]], ["Cases without \"fever\" are the reference class.Symptom dry cough (Y/N)Whether the SARS-CoV-2 case had \"dry cough\".", [["fever", "DISEASE", 15, 20], ["Symptom dry cough", "DISEASE", 46, 63], ["SARS", "DISEASE", 81, 85], ["dry cough", "DISEASE", 102, 111], ["fever", "PROBLEM", 15, 20], ["Symptom dry cough", "PROBLEM", 46, 63], ["the SARS", "PROBLEM", 77, 85], ["dry cough", "PROBLEM", 102, 111], ["cough", "OBSERVATION", 58, 63]]], ["Cases without symptom \"dry cough\", i.e. Dry Cough (N), is the reference class.Travel history to Wuhan (Y/N)If the SARS-CoV-2 case reported a travel history to Wuhan: cases without travel history to Wuhan are the reference category.", [["dry cough", "DISEASE", 23, 32], ["Dry Cough", "DISEASE", 40, 49], ["SARS", "DISEASE", 114, 118], ["symptom", "PROBLEM", 14, 21], ["dry cough", "PROBLEM", 23, 32], ["Dry Cough", "PROBLEM", 40, 49]]], ["Physical distancing (Before/After Jan. 25)Travel history to Wuhan (Y/N)Based on the within-city mobility index (Fig. S1A, insert) provided by Baidu Qianxi (10), we grouped the individual patients into categories depending on whether the patients symptom onsets occurred before and after January 25, 2020, corresponding to weak/strong physical distancing.", [["S1A", "GENE_OR_GENE_PRODUCT", 117, 120], ["patients", "ORGANISM", 187, 195], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 187, 195], ["patients", "SPECIES", 237, 245]]], ["This is used as a proxy for individuallevel intervention intensity.", [["individuallevel intervention intensity", "TREATMENT", 28, 66]]], ["The larger the value, the earlier the case is being isolated.", [["larger", "OBSERVATION_MODIFIER", 4, 10]]], ["Positive values indicate isolation before symptom onset, negative values indicate isolation after symptom onset.Isolation to onset (days)The regression is performed using the R package \"MASS\" (11) version 7.3-51.6 function \"glm.nb\" (https://cran.rproject.org/web/packages/MASS/index.html).", [["symptom onset", "PROBLEM", 42, 55], ["symptom onset", "PROBLEM", 98, 111], ["version", "TEST", 197, 204], ["MASS", "OBSERVATION", 186, 190]]], ["The point estimates rate ratios along with their 95% CIs for each of the variables are presented in the bottom panels of Fig. 2E .", [["The point estimates rate ratios", "TEST", 0, 31]]], ["We identify an effect of interventions on contact rates, along with clinical factors; these effects tend to be most intense in the social and transportation settings. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Isolation to onset (days)The copyright holder for this preprint this version posted August 13, 2020. . https://doi.org/10.1101/2020.08.09.20171132 doi: medRxiv preprint Phase III of epidemic control (after Feb. 4): time from onset to isolation distribution has a median of -0.1 days with IQR (-2.9, 1.7) days.", [["interventions", "TREATMENT", 25, 38], ["The copyright holder", "TREATMENT", 327, 347], ["medRxiv preprint Phase III of epidemic control", "TREATMENT", 454, 500], ["effect", "OBSERVATION_MODIFIER", 15, 21], ["med", "ANATOMY", 246, 249]]], ["No reuse allowed without permission.Isolation to onset (days)(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Isolation to onset (days)The copyright holder for this preprint this version posted August 13, 2020. . https://doi.org/10.1101/2020.08.09.20171132 doi: medRxiv preprint", [["The copyright holder", "TREATMENT", 221, 241], ["medRxiv", "TREATMENT", 348, 355], ["med", "ANATOMY", 140, 143]]]]}